



(12) **DEMANDE DE BREVET CANADIEN**  
**CANADIAN PATENT APPLICATION**


(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2020/06/23  
(87) Date publication PCT/PCT Publication Date: 2020/12/30  
(85) Entrée phase nationale/National Entry: 2021/12/24  
(86) N° demande PCT/PCT Application No.: US 2020/039166  
(87) N° publication PCT/PCT Publication No.: 2020/263850  
(30) Priorité/Priority: 2019/06/25 (US62/866,477)

(51) Cl.Int./Int.Cl. *A61K 39/12* (2006.01),  
*A61K 39/00* (2006.01), *A61P 31/14* (2006.01),  
*C12N 7/00* (2006.01)  
(71) Demandeur/Applicant:  
CODAGENIX INC., US  
(72) Inventeurs/Inventors:  
MUELLER, STEFFEN, US;  
COLEMAN, JOHN ROBERT, US;  
STAUFF, CHARLES, US;  
WANG, YING, US  
(74) Agent: OYEN WIGGS GREEN & MUTALA LLP

(54) Titre : VIRUS DE LA DENGUE ATTENUÉS  
(54) Title: ATTENUATED DENGUE VIRUSES

FIG. 8B



(57) **Abrégé/Abstract:**

The present invention provides for modified Flavivirus such as a modified dengue virus type 1, 2, 3, 4, a combination of these, or a tetravalent combination of these. The modification according to various aspects of the invention results in reduced viral protein expression compared to a parent virus, wherein the reduction in expression is the result of recoding one or more regions of the virus. For example, the prM, or envelope (E) region can be recoded. In various embodiments one or more regions are recoded by reducing the codon pair bias or codon usage bias of the protein-encoding sequence. These modified Flaviviruses are used as vaccine compositions to provide a protective immune response.



## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

30 December 2020 (30.12.2020)



(10) International Publication Number

WO 2020/263850 A1

## (51) International Patent Classification:

A61K 39/12 (2006.01) A61K 39/00 (2006.01)

C12N 7/00 (2006.01) A61P 31/14 (2006.01)

## (21) International Application Number:

PCT/US2020/039166

## (22) International Filing Date:

23 June 2020 (23.06.2020)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/866,477 25 June 2019 (25.06.2019) US

(71) Applicant: **CODAGENIX INC.** [US/US]; 3 Bioscience Park Drive, Building II, Suite 501, Farmingdale, New York 11735 (US).

(72) Inventors: **MUELLER, Steffen**; 7 Gay Dr., Great Neck, New York 11024 (US). **COLEMAN, John Robert**; 18 Pine Glen Dr., Blauvelt, New York 10913 (US). **STAUF, Charles**; 175 Main Ave, Apt 135, Wheatley Heights, New York 11798 (US). **WANG, Ying**; 5 Carry Court, South Seauket, New York 11720 (US).


(74) Agent: **HUBER, Linda B.** et al.; NIXON PEABODY LLP, 300 South Grand Avenue, Suite 4100, Los Angeles, California 90071-3151 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## (54) Title: ATTENUATED DENGUE VIRUSES

FIG. 8B



(57) Abstract: The present invention provides for modified Flavivirus such as a modified dengue virus type 1, 2, 3, 4, a combination of these, or a tetravalent combination of these. The modification according to various aspects of the invention results in reduced viral protein expression compared to a parent virus, wherein the reduction in expression is the result of recoding one or more regions of the virus. For example, the prM, or envelope (E) region can be recoded. In various embodiments one or more regions are recoded by reducing the codon pair bias or codon usage bias of the protein-encoding sequence. These modified Flaviviruses are used as vaccine compositions to provide a protective immune response.

[Continued on next page]



WO 2020/263850 A1

# WO 2020/263850 A1

---

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

## ATTENUATED DENGUE VIRUSES

## CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application includes a claim of priority under 35 U.S.C. §119(e) to U.S. provisional patent application No. 62/866,477, filed June 25, 2019, the entirety of which is hereby incorporated by reference.

## FIELD OF THE INVENTION

[0002] This invention provides highly attenuated flaviviruses and particularly, attenuated dengue viruses and vaccines. The attenuated viruses provide protective immunity from challenge by virus of the same lineage, as well as cross protection against heterologous viruses.

## BACKGROUND OF THE INVENTION

[0003] Dengue virus (DENV) is a single-stranded positive-sense RNA virus belonging to the *Flaviviridae* family, in the same genus (Flavivirus) that includes Zika virus (ZIKV), West Nile virus (WNV), and yellow fever virus (YFV). According to the World Health Organization (WHO) about 2.5 billion people, nearly half the world's population, are now at risk from DENV and estimates that there may be 50 million cases of DENV infection worldwide every year. DENV is closely related phylogenetically to ZIKV and shares a common mosquito vector, *Aedes aegypti*, with both ZIKV and Chikungunya virus (an alphavirus). There is special concern for tourists at risk for DENV infection, with an added concern of importation and spread of the epidemic to places like the southern U.S. The vector for DENV, *Aedes aegypti*, is found throughout the southern U.S. *Aedes albopictus*, the Asian tiger mosquito, is also competent for transmitting DENV. If DENV enters *A. albopictus* populations in the U.S., it will have a vastly expanded range extending into the American Midwest and Northeast.

[0004] Flavivirus vaccine development is compounded by the phenomenon of Antibody-Dependent Enhancement (ADE). ADE occurs when prior infection with one flavivirus predisposes an individual to an enhanced severity of disease upon re-infection with a different serotype. During ADE, antibodies against the first virus bind, but do not neutralize the second virus, instead increasing its infectivity. DENV is prevalent in many countries, thus any vaccine strategy should consider the impact on a population with established dengue immunity. It is worth noting that people with underlying DENV immunity could experience increased adverse events from a live DENV vaccine, since their DENV immunity could enhance infectivity of the DENV vaccine strain, leading to increased adverse events. These are plausible scenarios that needs to be considered when developing a DENV vaccine, whether live, inactivated or antigen/VLP/backbone carrier-based. Because of the high likelihood of enhancing flavivirus infection due to ADE, all vaccine development strategies need to consider how any given DENV vaccine might interact with existing antibodies to a flavivirus or a subsequent flavivirus infection.

[0005] Dengue virus comprised four serotypes (DENV1-4) of the mosquito-borne Flaviviruses in the family *Flaviviridae*. Dengue viruses are enveloped viruses with an icosahedral virion comprised of C (Core),

M(Membrane), and E (Envelope) glycoproteins that is 40-65 nanometers in diameter. The Dengue virus genome is a single positive-strand RNA molecule of 10,000-11,000 bases in length encoding structural (C, prM, E) and nonstructural (NS1, NS2, NS3, NS4, and NS5) proteins. Dengue viruses transcribe and replicate their genome in the cell cytoplasm, with the genome translated into a single polypeptide that is cleaved and processed by both host and viral proteins. Dengue virus is an emerging agent of international concern in the tropics and the individual serotypes are genetically as well as antigenically distinct viruses.

[0006] Accordingly, there remains a need in the art to develop a vaccine to prevent or reduce infection.

#### SUMMARY OF THE INVENTION

[0007] It is described herein that recoded dengue viruses made by modification of the E region by large numbers of synonymous nucleotide mutations are highly effective in providing protective immunity against lethal wild type challenge and cross protection against different lineages. Further, the viruses have exceptional safety profiles.

[0008] Accordingly, various embodiments of the invention provides an attenuated dengue virus in which expression of viral proteins is reduced through codon-pair deoptimization of the E coding regions. In certain embodiments, E is the only virus protein coding regions targeted. In certain embodiments, when another dengue virus protein encoding region other than E is deoptimized, the reduction is small compared to the reduction of E. According to the invention, reduction in expression of virus proteins of the invention is accomplished by changes in protein encoding sequence, for example by lowering the codon pair bias of the protein-encoding sequence, substituting rare codons, modifying G+C content, modifying CG and/or TA (or UA) dinucleotide content, or combinations. Reduced expression can also be accomplished by modifications to the regulatory sequences of the proteins.

[0009] In certain embodiments, reducing the codon-pair bias can comprise identifying a codon pair in the parent protein-encoding sequence having a codon-pair score that can be reduced, and reducing the codon-pair bias by substituting the codon pair with a codon pair that has a lower codon-pair score. In other embodiments, reducing the codon-pair bias comprises rearranging the codons of a parent protein-encoding sequence. In certain embodiments, the E protein-encoding sequence has a codon pair bias less than  $-0.1$ , or less than  $-0.2$ , or less than  $-0.3$ , or less than  $-0.4$ . Codon pair bias of a protein-encoding sequence (i.e., an open reading frame) is calculated as described in Coleman et al., 2000 and herein.

[0010] In an embodiment of the invention, expression of the E protein-encoding sequence is reduced by replacing one or more codons with synonymous codons that are less frequent in the host.

[0011] In an embodiment of the invention, the E protein-encoding sequence DENV serotype are present in a background from a different strain of the same DENV serotype or the homologous strain.

[0012] The invention also provides a dengue vaccine composition for inducing a protective immune response in a subject, wherein the vaccine composition comprises virus in which viral translation is reduced while maintaining at least 90% antigenic identity with wt virus. In some embodiments, the viral translation is

reduced while maintaining at least 95, 96, 97, 98 or 99% antigenic identity with wt virus. In some embodiments, the viral translation is reduced while maintaining 100% antigenic identity with wt virus.

[0013] The invention also provides a method of eliciting a protective immune response in a subject comprising administering to the subject a prophylactically or therapeutically effective dose of a vaccine composition comprising an attenuated dengue virus, wherein expression of viral proteins is reduced by at least 10%. In various embodiments, the expression of viral proteins is reduced by at least 15%, at least 20% or at least 25%. In an embodiment of the invention, an immune response is elicited that is effective against dengue virus of the same lineage as the attenuated virus of the vaccine. In another embodiment, an immune response is elicited that is effective against a heterologous dengue virus.

[0014] The invention also provides a method of making an attenuated dengue virus genome comprising a) obtaining the genomic nucleotide b) recoding the envelope-encoding nucleotide sequence to reduce expression and recoding the nonstructural protein 3-encoding nucleotide sequence to reduce expression, and substituting the recoded nucleotide sequences into a dengue virus genome to make an attenuated dengue virus genome. In certain embodiments, only the E region is targeted. In some embodiments, expression of another virus protein encoding region is also reduced.

[0015] The invention also provides a method of constructing template dengue virus DNA sequences for transcription of infectious viral RNA genomes by T7 polymerase using overlapping PCR. All dengue genomes with homologous backbone were divided into three fragments starting from 5' end (fragment 1: nt1-3596; fragment 2: nt3030-6959, and fragment 3: nt: nt6851-end) and chemically/biochemically synthesized. Instead of constructing an infectious cDNA clone, a long overlap extension PCR strategy was used to obtain full-length dengue genome (or: the syn-wt and min dengue genomes simultaneously). To construct the heterologous dengue genomes in DENV2 16681 backbone, the first 2.5 Kb fragments, containing the DENV2 16681 5'UTR, C domain and the prM/M, E (wildtype or deoptimized) domain from individual DENV serotype and a small fraction of the DENV2 16681 NS1 domain, were synthesized. The 8 Kb DENV2 16681 backbone containing all NS domains and the 3'UTR were obtained from infectious clones encoding wildtype or deoptimized DENV2 16681. The 2.5 Kb and 8 Kb fragments were fused together using an asymmetric-fusion PCR method.

[0016] Various embodiments of the present invention provide for a modified dengue virus, comprising a recoded prM protein, a recoded envelope (E) protein, or both, wherein the recoded prM protein has a reduced codon pair bias compared to its parent prM protein encoding sequence, or has at least 5 codons substituted with synonymous codons less frequently used, or has an increased number of CpG or UpA di-nucleotides compared its parent prM protein encoding sequence, and wherein the recoded E protein has a reduced codon pair bias compared to its parent E protein encoding sequence, or has at least 5 codons substituted with synonymous codons less frequently used, or has an increased number of CpG or UpA di-nucleotides compared its parent E protein encoding sequence.

[0017] In various embodiments, the expression of the prM protein or E protein or both can be reduced compared to its parent dengue virus.

[0018] In various embodiments, the recoded prM protein has a reduced codon pair bias compared to its parent prM protein encoding sequence. In various embodiments, the recoded prM protein can have at least 5 codons substituted with synonymous codons less frequently used. In various embodiments, the recoded prM protein can have an increased number of CpG or UpA di-nucleotides compared its parent prM protein encoding sequence. In various embodiments, the recoded E protein can have a reduced codon pair bias compared to its parent E protein encoding sequence. In various embodiments, the recoded E protein can have at least 5 codons substituted with synonymous codons less frequently used. In various embodiments, the recoded E protein can have an increased number of CpG or UpA di-nucleotides compared its parent E protein encoding sequence. In various embodiments, each of the recoded prM or E protein-encoding sequence can have a codon pair bias of less than -0.05. In various embodiments, the codon pair bias of each of the recoded prM or E protein-encoding sequence can be reduced by at least 0.05.

[0019] In various embodiments, the modified dengue virus can be selected from type 1, type 2, type 3, type 4 or a combination thereof. In various embodiments, the modified dengue virus is a modified tetravalent dengue virus.

[0020] Various embodiments of the invention provide for a dengue vaccine composition for inducing a protective immune response in a subject, comprising a modified dengue virus as described above and herein, and a pharmaceutically acceptable excipient or carrier. Various embodiments of the invention provide a method of eliciting an immune response in a subject, comprising: administering to the subject an effective dose of a composition comprising a modified dengue virus as described above and herein, and a pharmaceutically acceptable excipient or carrier.

[0021] In various embodiments, the immune response can be a protective immune response, and a prophylactically effective or therapeutically effective dose of a vaccine composition of claims can be administered. In various embodiments, the immune response can be cross-protective against a heterologous dengue virus.

[0022] In various embodiments, the method can further comprise administering to the subject at least one adjuvant.

[0023] Various embodiments of the present invention provide for a method of eliciting an immune response in a subject in need thereof, comprising: administering a prime dose of (i) an attenuated dengue virus produced by a method other than codon-pair deoptimization or codon deoptimization, or increasing of CpG or UpA di-nucleotides, or (ii) a modified dengue virus comprising a recoded prM protein, a recoded envelope (E) protein, or both, wherein the recoded prM protein has a reduced codon pair bias compared to its parent prM protein encoding sequence, or has at least 5 codons substituted with synonymous codons less frequently used, or has an increased number of CpG or UpA di-nucleotides compared its parent prM protein encoding sequence, and wherein the recoded E protein has a reduced codon pair bias compared to its parent E protein encoding sequence, or has at least 5 codons substituted with synonymous codons less frequently, or has an increased number of CpG or UpA di-nucleotides compared its parent E protein encoding sequence; and administering one or more boost dose of (i) the attenuated dengue virus produced by methods other than codon-pair deoptimization

or codon deoptimization, or increasing of CpG or UpA di-nucleotides, or (ii) the modified dengue virus to the subject in need thereof, wherein at least the prime dose or the one or more boost dose is the modified dengue virus.

[0024] In various embodiments, a first of the one or more boost dose can be administered about 2 weeks after the prime dose.

[0025] In various embodiments, the expression of the prM protein or E protein or both can be reduced compared to its parent dengue virus.

[0026] In various embodiments, the recoded prM protein can have a reduced codon pair bias compared to its parent prM protein encoding sequence. In various embodiments, the recoded prM protein can have at least 5 codons substituted with synonymous codons less frequently used. In various embodiments, the recoded prM protein can have an increased number of CpG or UpA di-nucleotides compared its parent prM protein encoding sequence. In various embodiments, the recoded E protein can have a reduced codon pair bias compared to its parent E protein encoding sequence. In various embodiments, the recoded E protein can have at least 5 codons substituted with synonymous codons less frequently used. In various embodiments, the recoded E protein can have an increased number of CpG or UpA di-nucleotides compared its parent E protein encoding sequence. In various embodiments, each of the recoded prM or E protein-encoding sequence has a codon pair bias of less than -0.05. In various embodiments, the codon pair bias of each of the recoded prM or E protein-encoding sequence is reduced by at least 0.05.

[0027] In various embodiments, the modified dengue virus is selected from type 1, type 2, type 3, type 4 or a combination thereof. In various embodiments, the modified dengue virus is a modified tetravalent dengue virus.

[0028] Various embodiments of the present invention provide for a method of making a modified dengue virus genome comprising: obtaining a nucleotide sequence encoding the envelope protein of a dengue virus; recoding the envelope encoding nucleotide sequence to reduce protein expression, and substituting a nucleic acid having the recoded envelope-encoding nucleotide sequence into a parent dengue virus genome to make a modified dengue virus genome; whereby expression of the recoded envelope-encoding nucleotide sequence is reduced compared to the parent virus.

#### BRIEF DESCRIPTION OF THE FIGURES

[0029] FIG. 1 depicts rapid construction of SAVE-deoptimized, live-attenuated dengue vaccine candidate with growth in Vero cells under animal component-free conditions. Codon pair bias of the dengue prM/E genes and their SAVE-deoptimized counterparts in relation to the human ORFeome. Codon-Pair Bias (CPB) is expressed as the average codon pair score of a given gene's open reading frame (ORF). Positive and negative CPB value signifies the predominance of statistically over- or under-represented codon-pairs, respectively in an ORF. Red circles indicate the CPB of each of the 14,795 human ORFs, representing the majority of the known, annotated human genes at the time of our analysis (ORFeome). The CPB of wild-type E gene fall within the normal range of human host cell's genes. Following codon pair 'deoptimization' via SAVE, the resulting

deoptimized prM/E gene segments were now encoded predominately by under-represented human codon-pairs as evident by their extremely negative CPB, and are drastically different from any human gene. B. cDNA genomes of wild-type and synthetically ‘de-optimized’ chimeric dengue vaccine variants. The SAVE-deoptimized synthetic E were synthesized *de novo* and using overlapping PCR subcloned individually into the WT DENV genomes - yielding eight independent cDNA genomes each containing a synthetically ‘de-optimized’ fragment(s). We constructed infectious cDNA genomes for wt DENV1-4 and then recovered fully infectious, replicating virus for the deoptimized DENV vaccine candidates via transfection of RNA into Vero (all DENV WT, E-W/MIN, and E-MIN viruses) or BHK cells.

[0030] FIG. 2 depicts diagram of subcloning strategies for decreasing attenuation or increasing immunogenicity by reducing the length of deoptimized sequence in the E encoding region. The second generation of dengue vaccine candidates leverages the flexibility of the SAVE platform to reduce the deoptimized region from full-length (E-min) to approximately half of the length (W-E-Min) while keeping the amino acid sequence 100% identical.

[0031] FIG. 3 depicts growth of heterologous backbone dengue vaccine candidates in Vero cells under animal component-free conditions. DENV1-4 E-Min were used to infect Vero cells under animal-component free conditions at a MOI of 0.01 and supernatant titrated daily in a multiple-step growth curve over the course of 10 days post-infection. DENV2, DENV3, and DENV4 candidates reached titers of  $1-2 \times 10^5$  FFU/ml while DENV1 E-Min titer was reduced by  $\sim 1 \log_{10}$  compared to the others.

[0032] FIG. 4A-4C depicts multiple step growth curves that were conducted in Vero cells for synthetic DENV1 WT virus in a full-length DENV1 backbone (FIG. 4A) and attenuated live vaccine candidates DENV1 E-W/MIN (FIG. 4B) and E-MIN (FIG. 4C) derived from DENV1 WT. Synthetic DENV1 WT grows well in Vero cells at 33°C and 37°C. Typical of DENV, a transient reduction in virus yield was observed at 39°C, however, titers recovered to 37°C levels by 7 dpi. DENV1 E-W/MIN, however, reached serviceable titers  $\sim 10$ -fold lower than DENV1 WT at both 33°C and 37°C. DENV1 E-MIN was highly attenuated in Vero cells and only reached detectable titers at 33°C starting on days 10-14 post-infection.

[0033] FIG. 5 depicts multiple step growth curves that were conducted in Vero cells for synthetic DENV2 WT virus (in a full-length DENV2 backbone) and attenuated live vaccine candidates DENV2 E-W/MIN and E-MIN derived from DENV2 WT. DENV2 E-W/MIN and E-MIN were both attenuated *in vitro* with a  $1-2 \log_{10}$  FFU/ml reduction for E-W/MIN and a more pronounced  $2-3 \log_{10}$  FFU/ml reduction for DENV2 E-MIN (Figure 3). While growth kinetics were delayed, with regular medium replacement every 1-2 days virus titers reached  $>10^6$  FFU/ml for DENV2 E-W/MIN. Importantly, attenuation was correlated with the extent of deoptimization in the E region. While temperature sensitivity (difference between titers at 37°C and 39°C) was similar for DENV2-WT and DENV2 E-W/MIN through day 4 post-infection, there were significant differences on days 5, 6, and 7. Temperature sensitivity was not observed for DENV2 E-MIN because there was no replication at any temperature through 6 DPI. However, starting at day 7-14 DENV2 E-MIN started producing detectable virus (but only at 33°C and 37°C).

[0034] FIG. 6 depicts multiple step growth curves that were conducted in Vero cells for synthetic DENV3 WT virus (in a full-length DENV3 backbone) and attenuated live vaccine candidates DENV3 E-W/MIN and E-MIN derived from DENV3 WT. It was apparent that DENV3 E-W/MIN was more temperature sensitive at 39 °C than the WT with a significantly greater difference observable on days 3, 4, 5, and 7 post-infection. Because DENV3 E-MIN had minimal levels of replication in Vero cells at 39°C, the difference in virus yield from 37°C to 39°C were as high as 10<sup>7</sup> FFU/ml. When grown at permissible temperatures, however, DENV3 E-MIN reached high titers which is promising for cGMP manufacture.

[0035] FIG. 7 depicts multiple step growth curves that were conducted in Vero cells for synthetic DENV4 WT virus (in a full-length DENV4 backbone) and attenuated live vaccine candidates DENV4 E-W/MIN and E-MIN derived from DENV4 WT. Both DENV4 WT and E-W/MIN grew to high titers in Vero cells, with the peak DENV4 E-W/MIN titers approximately 10-fold lower but still high (~10<sup>7</sup> FFU/ml) at 33°C and 37°C. Both viruses were partially restricted at 39°C, but not to the extent seen with DENV1-3. On day 5 a small but significant (~5-fold) change in titer from 37°C to 39°C compared to WT was observed. DENV4 E-MIN was attenuated in Vero cells with peak titers 100-fold lower than WT. DENV4 E-MIN replication at 33°C and 37°C was similar, however, DENV4 E-MIN was not viable at 39°C with no detectable virus on days 1-14 post-infection.

[0036] FIG. 8A-8B depicts evaluation of the attenuation, immunogenicity, and efficacy of DENV2 vaccine candidates in AG129 mice. DENV-2 E-min based on a DENV2 16681 backbone was tested in an immunogenicity/dose escalation study in AG129 mice lacking interferon alpha or gamma receptors. Animals were immunized with DENV-2 E-min or DENV-2 16681 at two different concentrations. Resultant neutralizing antibody titers were determined, and the protective efficacy afforded evaluated against a mouse-adapted lethal strain of DENV2, D2S10.

[0037] FIG. 9 depicts constructed D2-E-min and D2-1/2-E-min with E sequence derived from DENV-2/NI/BID-V533/2005 in the heterologous DENV2 16681 backbone to improve the clinical relevance of our DENV2 candidate. We tested D2-1/2-E-min, with the E region consisting of half wt DENV-2/NI/BID-V533/2005 sequence and half CPD, to improve the immunogenicity of our virus. AG129 and BALB/c mice (n=5) were vaccinated with 10<sup>6</sup> or 10<sup>4</sup> FFU of D2-E-min, D2-1/2-E-min, or D2-WTE (DENV2 16681 backbone with WT DENV-2/NI/BID-V533/2005 E region). No mortality or morbidity was observed in the DENV2 D2-E-min, D2-1/2-E-min group indicating at least a 100-fold attenuation. The immunogenicity of our candidate was improved by reducing the extent of CPD with PRNT50 values of serum from D2-1/2-E-min being higher compared to D2-E-Min vaccinated AG129 mice. Additionally, high neutralizing antibody titers were maintained with D2-1/2-E-min vaccination as no significant difference was observed between the 10<sup>6</sup> (GM=3447) and 10<sup>4</sup> (GM= 2867) FFU vaccinated groups. In immune-competent BALB/c mice, both D2-E-min and D2-1/2-E-min engendered levels of neutralizing antibody comparable to wild-type.

[0038] FIG. 10A-10B depicts AG129 mice used to test the immunogenicity and protective efficacy of DENV-3 vaccine candidate DENV D2/D3-E-min, which comprises the DENV-2 strain 16681 backbone with a codon-deoptimized prME cassette from DENV-3/VE/BID-V2268/2008. This study was designed to evaluate

the immunogenicity and efficacy of this candidate vaccine against challenge with virulent DENV3 CO360/94. The first immunization was well tolerated by all of the animals with no major associated weight loss and none of the animals developed clinical signs. After lethal challenge with  $1.2 \times 10^7$  PFU DENV-3 CO360/94, animals in the media control group developed a rapid progressive infection that was lethal in 8/9 animals with the mean day of death (MDD) among the animals that died of  $4.0 \pm 0.8$  days. Immunization with the higher inoculum of DENV D2/D3-E-min provided significant protection with no lethality or morbidity (as measured by  $>10\%$  weight loss) among the animals in the group.

[0039] FIG. 11A-11B depicts AG129 mice used to test the immunogenicity and protective efficacy of DENV-4 vaccine candidates DENV D2/D4-E-min and D2/D4-1/2-E-min, which comprise the DENV-2 strain 16681 backbone with a codon-deoptimized prME cassette from DENV4. AG 129 Mice were vaccinated with  $10^6$  D2/D4-E-min (N=12),  $10^6$  D2/D4-1/2-E-min (N=12),  $10^6$  D2/D4-WTE, or media as a control (N=9). This study was designed to evaluate the immunogenicity and efficacy of this candidate vaccine against challenge with virulent DENV4 703/4. The first immunization with all strains was well tolerated by all groups of animals with no sustained weight loss over the 5 day observation period, however, in the D2/D4-WTE group one mouse had to be euthanized prior to the second immunization and additional animals died after the second immunization. No animals in any of the other vaccine groups experienced progressive weight loss. Sera were collected on day 35 to test for neutralizing antibodies prior to challenge and on day 30 post-challenge from all surviving animals to test final titers by FRNT50. Using a 96-well plate method with Vero cells, each serum sample was tested in duplicate using serum dilutions from 1:64-1:32784 incubated with 50 FFU of DENV4 WT virus. Each vaccine candidate was immunogenic at 35 DPI with vaccination with D2/D4-E-min (GMT 332.9) and D2/D4-1/2-E-min (GMT 738.4) lower than vaccination with D2/D4-WTE (GMT 1640). At 2 days post-challenge (DPC), viremia was detected in 4/12 mice inoculated with D2/D4-WTE. For all of the mice immunized with the other two viruses, viremia levels were below the limit of detection of the assay (500 genome equivalents/ml). DENV-4 703/4 challenge produced rapid progressive infection with universal lethality in the media control group. In addition, three animals immunized with D2/D4-E-min experienced lethal infection with the other animals in this group remaining healthy for the duration of the study. Importantly, no lethality or evidence of morbidity as determined by weight loss was seen in any of the D2/D4-1/2-E-min immunized animals after DENV-4 703/4 challenge.

[0040] FIG. 12 depicts tested DENV1-4 WT as well as vaccine candidates for DENV2-4 for immunogenicity in IFN $\alpha$  receptor knockout mice. All WT viruses were highly immunogenic in these mice, with neutralizing antibody titers  $>1024$ . DENV2-E-W/MIN was equally immunogenic to DENV2 WT virus at both a  $10^6$  and  $10^4$  FFU dose. Immunogenicity of DENV3 viruses waned with decreasing dose and increased deoptimization, however, DENV3 E-W/MIN was still highly immunogenic at a  $10^4$  FFU dose ( $\sim 1024$  FRNT50). We noticed a pronounced improvement in the immunogenicity of DENV4 E-W/MIN and WT as compared to the heterologous DENV4 WT in the DENV2 16681 backbone, which was poorly immunogenic in mice.

[0041] FIG. 13 depicts immunogenicity and efficacy of tetravalent vaccination in AG129 mice against lethal challenge with DENV3 CO360/94. AG129 mice were vaccinated on days 0 and 21 with  $10^6$  IFU monovalent D2/D3-E-min vaccine (N=16; 10 male and 6 female), tetravalent vaccine containing  $10^6$  IFU of each of the four monovalent DENV E-min viruses (N=16; 10 male and 6 female), or mock vaccinated with media (N=13; 8 male and 5 female). Serum was collected prior to challenge for measurement of neutralizing antibodies by FRNT50. All of the mice immunized with the monovalent vaccine developed detectable neutralizing antibody titers (range 20 - 160). In mice immunized with the tetravalent vaccine formulation, titers were generally lower (range <20 - 80). On day 35, all remaining mice were challenged with  $10^7$  IFU DENV3 CO360/94 delivered by the intraperitoneal route. As anticipated, animals in the media control group developed a rapid progressive infection that was lethal in 8/9 (89%) animals with the mean day of death (MDD) among the animals that died of  $4.1 \pm 0.4$  days. Immunization with monovalent DENV D2/D3-E-min or the tetravalent vaccine provided significant protection with no lethality or morbidity (as measured by >10% weight loss) among the animals in either group.

[0042] FIG. 14 depicts attenuation of homologous backbone viruses - focus size of vaccine strains vs wt - vaccine viruses spread less *in vitro* as compared to wt. Individual foci areas ( $\text{mm}^2$ ) were calculated for Vero cells infected with DENV1-4 WT, E-W/MIN, or E-MIN and incubated for 3 days at temperatures of 33°C, 37°C, or 39°C. We completed analysis of focus-forming unit (FFU) size of each virus using ImageJ software (NIH, v1.52a). Each image of the FFA plates was converted into a binary 8-bit image using ImageJ (an example is presented in Figure 2), and the scale for measuring FFU area was set to the diameter of the wells of 24-well plates (15.5 mm). Using the “analyze particles” function, the area of each FFU was calculated by ImageJ and the results compared by Sidak’s multiple comparisons test (GraphPad Prism 8.1.2).

[0043] FIG. 15 depicts *in vivo* immunogenicity data for tetravalent homologous backbone vaccine. Tetravalent and monovalent homologous backbone dengue vaccine candidates were immunogenic in IFN $\alpha$  receptor knockout mice after vaccination with  $10^6$  or  $10^4$  FFU delivered by the subcutaneous route on day 0 and 21. Neutralizing antibodies were tested using a focus-reduction neutralization 50% test at days 0, 21, and 35 post-vaccination against each strain of DENV1-4 wt.

#### DETAILED DESCRIPTION

[0044] All references cited herein are incorporated by reference in their entirety as though fully set forth. Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defined below.

[0045] As used herein the term “about” when used in connection with a referenced numeric indication means the referenced numeric indication plus or minus up to 5% of that referenced numeric indication, unless otherwise specifically provided for herein. For example, the language “about 50%” covers the range of 45% to

55%. In various embodiments, the term “about” when used in connection with a referenced numeric indication can mean the referenced numeric indication plus or minus up to 4%, 3%, 2%, 1%, 0.5%, or 0.25% of that referenced numeric indication, *if* specifically provided for in the claims.

[0046] Codon-Pair Bias (CPB) is expressed as the average codon pair score of a given gene’s open reading frame (ORF).

[0047] A “subject” means any animal or artificially modified animal. Animals include, but are not limited to, humans, non-human primates, cows, horses, sheep, pigs, dogs, cats, rabbits, ferrets, rodents such as mice, rats and guinea pigs, and birds. Artificially modified animals include, but are not limited to, SCID mice with human immune systems. In a preferred embodiment, the subject is a human. Embodiments of birds are domesticated poultry species, including, but not limited to, chickens, turkeys, ducks, and geese.

[0048] A “viral host” means any animal or artificially modified animal, or insect that the virus can infect. Animals include, but are not limited to, humans, non-human primates, cows, horses, sheep, pigs, dogs, cats, rabbits, ferrets, rodents such as mice, rats and guinea pigs, and birds. Artificially modified animals include, but are not limited to, SCID mice with human immune systems. In a specific embodiment, the viral host is a human. Embodiments of birds are domesticated poultry species, including, but not limited to, chickens, turkeys, ducks, and geese. Insects include, but are not limited to mosquitos.

[0049] A “prophylactically effective dose” is any amount of a vaccine that, when administered to a subject prone to viral infection or prone to affliction with a virus-associated disorder, induces in the subject an immune response that protects the subject from becoming infected by the virus or afflicted with the disorder. “Protecting” the subject means either reducing the likelihood of the subject’s becoming infected with the virus, or lessening the likelihood of the disorder’s onset in the subject, by at least two-fold, preferably at least ten-fold, 25-fold, 50-fold, or 100-fold. For example, if a subject has a 1% chance of becoming infected with a virus, a two-fold reduction in the likelihood of the subject becoming infected with the virus would result in the subject having a 0.5% chance of becoming infected with the virus.

[0050] As used herein, a “therapeutically effective dose” is any amount of a vaccine that, when administered to a subject afflicted with a disorder against which the vaccine is effective, induces in the subject an immune response that causes the subject to experience a reduction, remission or regression of the disorder and/or its symptoms. In preferred embodiments, recurrence of the disorder and/or its symptoms is prevented. In other preferred embodiments, the subject is cured of the disorder and/or its symptoms.

[0051] The present invention relates to attenuated dengue viruses and the production of attenuated dengue viruses that can be used to protect against viral infection and disease. A basic premise in vaccination is adequate delivery of protective antigens to vaccine recipients assuming that a very high dose (“Peptide or Virus-Like Particle”) or a dose corresponding to live viral infection (“ChimeriVax”) of these traditionally dominant antigenic polypeptides alone are sufficient for adequate vaccine efficacy. Those expectations aside, the present invention benefits from a contrary approach. The invention provides attenuated dengue viruses in which expression of viral proteins is reduced, which have excellent growth properties useful to vaccine production, yet possess an extraordinary safety profile and enhanced protective characteristics. The attenuated viruses

proliferate nearly as well as wild type virus, have highly attenuated phenotypes, as revealed by LD<sub>50</sub> values, are unusually effective in providing protective immunity against challenge by dengue virus of the same strain, and also provide protective immunity against challenge by dengue virus of other strains.

[0052] In certain embodiments of the invention, the attenuated dengue viruses of the invention comprise a recoded pre-membrane (prM)/Envelope (E) encoding region. In embodiments wherein the C, NS1, NS2, NS3, NS4, or NS5 protein encoding regions are not recoded does not exclude mutations and other variations in those sequences, but only means that any mutations or variations made in those sequences have little or no effect on attenuation. Little or no effect on attenuation includes one or both of the following: 1) The mutations or variations in the C, NS1, NS2, NS3, NS4, or NS5 encoding regions do not reduce viral replication or viral infectivity more than 20% when the variant C, NS1, NS2, NS3, NS4, or NS5 encoding region is the only variant in a test dengue virus; 2) Mutations or variations in any of the C, NS1, NS2, NS3, NS4, or NS5 encoding regions represent fewer than 10% of the nucleotides in that coding sequence. If specifically provided for in the claims, little or no effect on attenuation includes one or both of the following: 1) The mutations or variations in the C, NS1, NS2, NS3, NS4, or NS5 encoding regions do not reduce viral replication or viral infectivity more than 10% when the variant C, NS1, NS2, NS3, NS4, or NS5 encoding region is the only variant in a test dengue virus; 2) Mutations or variations in any of the C, NS1, NS2, NS3, NS4, or NS5 encoding regions represent fewer than 5% of the nucleotides in that coding sequence.

[0053] In various embodiments, viruses of the invention are attenuated. In embodiments of the invention, compared to wild type, the viruses are at least 10 fold attenuated, at least 50 fold attenuated, or at least 100 fold attenuated, or at least 200 fold attenuated, or at least 500 fold attenuated, or at least 1000 fold attenuated, or at least 2000 fold attenuated in the AG129 mouse model compared to a wild type virus having proteins of the same amino acid sequence but encoded by a different nucleotide sequence.

[0054] The attenuated viruses are also highly protective against wild type virus of the same strain. In embodiments of the invention, the protective dose (PD<sub>50</sub>) of the viruses is, when measured by a mouse model, such as exemplified herein.

[0055] The attenuated viruses of the invention also exhibit a large margin of safety (i.e., the difference between LD<sub>50</sub> and PD<sub>50</sub>), thus have high safety factors, defined herein as the ratio of LD<sub>50</sub>/PD<sub>50</sub>. In certain embodiments of the invention, the safety factor is at least 10<sup>2</sup>, or at least 10<sup>3</sup>, or at least 10<sup>4</sup>, or at least 10<sup>5</sup>, or at least 2×10<sup>5</sup>, or at least 3×10<sup>5</sup>, or at least 4×10<sup>5</sup> or at least 5×10<sup>5</sup>, or at least 10<sup>6</sup>, or at least 2×10<sup>6</sup>, or at least 3×10<sup>6</sup>, or at least 4×10<sup>6</sup>, or at least 5×10<sup>6</sup>. In certain embodiments, the safety factor is from 10<sup>2</sup> to 10<sup>3</sup>, or from 10<sup>3</sup> to 10<sup>4</sup>, or from 10<sup>4</sup> to 10<sup>5</sup>, or from 10<sup>5</sup> to 10<sup>6</sup>.

[0056] The attenuated viruses of the invention are also highly protective against heterologous strains of the dengue virus within the same serotype. In certain embodiments of the invention, the protective dose (PD<sub>50</sub>) of an attenuated virus of the invention is less than 1000 PFU, or less than 750 PFU, or less than 500 PFU, or less than 200 PFU, or less than 100 PFU, or less than 50 PFU when measured by a mouse model, such as exemplified herein.

[0057] The recoding of E protein encoding sequences of the attenuated viruses of the invention have been made or can be made by one of skill in the art in light of disclosure discussed herein. According to the invention, nucleotide substitutions are engineered in multiple locations in the E coding sequence, wherein the substitutions introduce a plurality of synonymous codons into the genome. In certain embodiments, the synonymous codon substitutions alter codon bias, codon pair bias, the density of infrequent codons or infrequently occurring codon pairs, RNA secondary structure, CG and/or TA (or UA) dinucleotide content, C+G content, translation frameshift sites, translation pause sites, the presence or absence of microRNA recognition sequences or any combination thereof, in the genome. The codon substitutions may be engineered in multiple locations distributed throughout the E coding sequence, or in the multiple locations restricted to a portion of the E coding sequence. Because of the large number of defects (i.e., nucleotide substitutions) involved, the invention provides a means of producing stably attenuated viruses and live vaccines.

[0058] As discussed further below, in some embodiments, a virus coding sequence is recoded by substituting one or more codon with synonymous codons used less frequently in the dengue host (e.g., mammals, humans, mosquitoes). In some embodiments, a virus coding sequence is recoded by substituting one or more codons with synonymous codons used less frequently in the dengue virus. In certain embodiments, the number of codons substituted with synonymous codons is at least 5. In some embodiments, at least 10, or at least 20 codons are substituted with synonymous codons. In some embodiments, the number of codons substituted with synonymous codons is at least 30, or at least 40, or at least 50, or at least 75, or at least 100, or at least 125, or at least 150, or at least 175.

[0059] In some embodiments, virus codon pairs are recoded to reduce (i.e., lower the value of) codon-pair bias. In certain embodiments, codon-pair bias is reduced by identifying a codon pair in an E coding sequence having a codon-pair score that can be reduced and reducing the codon-pair bias by substituting the codon pair with a codon pair that has a lower codon-pair score. In some embodiments, this substitution of codon pairs takes the form of rearranging existing codons of a sequence. In some such embodiments, a subset of codon pairs is substituted by rearranging a subset of synonymous codons. In other embodiments, codon pairs are substituted by maximizing the number of rearranged synonymous codons. It is noted that while rearrangement of codons leads to codon-pair bias that is reduced (made more negative) for the virus coding sequence overall, and the rearrangement results in a decreased CPS at many locations, there may be accompanying CPS increases at other locations, but on average, the codon pair scores, and thus the CPB of the modified sequence, is reduced. In some embodiments, recoding of codons or codon-pairs can take into account altering the G+C content of the E coding sequence. In some embodiments, recoding of codons or codon-pairs can take into account altering the frequency of CG and/or TA dinucleotides in the E coding sequence.

[0060] In certain embodiments, the recoded E protein-encoding sequence has a codon pair bias less than  $-0.05$ , or less than  $-0.06$ , or less than  $-0.07$ , or less than  $-0.08$ , or less than  $-0.09$ , or less than  $-0.1$ , or less than  $-0.11$ , or less than  $-0.12$ , or less than  $-0.13$ , or less than  $-0.14$ , or less than  $-0.15$ , or less than  $-0.16$ , or less than  $-0.17$ , or less than  $-0.18$ , or less than  $-0.19$ , or less than  $-0.2$ , or less than  $-0.25$ , or less than  $-0.3$ , or less than  $-0.35$ , or less than  $-0.4$ , or less than  $-0.45$ , or less than  $-0.5$ . In certain embodiments, the codon pair bias

of the recoded E protein encoding sequence is reduced by at least 0.05, or at least 0.06, or at least 0.07, or at least 0.08, or at least 0.09, or at least 0.1, or at least 0.11, or at least 0.12, or at least 0.13, or at least 0.14, or at least 0.15, or at least 0.16, or at least 0.17, or at least 0.18, or at least 0.19, or at least 0.2, or at least 0.25, or at least 0.3, or at least 0.35, or at least 0.4, or at least 0.45, or at least 0.5, compared to the parent E protein encoding sequence from which it is derived. In certain embodiments, it is in comparison to an E protein encoding sequence from which the calculation is to be made; for example, the E protein encoding sequence of a wild type virus.

[0061] In certain embodiments, rearrangement of synonymous codons of the E protein-encoding sequence provides a codon-pair bias reduction of at least 0.05, or at least 0.06, or at least 0.07, or at least 0.08, or at least 0.09, or at least 0.1, or at least 0.11, or at least 0.12, or at least 0.13, or at least 0.14, or at least 0.15, or at least 0.16, or at least 0.17, or at least 0.18, or at least 0.19, or at least 0.2, or at least 0.25, or at least 0.3, or at least 0.35, or at least 0.4, or at least 0.45, or at least 0.5, compared to the parent E protein encoding sequence from which it is derived. In certain embodiments, it is in comparison to an E protein encoding sequence from which the calculation is to be made; for example, the E protein encoding sequence of a wild type virus.

[0062] Usually, these substitutions and alterations are made and reduce expression of the encoded virus proteins without altering the amino acid sequence of the encoded protein. In certain embodiments, the invention also includes alterations in the E coding sequence that result in substitution of non-synonymous codons and amino acid substitutions in the encoded protein, which may or may not be conservative. In various embodiments, there are up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotide substitutions.

[0063] Most amino acids are encoded by more than one codon. See the genetic code in Table 1. For instance, alanine is encoded by GCU, GCC, GCA, and GCG. Three amino acids (Leu, Ser, and Arg) are encoded by six different codons, while only Trp and Met have unique codons. “Synonymous” codons are codons that encode the same amino acid. Thus, for example, CUU, CUC, CUA, CUG, UUA, and UUG are synonymous codons that code for Leu. Synonymous codons are not used with equal frequency. In general, the most frequently used codons in a particular organism are those for which the cognate tRNA is abundant, and the use of these codons enhances the rate and/or accuracy of protein translation. Conversely, tRNAs for the rarely used codons are found at relatively low levels, and the use of rare codons is thought to reduce translation rate and/or accuracy.

Table 1. Genetic Code

| U | C   | A   | G    |      |   |
|---|-----|-----|------|------|---|
| U | Phe | Ser | Tyr  | Cys  | U |
|   | Phe | Ser | Tyr  | Cys  | C |
|   | Leu | Ser | STOP | STOP | A |
|   | Leu | Ser | STOP | Trp  | G |
| C | Leu | Pro | His  | Arg  | U |
|   | Leu | Pro | His  | Arg  | C |
|   | Leu | Pro | Gln  | Arg  | A |
|   | Leu | Pro | Gln  | Arg  | G |
| A | Ile | Thr | Asn  | Ser  | U |
|   | Ile | Thr | Asn  | Ser  | C |
|   | Ile | Thr | Lys  | Arg  | A |
|   | Met | Thr | Lys  | Arg  | G |

|   |     |     |     |     |   |
|---|-----|-----|-----|-----|---|
| G | Val | Ala | Asp | Gly | U |
|   | Val | Ala | Asp | Gly | C |
|   | Val | Ala | Glu | Gly | A |
|   | Val | Ala | Glu | Gly | G |

<sup>a</sup> The first nucleotide in each codon encoding a particular amino acid is shown in the left-most column; the second nucleotide is shown in the top row; and the third nucleotide is shown in the right-most column.

#### *Codon Bias*

[0064] As used herein, a “rare” codon is one of at least two synonymous codons encoding a particular amino acid that is present in an mRNA at a significantly lower frequency than the most frequently used codon for that amino acid. Thus, the rare codon may be present at about a 2-fold lower frequency than the most frequently used codon. Preferably, the rare codon is present at least a 3-fold, more preferably at least a 5-fold, lower frequency than the most frequently used codon for the amino acid. Conversely, a “frequent” codon is one of at least two synonymous codons encoding a particular amino acid that is present in an mRNA at a significantly higher frequency than the least frequently used codon for that amino acid. The frequent codon may be present at about a 2-fold, preferably at least a 3-fold, more preferably at least a 5-fold, higher frequency than the least frequently used codon for the amino acid. For example, human genes use the leucine codon CTG 40% of the time, but use the synonymous CTA only 7% of the time (see Table 2). Thus, CTG is a frequent codon, whereas CTA is a rare codon. Roughly consistent with these frequencies of usage, there are 6 copies in the genome for the gene for the tRNA recognizing CTG, whereas there are only 2 copies of the gene for the tRNA recognizing CTA. Similarly, human genes use the frequent codons TCT and TCC for serine 18% and 22% of the time, respectively, but the rare codon TCG only 5% of the time. TCT and TCC are read, via wobble, by the same tRNA, which has 10 copies of its gene in the genome, while TCG is read by a tRNA with only 4 copies. It is well known that those mRNAs that are very actively translated are strongly biased to use only the most frequent codons. This includes genes for ribosomal proteins and glycolytic enzymes. On the other hand, mRNAs for relatively non-abundant proteins may use the rare codons.

Table 2. Codon usage in *Homo sapiens* (source: [www.kazusa.or.jp/codon/](http://www.kazusa.or.jp/codon/))

| Amino Acid | Codon | Number     | /1000 | Fraction |
|------------|-------|------------|-------|----------|
| Gly        | GGG   | 636457.00  | 16.45 | 0.25     |
| Gly        | GGA   | 637120.00  | 16.47 | 0.25     |
| Gly        | GGT   | 416131.00  | 10.76 | 0.16     |
| Gly        | GGC   | 862557.00  | 22.29 | 0.34     |
| Glu        | GAG   | 1532589.00 | 39.61 | 0.58     |
| Glu        | GAA   | 1116000.00 | 28.84 | 0.42     |
| Asp        | GAT   | 842504.00  | 21.78 | 0.46     |
| Asp        | GAC   | 973377.00  | 25.16 | 0.54     |
| Val        | GTG   | 1091853.00 | 28.22 | 0.46     |
| Val        | GTA   | 273515.00  | 7.07  | 0.12     |
| Val        | GTT   | 426252.00  | 11.02 | 0.18     |
| Val        | GTC   | 562086.00  | 14.53 | 0.24     |
| Ala        | GCG   | 286975.00  | 7.42  | 0.11     |
| Ala        | GCA   | 614754.00  | 15.89 | 0.23     |
| Ala        | GCT   | 715079.00  | 18.48 | 0.27     |
| Ala        | GCC   | 1079491.00 | 27.90 | 0.40     |
| Arg        | AGG   | 461676.00  | 11.93 | 0.21     |

|     |     |            |       |      |
|-----|-----|------------|-------|------|
| Arg | AGA | 466435.00  | 12.06 | 0.21 |
| Ser | AGT | 469641.00  | 12.14 | 0.15 |
| Ser | AGC | 753597.00  | 19.48 | 0.24 |
| Lys | AAG | 1236148.00 | 31.95 | 0.57 |
| Lys | AAA | 940312.00  | 24.30 | 0.43 |
| Asn | AAT | 653566.00  | 16.89 | 0.47 |
| Asn | AAC | 739007.00  | 19.10 | 0.53 |
| Met | ATG | 853648.00  | 22.06 | 1.00 |
| Ile | ATA | 288118.00  | 7.45  | 0.17 |
| Ile | ATT | 615699.00  | 15.91 | 0.36 |
| Ile | ATC | 808306.00  | 20.89 | 0.47 |
| Thr | ACG | 234532.00  | 6.06  | 0.11 |
| Thr | ACA | 580580.00  | 15.01 | 0.28 |
| Thr | ACT | 506277.00  | 13.09 | 0.25 |
| Thr | ACC | 732313.00  | 18.93 | 0.36 |
| Trp | TGG | 510256.00  | 13.19 | 1.00 |
| End | TGA | 59528.00   | 1.54  | 0.47 |
| Cys | TGT | 407020.00  | 10.52 | 0.45 |
| Cys | TGC | 487907.00  | 12.61 | 0.55 |
| End | TAG | 30104.00   | 0.78  | 0.24 |
| End | TAA | 38222.00   | 0.99  | 0.30 |
| Tyr | TAT | 470083.00  | 12.15 | 0.44 |
| Tyr | TAC | 592163.00  | 15.30 | 0.56 |
| Leu | TTG | 498920.00  | 12.89 | 0.13 |
| Leu | TTA | 294684.00  | 7.62  | 0.08 |
| Phe | TTT | 676381.00  | 17.48 | 0.46 |
| Phe | TTC | 789374.00  | 20.40 | 0.54 |
| Ser | TCG | 171428.00  | 4.43  | 0.05 |
| Ser | TCA | 471469.00  | 12.19 | 0.15 |
| Ser | TCT | 585967.00  | 15.14 | 0.19 |
| Ser | TCC | 684663.00  | 17.70 | 0.22 |
| Arg | CGG | 443753.00  | 11.47 | 0.20 |
| Arg | CGA | 239573.00  | 6.19  | 0.11 |
| Arg | CGT | 176691.00  | 4.57  | 0.08 |
| Arg | CGC | 405748.00  | 10.49 | 0.18 |
| Gln | CAG | 1323614.00 | 34.21 | 0.74 |
| Gln | CAA | 473648.00  | 12.24 | 0.26 |
| His | CAT | 419726.00  | 10.85 | 0.42 |
| His | CAC | 583620.00  | 15.08 | 0.58 |
| Leu | CTG | 1539118.00 | 39.78 | 0.40 |
| Leu | CTA | 276799.00  | 7.15  | 0.07 |
| Leu | CTT | 508151.00  | 13.13 | 0.13 |
| Leu | CTC | 759527.00  | 19.63 | 0.20 |
| Pro | CCG | 268884.00  | 6.95  | 0.11 |
| Pro | CCA | 653281.00  | 16.88 | 0.28 |
| Pro | CCT | 676401.00  | 17.48 | 0.29 |
| Pro | CCC | 767793.00  | 19.84 | 0.32 |

[0065] The propensity for highly expressed genes to use frequent codons is called “codon bias.” A gene for a ribosomal protein might use only the 20 to 25 most frequent of the 61 codons, and have a high codon bias (a codon bias close to 1), while a poorly expressed gene might use all 61 codons, and have little or no codon bias (a codon bias close to 0). It is thought that the frequently used codons are codons where larger amounts of

the cognate tRNA are expressed, and that use of these codons allows translation to proceed more rapidly, or more accurately, or both. The PV capsid protein, for example, is very actively translated, and has a high codon bias.

#### *Codon Pair Bias*

[0066] In addition, a given organism has a preference for the nearest codon neighbor of a given codon A, referred to a bias in codon pair utilization. A change of codon pair bias, without changing the existing codons, can influence the rate of protein synthesis and production of a protein.

[0067] Codon pair bias may be illustrated by considering the amino acid pair Ala-Glu, which can be encoded by 8 different codon pairs. If no factors other than the frequency of each individual codon (as shown in Table 2) are responsible for the frequency of the codon pair, the expected frequency of each of the 8 encodings can be calculated by multiplying the frequencies of the two relevant codons. For example, by this calculation the codon pair GCA-GAA would be expected to occur at a frequency of 0.097 out of all Ala-Glu coding pairs ( $0.23 \times 0.42$ ; based on the frequencies in Table 2). In order to relate the expected (hypothetical) frequency of each codon pair to the actually observed frequency in the human genome the Consensus CDS (CCDS) database of consistently annotated human coding regions, containing a total of 14,795 human genes, was used. This set of genes is the most comprehensive representation of human coding sequences. Using this set of genes, the frequencies of codon usage were re-calculated by dividing the number of occurrences of a codon by the number of all synonymous codons coding for the same amino acid. As expected the frequencies correlated closely with previously published ones such as the ones given in Table 2. Slight frequency variations are possibly due to an oversampling effect in the data provided by the codon usage database at Kazusa DNA Research Institute ([www.kazusa.or.jp/codon/codon.html](http://www.kazusa.or.jp/codon/codon.html)) where 84949 human coding sequences were included in the calculation (far more than the actual number of human genes). The codon frequencies thus calculated were then used to calculate the expected codon-pair frequencies by first multiplying the frequencies of the two relevant codons with each other (see Table 3 expected frequency), and then multiplying this result with the observed frequency (in the entire CCDS data set) with which the amino acid pair encoded by the codon pair in question occurs. In the example of codon pair GCA-GAA, this second calculation gives an expected frequency of 0.098 (compared to 0.097 in the first calculation using the Kazusa dataset). Finally, the actual codon pair frequencies as observed in a set of 14,795 human genes was determined by counting the total number of occurrences of each codon pair in the set and dividing it by the number of all synonymous coding pairs in the set coding for the same amino acid pair (Table 3; observed frequency). Frequency and observed/expected values for the complete set of 3721 ( $61^2$ ) codon pairs, based on the set of 14,795 human genes, are provided herewith as Table 3.

*Table 3. Codon Pair Scores Exemplified by the Amino Pair Ala-Glu*

| amino acid pair | codon pair | expected frequency | observed frequency | obs/exp ratio |
|-----------------|------------|--------------------|--------------------|---------------|
| AE              | GCAGAA     | 0.098              | 0.163              | 1.65          |
| AE              | GCAGAG     | 0.132              | 0.198              | 1.51          |
| AE              | GCCGAA     | 0.171              | 0.031              | 0.18          |
| AE              | GCCGAG     | 0.229              | 0.142              | 0.62          |
| AE              | GCGGAA     | 0.046              | 0.027              | 0.57          |

|       |        |       |       |      |
|-------|--------|-------|-------|------|
| AE    | GCGGAG | 0.062 | 0.089 | 1.44 |
| AE    | GCTGAA | 0.112 | 0.145 | 1.29 |
| AE    | GCTGAG | 0.150 | 0.206 | 1.37 |
| Total |        | 1.000 | 1.000 |      |

[0068] If the ratio of observed frequency/expected frequency of the codon pair is greater than one the codon pair is said to be overrepresented. If the ratio is smaller than one, it is said to be underrepresented. In the example, the codon pair GCA-GAA is overrepresented 1.65 fold while the coding pair GCC-GAA is more than 5-fold underrepresented.

[0069] Many other codon pairs show very strong bias; some pairs are under-represented, while other pairs are over-represented. For instance, the codon pairs GCCGAA (AlaGlu) and GATCTG (AspLeu) are three- to six-fold under-represented (the preferred pairs being GCAGAG and GACCTG, respectively), while the codon pairs GCCAAG (AlaLys) and AATGAA (AsnGlu) are about two-fold over-represented. It is noteworthy that codon pair bias has nothing to do with the frequency of pairs of amino acids, nor with the frequency of individual codons. For instance, the under-represented pair GATCTG (AspLeu) happens to use the most frequent Leu codon, (CTG).

[0070] As discussed more fully below, codon pair bias takes into account the score for each codon pair in a coding sequence averaged over the entire length of the coding sequence. According to the invention, codon pair bias is determined by

$$CPB = \sum_{i=1}^k \frac{CPS_i}{K-1}$$

[0071] Accordingly, similar codon pair bias for a coding sequence can be obtained, for example, by minimized codon pair scores over a subsequence or moderately diminished codon pair scores over the full length of the coding sequence.

#### *Calculation of Codon Pair Bias*

[0072] Every individual codon pair of the possible 3721 non-“STOP” containing codon pairs (e.g., GTT-GCT) carries an assigned “codon pair score,” or “CPS” that is specific for a given “training set” of genes. The CPS of a given codon pair is defined as the log ratio of the observed number of occurrences over the number that would have been expected in this set of genes (in this example the human genome). Determining the actual number of occurrences of a particular codon pair (or in other words the likelihood of a particular amino acid pair being encoded by a particular codon pair) is simply a matter of counting the actual number of occurrences of a codon pair in a particular set of coding sequences. Determining the expected number, however, requires additional calculations. The expected number is calculated so as to be independent of both amino acid frequency and codon bias similarly to Gutman and Hatfield. That is, the expected frequency is calculated based on the relative proportion of the number of times an amino acid is encoded by a specific codon. A positive CPS value signifies that the given codon pair is statistically over-represented, and a negative CPS indicates the pair is statistically under-represented in the human genome.

[0073] To perform these calculations within the human context, the most recent Consensus CDS (CCDS) database of consistently annotated human coding regions, containing a total of 14,795 genes, was used. This data set provided codon and codon pair, and thus amino acid and amino-acid pair frequencies on a genomic scale.

[0074] The paradigm of Federov et al. (2002), was used to further enhanced the approach of Gutman and Hatfield (1989). This allowed calculation of the expected frequency of a given codon pair independent of codon frequency and non-random associations of neighboring codons encoding a particular amino acid pair. The detailed equations used to calculate CPB are disclosed in WO 2008/121992 and WO 2011/044561, which are incorporated by reference.

$$S(P_{ij}) = \ln \left( \frac{N_o(P_{ij})}{N_e(P_{ij})} \right) = \ln \left( \frac{N_o(P_{ij})}{F(C_i)F(C_j)N_o(X_{ij})} \right)$$

[0075] In the calculation,  $P_{ij}$  is a codon pair occurring with a frequency of  $N_o(P_{ij})$  in its synonymous group.  $C_i$  and  $C_j$  are the two codons comprising  $P_{ij}$ , occurring with frequencies  $F(C_i)$  and  $F(C_j)$  in their synonymous groups respectively. More explicitly,  $F(C_i)$  is the frequency that corresponding amino acid  $X_i$  is coded by codon  $C_i$  throughout all coding regions and  $F(C_i) = N_o(C_j)/N_o(X_i)$ , where  $N_o(C_i)$  and  $N_o(X_i)$  are the observed number of occurrences of codon  $C_i$  and amino acid  $X_i$  respectively.  $F(C_j)$  is calculated accordingly. Further,  $N_o(X_{ij})$  is the number of occurrences of amino acid pair  $X_{ij}$  throughout all coding regions. The codon pair bias score  $S(P_{ij})$  of  $P_{ij}$  was calculated as the log-odds ratio of the observed frequency  $N_o(P_{ij})$  over the expected number of occurrences of  $N_e(P_{ij})$ .

[0076] Using the formula above, it was then determined whether individual codon pairs in individual coding sequences are over- or under-represented when compared to the corresponding genomic  $N_e(P_{ij})$  values that were calculated by using the entire human CCDS data set. This calculation resulted in positive  $S(P_{ij})$  score values for over-represented and negative values for under-represented codon pairs in the human coding regions.

[0077] The “combined” codon pair bias of an individual coding sequence was calculated by averaging all codon pair scores according to the following formula:

$$S(P_{ij}) = \sum_{l=1}^k \frac{S(P_{ij})_l}{k-1}$$

[0078] The codon pair bias of an entire coding region is thus calculated by adding all of the individual codon pair scores comprising the region and dividing this sum by the length of the coding sequence.

#### *Calculation of Codon Pair Bias, Implementation of Algorithm to Alter Codon-Pair Bias.*

[0079] An algorithm was developed to quantify codon pair bias. Every possible individual codon pair was given a “codon pair score”, or “CPS”. CPS is defined as the natural log of the ratio of the observed over the expected number of occurrences of each codon pair over all human coding regions, where humans represent the host species of the instant vaccine virus to be recoded.

$$CPS = \ln \left( \frac{F(AB)_o}{\frac{F(A) \times F(B)}{F(X) \times F(Y)} \times F(XY)} \right)$$

[0080] Although the calculation of the observed occurrences of a particular codon pair is straightforward (the actual count within the gene set), the expected number of occurrences of a codon pair requires additional calculation. We calculate this expected number to be independent both of amino acid frequency and of codon bias, similar to Gutman and Hatfield. That is, the expected frequency is calculated based on the relative proportion of the number of times an amino acid is encoded by a specific codon. A positive CPS value signifies that the given codon pair is statistically over-represented, and a negative CPS indicates the pair is statistically under-represented in the human genome.

[0081] Using these calculated CPSs, any coding region can then be rated as using over- or under-represented codon pairs by taking the average of the codon pair scores, thus giving a Codon Pair Bias (CPB) for the entire gene.

$$CPB = \sum_{i=1}^k \frac{CPS_i}{k-1}$$

[0082] The CPB has been calculated for all annotated human genes using the equations shown and plotted (FIG. 1). Each point in the graph corresponds to the CPB of a single human gene. The peak of the distribution has a positive codon pair bias of 0.07, which is the mean score for all annotated human genes. Also, there are very few genes with a negative codon pair bias. Equations established to define and calculate CPB were then used to manipulate this bias.

Algorithm for Reducing Codon-Pair Bias to Attenuate.

[0083] Recoding of protein-encoding sequences may be performed with or without the aid of a computer, using, for example, a gradient descent, or simulated annealing, or other minimization routine. An example of the procedure that rearranges codons present in a starting sequence can be represented by the following steps:

- (1) Obtain wildtype viral genome sequence.
- (2) Select protein coding sequences to target for attenuated design.
- (3) Lock down known or conjectured DNA segments with non-coding functions.
- (4) Select desired codon distribution for remaining amino acids in redesigned proteins.
- (5) Perform random shuffle of at least two synonymous unlocked codon positions and calculate codon-pair score.
- (6) Further reduce (or increase) codon-pair score optionally employing a simulated annealing procedure.
- (7) Inspect resulting design for excessive secondary structure and unwanted restriction site:
  - if yes-> go to step (5) or correct the design by replacing problematic regions with wildtype sequences and go to step (8).
- (8) Synthesize DNA sequence corresponding to virus design.
- (9) Create viral construct and assess viral phenotype:

- if too attenuated, prepare subclone construct and go to 9;
- if insufficiently attenuated, go to 2.

[0084] Attenuation of viruses by reducing codon pair bias is disclosed in WO 2008/121992 and WO 2011/044561, which are incorporated by reference.

[0085] Methods of obtaining full-length Flavivirus or dengue genome sequence or codon pair deoptimized sequences embedded in a wild-type Flavivirus or dengue genome sequence can include for example, constructing an infectious cDNA clone, using an overlap extension PCR strategy, or long PCR-based fusion strategy.

### *Modified Flavivirus*

[0086] Various embodiments of the invention provide for a modified Flavivirus virus in which expression of viral proteins is reduced compared to a parent virus. The reduction in expression is the result of recoding the prM, or envelope (E) region or both. In some embodiments the parent virus is a wild type Flavivirus, and thus, comparisons are made to the wild-type virus or sequences in the wild-type virus.

[0087] In various embodiments, the E protein-encoding sequence is recoded by reducing the codon pair bias or codon usage bias of the protein-encoding sequence. In various embodiments, reducing the codon-pair bias comprises identifying a codon pair in the parent protein-encoding sequence having a codon-pair score that can be reduced, and reducing the codon-pair bias by substituting the codon pair with a codon pair that has a lower codon-pair score. In other embodiments, reducing the codon-pair bias comprises rearranging the codons of a parent protein-encoding sequence.

[0088] In various embodiments, each of the recoded prM/E protein-encoding sequence have a codon pair bias less than, -0.05, -0.1, or less than -0.2, or less than -0.3, or less than -0.4.

[0089] In certain embodiments, the recoded prM protein-encoding sequence has a codon pair bias less than -0.05, or less than -0.06, or less than -0.07, or less than -0.08, or less than -0.09, or less than -0.1, or less than -0.11, or less than -0.12, or less than -0.13, or less than -0.14, or less than -0.15, or less than -0.16, or less than -0.17, or less than -0.18, or less than -0.19, or less than -0.2, or less than -0.25, or less than -0.3, or less than -0.35, or less than -0.4, or less than -0.45, or less than -0.5.

[0090] In certain embodiments, the recoded E protein-encoding sequence has a codon pair bias less than -0.05, or less than -0.06, or less than -0.07, or less than -0.08, or less than -0.09, or less than -0.1, or less than -0.11, or less than -0.12, or less than -0.13, or less than -0.14, or less than -0.15, or less than -0.16, or less than -0.17, or less than -0.18, or less than -0.19, or less than -0.2, or less than -0.25, or less than -0.3, or less than -0.35, or less than -0.4, or less than -0.45, or less than -0.5.

[0091] In certain embodiments, the codon pair bias of the recoded prM protein encoding sequence is reduced by at least 0.05, or at least 0.06, or at least 0.07, or at least 0.08, or at least 0.09, or at least 0.1, or at least 0.11, or at least 0.12, or at least 0.13, or at least 0.14, or at least 0.15, or at least 0.16, or at least 0.17, or at least 0.18, or at least 0.19, or at least 0.2, or at least 0.25, or at least 0.3, or at least 0.35, or at least 0.4, or at least 0.45, or at least 0.5, compared to the parent prM protein encoding sequence from which it is derived.

[0092] In certain embodiments, the codon pair bias of the recoded E protein encoding sequence is reduced by at least 0.05, or at least 0.06, or at least 0.07, or at least 0.08, or at least 0.09, or at least 0.1, or at least 0.11, or at least 0.12, or at least 0.13, or at least 0.14, or at least 0.15, or at least 0.16, or at least 0.17, or at least 0.18, or at least 0.19, or at least 0.2, or at least 0.25, or at least 0.3, or at least 0.35, or at least 0.4, or at least 0.45, or at least 0.5, compared to the parent E protein encoding sequence from which it is derived. In certain embodiments, it is in comparison to an E protein encoding sequence from which the calculation is to be made; for example, the E protein encoding sequence of a wild type virus.

[0093] In various embodiments, the E protein-encoding sequence is recoded by increasing the number of CpG or UpA di nucleotides compared to its parent virus. In various embodiments, the E protein-encoding sequence is recoded by modifying G+C content compared to its parent virus.

[0094] In various embodiments, the E protein-encoding sequence is recoded by replacing one or more codons with synonymous codons that are less frequent in the viral host; for example, human.

[0095] In various embodiments, the E protein-encoding sequence is recoded by replacing one or more codons with synonymous codons that are less frequent in the virus itself.

[0096] In some embodiments, the number of codons substituted in the prM protein encoding sequence with synonymous codons is at least 5, or at least 10, or at least 30, or at least 30, or at least 40, or at least 50, or at least 75, or at least 100, or at least 150.

[0097] In some embodiments, the number of codons substituted in the E protein encoding sequence with synonymous codons is at least 5, or at least 10, or at least 30, or at least 30, or at least 40, or at least 50, or at least 75, or at least 100, or at least 125 or at least 150, or at least 175.

[0098] In various embodiments, the parent virus is a Flavivirus selected from the group consisting of dengue fever virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, Spondweni virus, Zika virus, Saint Louis encephalitis virus, and Powassan virus. In various embodiments, the parent virus is a natural isolate. In various embodiments, the parent virus is a mutant of a natural isolate.

#### *Modified Dengue Viruses*

[0099] Various embodiments of the present invention provide for modified dengue viruses as the modified Flavivirus.

[0100] In various embodiments, a modified dengue virus is provided in which expression of viral proteins is reduced compared to a parent virus, wherein the reduction in expression is the result of recoding the prM, or envelope (E) region, or both. In some embodiments, a parent dengue virus is a wild-type dengue virus. As such, comparisons can be made in reference to a wild-type dengue virus.

[0101] In various embodiments, one or both of the E protein-encoding sequence is recoded by reducing the codon pair bias or codon usage bias of the protein-encoding sequence. In various embodiments, reducing the codon-pair bias comprises identifying a codon pair in the parent protein-encoding sequence having a codon-pair score that can be reduced, and reducing the codon-pair bias by substituting the codon pair with a codon pair

that has a lower codon-pair score. In various embodiments, reducing the codon-pair bias comprises rearranging the codons of a parent protein-encoding sequence.

[0102] Various embodiments of the present invention provide for a modified dengue virus, comprising a recoded prM protein, a recoded envelope (E) protein, or both, wherein the recoded prM protein has a reduced codon pair bias compared to its parent prM protein encoding sequence, or has at least 5 codons substituted with synonymous codons less frequently used, or has an increased number of CpG or UpA di-nucleotides compared its parent prM protein encoding sequence, and wherein the recoded E protein has a reduced codon pair bias compared to its parent E protein encoding sequence, or has at least 5 codons substituted with synonymous codons less frequently used, or has an increased number of CpG or UpA di-nucleotides compared its parent E protein encoding sequence. In various embodiments, “its parent protein encoding sequence” is “a wild-type dengue protein encoding sequence”, for example, “a wild-type dengue E protein encoding sequence”, “a wild-type dengue prM protein encoding sequence”.

[0103] In various embodiments, the expression of the prM protein or E protein or both are reduced compared to its parent dengue virus.

[0104] In various embodiments, the recoded prM protein has a reduced codon pair bias compared to its parent prM protein encoding sequence. In various embodiments, the codon pair bias of the recoded prM encoding sequence is reduced by at least 0.05. In certain embodiments, the codon pair bias of the recoded prM protein encoding sequence of the dengue virus is reduced by at least 0.06, or at least 0.07, or at least 0.08, or at least 0.09, or at least 0.1, or at least 0.11, or at least 0.12, or at least 0.13, or at least 0.14, or at least 0.15, or at least 0.16, or at least 0.17, or at least 0.18, or at least 0.19, or at least 0.2, or at least 0.25, or at least 0.3, or at least 0.35, or at least 0.4, or at least 0.45, or at least 0.5, compared to the parent dengue virus' prM protein encoding sequence from which it is derived. In certain embodiments, it is in comparison to a prM protein encoding sequence from which the calculation is to be made; for example, a prM protein encoding sequence of a wild-type dengue virus.

[0105] In various embodiments, the recoded prM protein has at least 5 codons substituted with synonymous codons less frequently used. In various embodiments, the recoded prM protein has at least 10, 20, 25, 30, 35, 40, 45, 50 or 55 codons substituted with synonymous codons less frequently used. In some embodiments, the substitution with synonymous codons less frequently used are one that are less frequently used in the viral host; for example, human, mosquitos. In some embodiments, the substitution with synonymous codons less frequently used are one that are less frequently used in the virus itself.

[0106] In various embodiments, the recoded prM protein has an increased number of CpG or UpA di-nucleotides compared its parent prM protein encoding sequence. In various embodiments, the recoded prM protein has an increase of 15-55 CpG or UpA di-nucleotides compared its parent prM protein encoding sequence. In various embodiments, the recoded prM protein has an increase of about 15, 20, 25, 30, 35, 40, 45 or 55 CpG or UpA di-nucleotides compared its parent prM protein encoding sequence.

[0107] In various embodiments, the recoded E protein has a reduced codon pair bias compared to its parent E protein encoding sequence. In various embodiments, the codon pair bias of E protein-encoding sequence is

reduced by at least 0.05 compared to its parent E protein encoding sequence. In certain embodiments, the codon pair bias of the recoded E protein encoding sequence of the dengue virus is reduced by at least 0.06, or at least 0.07, or at least 0.08, or at least 0.09, or at least 0.1, or at least 0.11, or at least 0.12, or at least 0.13, or at least 0.14, or at least 0.15, or at least 0.16, or at least 0.17, or at least 0.18, or at least 0.19, or at least 0.2, or at least 0.25, or at least 0.3, or at least 0.35, or at least 0.4, or at least 0.45, or at least 0.5, compared to its parent dengue virus' E protein encoding sequence from which it is derived. In certain embodiments, it is in comparison to an E protein encoding sequence from which the calculation is to be made; for example, the E protein encoding sequence of a wild-type dengue virus.

[0108] In various embodiments, the recoded E protein has at least 5 codons substituted with synonymous codons less frequently used. In various embodiments, the recoded E protein has at least 10, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, or 175 codons substituted with synonymous codons less frequently used. In some embodiments, the substitution with synonymous codons less frequently used are one that are less frequently used in the viral host; for example, human, mosquitos. In some embodiments, the substitution with synonymous codons less frequently used are one that are less frequently used in the virus itself.

[0109] In various embodiments, the recoded E protein has an increased number of CpG or UpA dinucleotides compared its parent E protein encoding sequence. In various embodiments, the recoded prM protein has an increase of 5-12 CpG or UpA dinucleotides compared its parent E protein encoding sequence. In various embodiments, the recoded prM protein has an increase of about 5, 6, 7, 8, 9, 10 11 or 12 CpG or UpA dinucleotides compared its parent E protein encoding sequence.

[0110] In various embodiments, each of the recoded prM or E protein-encoding sequence has a codon pair bias of less than -0.05. In certain embodiments, the recoded prM protein encoding sequence has a codon pair bias of less than -0.05, or less than -0.06, or less than -0.07, or less than -0.08, or less than -0.09, or less than -0.1, or less than -0.11, or less than -0.12, or less than -0.13, or less than -0.14, or less than -0.15, or less than -0.16, or less than -0.17, or less than -0.18, or less than -0.19, or less than -0.2, or less than -0.25, or less than -0.3, or less than -0.35, or less than -0.4, or less than -0.45, or less than -0.5. In certain embodiments, the recoded E protein encoding sequence has a codon pair bias of less than -0.05, or less than -0.06, or less than -0.07, or less than -0.08, or less than -0.09, or less than -0.1, or less than -0.11, or less than -0.12, or less than -0.13, or less than -0.14, or less than -0.15, or less than -0.16, or less than -0.17, or less than -0.18, or less than -0.19, or less than -0.2, or less than -0.25, or less than -0.3, or less than -0.35, or less than -0.4, or less than -0.45, or less than -0.5.

[0111] In various embodiments, the modified dengue virus is selected from type 1, type 2, type 3, type 4 or a combination thereof. For example, type 1 and type 2, type 1 and type 3, type 1 and type 4, type 2 and type 3, type 2 and type 4, or type 3 and type 4. Additional examples are type 1, type 2 and type 3; type 1, type 3 and type 4; or type 2, type 3 and type 4. In various embodiments, the modified dengue virus is a modified tetravalent dengue virus (i.e., type 1, type 2, type 3 and type 4).

## *Methods*

[0112] Various embodiments provide for a method of eliciting an immune response in a subject, comprising: administering to the subject an effective dose of a composition comprising a modified dengue virus of the present invention as described above and herein.

[0113] In various embodiments, the immune response is a protective immune response, and a prophylactically effective or therapeutically effective dose from  $10^3$  to  $10^7$  of a vaccine composition of claims is administered. In various embodiments, the immune response is a protective immune response, and a prophylactically effective or therapeutically effective dose of  $10^3$ ,  $10^4$ ,  $10^5$ ,  $10^6$ , or  $10^7$  of a vaccine composition of claims is administered. In various embodiments, the method further comprises administering to the subject at least one adjuvant. In various embodiments, the immune response is cross-protective against a heterologous dengue virus.

[0114] Various embodiments provide for a method of eliciting an immune response in a subject in need thereof, comprising: administering a prime dose of (i) an attenuated dengue virus produced by a method other than codon-pair deoptimization or codon deoptimization, or increasing of CpG or UpA di-nucleotides, or (ii) a modified dengue virus comprising a recoded prM protein, a recoded envelope (E) protein, or both, wherein the recoded prM protein has a reduced codon pair bias compared to its parent prM protein encoding sequence, or has at least 5 codons substituted with synonymous codons less frequently used, or has an increased number of CpG or UpA di-nucleotides compared its parent prM protein encoding sequence, and wherein the recoded E protein has a reduced codon pair bias compared to its parent E protein encoding sequence, or has at least 5 codons substituted with synonymous codons less frequently, or has an increased number of CpG or UpA di-nucleotides compared its parent E protein encoding sequence; and administering one or more boost dose of (i) the attenuated dengue virus produced by methods other than codon-pair deoptimization, or codon deoptimization, or increasing of CpG or UpA di-nucleotides or (ii) the modified dengue virus to the subject in need thereof, wherein at least the prime dose or the one or more boost dose is the modified dengue virus.

[0115] In various embodiments, a first of the one or more boost dose is administered about 2 weeks after the prime dose.

[0116] In various embodiments, the expression of the prM protein or E protein or both are reduced compared to its parent dengue virus. In various embodiments the parent dengue virus is a wild-type dengue virus.

[0117] In various embodiments, the recoded prM protein has a reduced codon pair bias compared to its parent prM protein encoding sequence. In various embodiments, the codon pair bias of the recoded prM encoding sequence is reduced by at least 0.05. In certain embodiments, the codon pair bias of the recoded prM protein encoding sequence of the dengue virus is reduced by at least 0.06, or at least 0.07, or at least 0.08, or at least 0.09, or at least 0.1, or at least 0.11, or at least 0.12, or at least 0.13, or at least 0.14, or at least 0.15, or at least 0.16, or at least 0.17, or at least 0.18, or at least 0.19, or at least 0.2, or at least 0.25, or at least 0.3, or at least 0.35, or at least 0.4, or at least 0.45, or at least 0.5, compared to the parent dengue virus' prM protein encoding sequence from which it is derived. In certain embodiments, it is in comparison to a prM protein

encoding sequence from which the calculation is to be made; for example, a prM protein encoding sequence of a wild-type dengue virus.

[0118] In various embodiments, the recoded prM protein has at least 5 codons substituted with synonymous codons less frequently used. In various embodiments, the recoded prM protein has at least 10, 20, 25, 30, 35, 40, 45, 50 or 55 codons substituted with synonymous codons less frequently used. In some embodiments, the substitution with synonymous codons less frequently used are one that are less frequently used in the viral host; for example, human, mosquitos. In some embodiments, the substitution with synonymous codons less frequently used are one that are less frequently used in the virus itself.

[0119] In various embodiments, the recoded prM protein has an increased number of CpG or UpA di-nucleotides compared its parent prM protein encoding sequence. In various embodiments, the recoded prM protein has an increase of 15-55 CpG or UpA di-nucleotides compared its parent prM protein encoding sequence. In various embodiments, the recoded prM protein has an increase of about 15, 20, 25, 30, 35, 40, 45 or 55 CpG or UpA di-nucleotides compared its parent prM protein encoding sequence. In certain embodiments, it is in comparison to a prM protein encoding sequence from which the calculation is to be made; for example, a prM protein encoding sequence of a wild-type dengue virus.

[0120] In various embodiments, the recoded E protein has a reduced codon pair bias compared to its parent E protein encoding sequence. In various embodiments, the codon pair bias of E protein-encoding sequence is reduced by at least 0.05 compared to its parent E protein encoding sequence. In certain embodiments, the codon pair bias of the recoded E protein encoding sequence of the dengue virus is reduced by at least 0.06, or at least 0.07, or at least 0.08, or at least 0.09, or at least 0.1, or at least 0.11, or at least 0.12, or at least 0.13, or at least 0.14, or at least 0.15, or at least 0.16, or at least 0.17, or at least 0.18, or at least 0.19, or at least 0.2, or at least 0.25, or at least 0.3, or at least 0.35, or at least 0.4, or at least 0.45, or at least 0.5, compared to its parent dengue virus' E protein encoding sequence from which it is derived. In certain embodiments, it is in comparison to an E protein encoding sequence from which the calculation is to be made; for example, the E protein encoding sequence of a wild-type dengue virus.

[0121] In various embodiments, the recoded E protein has at least 5 codons substituted with synonymous codons less frequently used. In various embodiments, the recoded E protein has at least 10, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, or 175 codons substituted with synonymous codons less frequently used. In some embodiments, the substitution with synonymous codons less frequently used are one that are less frequently used in the viral host; for example, human, mosquitos. In some embodiments, the substitution with synonymous codons less frequently used are one that are less frequently used in the virus itself.

[0122] In various embodiments, the recoded E protein has an increased number of CpG or UpA di-nucleotides compared its parent E protein encoding sequence. In various embodiments, the recoded prM protein has an increase of 5-12 CpG or UpA di-nucleotides compared its parent E protein encoding sequence. In various embodiments, the recoded prM protein has an increase of about 5, 6, 7, 8, 9, 10 11 or 12 CpG or UpA di-nucleotides compared its parent E protein encoding sequence. In certain embodiments, it is in comparison to an

E protein encoding sequence from which the calculation is to be made; for example, the E protein encoding sequence of a wild-type dengue virus.

[0123] In various embodiments, each of the recoded prM or E protein-encoding sequence has a codon pair bias of less than -0.05. In certain embodiments, the recoded prM protein encoding sequence has a codon pair bias of less than -0.05, or less than -0.06, or less than -0.07, or less than -0.08, or less than -0.09, or less than -0.1, or less than -0.11, or less than -0.12, or less than -0.13, or less than -0.14, or less than -0.15, or less than -0.16, or less than -0.17, or less than -0.18, or less than -0.19, or less than -0.2, or less than -0.25, or less than -0.3, or less than -0.35, or less than -0.4, or less than -0.45, or less than -0.5. In certain embodiments, the recoded E protein encoding sequence has a codon pair bias of less than -0.05, or less than -0.06, or less than -0.07, or less than -0.08, or less than -0.09, or less than -0.1, or less than -0.11, or less than -0.12, or less than -0.13, or less than -0.14, or less than -0.15, or less than -0.16, or less than -0.17, or less than -0.18, or less than -0.19, or less than -0.2, or less than -0.25, or less than -0.3, or less than -0.35, or less than -0.4, or less than -0.45, or less than -0.5.

[0124] In various embodiments, the modified dengue virus is selected from type 1, type 2, type 3, type 4 or a combination thereof. For example, type 1 and type 2, type 1 and type 3, type 1 and type 4, type 2 and type 3, type 2 and type 4, or type 3 and type 4. Additional examples are type 1, type 2 and type 3; type 1, type 3 and type 4; or type 2, type 3 and type 4. In various embodiments, the modified dengue virus is a modified tetravalent dengue virus (i.e., type 1, type 2, type 3 and type 4).

#### *Methods of Making Modified Flavivirus virus genome*

[0125] Various embodiments of the present invention provide for a method of making a modified Flavivirus virus genome. The method comprises obtaining the nucleotide sequence encoding the envelope protein of a Flavivirus virus and the nucleotide sequence encoding the nonstructural 3 proteins of a Flavivirus virus; recoding the envelope encoding nucleotide sequence to reduce protein expression and recoding the nonstructural protein 3-encoding nucleotide sequence to reduce protein expression, and substituting a nucleic acid having the recoded envelope-encoding nucleotide sequence and a nucleic acid having the recoded nonstructural protein 3-encoding nucleotide sequence into a parent Flavivirus virus genome to make a modified Flavivirus virus genome; whereby expression of the recoded envelope-encoding nucleotide sequence and expression of the recoded nonstructural protein 3-encoding nucleotide sequence is reduced compared to the parent virus.

[0126] Various embodiments of the present invention provide for a method of making a modified dengue virus genome comprising: obtaining the nucleotide sequence encoding the envelope protein of a dengue virus and the nucleotide sequence encoding the nonstructural 3 proteins of a dengue virus; recoding the envelope encoding nucleotide sequence to reduce protein expression and recoding the nonstructural protein 3-encoding nucleotide sequence to reduce protein expression, and substituting a nucleic acid having the recoded envelope-encoding nucleotide sequence and a nucleic acid having the recoded nonstructural protein 3-encoding nucleotide sequence into a parent dengue virus genome to make a modified dengue virus genome; whereby expression of

the recoded envelope-encoding nucleotide sequence and expression of the recoded nonstructural protein 3-encoding nucleotide sequence is reduced compared to the parent virus.

[0127] Various embodiments of the present invention provide for a method of making a modified dengue virus genome comprising: obtaining a nucleotide sequence encoding the envelope protein of a dengue virus; recoding the envelope encoding nucleotide sequence to reduce protein expression, and substituting a nucleic acid having the recoded envelope-encoding nucleotide sequence into a parent dengue virus genome to make a modified dengue virus genome; whereby expression of the recoded envelope-encoding nucleotide sequence is reduced compared to the parent virus.

[0128] According to various embodiments the invention, viral attenuation is accomplished by reducing expression viral proteins through codon pair deoptimization of E coding sequence. One way to reduce expression of the coding sequences is by a reduction in codon pair bias, but other methods can also be used, alone or in combination. While codon bias may be changed, adjusting codon pair bias is particularly advantageous. For example, attenuating a virus through codon bias generally requires elimination of common codons, and so the complexity of the nucleotide sequence is reduced. In contrast, codon pair bias reduction or minimization can be accomplished while maintaining far greater sequence diversity, and consequently greater control over nucleic acid secondary structure, annealing temperature, and other physical and biochemical properties.

[0129] Codon pair bias of a protein-encoding sequence (i.e., an open reading frame) is calculated as set forth above and described in Coleman et al., 2008.

[0130] Viral attenuation and induction or protective immune responses can be confirmed in ways that are well known to one of ordinary skill in the art, including but not limited to, the methods and assays disclosed herein. Non-limiting examples include plaque assays, growth measurements, reduced lethality in test animals, and protection against subsequent infection with a wild type virus.

[0131] In various embodiments, the invention provides viruses that are highly attenuated, and induce immunity against a plurality of dengue types and/or subtypes. Such dengue virus varieties include viruses in serogroups 1, 2, 3, and 4. Examples of attenuated dengue protein coding sequences are provided below.

*Table 4. Reduced-Expression Dengue Virus Genes*

| Gene          | WT Coding Sequence<br>SEQ ID NO: | Recoded Coding Sequence<br>SEQ ID NO: |
|---------------|----------------------------------|---------------------------------------|
| DENV1-WT      | 1                                |                                       |
| DENV1-E-Min   |                                  | 2                                     |
| DENV2-WT      | 3                                |                                       |
| DENV2-E-Min   |                                  | 4                                     |
| DENV3-WT      | 5                                |                                       |
| DENV3-E-Min   |                                  | 6                                     |
| DENV4-WT      | 7                                |                                       |
| DENV4-E-Min   |                                  | 8                                     |
| DENV1-E-W/Min |                                  | 9                                     |
| DENV2-E-W/Min |                                  | 10                                    |
| DENV3-E-W/Min |                                  | 11                                    |
| DENV4-E-W/Min |                                  | 12                                    |

*Compositions*

[0132] Various embodiments provide for a Flavivirus composition for inducing an immune response in a subject, which comprises the modified Flavivirus of the present invention as described herein.

[0133] Various embodiments provide for a Flavivirus vaccine composition for inducing a protective immune response in a subject, which comprises the modified Flavivirus of the present invention as described herein.

[0134] Various embodiments provide for a modified dengue virus composition for inducing an immune response in a subject, comprising a modified dengue virus of the present invention as described above and herein, and a pharmaceutically acceptable excipient or carrier.

[0135] Various embodiments provide for a dengue vaccine composition for inducing a protective immune response in a subject, comprising a modified dengue virus of the present invention as described above and herein, and a pharmaceutically acceptable excipient or carrier.

[0136] In various embodiments, the modified dengue virus is selected from type 1, type 2, type 3, type 4 or a combination thereof.

[0137] In various embodiments, the modified dengue virus is a type 1 and type 2 modified dengue virus; a type 1 and type 3 modified dengue virus; a type 1 and type 4 modified dengue virus; a type 2 and type 3 modified dengue virus; a type 2 and type 4 modified dengue virus; a type 3 and type 4 modified dengue virus.

[0138] In various embodiments, the modified dengue virus is a type 1, type 2 and type 3 modified dengue virus; a type 1, type 2 and type 4 modified dengue virus; a type 1, type 3 and type 4 modified dengue virus; or a type 2, type 3 and type 4 modified dengue virus.

[0139] In various embodiments, the modified dengue virus modified tetravalent dengue virus; (type 1, type 2, type 3 and type 4).

[0140] Non-limiting examples of wild-type and modified dengue viruses are herein:

[0141] SEQ ID NO:1 – DENV-1-VN-BID-V1774-2007(WT)

AGTTGTTAGTCTACGTGGACCGACAAGAACAGTTTTCGAATCGGAAGCTTGCTTAACGTAGTTCT  
AACAGTTTTTTTATTAGAGAGCAGATCTCTGATGAACAACCAACGGAAAAAGACGGCTCGACCG  
TCTTTCAATATGCTGAAACGCGCGAGAAACCGCGTGTCAACTGTTTCACAGTTGGCGAAGAGA  
TTCTCAAAAGGATTGCTCTCAGGCCAAGGACCCATGAAATTGGTGATGGCTTTCATAGCATTCC  
TAAGATTTCTAGCCATACCCCCAACAGCAGGAATTTTGGCTAGATGGGGTTCATTCAAGAAGA  
GTGGAGCGATCAAAGTGCTACGGGGTTTCAAGAAAGAAATCTCAAACATGTTGAATATAATGA  
ATAGAAGGAAAAGATCTGTGACCATGCTCCTTATGCTGATGCCTACAGCCTTGGCGTTCCATTT  
GACTACACGAGGGGGAGAGCCGCACATGATAGTCAGCAAGCAGGAAAGAGGAAAGTCACTCT  
TGTTTAAGACCTCAGCAGGTGTCAACATGTGCACCCTTATAGCGATGGATTTGGGAGAGTTATG  
TGAGGACACAATGACTTACAAATGCCCTCGAATCACTGAACTGAACCAGATGACGTTGATTG  
TTGGTGTAATGCCACAGACACATGGGTGACCTATGGAACATGTTCCCAAACCTGGCGAGCACCG  
ACGAGACAAACGTTCCGTCGCACTGGCCCCACACGTGGGACTTGGTTTGGAAACAAGAACCGA

AACGTGGATGTCCTCTGAAGGCGCTTGGAACAGATACAAAGAGTGGAGACTTGGGCCCTGA  
GACACCCAGGATTCACGGTGATAGCCCTTTTTCTAGCACATGCCATAGGAACATCCATCACCC  
AGAAAGGGATTATTTTCATTTTGTTAATGCTGGTAACACCATCCATGGCCATGCGATGCGTGGG  
AATAGGCAGCAGGGACTTCGTGGAAGGACTGTGAGGAGCAACTTGGGTAGATGTGGTACTGG  
AACATGGAAGTTGCGTCACCACCATGGCAAAAGACAAACCAACATTGGACATTGAACTCTTGA  
AGACGGAAGTCACAAACCCTGCCGTCTGCGCAAACTGTGCATTGAAGCTAAAATATCAAACA  
CCACCACCGACTCAAGATGTCCAACACAAGGAGAAGCCACACTAGTGGAAGAACAAGACGCG  
AACTTTGTGTGTCGACGAACGTTTGTGGACAGAGGCTGGGGCAATGGCTGTGGCCTCTTCGGA  
AAAGGAAGCCTAATAACGTGTGCAAAGTTCAAGTGTGTGACAAAACCTGGAAGGAAAGATAGT  
TCAATATGAGAACTTGAAATATTCAGTAATAGTCACCGTTCACACCGGAGACCAGCATCAAGT  
GGGAAATGAAAGCACAGAACATGGGACAACTGCAACTATAACACCTCAAGCTCCTACGACGG  
AAATACAGCTGACCGACTACGGAGCTCTTACATTGGATTGTTACCTAGAACAGGACTAGACT  
TTAATGAAATGGTGTGTTGACAATGAAAGAAAAATCATGGCTAGTCCACAAACAATGGTTTT  
TAGACCTACCACTGCCTTGGACCTCGGGAGCTTCAACATCACAAGAGACTTGGAACAGACAAG  
ATTTGCTGGTGACATTTAAGACAGCTCATGCAAAGAAGCAGGAAGTAGTCGTACTAGGATCAC  
AAGAAGGAGCAATGCACACTGCGTTGACCGGAGCGACAGAAATCCAAACGTCTGGAACGACA  
ACAATTTTTGCAGGACACTTGAAATGCAGACTAAAGATGGACAACTGACTCTAAAAGGGATG  
TCATATGTGATGTGCACAGGCTCATTCAAGCTAGAGAAAGAAGTGGCTGAGACCCAGCATGGA  
ACCGTTCTAGTGCAGATTAAATACGAAGGAACAGATGCACCATGCAAGATCCCTTTTTCGACC  
CAAGATGAAAAAGGAGTAACCCAGAATGGGAGATTGATAACAGCTAACCCCATAGTTACTGA  
CAAAGAAAAACCAGTCAACATTGAGGCAGAACCGCCCTTTGGTGAGAGTTACATCGTAATAGG  
AGCAGGTGAAAAAGCTTTGAAACTAAGCTGGTTCAAGAAAGGAAGCAGCATAGGGAAAATGT  
TTGAGGCAACTGCCAGAGGAGCACGAAGGATGGCCATACTGGGAGACACCGCATGGGACTTT  
GGTTCTATAGGAGGAGTGTTACGTCTGTTGGAATAATAGTACACCAGATTTTTGGAAGTGCAT  
ATGGAGTTTTTGTTCAGCGGTGTTTCCTGGACCATGAAAATAGGAATAGGGGTCTGCTGACATG  
GCTGGGATTAACTCAAGGAGCACGTCCCTTTTCGATGACGTGCATTGCAGTTGGCCTAGTAAC  
ACTATACCTAGGAGTCATGGTTCAAGCGGATTCAAGGATGTGTAATTAATTGGAAGGTAGAGA  
ACTCAAGTGTGGAAGTGGCATTTTTTGTACCAATGAAGTTCACACTTGGACAGAGCAATACAA  
ATTTCAAGCTGACTCCCCTAAGAGACTATCAGCAGCCATCGGGAAGGCATGGGAGGAGGGTGT  
GTGTGGAATTCGATCAGCAACTCGTCTCGAGAACATCATGTGGAAGCAAATATCAAATGAACT  
GAATCACATCTTACTTGAAAATGATATGAAATTCACAGTGGTTGTAGGAGATGTTGCTGGGAT  
CTTGGCTCAAGGAAAGAAAATGATTAGGCCACAACCCATGGAATACAAATACTCGTGGA  
GCTGGGGAAAGGCTAAAATCATAGGGGCAGATGTACAGAACACCACCTTCATCATCGATGGCC  
CAAACACCCCAGAATGCCCTGATGACCAAAGAGCATGGAACATTTGGGAAGTTGAGGACTAT  
GGATTTGGAATTTTCACGACAAACATATGGCTGAAATTGCGTGATTCTACACCCAAGTGTGTG  
ACCACCGGCTAATGTCAGCTGCCATCAAGGACAGCAAGGCAGTTCACGCTGACATGGGGTACT  
GGATAGAAAGTGAAAAGAACGAGACCTGGAAGCTGGCAAGAGCCTCATTCATAGAAGTTAAA

ACATGTATCTGGCCAAAATCCCACACTCTATGGAGCAATGGAGTTCTGGAAAGTGAAATGATA  
ATTCCAAAGATCTATGGAGGACCAATATCTCAGCACAACCTACAGACCAGGATATTTTACACAA  
GCAGCAGGGCCCGTGGCACCTAGGCAAGTTGGAACCTGGATTTTGTGTTGTGAGGGTACCACA  
GTTGTTGTGGATGAACATTGTGGAAATCGAGGACCATCTCTTAGGACCACAACAGTCACAGGA  
AAGATAATTCATGAATGGTGTTCAGATCTTGCACGCTACCACCCTTACGTTTCAGAGGAGAA  
GATGGGTGCTGGTACGGTATGGAAATCAGACCAGTCAAGGAAAAGGAAGAAAATCTAGTCAA  
ATCAATGGTCTCTGCAGGGTCAGGGGAAGTGGACAGCTTTTCACTAGGACTGCTATGCATATC  
AATAATGATCGAGGAGGTGATGAGATCCAGATGGAGTAGAAGAATGCTGATGACTGGAACAC  
TGGCTGTGTTCTTCCCTTCTCATAATGGGACAATTGACATGGAACGATCTGATCAGATTATGCAT  
CATGGTTGGAGCCAACGCTTCCGACAGGATGGGGATGGGAACGACGTACCTAGCCCTGATGGC  
CACTTTTAAAATGAGACCGATGTTTCGCTGTAGGGCTATTATTTTCGCAGACTAACATCCAGAGAA  
GTTCTTCTTCTAACAATTGGATTGAGTCTAGTGGCATCTGTGGAGTTACCAAATTCCTTGGAGG  
AGCTGGGGGATGGACTTGCAATGGGCATTATGATTTTAAAATTATTGACTGACTTTCAATCACA  
TCAGCTGTGGGCTACCTTGCTGTCCTTGACATTTATCAAAACAACGTTTTCTTGCCTACGCAT  
GGAAGACAATGGCTATGGTACTGTCAATTGTATCTCTCTTCCCTTTATGCCTGTCCACGACCTC  
CCAAAAACAACATGGCTTCCGGTGCTATTGGGATCCCTTGGATGCAAACCACTAACCATGTTT  
CTTATAGCAGAAAACAAAATCTGGGGAAGGAGAAGTTGGCCCCTCAATGAAGGAATCATGGC  
TGTTGGAATAGTCAGCATCCTACTAAGTTCCTCTCAAAAATGATGTACCGCTAGCTGGGCCA  
CTAATAGCTGGAGGCATGCTAATAGCATGTTATGTTATATCTGGAAGCTCAGCCGACCTATCAT  
TAGAGAAAGCGGCTGAGGTCTCCTGGGAAGAAGAAGCAGAACACTCTGGTGCCTCACACAAC  
ATATTAGTGGAAGTCCAAGATGATGGAACCATGAAGATAAAGGATGAAGAGAGAGATGACAC  
GCTAACCATTTCTCCTTAAAGCAACTCTGTTAGCAGTTTCAGGGGTGTACCCATTATCAATACCA  
GCGACCCTTTTCGTGTGGTACTTTTGGCAGAAAAAGAAACAGAGATCTGGAGTGTTATGGGAC  
ACACCCAGCCCTCCAGAAGTGGAAGAGCAGTTCTTGATGATGGTATCTATAGAATTATGCAG  
AGAGGACTGTTGGGCAGGTCCCAAGTAGGGGTAGGAGTTTTCCAAGAAAACGTGTTCCACACA  
ATGTGGCATGTCACCAGGGGAGCTGTACTCATGTATCAAGGGAAGAGATTGGAACCGAGCTGG  
GCCAGTGTCAAAAAAGACCTGATCTCATATGGAGGAGGTGGAGGCTTCAAGGATCCTGGAAC  
ACAGGAGAAGAAGTGCAGGTGATTGCTGTTGAACCAGGGAAAAACCCCAAAAATGTACAAAC  
AGCGCCGGGCACCTTTAAGACCCCTGAAGGTGAAGTTGGAGCCATTGCCCTAGACTTTAAACC  
TGGCACATCTGGATCTCCCATCGTGAACAGAGAAGGAAAAATAGTAGGTCTTTATGGAAATGG  
AGTAGTGACAACAAGTGGAACCTACGTCAGTGCCATAGCTCAAGCCAAAGCATCACAAGAAG  
GGCCCCTACCAGAGATTGAAGACGAGGTGTTTAGGAAAAGAACTTAACAATAATGGACCTA  
CATCCAGGATCGGGGAAAAACAAGAAGATATCTTCCAGCCATAGTCCGTGAGGCCATAAAAAG  
GAAGCTGCGCACACTAATCCTGGCTCCCACAAGGGTTGTCGCTTCCGAAATGGCAGAGGCGCT  
CAAGGGAATGCCAATAAGGTACCAAACAACAGCAGTGAAGAGTGAACATACAGGAAAAGAG  
ATAGTTGACCTCATGTGTCACGCCACTTTCACCATGCGCCTCCTGTCTCCCGTAAGAGTTCCCA  
ATTACAACATGATCATCATGGATGAAGCACATTTCAACGATCCATCCAGTATAGCGGCCAGAG

GGTACATCTCAACCCGAGTGGGCATGGGTGAAGCAGCTGCAATCTTCATGACAGCCACTCCCC  
CAGGATCAGTGGAGGCCTTTCCACAGAGCAACGCAGTTATCCAAGATGAGGAAAGAGACATT  
CCTGAGAGATCATGGAACCTCAGGCTATGAGTGGATCACTGACTTCCCAGGTAAAACAGTTTGG  
TTTGTTCOAAGCATTAAATCAGGAAATGACATTGCCAACTGCTTAAGAAAGAATGGGAAACGG  
GTGATTCAATTGAGCAGGAAAACCTTTGATACAGAGTACCAAAAAACAAAAACAACGACTG  
GGACTACGTCGTCACAACAGACATCTCCGAAATGGGAGCAAATTTCCGAGCCGACAGGGTGAT  
AGACCCAAGACGGTGTCTGAAACCGGTAATACTAAAAGATGGTCCAGAGCGTGTCAATTTTAGC  
AGGACCAATGCCAGTGACTGTGGCCAGTGCCGCTCAGAGGAGAGGAAGAATTGGAAGGAACC  
ACAATAAGGAAGGTGATCAGTACATCTACATGGGACAGCCTTTAAACAACGATGAAGATCAC  
GCTCACTGGACAGAAGCAAAAATGCTCCTTGATAATATAAACACACCAGAAGGGATTATCCCA  
GCCCTCTTTGAGCCAGAGAGAGAAAAGAGTGCAGCAATAGACGGGGAATACAGACTGCGGGG  
TGAAGCAAGGAAAACGTTTGTGGAGCTCATGAGAAGAGGAGATCTACCTGTCTGGCTATCCTA  
CAAAGTTGCCTCAGAAGGCTTCCAGTACTCTGACAGAAGATGGTGCTTTGACGGGGAAAGGAA  
CAACCAGGTGTTGGAGGAGAACATGGACGTGGAGATCTGGACAAAAGAAGGAGAAAGAAAG  
AAACTACGACCCCGCTGGCTGGATGCCAGAACATACTCAGACCCACTAGCCCTGCGCGAGTTT  
AAAGAGTTTGCAGCAGGGAGAAGAAGCGTCTCAGGTGATTTAATATTAGAAATAGGGAAGCT  
TCCACAACACTTGACGCAAAGGGCCCAGAATGCCCTGGACAACCTGGTTATGTTGCACAACCTC  
CGAACAAGGAGGCAGAGCCTATAGACATGCAATGGAAGAAGTCCAGACACCATAGAAACGT  
TGATGCTCCTAGCTTTGATAGCTGTGTTAACTGGTGGAGTGACACTGTTCTTCCTATCAGGAAG  
GGGCTAGGGAAAACATCTATCGGCCTACTCTGCGTAATGGCTTCAAGCGTACTGCTATGGAT  
GGCCAGTGTGGAGCCCCATTGGATAGCGGCCTCCATCATACTGGAGTTCTTCCTGATGGTGCTG  
CTTATTCCAGAGCCAGACAGACAACGCACTCCGCAGGACAACCAGCTGGCATATGTGGTGATA  
GGTTTGTATTTCATGATACTGACAGTAGCAGCCAATGAGATGGGACTGCTGGAACCACAAAG  
AAAGACTTAGGGATTGGCCATGTGGCTGTTGAAAATCACACCATGCCGCAATGCTGGACGTA  
GACTTACATCCAGCTTCAGCCTGGACCCTCTATGCAGTGGCCACAACAATTATCACTCCCATGA  
TGAGGCACACAATCGAAAACACAACGGCAAACATTTCCCTGACAGCCATTGCAAACCAGGCA  
GCTATATTGATGGGACTTGACAAAGGATGGCCAATATCGAAGATGGACATAGGAGTTCCACTT  
CTCGCCTTGGGGTGCTATTCCCAGGTGAATCCACTGACGCTGACAGCGGCGGTATTGATGCTAG  
TGGCTCATTACGCCATAATTGGACCTGGACTGCAAGCAAAAGCTACTAGAGAAGCTCAAAAAA  
GGACAGCGGCCCGAATAATGAAAAATCCAACCGTTGATGGAATTGTTGCAATAGATTGGACC  
CTGTGGTTTATGATGCAAAATTTGAAAAACAACCTAGGCCAAATAATGTTGTTGATACTATGCAC  
ATCACAGATCCTCTTGATGCGGACTACATGGGCCTTGTGCGAGTCCATCACACTGGCCACTGG  
ACCTCTGACCACGCTTTGGGAGGGATCTCCAGGAAAATTTTGGAACACCACGATAGCGGTTTC  
CATGGCAAACATTTTCAGAGGAAGTTATCTAGCAGGAGCAGGTCTGGCCTTCTCATTAAATGAA  
ATCTCTAGGAGGAGGTAGGAGAGGCACGGGAGCCCAAGGGGAAACACTGGGAGAGAAATGG  
AAAAGACAGCTGAACCAACTGAGCAAGTCAGAATTTAACACCTATAAAAGGAGTGGGATTAT  
GGAAGTGGACAGATCCGAAGCCAAGAGGGATTGAAAAGAGGAGAAACAACCAAACATGCA

GTGTCGAGAGGAACCGCTAAACTGAGGTGGTTCGTGGAGAGGAACCTTGTGAAACCAGAAGG  
GAAAGTCATAGACCTCGGTTGTGGAAGAGGTGGCTGGTCATACTATTGCGCTGGGCTGAAGAA  
AGTCACAGAAGTGAAGGGGTATACAAAAGGAGGACCTGGACATGAGGAACCAATCCCAATGG  
CGACCTATGGATGGAACCTAGTAAAGCTGCACTCTGGGAAAGACGTATTTTTATACCACCTG  
AGAAATGTGACACCCTTTTGTGTGATATTGGTGAGTCCTCTCCAAACCCAACTATAGAGGAAG  
GAAGAACGCTACGCGTCCTAAAGATGGTGGAACCATGGCTCAGAGGAAACCAATTTTGCATAA  
AAATTCTGAATCCCTACATGCCAAGTGTGGTGGAACTCTGGAGCAAATGCAAAGAAAACATG  
GAGGAATGCTAGTGCGAAATCCACTTTCAAGAAATTCTACTCATGAAATGTATTGGGTTTCATG  
TGGAACAGGAAACATTGTGTGTCAGCAGTAAACATGACATCTAGAATGTTGCTAAATCGATTAC  
AATGGCTCACAGGAAACCAACATATGAAAGAGACGTGGACCTAGGCGCCGGAACAAGACATG  
TGGCAGTGGAACCAGAGGTAGCCAACCTAGATATCATTGGCCAGAGGATAGAGAACATAAAA  
CATGAACATAAGTCAACATGGCATTATGATGAGGACAATCCATATAAAACATGGGCCTATCAT  
GGATCATATGAGGTCAAGCCATCAGGATCAGCCTCATCCATGGTCAATGGCGTGGTGAAACTG  
CTCACCAAACCATGGGATGTCATCCCTATGGTCACACAAATAGCCATGACTGACACTACACCC  
TTTGGACAACAGAGGGTGTTTAAAGAGAAAGTTGACACACGCACACCAAAGCAAAACGGGG  
CACAGCACAAATCATGGAGGTGACAGCCAAGTGGTTATGGGGTTTTCTTTCTAGAAACAAGAA  
ACCAAGAATTTGCACAAGAGAGGAGTTCACAAGAAAAGTTAGGTCAAACGCAGCCATTGGAG  
CAGTGTTCGTTGATGAAAATCAATGGAAGTCAAGCAAAAGAAAGCAGTGGAAGATGAGCGGTTCT  
GGGACCTTGTGCATAGAGAGAGGGAGCTTCACAAACAGGGAAAATGTGCTACGTGTGTTTACA  
ACATGATGGGGAAGAGAGAGAAAAAGCTAGGAGAGTTCCGAAAGGCAAAAGGAAGTCGTGC  
AATATGGTACATGTGGTTGGGAGCACGCTTTCTAGAGTTCGAAGCTCTTGGTTTCATGAACGAA  
GATCACTGGTTTCAGCAGAGAGAATTCAGTCAAGCGGAGTGGAAGGAGAAGGACTCCACAAACT  
TGGATATATACTCAGAGACATATCAAAGATTCCAGGGGGAAACATGTATGCAGATGACACAGC  
CGGATGGGATACAAGGATAACAGAGGATGACCTTCAGAATGAGGCCAGAATTACTGACATCA  
TGGAACCCGAACATGCCCTCCTGGCTAAGTCAATCTTCAAGTTAACCTACCAAATAAGGTGG  
TAAGGGTACAGAGACCAGCAAAAAATGGAACCGTGATGGATGTCATATCCAGACGTGACCAG  
AGAGGAAGTGGTCAGGTCGGAACCTTATGGCTTAAACACTTTACCAACATGGAAGCCCAGCTG  
ATAAGACAAATGGAGTCTGAGGGAATCTTTTACCCAGCGAATTAGAGACCCCAAATTTAGCC  
GAGAGAGTTCTCGACTGGCTGGAAAAATATGGCGTCGAAAGGCTGAAAAGAATGGCAATCAG  
CGGAGATGACTGCGTAGTGAAACCAATTGATGATAGGTTTGCAACAGCCTTGACAGCTCTGAA  
TGATATGGGAAAAGTAAGAAAAGATATACCACAATGGGAACCTTCAAAAGGATGGAATGATT  
GGCAACAAGTGCCTTTTTGTTCACACCACTTCCACCAGCTGATTATGAAGGATGGGAGGGAAA  
TAGTGGTGCCATGCCGCAACCAAGATGAACTTGTGGGTAGGGCTAGAGTATCACAAGGTGCTG  
GATGGAGCCTGAGAGAACTGCATGCCTAGGCAAGTCATATGCACAAATGTGGCAGCTGATGT  
ACTTCCACAGGAGAGACCTGAGACTAGCCGCTAATGCTATCTGTTTCAGCCGTTCCAGTTGATTG  
GATCCCAACCAGCCGTACCACCTGGTCGATCCATGCCCATCACCAATGGATGACAACAGAAGA  
CATGCTGTCAAGTGTGGAATAGGGTTTGGATAGAGGAAAACCCATGGATGGAGGACAAAACCC

ACATATCCAGTTGGGGAGATGTTCCATATTTAGGAAAAAGGGAAGACCAATGGTGTGGATCCC  
 TGATAGGCTTAACAGCAAGGGCCACCTGGGGCCACCAACATACAAGTGGCCATAAACCAAGTG  
 AGAAGACTAATTGGGAATGAGAATTATCTAGATTACATGACATCAATGAAGAGATTCAAGAAC  
 GAGAGTGATCCCGAAGGGGCACTCTGGTGAGTCAACACATTTACAAAATAAAGGAAAATAAG  
 AAATCAAACAAGGCAAGAAGTCAGGCCGGATTAAGCCATAGTACGGTAAGAGCTATGCTGCC  
 TGTGAGCCCCGTCTAAGGACGTAAAATGAAGTCAGGCCGAAAGCCACGGCTTGAGCAAACCG  
 TGCTGCCTGTAGCTCCATCGTGGGGATGTAAAAACCTGGGAGGCTGCAACCCATGGAAGCTGT  
 ACGCATGGGGTAGCAGACTAGTGGTTAGAGGAGACCCCTCCCGAAACATAACGCAGCAGCGG  
 GGCCCAACACCAGGGGAAGCTGTACCCTGGTGGTAAGGACTAGAGGTTAGAGGAGACCCCC  
 GCATAACAATAAACAGCATATTGACGCTGGGAGAGACCAGAGATCCTGCTGTCTCTACAGCAT  
 CATTCCAGGCACAGAACGCCAGAAAATGGAATGGTGTGTTGAATCAACAGGTTCT

[0142] SEQ ID NO:2 – DENV-1-VN-BID-V1774-2007-EMin

AGTTGTTAGTCTACGTGGACCGACAAGAACAGTTTTCGAATCGGAAGCTTGCTTAACGTAGTTCT  
 AACAGTTTTTTTATTAGAGAGCAGATCTCTGATGAACAACCAACGGAAAAAGACGGCTCGACCG  
 TCTTTCAATATGCTGAAACGCGCGAGAAACCGCGTGTCAACTGTTTCACAGTTGGCGAAGAGA  
 TTCTCAAAAGGATTGCTCTCAGGCCAAGGACCCATGAAATTGGTGATGGCTTTCATAGCATTCC  
 TAAGATTTCTAGCCATAACCCCAACAGCAGGAATTTTGGCTAGATGGGGTTCATTCAAGAAGA  
 GTGGAGCGATCAAAGTGCTACGGGGTTTCAAGAAAGAAATCTCAAACATGTTGAATATAATGA  
 ATAGAAGGAAAAGATCTGTGACCATGCTCCTTATGCTGATGCCTACAGCCTTGGCGTTCCATTT  
 GACTACACGAGGGGGAGAGCCGCACATGATAGTCAGCAAGCAGGAAAGAGGAAAGTCACTCT  
 TGTTTAAGACCTCAGCAGGTGTCAACATGTGCACCCTTATAGCGATGGATTTGGGAGAGTTATG  
 TGAGGACACAATGACTTACAAATGCCCTCGAATCACTGAAACTGAACCAGATGACGTTGATTG  
 TTGGTGTAATGCCACAGACACATGGGTGACCTATGGAACATGTTCCCAAACCTGGCGAGCACCG  
 ACGAGACAAACGTTCCGTCGCACTGGCCCCACACGTGGGACTTGGTTTGGAAACAAGAACCGA  
 AACGTGGATGTCCTCTGAAGGCGCTTGGAACAGATACAAAGAGTGGAGACTTGGGCCCTGA  
 GACACCCAGGATTCACGGTGATAGCCCTTTTTCTAGCACATGCCATAGGAACATCCATCACCC  
 AGAAAGGGATTATTTTCATTTTGTTAATGCTGGTAACACCATCCATGGCCATGCGATGCGTAGG  
 GATAGGGTCACGCGATTTTCGTCTGAAGGACTATCCGGAGCGACATGGGTGACGTCGTAAGTCA  
 ACACGGATCATGCGTTACGACTATGGCTAAAGACAAACCTACACTAGACATAGAGTTACTGAA  
 AACCGAAGTTACGAATCCCGCCGTACTGCGAAAATTGTGTATCGAAGCGAAAATTAGCAATAC  
 GACTACAGACTCTAGGTGTCCTACACAAGGCGAAGCGACATTGGTCTGAAGAACAGGACGCTA  
 ACTTCGTATGTAGACGAACATTCGTCGATAGGGGGTGGGGAAACGGATGCGGATTGTTTCGGTA  
 AAGGATCACTGATTACATGCGCAAAGTTCAAATGCGTTACGAAACTGGAAGGTAAATAGTGC  
 AATACGAAAACCTAAAGTATAGCGTAATCGTTACAGTGCATACCGGAGACCAACATCAGGTCTG  
 GAAACGAATCAACCGAACACGGAACAACCGCAACAATTACACCACAGGCACCTACAACCGAA  
 ATCAACTAACCGATTACGGAGCTTTACACTAGATTGCTCACCTAGAACCGGATTGGACTTTA

ACGAAATGGTACTGTTGACTATGAAGGAGAAATCATGGTTAGTGCATAAAACAATGGTTTCTAG  
ACCTACCACTACCATGGACTAGCGGAGCGAGTACGTACAGGAAACATGGAATAGACAGGAC  
CTATTGGTGACATTTAAGACCGCACACGCTAAGAAGCAGGAAGTCGTAGTGTAGGGTCACAA  
GAGGGAGCAATGCATACCGCACTAACCGGAGCAACCGAAATACAGACTAGCGGAACTACAAC  
GATTTTTGCCGGTCACCTGAAATGTAGACTGAAGATGGACAACTGACACTTAAAGGAATGTC  
ATACGTTATGTGTACGGGATCCTTTAAGCTCGAAAAAGAGGTTGCCGAAACGCAACACGGAAC  
AGTGCTAGTGCAAATTAATATGAGGGAACCGACGCACCATGTAAGATACCGTTTAGTACGCA  
AGACGAAAAGGGCGTTACGCAAAACGGAAGACTGATTACCGCTAACCTATCGTTACAGACA  
AAGAGAAACCCGTTAACATAGAGGCCGAACCACTTTTGGCGAATCATATATAGTGATAGGCG  
CAGGCGAAAAAGCACTAAAGCTGTCATGGTTCAAAAAAGGATCTAGCATAGGGAAGATGTTC  
GAAGCAACCGCTAGGGGAGCTAGACGAATGGCAATACTGGGAGATACCGCATGGGACTTCGG  
ATCGATAGGGGGAGTGTTTACTAGCGTAGGTAAGTTGGTGCATCAGATATTCGGAACCGCATA  
CGGAGTGTTGTTTAGCGGAGTGTCATGGACTATGAAGATAGGGATAGGAGTGCTATTGACATG  
GCTCGGACTGAATTCGAGATCGACTAGCCTATCTATGACATGCATAGCCGTCGGACTGGTTAC  
ACTGTATCTAGGCGTAATGGTGCAAGCAGATTCAGGATGTGTAATTAATTGGAAAGGTAGAGA  
ACTCAAGTGTGGAAGTGGCATTTTTGTACCAATGAAGTTCACACTTGGACAGAGCAATACAA  
ATTTCAAGCTGACTCCCCTAAGAGACTATCAGCAGCCATCGGGAAGGCATGGGAGGAGGGTGT  
GTGTGGAATTCGATCAGCAACTCGTCTCGAGAACATCATGTGGAAGCAAATATCAAATGAACT  
GAATCACATCTTACTTGAAAATGATATGAAATTCACAGTGGTTGTAGGAGATGTTGCTGGGAT  
CTTGGCTCAAGGAAAGAAAATGATTAGGCCACAACCCATGGAATACAAATACTCGTGGA  
GCTGGGGAAAGGCTAAAATCATAGGGGCAGATGTACAGAACACCACCTTCATCATCGATGGCC  
CAAACACCCCAGAATGCCCTGATGACCAAAGAGCATGGAACATTTGGGAAGTTGAGGACTAT  
GGATTTGGAATTTTACGACAAACATATGGCTGAAATTGCGTGATTCTACACCCAAGTGTGTG  
ACCACCGGCTAATGTCAGCTGCCATCAAGGACAGCAAGGCAGTTCACGCTGACATGGGGTACT  
GGATAGAAAGTGAAAAGAACGAGACCTGGAAGCTGGCAAGAGCCTCATTCATAGAAGTTAAA  
ACATGTATCTGGCCAAAATCCCACACTCTATGGAGCAATGGAGTTCTGGAAAGTGAAATGATA  
ATTCCAAAGATCTATGGAGGACCAATATCTCAGCACAACCTACAGACCAGGATATTTTACACAA  
GCAGCAGGGCCGTGGCACCTAGGCAAGTTGGAACCTGGATTTTGAATTTGTGTGAGGGTACCACA  
GTTGTTGTGGATGAACATTGTGGAAATCGAGGACCATCTCTTAGGACCACAACAGTCACAGGA  
AAGATAATTCATGAATGGTGTTGCAGATCTTGCACGCTACCACCCTTACGTTTCAGAGGAGAA  
GATGGGTGCTGGTACGGTATGGAAATCAGACCAGTCAAGGAAAAGGAAGAAAATCTAGTCAA  
ATCAATGGTCTCTGCAGGGTCAGGGGAAGTGGACAGCTTTTCACTAGGACTGCTATGCATATC  
AATAATGATCGAGGAGGTGATGAGATCCAGATGGAGTAGAAGAATGCTGATGACTGGAACAC  
TGGCTGTGTTCTTCTTCTCATAATGGGACAATTGACATGGAACGATCTGATCAGATTATGCAT  
CATGGTTGGAGCCAACGCTTCCGACAGGATGGGGATGGGAACGACGTACCTAGCCCTGATGGC  
CACTTTTAAAATGAGACCGATGTTTCGCTGTAGGGCTATTATTTTCGCAGACTAACATCCAGAGAA  
GTTCTTCTTCTAACAATTGGATTGAGTCTAGTGGCATCTGTGGAGTTACCAAATTCCTTGGAGG

AGCTGGGGGATGGACTTGCAATGGGCATTATGATTTTAAAATTATTGACTGACTTTCAATCACA  
TCAGCTGTGGGCTACCTTGCTGTCCTTGACATTTATCAAAACAACGTTTTCTTGCACTACGCAT  
GGAAGACAATGGCTATGGTACTGTCAATTGTATCTCTCTTCCCTTTATGCCTGTCCACGACCTC  
CCAAAAACAACATGGCTTCCGGTGCTATTGGGATCCCTTGATGCAAACCACTAACCATGTTT  
CTTATAGCAGAAAACAAAATCTGGGGAAGGAGAAGTTGGCCCCTCAATGAAGGAATCATGGC  
TGTTGGAATAGTCAGCATCCTACTAAGTTCCTCTCAAAAATGATGTACCGCTAGCTGGGCCA  
CTAATAGCTGGAGGCATGCTAATAGCATGTTATGTTATATCTGGAAGCTCAGCCGACCTATCAT  
TAGAGAAAGCGGCTGAGGTCTCCTGGGAAGAAGAAGCAGAACACTCTGGTGCCTCACACAAC  
ATATTAGTGGAAGTCCAAGATGATGGAACCATGAAGATAAAGGATGAAGAGAGAGATGACAC  
GCTAACCATTTCTCCTTAAAGCAACTCTGTTAGCAGTTTCAGGGGTGTACCCATTATCAATACCA  
GCGACCCTTTTTCGTGTGGTACTTTTGGCAGAAAAAGAAACAGAGATCTGGAGTGTTATGGGAC  
ACACCCAGCCCTCCAGAAGTGGAAGAGCAGTTCTTGATGATGGTATCTATAGAATTATGCAG  
AGAGGACTGTTGGGCAGGTCCCAAGTAGGGGTAGGAGTTTTCCAAGAAAACGTGTTCCACACA  
ATGTGGCATGTCACCAGGGGAGCTGTACTCATGTATCAAGGGAAGAGATTGGAACCGAGCTGG  
GCCAGTGTCAAAAAAGACCTGATCTCATATGGAGGAGGTGGAGGCTTCAAGGATCCTGGAAC  
ACAGGAGAAGAAGTGCAGGTGATTGCTGTTGAACCAGGGAAAAACCCCAAAAATGTACAAAC  
AGCGCCGGGCACCTTTAAGACCCCTGAAGGTGAAGTTGGAGCCATTGCCCTAGACTTTAAACC  
TGGCACATCTGGATCTCCCATCGTGAACAGAGAAGGAAAAATAGTAGGTCTTTATGGAAATGG  
AGTAGTGACAACAAGTGGAACCTACGTCAGTGCCATAGCTCAAGCCAAAGCATCACAAGAAG  
GGCCCCTACCAGAGATTGAAGACGAGGTGTTTAGGAAAAGAACTTAACAATAATGGACCTA  
CATCCAGGATCGGGGAAAAACAAGAAGATATCTTCCAGCCATAGTCCGTGAGGCCATAAAAAG  
GAAGCTGCGCACACTAATCCTGGCTCCCACAAGGGTTGTCGCTTCCGAAATGGCAGAGGGCGCT  
CAAGGGAATGCCAATAAGGTACCAACAACAGCAGTGAAGAGTGAACATACAGGAAAAGAG  
ATAGTTGACCTCATGTGTCACGCCACTTTCACCATGCGCCTCCTGTCTCCCGTAAGAGTTCCCA  
ATTACAACATGATCATCATGGATGAAGCACATTTACCGATCCATCCAGTATAGCGGCCAGAG  
GGTACATCTCAACCCGAGTGGGCATGGGTGAAGCAGCTGCAATCTTCATGACAGCCACTCCCC  
CAGGATCAGTGGAGGCCTTTCCACAGAGCAACGCAGTTATCCAAGATGAGGAAAGAGACATT  
CCTGAGAGATCATGGAACCTCAGGCTATGAGTGGATCACTGACTTCCCAGGTAAAACAGTTTGG  
TTTGTTCGAAGCATTAAATCAGGAAATGACATTGCCAACTGCTTAAGAAAGAATGGGAAACGG  
GTGATTCAATTGAGCAGGAAAACCTTTGATACAGAGTACCAAAAAACAAAAACAACGACTG  
GGACTACGTCGTCACAACAGACATCTCCGAAATGGGAGCAAATTTCCGAGCCGACAGGGTGAT  
AGACCCAAGACGGTGTCTGAAACCGGTAATACTAAAAGATGGTCCAGAGCGTGTCATTTTAGC  
AGGACCAATGCCAGTGACTGTGGCCAGTGCCGCTCAGAGGAGAGGAAGAATTGGAAGGAACC  
ACAATAAGGAAGGTGATCAGTACATCTACATGGGACAGCCTTTAAACAACGATGAAGATCAC  
GCTCACTGGACAGAAGCAAAAATGCTCCTTGATAATATAAACACACCAGAAGGGATTATCCCA  
GCCCTCTTTGAGCCAGAGAGAGAAAAGAGTGCAGCAATAGACGGGGAATACAGACTGCGGGG  
TGAAGCAAGGAAAACGTTTGTGGAGCTCATGAGAAGAGGAGATCTACCTGTCTGGCTATCCTA

CAAAGTTGCCTCAGAAGGCTTCCAGTACTCTGACAGAAGATGGTGCTTTGACGGGGAAAGGAA  
CAACCAGGTGTTGGAGGAGAACATGGACGTGGAGATCTGGACAAAAGAAGGAGAAAGAAAG  
AAACTACGACCCCGCTGGCTGGATGCCAGAACATACTCAGACCCACTAGCCCTGCGCGAGTTT  
AAAGAGTTTGCAGCAGGGAGAAGAAGCGTCTCAGGTGATTTAATATTAGAAATAGGGAAGCT  
TCCACAACACTTGACGCAAAGGGCCCAGAATGCCCTGGACAACCTGGTTATGTTGCACAACCTC  
CGAACAAGGAGGCAGAGCCTATAGACATGCAATGGAAGAAGTCCAGACACCATAGAAACGT  
TGATGCTCCTAGCTTTGATAGCTGTGTTAACTGGTGGAGTGACACTGTTCTTCCTATCAGGAAG  
GGGCCTAGGGAAAACATCTATCGGCCTACTCTGCGTAATGGCTTCAAGCGTACTGCTATGGAT  
GGCCAGTGTGGAGCCCCATTGGATAGCGGCCTCCATCATACTGGAGTTCTTCCTGATGGTGCTG  
CTTATTCCAGAGCCAGACAGACAACGCACTCCGCAGGACAACCAGCTGGCATATGTGGTGATA  
GGTTTGTATTTCATGATACTGACAGTAGCAGCCAATGAGATGGGACTGCTGGAACCACAAAG  
AAAGACTTAGGGATTGGCCATGTGGCTGTTGAAAATCACCACCATGCCGCAATGCTGGACGTA  
GACTTACATCCAGCTTCAGCCTGGACCCTCTATGCAGTGGCCACAACAATTATCACTCCCATGA  
TGAGGCACACAATCGAAAACACAACGGCAAACATTTCCCTGACAGCCATTGCAAACCAGGCA  
GCTATATTGATGGGACTTGACAAAGGATGGCCAATATCGAAGATGGACATAGGAGTTCCACTT  
CTCGCCTTGGGGTGCTATTCCCAGGTGAATCCACTGACGCTGACAGCGGCGGTATTGATGCTAG  
TGGCTCATTACGCCATAATTGGACCTGGACTGCAAGCAAAAGCTACTAGAGAAGCTCAAAAAA  
GGACAGCGGCCCGGAATAATGAAAAATCCAACCGTTGATGGAATTGTTGCAATAGATTTGGACC  
CTGTGGTTTATGATGCAAAATTTGAAAAACAACCTAGGCCAAATAATGTTGTTGATACTATGCAC  
ATCACAGATCCTCTTGATGCGGACTACATGGGCCTTGTGCGAGTCCATCACACTGGCCACTGG  
ACCTCTGACCACGCTTTGGGAGGGATCTCCAGGAAAATTTTGGAACACCACGATAGCGGTTTC  
CATGGCAAACATTTTCAGAGGAAGTTATCTAGCAGGAGCAGGTCTGGCCTTCTCATTAAATGAA  
ATCTCTAGGAGGAGGTAGGAGAGGCACGGGAGCCCAAGGGGAAACACTGGGAGAGAAATGG  
AAAAGACAGCTGAACCAACTGAGCAAGTCAGAATTTAACACCTATAAAAGGAGTGGGATTAT  
GGAAGTGGACAGATCCGAAGCCAAAGAGGGATTGAAAAGAGGAGAAACAACCAAACATGCA  
GTGTCGAGAGGAACCGCTAAACTGAGGTGGTTCGTGGAGAGGAACCTTGTGAAACCAGAAGG  
GAAAGTCATAGACCTCGGTTGTGGAAGAGGTGGCTGGTCATACTATTGCGCTGGGCTGAAGAA  
AGTCACAGAAGTGAAGGGGTATACAAAAGGAGGACCTGGACATGAGGAACCAATCCCAATGG  
CGACCTATGGATGGAACCTAGTAAAGCTGCACTCTGGGAAAGACGTATTTTTTATACCACCTG  
AGAAATGTGACACCCTTTTGTGTGATATTGGTGAGTCCTCTCCAAACCCAACTATAGAGGAAG  
GAAGAACGCTACGCGTCCTAAAGATGGTGGAAACCATGGCTCAGAGGAAACCAATTTTGCATAA  
AAATTCTGAATCCCTACATGCCAAGTGTGGTGGAACTCTGGAGCAAATGCAAAGAAAACATG  
GAGGAATGCTAGTGCAGAAATCCACTTTCAAGAAATTCTACTCATGAAATGTATTGGGTTTCATG  
TGGAACAGGAAACATTGTGTGAGCAGTAAACATGACATCTAGAATGTTGCTAAATCGATTAC  
AATGGCTCACAGGAAACCAACATATGAAAGAGACGTGGACCTAGGCGCCGGAACAAGACATG  
TGGCAGTGGAAACCAGAGGTAGCCAACCTAGATATCATTGGCCAGAGGATAGAGAACATAAAA  
CATGAACATAAGTCAACATGGCATTATGATGAGGACAATCCATATAAAACATGGGCCTATCAT

GGATCATATGAGGTCAAGCCATCAGGATCAGCCTCATCCATGGTCAATGGCGTGGTGAAACTG  
CTCACCAAACCATGGGATGTCATCCCTATGGTCACACAAATAGCCATGACTGACACTACACCC  
TTTGGACAACAGAGGGTGTTTAAAGAGAAAGTTGACACACGCACACCAAAAGCAAAACGGGG  
CACAGCACAAATCATGGAGGTGACAGCCAAGTGGTTATGGGGTTTTCTTTCTAGAAACAAGAA  
ACCAAGAATTTGCACAAGAGAGGAGTTCACAAGAAAAGTTAGGTCAAACGCAGCCATTGGAG  
CAGTGTTCGTTGATGAAAATCAATGGAAGTTCAGCAAAAGAAGCAGTGGAAGATGAGCGGTTCT  
GGGACCTTGTGCATAGAGAGAGGGAGCTTCACAAACAGGGAAAATGTGCTACGTGTGTTTACA  
ACATGATGGGGAAGAGAGAGAAAAAGCTAGGAGAGTTTCGGAAAGGCAAAAGGAAGTCGTGC  
AATATGGTACATGTGGTTGGGAGCACGCTTTCTAGAGTTCTGAAGCTCTTGGTTTCATGAACGAA  
GATCACTGGTTCAGCAGAGAGAATTCAGTTCAGCGGAGTGGAAGGAGAAGGACTCCACAAACT  
TGGATATATACTCAGAGACATATCAAAGATTCCAGGGGGAAACATGTATGCAGATGACACAGC  
CGGATGGGATACAAGGATAACAGAGGATGACCTTCAGAATGAGGCCAGAATTACTGACATCA  
TGGAACCCGAACATGCCCTCCTGGCTAAGTCAATCTTCAAGTTAACCTACCAAAATAAGGTGG  
TAAGGGTACAGAGACCAGCAAAAAATGGAACCGTGATGGATGTCATATCCAGACGTGACCAG  
AGAGGAAGTGGTCAGGTCGGAACCTTATGGCTTAAACACTTTACCAACATGGAAGCCCAGCTG  
ATAAGACAAATGGAGTCTGAGGGAATCTTTTCACCCAGCGAATTAGAGACCCCAAATTTAGCC  
GAGAGAGTTCTCGACTGGCTGGAAAAATATGGCGTCGAAAGGCTGAAAAGAATGGCAATCAG  
CGGAGATGACTGCGTAGTGAAACCAATTGATGATAGGTTTGCAACAGCCTTGACAGCTCTGAA  
TGATATGGGAAAAGTAAGAAAAGATATACCACAATGGGAACCTTCAAAAGGATGGAATGATT  
GGCAACAAGTGCCTTTTTGTTCACACCACTTCCACCAGCTGATTATGAAGGATGGGAGGGAAA  
TAGTGGTGCCATGCCGCAACCAAGATGAACTTGTGGGTAGGGCTAGAGTATCACAAGGTGCTG  
GATGGAGCCTGAGAGAAACTGCATGCCTAGGCAAGTCATATGCACAAATGTGGCAGCTGATGT  
ACTTCCACAGGAGAGACCTGAGACTAGCCGCTAATGCTATCTGTTTCAGCCGTTCCAGTTGATTG  
GATCCCAACCAGCCGTACCACCTGGTCGATCCATGCCCATCACCAATGGATGACAACAGAAGA  
CATGCTGTCACTGTGGAATAGGGTTTGGATAGAGGAAAACCCATGGATGGAGGACAAAACCC  
ACATATCCAGTTGGGGAGATGTTCCATATTTAGGAAAAAGGGAAGACCAATGGTGTGGATCCC  
TGATAGGCTTAACAGCAAGGGCCACCTGGGCCACCAACATACAAGTGGCCATAAACCAAGTG  
AGAAGACTAATTGGGAATGAGAATTATCTAGATTACATGACATCAATGAAGAGATTCAAGAAC  
GAGAGTGATCCCGAAGGGGCACTCTGGTGAGTCAACACATTTACAAAATAAAGGAAAATAAG  
AAATCAAACAAGGCAAGAAGTCAGGCCGATTAAAGCCATAGTACGGTAAGAGCTATGCTGCC  
TGTGAGCCCCGTCTAAGGACGTAAAATGAAGTCAGGCCGAAAGCCACGGCTTGAGCAAACCG  
TGCTGCCTGTAGCTCCATCGTGGGGATGTAAAAACCTGGGAGGCTGCAACCCATGGAAGCTGT  
ACGCATGGGGTAGCAGACTAGTGGTTAGAGGAGACCCCTCCCGAAACATAACGCAGCAGCGG  
GGCCCAACACCAGGGGAAGCTGTACCCTGGTGGTAAGGACTAGAGGTTAGAGGAGACCCCCC  
GCATAACAATAAACAGCATATTGACGCTGGGAGAGACCAGAGATCCTGCTGTCTCTACAGCAT  
CATTCCAGGCACAGAACGCCAGAAAATGGAATGGTGTGCTGTTGAATCAACAGGTTCT

[0143] SEQ ID NO:3 – DENV-2-NI-BID-V533-2005

AGTTGTTAGTCTACGTGGACCGACAAAGACAGATTCTTTGAGGGAGCTAAGCTCAACGTAGTT  
CTAACAGTTTTTTAATTAGAGAGCAGATCTCTGATGAATAACCAACGAAAAAAGGCGAGAAGT  
ACGCCTTTC AATATGCTGAAACGCGAGAGAAACCGCGTGTCAACTGTGCAACAGCTGACAAAG  
AGATTCTCACTTGGAATGCTGCAAGGACGCGGACCATTAAAACTGTTTCATGGCCCTTGTGGCGT  
TCCTTCGTTTCCTAACAATCCCACCAACAGCAGGGATACTAAAAAGATGGGGAACGATCAAAA  
AATCAAAAAGCTATCAATGTTTTGAGAGGGTTCAGGAAAGAGATTGGAAGGATGCTGAACATCT  
TGAACAAGAGACGCAGGACAGCAGGCGTGATTGTTATGTTGATTCCAACAGCGATGGCGTTCC  
ATTTAACCACACGCAATGGAGAACCACACATGATCGTTGGTAGGCAGGAGAAAGGGAAAAAGT  
CTTCTGTTCAAAACAGAGGATGGTGTTAACATGTGTACTCTCATGGCCATAGACCTTGGTGAAT  
TGTGTGAAGATACAATCACGTACAAGTGTCCTCTCCTCAGACAAAATGAACCAGAAGACATAG  
ATTGTTGGTGCAACTCTACGTCCACATGGGTAACTTATGGGACATGTACCACCACAGGAGAAC  
ACAGAAGAGAAAAAAGATCAGTGGCGCTCGTTCCACATGTAGGTATGGGACTGGAGACACGA  
ACTGAAACATGGATGTCATCAGAAGGGGCCTGGAAACATGTTTCAGAGAATTGAAACCTGGATC  
TTGAGACATCCAGGTTTTTACCATAATGGCAGCAATCCTGGCATAACCCATAGGAACGACACAT  
TTCCAAAGGGCCTTGATTTTCATTTTACTGACAGCTGTCGCTCCTTCAATGACAATGCGCTGCA  
TAGGAATATCAAATAGAGACTTCGTAGAAGGGGTTTCAGGAGGAAGCTGGGTGACATAGTCT  
TAGAACATGGAAGTTGTGTGACGACGATGGCAAAAAACAAACCAACATTGGATTTTGAAGTGA  
TAAAAACAGAAGCCAAACAACCTGCCACTCTAAGGAAGTACTGTATAGAAGCAAAGCTGACC  
AACACAACAACAGAATCGCGTTGCCCAACACAAGGGGAACCCAGTCTAAATGAGGAGCAGGA  
CAAAAGGTTTCATCTGCAAACTCCATGGTAGACAGAGGATGGGGAAATGGATGTGGATTATT  
TGGAAGGGAGGCATTGTGACCTGTGCTATGTTTACATGCAAAAAGAACATGGAAGGAAAAG  
TCGTGCAGCCAGAAAATTTGGAATACACCATCGTGATAACACCTCACTCAGGAGAGGAGCACG  
CTGTAGGTAATGACACAGGAAAGCATGGCAAGGAAATCAAATAACACCACAGAGCTCCATC  
ACAGAAGCAGAACTGACAGGCTATGGCACTGTACGATGGAGTGCTCTCCGAGAACGGGCCTC  
GACTTCAATGAGATGGTACTGCTGCAGATGGAAGACAAAGCTTGGCTGGTGCACAGGCAATGG  
TTCCTAGACCTGCCGTTACCATGGCTACCCGGAGCGGACACACAAGGATCAAATTGGATACAG  
AAAGAGACATTGGTCACTTTCAAAAATCCCCACGCGAAGAAACAGGATGTCGTTGTCTTAGGG  
TCTCAAGAAGGGGCCATGCACACGGCACTCACAGGGGCCACAGAAATCCAGATGTCATCAGG  
AACTTACTGTTACAGGACATCTCAAGTGCAGGCTGAGAATGGACAACTACAGCTCAAAGG  
AATGTCATACTCTATGTGTACAGGAAAGTTTAAAATTGTGAAGGAAATAGCAGAAACACAACA  
TGGAACAATAGTTATCAGAGTACAATATGAAGGGGACGGTTCTCCATGCAAGATCCCTTTTGA  
GATAACAGATTTGGAAAAAAGACACGTCTTAGGTGCTTGATTACAGTTAACCCAATCGTAAC  
AGAAAAAGATAGCCCAGTCAACATAGAAGCAGAACCTCCATTCCGAGACAGCTACATCATTAT  
AGGAGTAGAGCCGGGACAATTGAAACTCAATTGGTTTAAGAAGGGAAGTTCCATCGGCCAAA  
TGTTTGAGACAACAATGAGAGGAGCAAAGAGAATGGCCATTTTAGGTGACACAGCCTGGGAC  
TTTGGATCCCTGGGAGGAGTGTTTACATCTATAGGAAAGGCTCTCCACCAAGTTTTTCGGAGCAA

TCTATGGGGCTGCTTTTAGTGGGGTCTCATGGACTATGAAAATCCTCATAGGAGTCATCATCAC  
ATGGATAGGAATGAATTCACGTAGCACCTCACTGTCTGTGTCGCTAGTATTGGTGGGCGTTGTG  
ACACTGTACCTGGGAGCTATGGTGCAAGCTGATAGTGGTTGCGTTGTGAGCTGGAAAAATAAA  
GAACTGAAATGTGGCAGCGGGATCTTCATCACAGATAACGTACACACATGGACAGAACAATAT  
AAGTTCCAACCAGAATCCCCCTTCAAACTAGCTTCAGCTATCCAAAAAGCTCATGAAGAGGGC  
ATTTGTGGAATCCGCTCAGTAACAAGATTGGAGAATCTGATGTGGAAACAAATAACACCAGAA  
TTGAATCATATTCTATCAGAAAATGAGGTAAAGTTGACCATTATGACAGGAGACATTAGAGGA  
ATCATGCAGGCAGGAAAACGATCCTTGCGGCCCCAGCCCACTGAGCTGAAGTACTCATGGAAA  
ACATGGGGAAAGGCGAAAATGCTCTCCACAGAGTCTCACAATCAGACCTTTCTTATTGATGGC  
CCTGAAACAGCAGAATGCCCCAACACAAACAGAGCCTGGAACCTCGCTGGAAGTTGAAGACTA  
TGGTTTTGGAGTTTTTACCACCAATATATGGCTGAAATTGAGAGAAAAACAGGATGTATTTTGT  
GACTCAAACTCATGTCAGCGGCCATTAAAGACAACAGAGCCGTTTCATGCTGATATGGGTTAT  
TGGATAGAAAGTGCACCTCAATGACACATGGAAGATGGAGAAAGCCTCCTTCATTGAAGTTAAA  
AGCTGCCACTGGCCAAAGTCACACACCCCTTTGGAGCAATGGAGTATTAGAAAGTGAGATGATA  
ATCCCCAAAAATTTTGCCGGGCCAGTGTACAAACACAACTACAGACCAGGCTACCATACACAA  
ACAGCAGGACCTTGGCATCTAGGTAAGCTTGAGATGGACTTTGATCTCTGCGAAGGAACTACA  
GTGGTGGTGACTGAGGACTGTGGAATAGAGGACCCTCTTTAAGAACGACCACTGCCTCTGGA  
AACTCATAACAGAATGGTGCTGCCGATCCTGCACACTACCACCTCTAAGATACAGAGGTGAG  
GATGGATGCTGGTACGGGATGGAAATCAGACCATTGAAAGAGAAAGAAGAGAATTTGGTCAA  
CTCCTTGGTCACAGCCGGACATGGGCAGATTGACAACCTTTTCACTAGGAGTCTTGGAATGGC  
ACTGTTCTGGAAGAAATGCTCAGGACCCGAATAGGAACGAAACATGCAATACTGCTAGTTGC  
AGTATCTTTTGTGACATTGATTACTGGGAACATGTCTTTTAGAGACCTGGGAAGAGTGATGGTT  
ATGGTGGGCGCTACCATGACGGATGACATAGGTATGGGAGTGACTTATCTTGCCCTACTAGCA  
GCTTTTAAGGTTAGACCAACTTTTGCAGCTGGACTACTCTTAAGAAAAGTACCTCCAAGGAAT  
TGATGATGGCCACCATAGGAATCGCACTCCTTTCCCAAAGCACCATAACCAGAGACCATTCTTG  
AACTGACTGATGCATTAGCCCTGGGCATGATGGTCCTCAAAATAGTGAGAAATATGGAAAAAT  
ACCAATTGGCAGTGACTATCATGGCTATTTTCATGTGTCCCAAATGCAGTGATACTGCAAAACGC  
ATGGAAGGTGAGTTGCACAATATTGGCAGCGGTGTCCGTTTCACTGCTCTTAACATCCTCA  
CAGCAGAAAGCGGATTGGATACCACTGGCATTGACGATAAAAGGTCTCAATCCAACAGCCATT  
TTTTTAACAACTCTCTCGAGGACCAGCAAGAAAAGGAGCTGGCCGCTAAATGAAGCTATCATG  
GCAGTTGGGATGGTGAGCATTTTAGCCAGTTCTCTCCTAAAGAATGATATTCCTATGACAGGTC  
CATTAGTGGCTGGAGGACTCCTCACCGTATGTTACGTGCTCACTGGACGATCGGCCGATTTGGA  
ACTGGAGAGAGCTGCCGATGTAAAATGGGAAGATCAGGCAGAAATATCAGGAAGCAGCCCAA  
TCCTGTCAATAACAATATCAGAAGATGGCAGCATGTGATAAAAAATGAAGAGGAAGAACAA  
ACACTGACCATACTCATCAGAACGGGATTGTTGGTGATCTCAGGAGTCTTTCCAGTATCGATAC  
CAATTACGGCAGCAGCATGGTACCTGTGGGAAGTAAAGAAACAACGGGCTGGAGTACTGTGG  
GACGTCCCTTCACCCCCACCAGTGGAAAAAGCCGAAGTGGAGGATGGAGCCTACAGAATCAA

GCAAAGAGGGATCCTTGATATTCTCAGATTGGAGCCGGAGTTTACAAAGAAGGAACATTCCA  
TACAATGTGGCACGTCACACGTGGTGCTGTTCTGATGCATAGAGGGAAGAGGATTGAACCATC  
ATGGGCAGATGTCAAGAAAGACCTAATATCATATGGAGGAGGCTGGAAGCTAGAAGGAGAAT  
GGAAGGAAGGAGAGGAAGTCCAAGTCCTGGCATTGGAACCTGGAAAAAATCCAAGAGCCGTC  
CAAACGAAACCTGGAATATTCAAAACCAACACCGGAACCATAGGCGCCGTATCTCTGGACTTT  
TCCCCTGGAACGTCAGGATCTCCAATCGTCGACAGAAAAGGAAAAGTTGTGGGTCTTTACGGT  
AATGGTGTTGTCACAAGGAGTGGAGCATATGTAAGTGCTATAGCCCAGACCGAAAAAAGCATT  
GAAGACAATCCAGAGATCGAAGATGACATTTTCCGAAAGAAAAGATTGACCATCATGGACCTC  
CATCCAGGAGCAGGAAAGACAAAAAGATACCTTCCAGCCATAGTTAGAGAAGCCATAAAACG  
TGGCTTGAGAACATTGATCCTGGCTCCCACTAGAGTAGTGGCAGCTGAAATGGAGGAAGCTCT  
TAGAGGACTTCCAATAAGATACCAAACCTACAGCCATCAAAACCGAGCATACCGGGCGGGAGA  
TCGTGGACCTAATGTGTCATGCCACATTTACTATGAGGCTGTTATCACCAGTCAGAGTGCCAAA  
TTACAACCTGATCATCATGGACGAAGCCCACTTCACAGACCCAGCAAGTATAGCAGCTAGAGG  
ATACATTTCAACTCGAGTAGAGATGGGTGAAGCAGCCGGGATTTTCATGACAGCCACTCCTCC  
GGGAAGTAGAGACCCATTTCTCAGAGCAATGCACCAATTATGGATGAGGAAAGAGAAATCC  
CTGAGCGTTCATGGAATTCAGGACACGAATGGGTACCGATTTTAAGGGGAAGACTGTTTGGT  
TTGTTCCAAGTATAAAAGCAGGAAATGATATAGCAGCTTGTCTTAGGAAAAATGGAAAGAAA  
GTGATACAACCTCAGTAGGAAGACTTTTGACTCTGAGTATGTTAAGACTAGAGCCAATGATTGG  
GACTTTGTGGTCACAACCTGACATTTTCAGAAATGGGTGCCAACTTCAAGGCTGAGAGGGTTATA  
GACCCAGACGTTGCATGAAACCAGTTATACTAACAGATGGCGAGGAGCGGGTGATCTTGGCT  
GGACCTATGCCAGTGACCCACTCTAGTGCAGCGCAAAGAAGAGGGGAGAATAGGAAGAAATCC  
AAAAAATGAAAATGACCAGTACATATACATGGGGGAACCTCTTGAAAATGATGAAGACTGTG  
CACATTGGAAAGAAGCTAAAATGCTCCTAGATAACATCAACACACCTGAAGGAATCATTCTTA  
GTATGTTTGAACCAGAGCGTGAAAAAGTGGATGCCATTGATGGTGAATACCGTTTGAGAGGAG  
AAGCAAGGAAAACCTTTGTGGACCTAATGAGAAGAGGGGACTTACCAGTCTGGTTGGCCTACA  
AAGTGGCAGCTGAAGGCATCAACTACGCAGACAGAAAGTGGTGTTTTGATGGAATTAAGAAC  
AACCAATACTGGAAGAAAATATGGAAGTGGAAATCTGGACAAAAGAAGGGGAAAGGAAAA  
AATTA AAAACCCAGATGGTTGGATGCTAGGATCTATTCTGACCCACTAGCACTAAAAGAATTCA  
AGGAATTTGCAGCTGGAAGAAAATCTTTGACCCTGAACCTAATCACAGAAATGGGTAGGCTTC  
CAACTTTCATGACTCAGAAAGCAAGAAACGCACTGGACAACCTGGCTGTGCTGCATACGGCTG  
AGGCAGGTGGAAGGGCGTACAATCATGCTCTCAGTGAAGTCCGGAGACCTGGAGACACTG  
CTCCTACTGACACTTCTGGCAACAGTCACAGGAGGAATCTTCTTATTCTTAATGAGCGGAAAAG  
GTATAGGGAAGATGACCTGGGAATGTGTTGCATAATCACGGCTAGTATCCTCCTATGGTATG  
CACAGATACAACCACACTGGATAGCAGTTCAATAATACTGGAGTTTTTTCTCATAGTTTTTGCT  
CATTCCAGAACCAGAAAAACAGAGAACACCCCAAGACAACCAATTGACCTACGTTGTCATAGC  
CATCCTCACAGTGGTGGCCGCAACCATGGCAAACGAGATGGGTTTCCTGGAAAAAACCAAGA  
AAGACCTCGGATTGGGAAGCATTACAACCCAGGAATCTGAGAGCAATATCCTGGACATAGATC

TACGCCCTGCATCAGCATGGACGCTGTATGCCGTAGCTACAACATTTGTCACACCAATGTTGAG  
ACATAGCATTGAAAATTCCTCAGTGAATGTCTCCCTAACAGCCATTGCTAACCAAGCTACAGTG  
CTAATGGGTCTTGGGAAAGGATGGCCATTGTCAAAGATGGACATTGGAGTTCCCCTCCTTGCC  
ATTGGATGCTATTACAAGTCAACCCTATAACTCTCACAGCAGCTCTCCTTTTATTGGTAGCAC  
ATTATGCCATTATAGGGCCAGGACTTCAAGCAAAAGCAACCAGAGAAGCCCAGAAAAGAGCA  
GCAGCAGGCATCATGAAAAACCCAACAGTCGATGGAATAACAGTGATTGACCTAGAACCAAT  
ACCCTATGATCCAAAATTTGAAAAGCAGTTAGGACAAGTAATGCTCCTAATCCTCTGCGTGACT  
CAAGTATTAATGATGAGGACTACATGGGCTTTATGTGAGGCTCTAACCTAGCGACCGGGCCC  
ATCTCCACACTGTGGGAAGGAAATCCAGGGAGGTTTTGGAACACTACCATTGCAGTGTCAATG  
GCTAACATCTTTAGGGGGGAGCTACTTGGCCGGAGCTGGACTTCTCTTTTCCATCATGAAAAACA  
CAACAAACACAAGAAGAGGAACTGGCAACATAGGAGAGACACTTGGAGAAAAATGGAAAAG  
TCGATTAAACGCACTGGGGAAAAGTGAATTTCAAATCTACAAGAAAAGTGGAATCCAGGAAG  
TGGATAGAACCCTAGCAAAAAGAAGGTATCAAAAGAGGAGAAACGGACCACCATGCTGTGTGCG  
CGAGGTTTCAGCAAACTGAGATGGTTCGTCGAGAGAAATATGGTCACACCGGAAGGGAAGGT  
GGTGGATCTCGGTTGCGGCAGAGGGGGCTGGTCATACTATTGCGGGGGACTAAAGAATGTAAG  
AGAAGTCAAAGGCCTAACAAAAGGAGGACCAGGACATGAAGAACCCATCCCCATGTCAACAT  
ATGGGTGGAATCTAGTGCGTCTGCAAAGTGGAGTTGACGTTTTCTTCACCCCGCCAGAAAAGT  
GTGATACATTGTTGTGTGACATAGGGGAGTTCGTACCAAATCCCACGATAGAAGCAGGACGAA  
CACTCAGAGTCCTCAACTTAGTGGAATTTGGTTGAACAATAACACCCAATTTTGCATAAAGG  
TCCTCAACCCATATATGCCTTCAGTCATAGAAAAAATGGAAGCATTACAAAGGAAATATGGAG  
GAGCCTTAGTGAGGAATCCACTCTCACGAACTCCACGCATGAAATGTACTGGGTATCTAATG  
CCACCGGGAACATAGTGTTCATCAGTGAACATGATTTCAAGGATGTTGATTAACAGATTACAA  
TGAAACACAAGAAAGCCACTTACGAGCCAGATGTTGACCTAGGAAGTGGAACCCGCAACATT  
GGAATTGAAAGTGAGATACCAAATCTAGACATAATAGGAAAGAGAATAGAGAAAATAAAACA  
AGAGCATGAAACATCATGGCACTATGATCAAGACCACCCATACAAAACGTGGGCTTACCATGG  
CAGCTATGAAACAAAACAACTGGATCAGCATCATCTATGGTGAACGGAGTGGTCAGATTGCT  
GACAAAACCTTGGGACGTCGTCCCTATGGTGACACAGATGGCAATGACAGACACGACTCCTTT  
TGGACAACAGCGCGTTTTTCAAAGAGAAAGTAGACACGAGAACCCAAGAACCGAAGGAAGGCA  
CAAAGAACTGATGAAAATTACGGCAGAGTGGCTTTGGAAAGAACTAGGAAAGAAAAAGACA  
CCTAGGATGTGTACCAGAGAAGAATTCACAAGAAAAGTGAGAAGCAATGCAGCCTTGGGGGC  
CATATTCATGATGAGAACAAATGGAAATCGGCACGTGAGGCTGTTGAAGATGGTAGGTTCTG  
GGAGCTGGTTGACAGGGAAAGAAATCTCCATCTTGAAGGAAAGTGTGAAACATGTGTGTACA  
ACATGATGGGAAAAAGAGAGAAGAACTAGGGGAGTTCCGGCAAGGCAAAAGGTAGCAGAGC  
CATATGGTACATGTGGCTTGGAGCACGCTTCTTAGAGTTTGAAGCCCTAGGATTCTGAATGAA  
GATCACTGGTTCTCCAGAGGGAACTCCCTGAGTGGAGTGGAAAGGAGAAGGGCTGCACAGGCT  
AGGCTACATTTTAAGAGACGTGGGCAAGAAGGAAGGGGGGGCAATGTACGCCGATGATACAG  
CAGGATGGGACACAAGAATCACACTAGAAGACTTAAAAAATGAAGAAATGGTAACGAACCAC

ATGAAAGGAGAACACAAGAACTAGCCGAGGCCATATTCAAACCTAACGTACCAAAACAAGGT  
 GGTGCGTGTGCAAAGACCAACACCAAGAGGTACAGTAATGGATATCATATCGAGAAGAGACC  
 AAAGAGGCAGTGGGCAAGTCGGCACCTATGGCCTTAATACCTTCACCAATATGGAAGCCCAAT  
 TAATTAGACAGATGGAGGGAGAAGGAATCTTCAAAGCATTACAGCACCTGACAGCCACAGAA  
 GAAATCGCTGTACAGAACTGGCTAGCAAGAGTGGGGCGTGAAAGGCTATCAAGAATGGCAAT  
 CAGTGGAGATGATTGTGTTGTAAAACCTATAGATGACAGATTTGCAAGTGCTTTAACAGCTCTA  
 AATGACATGGGAAAAGTTAGAAAAGATATACAACAATGGGAACCTTCAAGAGGATGGAACGA  
 TTGGACACAAGTGCCTTTCTGTTCACACCACTTTTCATGAGTTAGTCATGAAAGATGGTCGCGTG  
 CTCGTAGTCCCATGCAGAAACCAAGATGAACTGATTGGTAGAGCCCGAATTTCCAGGGAGCT  
 GGGTGGTCTTTGAAAGAGACGGCCTGTTTGGGAAAGTCTTACGCCCAAATGTGGACTCTGATG  
 TACTTCCACAGACGTGACCTCAGACTGGCGGCAAATGCCATCTGCTCGGCAGTCCCGTCACATT  
 GGGTTCCAACAAGTCGAACAACCTGGTCCATACACGCTAAGCATGAATGGATGACGACGGAA  
 GACATGCTGGCAGTCTGGAACAGGGTGTGGATCCAAGAAAACCCGTGGATGGAAGATAAAAC  
 TCCAGTGGAATCATGGGAAGAAGTCCCATACTTGGGAAAAAGAGAAGACCAATGGTGCGGCT  
 CATTGATTGGGCTAACAAGCAGGGCTACCTGGGCAAAGAACATCCAAACAGCAATAAATCAA  
 GTCAGATCCCTTATAGGCAATGAGGAATACACAGACTACATGCCATCCATGAAGAGATTTAGA  
 AGGGAAGAGGAAGAGGCAGGTGTCCTGTGGTAGAAGGCAAAACCTAACATGAAACAAGGCTAA  
 AAGTCAGGTTCGATTAAGCCATAGTACGGAAAAAACTATGCTACCTGTGAGCCCCGTCCAAGG  
 ACGTTAAAAGAAGTCAGGCCATCACAAAATGCCACAGCTTGAGTAAACTGTGCAGCCTGTAGC  
 TCCACCTGAGGAGGTGTAAAAAACCTGGGAGGCCACAAACCATGGAAGCTGTACGCATGGCG  
 TAGTGGACTAGCGGTTAGAGGAGACCCCTCCCTTACAAATCGCAGCAAACAACGGGGGGCCCA  
 AGGTGAGATGAAGCTGTAATCTCACTGGAAGGACTAGAGGTTAGAGGAGACCCCCCAAAC  
 AAAAAACAGCATATTGACGCTGGGAAAGACCAGAGATCCTGCTGTCTCCTCAGCATCATTCCA  
 GGCACAGAACGCCAGAAAATGGAATGGTGCTGTTGAATCAACAGGTTCT

[0144] SEQ ID NO: 4 – DENV-2-NI-BID-V533-2005-E-Min

AGTTGTTAGTCTACGTGGACCGACAAAGACAGATTCTTTGAGGGAGCTAAGCTCAACGTAGTT  
 CTAACAGTTTTTTAATTAGAGAGCAGATCTCTGATGAATAACCAACGAAAAAAGGCGAGAAGT  
 ACGCCTTTCAATATGCTGAAACGCGAGAGAAACCGCGTGCTCAACTGTGCAACAGCTGACAAAG  
 AGATTCTCACTTGGAATGCTGCAAGGACGCGGACCATTAAAACCTGTTTCATGGCCCTTGTGGCGT  
 TCCTTCGTTTCCTAACAATCCCACCAACAGCAGGGATACTAAAAAGATGGGGAACGATCAAAA  
 AATCAAAAGCTATCAATGTTTTGAGAGGGTTTCAGGAAAGAGATTGGAAGGATGCTGAACATCT  
 TGAACAAGAGACGCAGGACAGCAGGCGTGATTGTTATGTTGATTCCAACAGCGATGGCGTTCC  
 ATTTAACACACGCAATGGAGAACCACACATGATCGTTGGTAGGCAGGAGAAAGGGAAAAAGT  
 CTTCTGTTCAAAACAGAGGATGGTGTTAACATGTGTACTCTCATGGCCATAGACCTTGGTGAAT  
 TGTGTGAAGATACAATCACGTACAAGTGTCTCTCCTCAGACAAAATGAACCAGAAGACATAG  
 ATTGTTGGTGCAACTCTACGTCCACATGGGTAACTTATGGGACATGTACCACCACAGGAGAAC

ACAGAAGAGAAAAAAGATCAGTGGCGCTCGTTCCACATGTAGGTATGGGACTGGAGACACGA  
ACTGAAACATGGATGTCATCAGAAGGGGCCTGGAAACATGTTTCAGAGAATTGAAACCTGGATC  
TTGAGACATCCAGGTTTTTACCATAATGGCAGCAATCCTGGCATAACCCATAGGAACGACACAT  
TTCCAAAGGGCCTTGATTTTCATTTTACTGACAGCTGTCGCTCCTTCAATGACAATGAGATGCA  
TAGGGATATCGAATCGCGATTTTCGTCGAAGGCGTATCCGGAGGGTCATGGGTCGACATCGTAC  
TCGAACACGGATCATGCGTTACGACTATGGCTAAGAATAAGCCTACACTAGACTTCGAACTGA  
TTAAGACAGAGGCTAAGCAACCGGCAACATTGCGTAAGTACTGTATCGAAGCGAACTGACTA  
ACACTACAACCGAATCTAGATGCCCTACACAGGGCGAACCTAGTCTGAACGAAGAGCAAGAC  
AAAAGGTTTATATGCAAACACTCTATGGTCGATCGCGGATGGGGAAACGGATGCGGATTGTTT  
GGTAAGGGGGGAATCGTTACATGCGCTATGTTTACATGTAAAAAAATATGGAGGGAAAGGT  
CGTGCAACCAGAGAATCTCGAATATACAATCGTAATCACACCGCATAGCGGAGAGGAACACG  
CAGTCGGAACGATACCGGAAAACACGGAAAAGAGATTAAGATTACACCACAGAGCTCCATA  
ACCGAAGCCGAACGACAGGGTACGGAACAGTGACAATGGAATGCTCACCTAGAACAGGCCT  
AGACTTTAACGAAATGGTGTTACTGCAAATGGAAGACAAAGCATGGTTAGTGCATAGGCAATG  
GTTTTTAGACCTACCACTACCATGGTTGCCCGAGCCGATACACAGGGATCGAACTGGATACA  
GAAAGAGACACTCGTTACGTTTAAAAACCCACACGCTAAAAAACAGGACGTAGTCGTACTCGG  
ATCACAGGAAGGCGCAATGCATACCGCATTGACAGGCGCTACAGAGATACAGATGTCTAGCG  
GAAATCTGTTGTTTACAGGGCATCTGAAATGTAGACTGAGAATGGACAAACTGCAATTGAAGG  
GAATGTCATACTCTATGTGTACGGGTAAAGTTTAAAGATAGTCAAAGAGATAGCCGAAACACAAC  
ACGGAACAATCGTAATTAGGGTGCAATACGAAGGCGACGGGTACCATGTAAGATACCATTG  
AAATTACAGACCTCGAAAAAAGACACGTAAGTCTCGGAAGACTGATAACAGTGAATCCGATCGTTA  
CGGAAAAAGACTCACCCGTTAATATCGAAGCCGAACCACCATTCGGAGACTCATAATAATAA  
TCGGAGTCGAACCCGGACAATTGAACTGAATTGGTTTAAAAAAGGGTCATCAATCGGACAAA  
TGTTTCGAAACAACTATGAGAGGCGCTAAGCGTATGGCTATACTCGGAGACACAGCATGGGACT  
TCGGATCCTTAGGGGGAGTGTTTACGTCAATCGGTAAGGCACTACACCAGGTATTTCGGAGCGA  
TATACGGAGCCGCATTTAGCGGAGTGTCGTGGACAATGAAGATACTGATCGGAGTGATAATCA  
CATGGATCGGAATGAATAGTAGGTCTACAAGTCTATCCGTTAGCTTAGTGTTAGTCGGAGTCGT  
TAACTGTATCTAGGCGCTATGGTGCAAGCCGATAGTGGTTGCGTTGTGAGCTGGAAAAATAA  
AGAACTGAAATGTGGCAGCGGGATCTTCATCACAGATAACGTACACACATGGACAGAACAAT  
ATAAGTTCCAACCAGAATCCCCTTCAAACACTAGCTTCAGCTATCCAAAAAGCTCATGAAGAGG  
GCATTTGTGGAATCCGCTCAGTAACAAGATTGGAGAATCTGATGTGGAACAAATAACACCAG  
AATTGAATCATATTCTATCAGAAAATGAGGTAAAGTTGACCATTATGACAGGAGACATTAGAG  
GAATCATGCAGGCAGGAAAACGATCCTTGCGGCCCCAGCCCACTGAGCTGAAGTACTCATGGA  
AAACATGGGGAAAGGCGAAAATGCTCTCCACAGAGTCTACAATCAGACCTTTCTTATTGATG  
GCCCTGAAACAGCAGAATGCCCCAACACAAACAGAGCCTGGAACCTCGCTGGAAGTTGAAGAC  
TATGGTTTTGGAGTTTTTACCACCAATATATGGCTGAAATTGAGAGAAAAACAGGATGTATTTT  
GTGACTCAAACTCATGTCAGCGGCCATTAAAGACAACAGAGCCGTTTCATGCTGATATGGGTT

ATTGGATAGAAAGTGCACTCAATGACACATGGAAGATGGAGAAAGCCTCCTTCATTGAAGTTA  
AAAGCTGCCACTGGCCAAAGTCACACACCCTTTGGAGCAATGGAGTATTAGAAAGTGAGATGA  
TAATCCCAAAAAATTTTGCCGGGCCAGTGTACAAACACAACCTACAGACCAGGCTACCATACAC  
AAACAGCAGGACCTTGGCATCTAGGTAAGCTTGAGATGGACTTTGATCTCTGCGAAGGAACCTA  
CAGTGGTGGTGAAGTACTGAGGACTGTGGAAATAGAGGACCCTCTTTAAGAACGACCACTGCCTCTG  
GAAAACTCATAACAGAATGGTGCTGCCGATCCTGCACACTACCACCTCTAAGATACAGAGGTG  
AGGATGGATGCTGGTACGGGATGGAAATCAGACCATTGAAAGAGAAAGAAGAGAATTTGGTC  
AACTCCTTGGTCACAGCCGGACATGGGCAGATTGACAACCTTTTCACTAGGAGTCTTGGGAATG  
GCACTGTTCTGGAAGAAATGCTCAGGACCCGAATAGGAACGAAACATGCAATACTGCTAGTT  
GCAGTATCTTTTGTGACATTGATTACTGGGAACATGTCTTTTAGAGACCTGGGAAGAGTGATGG  
TTATGGTGGGCGCTACCATGACGGATGACATAGGTATGGGAGTGACTTATCTTGCCCTACTAGC  
AGCTTTTAAGGTTAGACCAACTTTTGCAGCTGGACTACTCTTAAGAAAAGTACCTCCAAGGA  
ATTGATGATGGCCACCATAGGAATCGCACTCCTTTCCCAAAGCACCATAACCAGAGACCATTCTT  
GAACTGACTGATGCATTAGCCCTGGGCATGATGGTCCTCAAAATAGTGAGAAATATGGAAAAA  
TACCAATTGGCAGTGACTATCATGGCTATTTTCATGTGTCCCAAATGCAGTGATACTGCAAAACG  
CATGGAAGGTGAGTTGCACAATATTGGCAGCGGTGTCCGTTTCACTGCTCTTAACATCCTC  
ACAGCAGAAAGCGGATTGGATACCACTGGCATTGACGATAAAAGGTCTCAATCCAACAGCCAT  
TTTTTTAACAACCTCTCTCGAGGACCAGCAAGAAAAGGAGCTGGCCGCTAAATGAAGCTATCAT  
GGCAGTTGGGATGGTGAGCATTTTAGCCAGTTCTCTCCTAAAGAATGATATTCCTATGACAGGT  
CCATTAGTGGCTGGAGGACTCCTCACCGTATGTTACGTGCTCACTGGACGATCGGCCGATTGG  
AACTGGAGAGAGCTGCCGATGTAAAATGGGAAGATCAGGCAGAAATATCAGGAAGCAGCCCA  
ATCCTGTCAATAACAATATCAGAAGATGGCAGCATGTGCGATAAAAAATGAAGAGGAAGAACA  
AACACTGACCATACTCATCAGAACGGGATTGTTGGTGATCTCAGGAGTCTTTCCAGTATCGATA  
CCAATTACGGCAGCAGCATGGTACCTGTGGGAAGTAAAGAAACAACGGGCTGGAGTACTGTG  
GGACGTCCCTTCACCCCCACCAGTGGA AAAAGCCGAACCTGGAGGATGGAGCCTACAGAATCA  
AGCAAAGAGGGATCCTTGGATATTCTCAGATTGGAGCCGGAGTTTACAAAGAAGGAACATTCC  
ATACAATGTGGCACGTACACGTGGTGCTGTTCTGATGCATAGAGGGAAGAGGATTGAACCAT  
CATGGGCAGATGTCAAGAAAGACCTAATATCATATGGAGGAGGCTGGAAGCTAGAAGGAGAA  
TGGAAGGAAGGAGAGGAAGTCCAAGTCCTGGCATTGGAACCTGGAAAAAATCCAAGAGCCGT  
CCAAACGAAACCTGGAATATTCAAACCAACACCGGAACCATAGGCGCCGTATCTCTGGACTT  
TTCCCCTGGAACGTCAGGATCTCCAATCGTCGACAGAAAAGGAAAAGTTGTGGGTCTTTACGG  
TAATGGTGTGTCACAAGGAGTGGAGCATATGTAAGTGCTATAGCCCAGACCGAAAAAAGCAT  
TGAAGACAATCCAGAGATCGAAGATGACATTTTCCGAAAGAAAAGATTGACCATCATGGACCT  
CCATCCAGGAGCAGGAAAGACAAAAAGATACCTTCCAGCCATAGTTAGAGAAGCCATAAAAC  
GTGGCTTGAGAACATTGATCCTGGCTCCCACTAGAGTAGTGGCAGCTGAAATGGAGGAAGCTC  
TTAGAGGACTTCCAATAAGATACCAAACCTACAGCCATCAAAACCGAGCATACCGGGCGGGAG  
ATCGTGGACCTAATGTGTCATGCCACATTTACTATGAGGCTGTTATCACCAGTCAGAGTGCCAA

ATTACAACCTGATCATCATGGACGAAGCCCACTTCACAGACCCAGCAAGTATAGCAGCTAGAG  
GATACATTTCAACTCGAGTAGAGATGGGTGAAGCAGCCGGGATTTTCATGACAGCCACTCCTC  
CGGGAAGTAGAGACCCATTTCTCAGAGCAATGCACCAATTATGGATGAGGAAAGAGAAATC  
CCTGAGCGTTCATGGAATTCAGGACACGAATGGGTCACGGATTTTAAGGGGAAGACTGTTTGG  
TTTGTTC AAGTATAAAAAGCAGGAAATGATATAGCAGCTTGTCTTAGGAAAAATGGAAAGAAA  
GTGATACAACCTCAGTAGGAAGACTTTTGACTCTGAGTATGTTAAGACTAGAGCCAATGATTGG  
GACTTTGTGGTCACAACCTGACATTTTCAGAAATGGGTGCCAACTTCAAGGCTGAGAGGGTTATA  
GACCCAGACGTTGCATGAAACCAGTTATACTAACAGATGGCGAGGAGCGGGTGATCTTGGCT  
GGACCTATGCCAGTGACCCACTCTAGTGCAGCGCAAAGAAGAGGGGAGAATAGGAAGAAATCC  
AAAAAATGAAAATGACCAGTACATATACATGGGGGAACCTCTTGAAAATGATGAAGACTGTG  
CACATTGGAAAGAAGCTAAAATGCTCCTAGATAACATCAACACACCTGAAGGAATCATTCTTA  
GTATGTTTGAACAGAGCGTGAAAAAGTGGATGCCATTGATGGTGAATACCGTTTGAGAGGAG  
AAGCAAGGAAAACCTTTGTGGACCTAATGAGAAGAGGGGACTTACCAGTCTGGTTGGCCTACA  
AAGTGGCAGCTGAAGGCATCAACTACGCAGACAGAAAGTGGTGTCTTTGATGGAATTAAGAAC  
AACCAAATACTGGAAGAAAATATGGAAGTGGAAATCTGGACAAAAGAAGGGGAAAGGAAAA  
AATTA AAAACCCAGATGGTTGGATGCTAGGATCTATTCTGACCCACTAGCACTAAAAGAATTCA  
AGGAATTTGCAGCTGGAAGAAAATCTTTGACCCTGAACCTAATCACAGAAATGGGTAGGCTTC  
CAACTTTTCATGACTCAGAAAGCAAGAAACGCACCTGGACAACCTGGCTGTGCTGCATACGGCTG  
AGGCAGGTGGAAGGGCGTACAATCATGCTCTCAGTGAACCTGCCGGAGACCCTGGAGACACTG  
CTCCTACTGACACTTCTGGCAACAGTCACAGGAGGAATCTTCTTATTCTTAATGAGCGGAAAAG  
GTATAGGGAAGATGACCCTGGGAATGTGTTGCATAATCACGGCTAGTATCCTCCTATGGTATG  
CACAGATACAACCACACTGGATAGCAGCTTCAATAATACTGGAGTTTTTTCTCATAGTTTTGTCT  
CATTCAGAACCCAGAAAAACAGAGAACACCCCAAGACAACCAATTGACCTACGTTGTCATAGC  
CATCCTCACAGTGGTGGCCGCAACCATGGCAAACGAGATGGGTTTCCTGGAAAAAACCAAGA  
AAGACCTCGGATTGGGAAGCATTACAACCCAGGAATCTGAGAGCAATATCCTGGACATAGATC  
TACGCCCTGCATCAGCATGGACGCTGTATGCCGTAGCTACAACATTTGTCACACCAATGTTGAG  
ACATAGCATTGAAAATTCCTCAGTGAATGTCTCCCTAACAGCCATTGCTAACCAAGCTACAGTG  
CTAATGGGTCTTGGGAAAGGATGGCCATTGTCAAAGATGGACATTGGAGTTCCCCCTCCTTGCC  
ATTGGATGCTATTACAAGTCAACCCTATAACTCTCACAGCAGCTCTCCTTTTATTGGTAGCAC  
ATTATGCCATTATAGGGCCAGGACTTCAAGCAAAAGCAACCAGAGAAGCCAGAAAAGAGCA  
GCAGCAGGCATCATGAAAAACCAACAGTCGATGGAATAACAGTGATTGACCTAGAACCAAT  
ACCCTATGATCCAAAATTTGAAAAGCAGTTAGGACAAGTAATGCTCCTAATCCTCTGCGTGACT  
CAAGTATTAATGATGAGGACTACATGGGCTTTATGTGAGGCTCTAACCCCTAGCGACCGGGCCC  
ATCTCCACACTGTGGGAAGGAAATCCAGGGAGGTTTTTGGAACTACTACCATTGCAGTGTCAATG  
GCTAACATCTTTAGGGGGAGCTACTTGGCCGGAGCTGGACTTCTCTTTTCCATCATGAAAAACA  
CAACAAACACAAGAAGAGGAACTGGCAACATAGGAGAGACACTTGGAGAAAAATGGAAAAG  
TCGATTAAACGCACTGGGGAAAAGTGAATTTCAAATCTACAAGAAAAGTGGGAATCCAGGAAG

TGGATAGAACCCTAGCAAAAAGAAGGTATCAAAAGAGGAGAAACGGACCACCATGCTGTGTGCG  
CGAGGTTTCAGCAAAACTGAGATGGTTCGTCGAGAGAAATATGGTCACACCGGAAGGGAAGGT  
GGTGGATCTCGGTTGCGGCAGAGGGGGCTGGTCATACTATTGCGGGGGACTAAAGAATGTAAG  
AGAAGTCAAAGGCCTAACAAAAGGAGGACCAGGACATGAAGAACCCATCCCCATGTCAACAT  
ATGGGTGGAATCTAGTGCGTCTGCAAAGTGGAGTTGACGTTTTCTTCACCCCGCCAGAAAAGT  
GTGATACATTGTTGTGTGACATAGGGGAGTTCGTCACCAAATCCCACGATAGAAGCAGGACGAA  
CACTCAGAGTCCTCAACTTAGTGGAATAATTGGTTGAACAATAACACCCAATTTTGCATAAAGG  
TCCTCAACCCATATATGCCTTCAGTCATAGAAAAAATGGAAGCATTACAAAGGAAATATGGAG  
GAGCCTTAGTGAGGAATCCACTCTCACGAACTCCACGCATGAAATGTACTGGGTATCTAATG  
CCACCGGGAACATAGTGTTCATCAGTGAACATGATTTCAAGGATGTTGATTAACAGATTACAA  
TGAAACACAAGAAAGCCACTTACGAGCCAGATGTTGACCTAGGAAGTGGAACCCGCAACATT  
GGAATTGAAAGTGAGATACCAAATCTAGACATAATAGGAAAGAGAATAGAGAAAATAAAACA  
AGAGCATGAAACATCATGGCACTATGATCAAGACCACCCATACAAAACGTGGGCTTACCATGG  
CAGCTATGAAACAAAACAACTGGATCAGCATCATCTATGGTGAACGGAGTGGTCAGATTGCT  
GACAAAACCTTGGGACGTCGTCCTATGGTGACACAGATGGCAATGACAGACACGACTCCTTT  
TGGACAACAGCGCGTTTTCAAAGAGAAAGTAGACACGAGAACCCAAGAACCGAAGGAAGGCA  
CAAAGAACTGATGAAAATTACGGCAGAGTGGCTTTGGAAAGAACTAGGAAAGAAAAAGACA  
CCTAGGATGTGTACCAGAGAAGAATTCACAAGAAAAGTGAGAAGCAATGCAGCCTTGGGGGC  
CATATTCATGATGAGAACAATGGAAATCGGCACGTGAGGCTGTTGAAGATGGTAGGTTCTG  
GGAGCTGGTTGACAGGGAAAGAAATCTCCATCTTGAAGGAAAGTGTGAAACATGTGTGTACA  
ACATGATGGGAAAAAGAGAGAAGAACTAGGGGAGTTTCGGCAAGGCAAAAGGTAGCAGAGC  
CATATGGTACATGTGGCTTGGAGCACGCTTCTTAGAGTTTGAAGCCCTAGGATTCTCTGAATGAA  
GATCACTGGTTCTCCAGAGGGAACTCCCTGAGTGGAGTGGAAAGGAGAAGGGCTGCACAGGCT  
AGGCTACATTTTAAGAGACGTGGGCAAGAAGGAAGGGGGGCAATGTACGCCGATGATACAG  
CAGGATGGGACACAAGAATCACACTAGAAGACTTAAAAAATGAAGAAATGGTAACGAACCAC  
ATGAAAGGAGAACACAAGAACTAGCCGAGGCCATATTCAAATAACGTACCAAAAACAAGGT  
GGTGCGTGTGCAAAGACCAACACCAAGAGGTACAGTAATGGATATCATATCGAGAAGAGACC  
AAAGAGGCAGTGGGCAAGTCGGCACCTATGGCCTTAATACCTTCACCAATATGGAAGCCCAAT  
TAATTAGACAGATGGAGGGAGAAGGAATCTTCAAAGCATTACAGCACCTGACAGCCACAGAA  
GAAATCGCTGTACAGAACTGGCTAGCAAGAGTGGGGCGTGAAAGGCTATCAAGAATGGCAAT  
CAGTGGAGATGATTGTGTTGTAACCTATAGATGACAGATTTGCAAGTGCTTTAACAGCTCTA  
AATGACATGGGAAAAGTTAGAAAAGATATACAACAATGGGAACCTTCAAGAGGATGGAACGA  
TTGGACACAAGTGCCTTTCTGTTACACCACTTTTCATGAGTTAGTCATGAAAGATGGTCGCGTG  
CTCGTAGTCCCATGCAGAAACCAAGATGAACTGATTGGTAGAGCCCGAATTTCCAGGGAGCT  
GGGTGGTCTTTGAAAGAGACGGCCTGTTTGGGAAAGTCTTACGCCCAAATGTGGACTCTGATG  
TACTTCCACAGACGTGACCTCAGACTGGCGGCAAATGCCATCTGCTCGGCAGTCCCGTCACATT  
GGGTTCCAACAAGTCGAACAACCTGGTCCATACACGCTAAGCATGAATGGATGACGACGGAA

GACATGCTGGCAGTCTGGAACAGGGTGTGGATCCAAGAAAACCCGTGGATGGAAGATAAAAC  
TCCAGTGGAAATCATGGGAAGAAGTCCCATACTTGGGAAAAAGAGAAGACCAATGGTGC GGCT  
CATTGATTGGGCTAACAAGCAGGGCTACCTGGGCAAAGAACATCCAAACAGCAATAAATCAA  
GTCAGATCCCTTATAGGCAATGAGGAATACACAGACTACATGCCATCCATGAAGAGATTTAGA  
AGGGAAGAGGAAGAGGCAGGTGTCCTGTGGTAGAAGGC AAACTAACATGAAACAAGGCTAA  
AAGTCAGGTTCGGATTAAGCCATAGTACGGAAAAAACTATGCTACCTGTGAGCCCCGTCCAAGG  
ACGTTAAAAGAAGTCAGGCCATCACAAAATGCCACAGCTTGAGTAACTGTGCAGCCTGTAGC  
TCCACCTGAGGAGGTGTAAAAAACCTGGGAGGCCACAAACCATGGAAGCTGTACGCATGGCG  
TAGTGGACTAGCGGTTAGAGGAGACCCCTCCCTTACAAATCGCAGCAAACAACGGGGGGCCCA  
AGGTGAGATGAAGCTGTAATCTCACTGGAAGGACTAGAGGTTAGAGGAGACCCCCCAAAC  
AAAAACAGCATATTGACGCTGGGAAAGACCAGAGATCCTGCTGTCTCCTCAGCATCATTCCA  
GGCACAGAACGCCAGAAAATGGAATGGTGCTGTTGAATCAACAGGTTCT

[0145] SEQ ID NO: 5 – DENV-3-VE-BID-V2268-2008

AGTTGTTAGTCTACGTGGACCGACAAGAACAGTTTTCGACTCGGAAGCTTGCTTAACGTAGTGCT  
AACAGTTTTTTATTAGAGAGCAGATCTCTGATGAACAACCAACGGAAGAAGACGGGAAAACC  
GTCTATCAATATGCTGAAACGCGTGAGAAACCGTGTGTCAACTGGATCACAGTTGGCGAAGAG  
ATTCTCAAAGGACTGCTGAACGGCCAGGGACCAATGAAATTGGTTATGGCGTTCATAGCTTT  
CCTCAGATTTCTAGCCATTCCACCAACAGCAGGAGTCTTGGCTAGATGGGGAACCTTCAAGAA  
GTCGGGGGGCCATTAAGGTCCTGAAAGGCTTTAAGAAGGAGATCTCAAACATGCTGAGCATAAT  
CAACAAACGGAAAAAGACATCGCTCTGTCTCATGATGATATTGCCAGCAGCACTTGCTTTCCA  
CTTGACTTCACGAGATGGAGAGCCGCGCATGATTGTGGGGAAGAATGAAAGAGGAAAAATCCC  
TACTTTTTAAGACAGCCTCTGGAATTAACATGTGCACACTCATAGCCATGGACTTGGGAGAGAT  
GTGTGATGACACGGTCACTTACAAATGCCCCCATATTACCGAAGTGGAACCTGAAGACATTGA  
CTGCTGGTGCAACCTCACATCAACATGGGTGACTTATGGAACGTGCAATCAAGCCGGAGAGCA  
TAGACGCGATAAGAGATCAGTGGCGTTAGCTCCCCATGTGGCATGGGACTGGATACACGCAC  
CCAAACTTGATGTGCGCTGAAGGAGCTTGGAGGCAAGTCGAGAAGGTAGAGACATGGGCCC  
TTAGGCACCCAGGGTTCACCATACTAGCCCTATTTCTTGCCCATACATAGGCACTTCCTTGAC  
CCAGAAGGTGGTTATTTTTATACTGCTAATGCTGGTCACCCCATCCATGACAATGAGATGTGTG  
GGAGTAGGAAACAGAGATTTTGTGGAAGGACTATCAGGAGCTACGTGGGTTGACGTGGTGCTC  
GAGCACGGGGGGTGTGTGACCACCATGGCTAAGAACAAGCCCACGTTGGATATAGAGCTTCA  
GAAGACCGAGGCCACCCAACCTGGCGACCCTAAGGAAGCTATGCATTGAGGGGAAAATCACCA  
ACATAACAACCTGACTCAAGATGTCCTACCCAAGGGGAAGCGGTTTTGCCTGAGGAGCAGGACC  
AAAACCTACGTGTGTAAGCATAACATAGTAGACAGAGGCTGGGGGAACGGATGTGGTTTGTGTTG  
GTAAGGGAAGCTTGGTAACATGTGCGAAATTTCAATGCCTGGAACCAATAGAGGGAAAAGTG  
GTGCAATATGAGAACCTCAAATACACCGTTATCATCACAGTGACACAGGAGACCAACACCAG  
GTGGGAAATGAAACGCAGGGAGTCACGGCTGAGATAACACCTCAGGCATCAACCACTGAAGC

CATCTTGCCTGAATATGGAACCCCTTGGGCTAGAATGCTCACCACGGACAGGTTTGGACTTCAAT  
GAAATGATCTTGCTAACAATGAAGAACAAAGCATGGATGGTACATAGACAATGGTTTTTTGAC  
CTACCTCTACCATGGACATCAGGAGCTACAACGGAAACACCAACCTGGAACAGGAAGGAGCT  
TCTTGTGACATTTAAAAACGCACATGCGAAGAAACAAGAAGTAGTTGTTCTTGGGTGCGAAGA  
GGGAGCAATGCATACCGCATTGACAGGAGCCACAGAAATCCAAAACCTCAGGAGGCACAAGCA  
TTTTTGCGGGGCACTTAAAATGTAGACTTAAGATGGACAAATTAGAACTCAAGGGGATGAGCT  
ATGCAATGTGCACGAATACCTTTGTGTTGAAGAAAGAAGTCTCAGAAACGCAGCATGGGACAA  
TACTTATCAAGGTCGAGTACAAAGGGGAAGATGTACCTTGCAAGATTCTTTCTCCACAGAGG  
ATGGACAAGGGAAAGCTCACAATGGCAGACTGATTACAGCCAACCCAGTGGTGACTAAGAAG  
GAGGAGCCTGTCAATATTGAGGCTGAACCTCCTTTTGGGGAAAGCAATATAGTAATTGGAATT  
GGAGACAACGCCTTGAAAATCAACTGGTACAAGAAGGGGAAGCTCTATTGGGAAGATGTTCTGA  
GGCCACTGCTAGAGGTGCAAGGCGCATGGCCATCTTGGGAGACACAGCTTGGGACTTTGGATC  
AGTGGGTGGTGTCTGAACTCATTAGGCAAAATGGTGCACCAAATATTTCGGAAGTGCTTACAC  
AGCCCTATTAGTGGAGTCTCTTGGGTAATGAAAATTGGAATAGGAGTTCTCTTGACTTGGATA  
GGGTTGAATTCAAAAAACACATCCATGTCAATTTTCATGCATTGCGATAGGAATCATCACACTCT  
ATCTGGGAGCTGTGGTGCAAGCTGACATGGGGTGTGTTATAAACTGGAAAGGCAAAGAACTCA  
AGTGTGGAAGTGGAATCTTCGTCACCAACGAGGTCCATACCTGGACAGAGCAATACAAATTCC  
AAGCAGACTCCCCAAAAAGATTGGCGACAGCCATTGCAGGCGCTTGGGAGAATGGAGTGTGC  
GGAATTAGGTCAACAACCAGAATGGAGAATCTCCTGTGGAAGCAAATAGCCAATGAACTGAA  
CTACATATTGTGGGAAAACAATATCAAATTAACGGTTGTTGTGGGCGATATAATTGGGGTCTTA  
GAGCAAGGGAAAAGAACAATAACACCACAACCCATGGAGCTAAAATACTCATGGAAAACGTG  
GGGAAAGGCAAAAATAGTGACAGCTGAAACACAAAATTCTTCTTTTCATAATAGATGGACCAA  
ACACACCGGAGTGTCCAAGTGCCTCAAGAGCATGGAATGTGTGGGAGGTGGAAGATTACGGG  
TTCGGAGTCTTCACAACCAACATATGGCTGAAACTCCGAGAGGTGTATACCCAACCTATGTGAC  
CATAGGTAAATGTGCGCAGCCGTCAAGGATGAAAGGGCCGTACATGCCGACATGGGCTATTGG  
ATAGAAAGTCAAAAGAATGGAAGTTGGAAGCTAGAAAAAGCATCCCTCATAGAGGTGAAAAC  
CTGCACATGGCCAAAATCACATACCCTTTGGAGTAATGGTGTGTTAGAGAGTGACATGATCAT  
TCCAAAAAGTCTAGCTGGTCCTATCTCGCAACACAACCTACAGGCCCGGGTACCACACCCAGAC  
GGCGGGACCTTGGCATTTAGGAAAATTAGAGCTGGACTTCAACTATTGTGAAGGAACAACAGT  
TGTCATCACAGAAAACCTGTGGGACAAGAGGCCCATCATTGAGAACAAACAGTGTGAGGGA  
AGTTAATACACGAATGGTGTGCGCTCGTGCACACTTCCTCCCCTGCGATACATGGGAGAAG  
ACGGTTGCTGGTATGGCATGGAAATCAGACCCATCAGTGAGAAAGAAGAAAACATGGTAAAG  
TCTTTAGTCTCAGCGGGAAGTGGAGAGGTGGACAACCTTACAATGGGTGTCTTGTGTTTGGCA  
ATCCTCTTTGAAGAGGTGATGAGAGGAAAATTTGGGAAGAAACACATGATTGCGGGGGTTTTTC  
TTCACGTTTGTACTCCTTCTCTCAGGGCAAATAACATGGAGAGATATGGCGCACACACTAATAA  
TGATTGGGTCCAATGCATCTGACAGGATGGGAATGGGCGTCACCTACCTAGCTTTAATTGCAA  
CATTTAAAATCCAGCCATTTTTGGCTTTGGGATTTTTCTTAAGAAAACCTGACATCCAGAGAAAA

TTTATTGTTAGGAGTTGGGCTGGCTATGGCAACAACGTTACAACCTGCCAGAGGACATTGAACA  
AATGGCAAATGGAATCGCTCTGGGGCTCATGGCTCTCAAACCTGATAACACAATTTGAAACATA  
CCAACTATGGACAGCATTAACTCTCCTTAACGTGTTCAAATACAATTTTTACGTTGACTGTTGCC  
TGGAGAACAGCCACCCTGATTTTGGCTGGAGTTTCACCTTTACCAGTGTGCCAGTCTTCGAGTA  
TGAGGAAAACAGACTGGCTTCCAATGACAGTGGCAGCTATGGGAGTTCACCTCTACCACTTT  
TTATTTTTAGCTTAAAAGACACACTCAAAGGAGAAGCTGGCCACTGAATGAAGGGGTGATGG  
CTGTTGGGCTTGTGAGCATTCTGGCCAGTTCTCTCCTTAGAAATGATGTACCCATGGCTGGACC  
ATTAGTGGCCGGGGGCTTGCTGATAGCGTGCTACGTCATAACTGGCACGTCAGCAGACCTCAC  
CGTAGAAAAAGCAGCAGATGTAACATGGGAGGAAGAGGCTGAGCAAACAGGAGTGTCCCACA  
ACTTAATGATCACAGTTGATGATGATGGAACAATGAGAATAAAAGATGATGAGACTGAGAAT  
ATCTTAACAGTGCTTTTGAAAACAGCATTACTAATAGTGTGAGGAATCTTTCCATACTCCATAC  
CCGCAACATTGTTGGTCTGGCATACTTGGCAAAGCAAACCCAAAGATCCGGCGTTCTATGGG  
ATGTACCCAGCCCTCCAGAGACACAGAAAGCAGAACTGGAAGAAGGGGTCTATAGGATCAAA  
CAGCAAGGAATTTTTGGGAAAACCCAAGTAGGGGTGGAGTACAGAAAGAAGGAGTCTTTCA  
CACCATGTGGCACGTTACAAGAGGGGCAGTGTTGACATATAATGGGAAAAGACTGGAACCAA  
ATTGGGCTAGCGTGAAAAAAGATCTGATTTTCATACGGAGGAGGATGGAGATTGAGCGCACAA  
TGGCAAAGGGGGAGGAGGTGCAGGTTATTGCCGTAGAGCCTGGGAAGAACCCAAAGAACTT  
TCAAACCATGCCAGGCACTTTTCAGACTACAACAGGGGAAATAGGAGCAATTGCACTGGATTT  
CAAGCCCGGAACCTCAGGATCTCCTATCATAAACAGAGAGGGAAAGGTAGTGGGACTGTATG  
GCAATGGAGTGGTTACAAAGAATGGTGGCTACGTCAGCGGAATAGCGCAAACGAATGCAGAA  
CCAGATGGACCGACACCAGAATTGGAAGAAGAGATGTTCAAAAAGCGAAATCTAACCATAAT  
GGATCTTCATCCTGGGTCAGGAAAGACACGGAAATACCTTCCAGCTATTGTTAGAGAGGCAAT  
CAAGAGACGTTTGAGAACTCTAATTCTGGCACCAACAAGGGTGGTTGCAGCTGAGATGGAAGA  
AGCATTGAAAGGGCTCCCAATAAGGTACCAAACAACAGCAACAAAATCTGAACACACAGGAA  
GAGAGATTGTTGATCTGATGTGCCACGCAACGTTACAATGCGTCTGCTGTCACCAGTTAGGGT  
TCCAAACTATAACTTGATAATAATGGATGAAGCCATTTACAGACCCAGCCAGTATAGCTGC  
TAGAGGGTACATATCAACTCGTGTTGGAATGGGAGAAGCAGCCGCAATATTCATGACAGCAAC  
GCCCCCTGGAACAGCTGATGCCTTTCCCCAGAGCAACGCTCCAATTCAAGATGAAGAAAGGGA  
CATACCAGAACGCTCATGGAATTCAGGCAATGAATGGATAACCGACTTCGCTGGGAAAACGGT  
GTGGTTTGTCCCCAGCATTAAAGCCGGAATGACATAGCAAATTGCCTGCGGAAAAACGGGAA  
AAAGGTCATTCAACTTAGTAGGAAGACTTTTGACACAGAATATCAGAAAACCAAACCTGAATGA  
TTGGGACTTTGTGGTGACGACTGACATTTTCAGAAATGGGGGCCAATTTCAAAGCAGATAGAGT  
GATCGACCCAAGAAGATGTCTCAAACCAGTGATCCTGACAGATGGACCAGAGCGGGTGATCCT  
GGCTGGACCAATGCCAGTCACCGCAGCGAGTGCTGCGCAAAGGAGAGGGAGAGTTGGCAGGA  
ACCCACAAAAAGAAAATGACCAGTACATATTCACGGGCCAGCCTCTCAACAATGATGAAGAC  
CATGCTCACTGGACAGAAGCAAAAATGCTGCTGGACAACATTAACACACCAGAAGGGATCAT  
ACCAGCTCTCTTTGAGCCAGAAAGGGAGAAGTCAGCCGCCATAGACGGTGAGTATCGCCTGAA

AGGTGAGTCCAGGAAGACTTTTCGTGGAACATCATGAGGAGGGGTGACCTTCCAGTCTGGTTAGC  
CCATAAAGTAGCATCAGAAGGGATCAAATATACAGATAGAAAATGGTGCTTTGATGGACAAC  
GTAATAATCAAATTTTAGAAGAGAACATGGATGTGGAAATCTGGACAAAGGAAGGAGAAAAG  
AAAAAATTGAGACCTAGGTGGCTTGATGCTCGCACCTATTAGATCCCTTAGCACTCAAGGAA  
TTCAAGGACTTTGCGGCTGGCAGGAAGTCAATAGCCCTTGATCTTGTGACAGAAATAGGAAGA  
GTGCCTTCACACCTAGCTCATAGAACGAGAAACGCTCTGGACAATCTGGTGATGCTGCATACG  
TCAGAACATGGCGGTAAGGCCTACAGGCATGCGGTGGAGGAACTACCAGAGACAATGGAAAC  
ACTCCTACTCTTGGGACTCATGATCTTGTGACAGGTGGAGCAATGCTTTTCTTAATATCAGGT  
AAAGGGATTGGAAAGACTTCAATAGGACTCATTGTGTGTAATTGCTTCCAGCGGCATGTTGTGG  
ATGGCCGAAATCCCACTCCAATGGATCGCGTCGGCCATAGTCCTGGAGTTTTTTATGATGGTGT  
TGCTTATACCAGAACCAGAGAAGCAGAGAACCCCCAAGACAACCAACTCGCATATGTCGTGA  
TAGGCATACTTACACTGGCAGCAATAATAGCAGCCAATGAAATGGGATTGTTGGAAACTACAA  
AGAGAGATTTAGGAATGTCTAAGGAGCCAGGTGTTGTTTCTCCAACCAGCTATTTAGATGTGG  
ACTTGCACCCAGCATCAGCCTGGACATTGTACGCTGTGGCCACTACAGTAATAACACCAATGT  
TAAGACATACCATAGAGAATTCCACAGCAAATGTGTCCTTGGCAGCTATAGCCAACCAGGCAG  
TGGTCCTGATGGGTTTGGACAAAGGATGGCCAATATCAAAAATGGACTTAGGAGTACCCCTGC  
TGGCATTGGGTTGCTATTCACAAGTGAACCCACTGACTCTAACAGCGGCAGTACTCTTGCTGAT  
CACACATTATGCCATTATAGGTCCAGGATTGCAGGCCAAAAGCCACCCGTGAAGCTCAGAAAAG  
GACAGCTGCTGGAATAATGAAGAATCCAACAGTGGATGGGATAATGACAATAGACCTAGATC  
CTGTAATATATGATTCAAAATTTGAAAAGCAACTGGGACAGGTTATGCTCCTGGTTTTGTGTGC  
AGTTCAACTTTTTGTTAATGAGAACATCATGGGCCTTGTGTGAAGCTTTAACCTAGCTACAGGA  
CCAATAACAACACTCTGGGAAGGATCACCTGGGAAGTTTTTGGAAACACCACGATAGCTGTTTCC  
ATGGCGAACATTTTTAGAGGGAGCTATTTAGCAGGAGCTGGGCTTGCTTTCTCTATTATGAAAT  
CAGTTGGAACAGGGAAAAGAGGAACAGGCTCACAGGGTGAACTTTGGGAGAAAAATGGAA  
AAAGAAGTTAAATCAATTATCCCGGAAAGAGTTTGACCTTTACAAGAAATCTGGAATCACTGA  
GGTGGATAGAACAGAAGCCAAAGAAGGGTTGAAAAGAGGAGAAATAACACATCATGCCGTGT  
CCAGAGGTAGTGCAAAACTTCAATGGTTTGTGGAGAGAAACATGGTCATTCCCGAAGGAAGA  
GTTATAGACTTGGGCTGTGGAAGAGGAGGCTGGTCATATTACTGTGCAGGACTGAAAAAAGTC  
ACAGAAGTGCGAGGATACACAAAAGGCGGTCCAGGACACGAAGAACCAGTACCTATGTCCAC  
ATATGGATGGAACATAGTTAAGTTAATGAGTGGAAAGGATGTGTTTTATCTTCCACCTGAAAA  
GTGTGACACCCTGTTGTGCGACATTGGAGAATCTTCACCAAGCCCAACAGTGGAAAGAAAGCAG  
AACTATAAGAGTTTTGAAGATGGTTGAACCATGGCTAAAGAACAACCAATTTTGTATTAAAGT  
ATTGAACCCTTACATGCCAACTGTGATTGAGCACCTAGAAAGACTACAAAGGAAACATGGAGG  
AATGCTTGTGAGAAATCCACTTTACGAAACTCCACGCACGAAATGTACTGGATATCCAATGG  
CACAGGTAACATTGTCGCTTCAGTCAACATGGTATCTAGACTGCTACTGAACAGGTTACGATG  
ACACACAGAAGACCCACCATTGAGAAAGATGTGGATTTAGGAGCAGGAACTCGACATGTTAA  
TGCGGAACCAGAAACACCCAACATGGATGTCATTGGGGAAAGAATAAAAAGGATCAAGGAGG

AGCATAATTCAACATGGCACTACGATGACGAAAACCCCTACAAAACGTGGGCTTACCATGGAT  
CTTATGAAGTCAAAGCCACAGGCTCAGCCTCCTCCATGATAAATGGAGTCGTGAAACTCCTCA  
CTAAACCATGGGATGTGGTGCCCATGGTGACACAGATGGCAATGACAGATACAACTCCATTTG  
GCCAGCAGAGAGTCTTTAAAGAGAAAGTGGACACCAGGACACCCAGGTCCATGCCAGGAACA  
AGAAGGGTTATGGGGATCACAGCGGAGTGGCTCTGGAGAACCCTGGGAAGGAATAAAAAACC  
CAGGTTATGCACAAGGGAAGAGTTTACAAAAAAGGTCAGAACTAACGCAGCCATGGGAGCTG  
TTTTACAGAGGAGAACCAATGGGACAGCGCGAAAGCTGCTGTTGAGGATGAGGATTTTTTGA  
AACTTGTGGACAGAGAACGTGAACTCCACAACTGGGCAAGTGTGGAAGCTGTGTTTACAACA  
TGATGGGTAAGAGAGAGAAGAACTTGGAGAGTTTGGCAAAGCAAAAGGCAGTAGAGCTATA  
TGGTACATGTGGTTGGGAGCCAGGTACCTTGAGTTCGAAGCCCTTGGATTCTTAAATGAAGAC  
CACTGGTTCTCGCGTGAGAACTCTTACAGTGGAGTGGAAAGGAGAAGGACTGCACAAGCTAGGC  
TATATATTAAGGGACATTTCCAAGATACCCGGAGGAGCTATGTATGCTGATGACACAGCTGGT  
TGGGACACAAGAATAACAGAAGATGACCTGCACAATGAGGAAAAGATCACACAGCAAATGGA  
CCCTGAACACAGGCAGTTAGCGAACGCTATATTTAAGCTCACATACCAAAACAAAGTGGTCAA  
AGTTCAACGACCGACTCCAACAGGCACGGTAATGGATATCATATCTAGGAAAGACCAAGAG  
GCAGTGGACAGGTAGGAACTTATGGTCTGAATACATTCACCAACATGGAAGCCCAGTTAATCA  
GACAAATGGAAGGAGAAGGTGTGCTGTCAAAGGCAGACCTCGAGAACCCTCATCTGCCAGAG  
AAGAAAATTACACAATGGTTGGAAACCAAGGAGTGGAGAGGTTAAAAAGAATGGCCATAAG  
TGGGGATGACTGCGTGGTGAAACCAATCGATGACAGGTTGCTAATGCCCTGCTCGCTCTGAA  
CGACATGGGAAAGGTTGCGAAAGACATACCTCAATGGCAGCCATCAAAGGGATGGCATGATT  
GGCAACAGGTTCTTTCTGCTCCCACCACTTTTCATGAATTGATCATGAAAGATGGAAGAAAGTT  
GGTGGTTCCCTGCAGACCCCAGGACGAACTAATAGGAAGGGCAAGAATCTCTCAAGGAGCGG  
GATGGAGCCTTAGAGAAACCGCATGTCTGGGGAAAGCCTACGCTCAAATGTGGAGTCTCATGT  
ATTTTCACAGAAGAGACCTCAGACTAGCATCCAACGCCATATGTTTCAGCAGTACCAGTCCACT  
GGGTCCCCACAAGTAGAACGACATGGTCTATTACGCTCACCATCAGTGGATGACCACAGAAG  
ACATGCTTACTGTCTGGAACAGAGTGTGGATCGAGGACAATCCATGGATGGAAGACAAAACCTC  
CAGTCACAACCTGGGAAAATGTTCCATATCTAGGGAAGAGAGAAGACCAATGGTGCGGATCA  
CTTATTGGTCTCACTTCCAGAGCAACCTGGGCCCAGAACATACCCACAGCAATTCAACAGGTT  
AGAAGCCTTATAGGCAATGAAGAGTTTCTGGACTACATGCCTTCAATGAAGAGATTTAGGAAG  
GAGGAGGAGTCCGAGGGAGCCATTTGGTAAAACGTAGGAAGTGAAAAAGAGGTTAACTGTCA  
GGCCATATTAAGCCACAGTACGGAAGAAGCTGTGCTGCCTGTGAGCCCCGTCCAAGGACGTTA  
AAAGAAGAAGTCAGGCCCCAAAGCCACGGTTTGAGCAAACCGTGCTGCCTGTAGCTCCGCTCGT  
GGGGACGTAAAACCTGGGAGGCTGCAAACCTGTGGAAGCTGTACGCACGGTGTAGCAGACTAG  
CGGTTAGAGGAGACCCCTCCCATGACACAACGCAGCAGCGGGGCCCGAGCACTGAGGGAAGC  
TGTACCTCCTTGCAAAGGACTAGAGGTTAGAGGAGACCCCCGCAAATAAAAAACAGCATATTG  
ACGCTGGGAGAGACCAGAGATCCTGCTGTCTCCTCAGCATCATTCCAGGCACAGAACGCCAGA  
AAATGGAATGGTGCTGTTGAATCAACAGGTTCT

[0146] SEQ ID NO: 6 – DENV-3-VE-BID-V2268-2008-E-Min

AGTTGTTAGTCTACGTGGACCGACAAGAACAGTTTTCGACTCGGAAGCTTGCTTAACGTAGTGCT  
AACAGTTTTTTTATTAGAGAGCAGATCTCTGATGAACAACCAACGGAAGAAGACGGGAAAACC  
GTCTATCAATATGCTGAAACGCGTGAGAAACCGTGTGTCAACTGGATCACAGTTGGCGAAGAG  
ATTCTCAAAAGGACTGCTGAACGGCCAGGGACCAATGAAATTGGTTATGGCGTTCATAGCTTT  
CCTCAGATTTCTAGCCATTCCACCAACAGCAGGAGTCTTGGCTAGATGGGGAACCTTCAAGAA  
GTCGGGGGCCATTAAGGTCCTGAAAGGCTTTAAGAAGGAGATCTCAAACATGCTGAGCATAAT  
CAACAAACGGAAAAAGACATCGCTCTGTCTCATGATGATATTGCCAGCAGCACTTGCTTTCCA  
CTTGACTTCACGAGATGGAGAGCCGCGCATGATTGTGGGGAAGAATGAAAGAGGAAAAATCCC  
TACTTTTTTAAGACAGCCTCTGGAATTAACATGTGCACACTCATAGCCATGGACTTGGGAGAGAT  
GTGTGATGACACGGTCACTTACAAATGCCCCCATATTACCGAAGTGGAACCTGAAGACATTGA  
CTGCTGGTGCAACCTCACATCAACATGGGTGACTTATGGAACGTGCAATCAAGCCGGAGAGCA  
TAGACGCGATAAGAGATCAGTGGCGTTAGCTCCCCATGTCCGCATGGGACTGGATACACGCAC  
CCAAACTTGATGTCCGCTGAAGGAGCTTGGAGGCAAGTCGAGAAGGTAGAGACATGGGCCC  
TTAGGCACCCAGGGTTCACCATACTAGCCCTATTTCTTGCCCATACATAGGCACTTCCTTGAC  
CCAGAAGGTGGTTATTTTTATACTGCTAATGCTGGTCACCCCATCCATGACAATGAGATGCGTG  
GGCGTAGGGAATAGAGACTTTGTAGAGGGATTGAGCGGAGCGACATGGGTTCGACGTCTGACT  
CGAACACGGGGGGTGCGTGACGACTATGGCTAAGAATAAGCCTACACTCGATATCGAACTGCA  
AAAAACCGAAGCGACACAATTGGCGACATTGCGCAAACTATGTATCGAAGGTAAGATTACGA  
ACATTACAACCGATAGTAGATGCCCTACACAAGGCGAAGCCGTTCTACCTGAGGAGCAAGACC  
AAAACCTACGTATGTAAGCATACATACGTTGATAGGGGGTGGGGGAACGGATGCGGATTGTTG  
GTAAGGGGTCATTGGTCACATGCGCTAAGTTCCAATGCTTAGAGCCTATCGAGGGTAAGGTGG  
TACAATACGAAAACCTTAAGTATACCGTGATAATTACAGTTCATACCGGAGACCAACACCAAG  
TGGGAAACGAGACACAGGGAGTGACAGCCGAAATTACGCCTCAGGCTAGTACAACCGAAGCG  
ATACTACCCGAATACGGAACATTGGGGTTGGAGTGTTACCTAGAACCGGATTGGACTTTAAC  
GAAATGATACTGTTGACTATGAAAAACAAGGCATGGATGGTGCATAGGCAATGGTTTTTTTGAC  
CTACCATTGCCTTGGACTIONGCGGAGCGACAACCGAAACACCTACATGGAATAGAAAAGAGCTC  
CTAGTGACATTTAAAAACGCTCACGCTAAGAAGCAGGAAGTGGTCGTTTTAGGGTCACAGGAG  
GGAGCTATGCATACCGCACTAACCGGAGCGACTGAGATACAGAATAGCGGAGGGACATCAAT  
CTTCGCCGGACACCTTAAGTGTAGATTGAAAATGGACAACTTGAGCTTAAGGGGATGTCATA  
CGCTATGTGTACGAACACATTCGTGCTGAAAAAAGAGGTAAGCGAAACGCAACACGGAACGA  
TACTGATTAAGGTTGAGTATAAGGGCGAAGACGTCCCATGTAAGATACCTTTTTTCGACAGAGG  
ACGGACAGGGTAAGGCCATAACGGAAGACTGATTACCGCTAACCCAGTGGTGACCAAAAAA  
GAGGAACCAGTCAATATCGAAGCCGAACCTCCATTTCGGAGAGTCAAACATAGTGATAGGGAT  
AGGCGATAACGCACTTAAGATTAAGTGGTACAAAAAAGGGTCATCAATCGGTAAGATGTTTGA  
GGCAACCGCTAGGGGGGCTAGACGGATGGCCATACTCGGAGACACCGCATGGGACTTCGGAT

CCGTGGGGGGGGTACTTAACTCACTCGGTAAGATGGTGCACCAAATTTTCGGATCCGCATATA  
 CCGCTCTATTTAGCGGAGTGTCATGGGTGATGAAAATCGGAATCGGAGTTCTATTGACATGGA  
 TCGGATTGAACTCTAAGAATACATCTATGTCATTTTCATGTATCGCAATCGGAATTATTACGCT  
 ATATCTCGGAGCCGTAGTGCAAGCCGACATGGGGTGTGTTATAAACTGGAAAGGCAAAGAAGT  
 CAAGTGTGGAAGTGGAATCTTCGTACCAACGAGGTCCATACCTGGACAGAGCAATACAAATT  
 CCAAGCAGACTCCCCAAAAAGATTGGCGACAGCCATTGCAGGCGCTTGGGAGAATGGAGTGT  
 GCGGAATTAGGTCAACAACCAGAATGGAGAATCTCCTGTGGAAGCAAATAGCCAATGAACTG  
 AACTACATATTGTGGGAAAACAATATCAAATTAACGGTTGTTGTGGGCGATATAATTGGGGTC  
 TTAGAGCAAGGGAAAAGAACAATAACACCACAACCCATGGAGCTAAAATACTCATGGAAAAC  
 GTGGGGAAAGGCAAAAATAGTGACAGCTGAAACACAAAATTCTTCTTTCATAATAGATGGACC  
 AAACACACCGGAGTGTCCAAGTGCCTCAAGAGCATGGAATGTGTGGGAGGTGGAAGATTACG  
 GGTTCCGAGTCTTCACAACCAACATATGGCTGAAACTCCGAGAGGTGTATACCCAACATATGTG  
 ACCATAGGTTAATGTCGGCAGCCGTCAAGGATGAAAGGGCCGTACATGCCGACATGGGCTATT  
 GGATAGAAAGTCAAAAGAATGGAAGTTGGAAGCTAGAAAAAGCATCCCTCATAGAGGTGAAA  
 ACCTGCACATGGCCAAAATCACATACCCTTTGGAGTAATGGTGTGTTAGAGAGTGACATGATC  
 ATTCCAAAAGTCTAGCTGGTCCTATCTCGCAACACAACCTACAGGCCCCGGGTACCACACCCAG  
 ACGGCGGGACCTTGGCATTTAGGAAAATTAGAGCTGGACTTCAACTATTGTGAAGGAACAACA  
 GTTGTATCACAGAAAACGTGGGACAAGAGGCCCATCATTGAGAACAACAACAGTGTGAGG  
 GAAGTTAATACACGAATGGTGCTGCCGCTCGTGACACTTCCTCCCCTGCGATACATGGGAGA  
 AGACGGTTGCTGGTATGGCATGGAAATCAGACCCATCAGTGAGAAAGAAGAAAACATGGTAA  
 AGTCTTTAGTCTCAGCGGGAAGTGGAGAGGTGGACAACCTTCACAATGGGTGTCTTGTGTTTGG  
 CAATCCTCTTTGAAGAGGTGATGAGAGGAAAATTTGGGAAGAAACACATGATTGCGGGGGTTT  
 TCTTACGTTTGTACTCCTTCTCTCAGGGCAAATAACATGGAGAGATATGGCGCACACACTAAT  
 AATGATTGGGTCCAATGCATCTGACAGGATGGGAATGGGCGTCACCTACCTAGCTTTAATTGC  
 AACATTTAAATCCAGCCATTTTTGGCTTTGGGATTTTTCCTAAGAAAACCTGACATCCAGAGAA  
 AATTTATTGTTAGGAGTTGGGCTGGCTATGGCAACAACGTTACAACCTGCCAGAGGACATTGAA  
 CAAATGGCAAATGGAATCGCTCTGGGGCTCATGGCTCTCAAACCTGATAACACAATTTGAAACA  
 TACCAACTATGGACAGCATTAATCTCCTTAACGTGTTCAAATACAATTTTTACGTTGACTGTTG  
 CCTGGAGAACAGCCACCCTGATTTTGGCTGGAGTTTCACTTTTACCAGTGTGCCAGTCTTCGAG  
 TATGAGGAAAACAGACTGGCTTCCAATGACAGTGGCAGCTATGGGAGTTCCACCTCTACCACT  
 TTTATTTTTAGCTTAAAAGACACACTCAAAGGAGAAGCTGGCCACTGAATGAAGGGGTGAT  
 GGCTGTTGGGCTTGTGAGCATTCTGGCCAGTTCTCTCCTTAGAAATGATGTACCCATGGCTGGA  
 CCATTAGTGGCCGGGGGCTTGCTGATAGCGTGCTACGTCATAACTGGCACGTCAGCAGACCTC  
 ACCGTAGAAAAAGCAGCAGATGTAACATGGGAGGAAGAGGCTGAGCAAACAGGAGTGTCCCA  
 CAACTTAATGATCACAGTTGATGATGATGGAACAATGAGAATAAAAGATGATGAGACTGAGA  
 ATATCTTAACAGTGCTTTTGAAAACAGCATTACTAATAGTGTGAGGAATCTTTCATACTCCAT  
 ACCCGCAACATTGTTGGTCTGGCATACTTGGCAAAAGCAAACCCAAAGATCCGGCGTTCTATG

GGATGTACCCAGCCCTCCAGAGACACAGAAAGCAGAACTGGAAGAAGGGGTCTATAGGATCA  
AACAGCAAGGAATTTTTGGGAAAACCCAAGTAGGGGTGGAGTACAGAAAGAAGGAGTCTTT  
CACACCATGTGGCACGTTACAAGAGGGGCAGTGTGACATATAATGGGAAAAGACTGGAACC  
AAATTGGGCTAGCGTGAAAAAAGATCTGATTTTCATACGGAGGAGGATGGAGATTGAGCGCAC  
AATGGCAAAAGGGGGAGGAGGTGCAGGTTATTGCCGTAGAGCCTGGGAAGAACCCAAAGAAC  
TTTCAAACCATGCCAGGCACTTTTCAGACTACAACAGGGGAAATAGGAGCAATTGCACTGGAT  
TTCAAGCCCGGAACTTCAGGATCTCCTATCATAAACAGAGAGGGAAAGGTAGTGGGACTGTAT  
GGCAATGGAGTGGTTACAAAGAATGGTGGCTACGTCAGCGGAATAGCGCAAACGAATGCAGA  
ACCAGATGGACCGACACCAGAATTGGAAGAAGAGATGTTCAAAAAGCGAAATCTAACCATAA  
TGGATCTTCATCCTGGGTCAGGAAAGACACGGAAATACCTTCCAGCTATTGTTAGAGAGGCAA  
TCAAGAGACGTTTGAGAACTCTAATTCTGGCACCAACAAGGGTGGTTGCAGCTGAGATGGAAG  
AAGCATTGAAAGGGCTCCCAATAAGGTACCAAACAACAGCAACAAAATCTGAACACACAGGA  
AGAGAGATTGTTGATCTGATGTGCCACGCAACGTTTACAATGCGTCTGCTGTCACCAGTTAGG  
GTTCCAAACTATAACTTGATAATAATGGATGAAGCCCATTTACAGACCCAGCCAGTATAGCT  
GCTAGAGGGTACATATCAACTCGTGTTGGAATGGGAGAAGCAGCCGCAATATTCATGACAGCA  
ACGCCCCCTGGAACAGCTGATGCCTTTCCCCAGAGCAACGCTCCAATTCAAGATGAAGAAAGG  
GACATACCAGAACGCTCATGGAATTCAGGCAATGAATGGATAACCGACTTCGCTGGGAAAAC  
GGTGTGGTTTTGTCCCCAGCATTAAAGCCGGAATGACATAGCAAATTGCCTGCGGAAAAACGG  
GAAAAAGGTCATTCAACTTAGTAGGAAGACTTTTGACACAGAATATCAGAAAACCAAATGA  
ATGATTGGGACTTTGTGGTGACGACTGACATTTTCAAGAAATGGGGGCCAATTTCAAAGCAGATA  
GAGTGATCGACCCAAGAAGATGTCTCAAACCAGTGATCCTGACAGATGGACCAGAGCGGGTG  
ATCCTGGCTGGACCAATGCCAGTCACCGCAGCGAGTGCTGCGCAAAGGAGAGGGAGAGTTGG  
CAGGAACCCACAAAAAGAAAATGACCAGTACATATTCACGGGCCAGCCTCTCAACAATGATG  
AAGACCATGCTCACTGGACAGAAGCAAAAATGCTGCTGGACAACATTAAACACACCAGAAGGG  
ATCATACCAGCTCTCTTTGAGCCAGAAAGGGAGAAGTCAGCCGCCATAGACGGTGAGTATCGC  
CTGAAAGGTGAGTCCAGGAAGACTTTTCGTGGAATCATGAGGAGGGGTGACCTTCCAGTCTGG  
TTAGCCCATAAAGTAGCATCAGAAGGGATCAAATATACAGATAGAAAATGGTGCTTTGATGGA  
CAACGTAATAATCAAATTTTAGAAGAGAACATGGATGTGGAAATCTGGACAAAGGAAGGAGA  
AAAGAAAAAATTGAGACCTAGGTGGCTTGATGCTCGCACCTATTCAGATCCCTTAGCACTCAA  
GGAATTCAAGGACTTTGCGGCTGGCAGGAAGTCAATAGCCCTTGATCTTGTGACAGAAATAGG  
AAGAGTGCCTTCACACCTAGCTCATAGAACGAGAAACGCTCTGGACAATCTGGTGATGCTGCA  
TACGTCAGAACATGGCGGTAAGGCCTACAGGCATGCGGTGGAGGAACTACCAGAGACAATGG  
AAACACTCCTACTCTTGGGACTCATGATCTTGTGACAGGTGGAGCAATGCTTTTCTTAATATC  
AGGTAAAGGGATTGGAAGACTTCAATAGGACTCATTTGTGTAATTGCTTCCAGCGGCATGTT  
GTGGATGGCCGAAATCCCACTCCAATGGATCGCGTCGGCCATAGTCCTGGAGTTTTTTATGATG  
GTGTTGCTTATACCAGAACCAGAGAAGCAGAGAACCCCCCAAGACAACCAACTCGCATATGTC  
GTGATAGGCATACTTACACTGGCAGCAATAATAGCAGCCAATGAAATGGGATTGTTGGAACT

ACAAAGAGAGATTTAGGAATGTCTAAGGAGCCAGGTGTTGTTTCTCCAACCAGCTATTTAGAT  
GTGGACTTGACCCCAGCATCAGCCTGGACATTGTACGCTGTGGCCACTACAGTAATAACACCA  
ATGTTAAGACATACCATAGAGAATTCCACAGCAAATGTGTCCTTGGCAGCTATAGCCAACCAG  
GCAGTGGTCCTGATGGGTTTGGACAAAGGATGGCCAATATCAAAAATGGACTTAGGAGTACCC  
CTGCTGGCATTGGGTTGCTATTCACAAGTGAACCCACTGACTCTAACAGCGGCAGTACTCTTGC  
TGATCACACATTATGCCATTATAGGTCCAGGATTGCAGGCAAAAGCCACCCGTGAAGCTCAGA  
AAAGGACAGCTGCTGGAATAATGAAGAATCCAACAGTGGATGGGATAATGACAATAGACCTA  
GATCCTGTAATATATGATTCAAAATTTGAAAAGCAACTGGGACAGGTTATGCTCCTGGTTTTGT  
GTGCAGTTCAACTTTTGTTAATGAGAACATCATGGGCCTTGTGTGAAGCTTTAACCTAGCTAC  
AGGACCAATAACAACACTCTGGGAAGGATCACCTGGGAAGTTTTGGAACACCACGATAGCTGT  
TTCCATGGCGAACATTTTTAGAGGGAGCTATTTAGCAGGAGCTGGGCTTGCTTTCTCTATTATG  
AAATCAGTTGGAACAGGGAAAAGAGGAACAGGCTCACAGGGTGAACTTTGGGAGAAAAATG  
GAAAAAGAAGTTAAATCAATTATCCCGGAAAGAGTTTGACCTTTACAAGAAATCTGGAATCAC  
TGAGGTGGATAGAACAGAAGCCAAAGAAGGGTTGAAAAGAGGAGAAATAACACATCATGCCG  
TGTCAGAGGTAGTGCAAACTTCAATGGTTTTGTGGAGAGAAACATGGTCATTCCCGAAGGAA  
GAGTTATAGACTTGGGCTGTGGAAGAGGAGGCTGGTCATATTACTGTGCAGGACTGAAAAAAG  
TCACAGAAGTGCGAGGATACACAAAAGGCGGTCCAGGACACGAAGAACCAGTACCTATGTCC  
ACATATGGATGGAACATAGTTAAGTTAATGAGTGGAAGGATGTGTTTTATCTTCCACCTGAA  
AAGTGTGACACCCTGTTGTGCGACATTGGAGAATCTTCACCAAGCCCAACAGTGGAAGAAAGC  
AGAACTATAAGAGTTTTGAAGATGGTTGAACCATGGCTAAAGAACAACCAATTTTGTATTAAA  
GTATTGAACCCTTACATGCCAACTGTGATTGAGCACCTAGAAAGACTACAAAGGAAACATGGA  
GGAATGCTTGTGAGAAATCCACTTTACGAAACTCCACGCACGAAATGTACTGGATATCCAAT  
GGCACAGGTAACATTGTGCTTCAGTCAACATGGTATCTAGACTGCTACTGAACAGGTTACG  
ATGACACACAGAAGACCCACCATTGAGAAAGATGTGGATTTAGGAGCAGGAACTCGACATGT  
TAATGCGGAACCAGAAACACCCAACATGGATGTCATTGGGGAAAGAATAAAAAGGATCAAGG  
AGGAGCATAATTCAACATGGCACTACGATGACGAAAACCCCTACAAAACGTGGGCTTACCATG  
GATCTTATGAAGTCAAAGCCACAGGCTCAGCCTCCTCCATGATAAATGGAGTCGTGAAACTCC  
TCACTAAACCATGGGATGTGGTGCCCATGGTGACACAGATGGCAATGACAGATACAACCTCCAT  
TTGGCCAGCAGAGAGTCTTTAAAGAGAAAGTGGACACCAGGACACCCAGGTCCATGCCAGGA  
ACAAGAAGGGTTATGGGGATCACAGCGGAGTGGCTCTGGAGAACCCTGGGAAGGAATAAAAA  
ACCCAGGTTATGCACAAGGGAAGAGTTTACAAAAAAGGTCAGAACTAACGCAGCCATGGGAG  
CTGTTTTTCACAGAGGAGAACCAATGGGACAGCGCGAAAGCTGCTGTTGAGGATGAGGATTTTT  
GGAACTTGTGGACAGAGAACGTGAACTCCACAACTGGGCAAGTGTGGAAGCTGTGTTTACA  
ACATGATGGGTAAAGAGAGAGAAGAACTTGGAGAGTTTGGCAAAGCAAAAGGCAGTAGAGCT  
ATATGGTACATGTGGTTGGGAGCCAGGTACCTTGAGTTTCAAGCCCTTGGATTCTTAAATGAA  
GACCACTGGTTCTCGCGTGAGAACTCTTACAGTGGAGTGGAAGGAGAAGGACTGCACAAGCTA  
GGCTATATATTAAGGGACATTTCCAAGATACCCGGAGGAGCTATGTATGCTGATGACACAGCT

GGTTGGGACACAAGAATAACAGAAGATGACCTGCACAATGAGGAAAAGATCACACAGCAAAT  
 GGACCCTGAACACAGGCAGTTAGCGAACGCTATATTTAAGCTCACATACCAAAACAAAGTGGT  
 CAAAGTTCAACGACCGACTCCAACAGGCACGGTAATGGATATCATATCTAGGAAAGACCAAA  
 GAGGCAGTGGACAGGTAGGAAGTTATGGTCTGAATACATTACCAACATGGAAGCCCAGTTAA  
 TCAGACAAATGGAAGGAGAAGGTGTGCTGTCAAAGGCAGACCTCGAGAACCCTCATCTGCCA  
 GAGAAGAAAATTACACAATGGTTGGAAACCAAGGAGTGGAGAGGTTAAAAAGAATGGCCAT  
 AAGTGGGGATGACTGCGTGGTGAAACCAATCGATGACAGGTTGCTAATGCCCTGCTCGCTCT  
 GAACGACATGGGAAAGGTTTCGGAAAGACATACCTCAATGGCAGCCATCAAAGGGATGGCATG  
 ATTGGCAACAGGTTCCCTTTCTGCTCCCACCACTTTTCATGAATTGATCATGAAAGATGGAAGAAA  
 GTTGGTGGTTCCCTGCAGACCCCAGGACGAACTAATAGGAAGGGCAAGAATCTCTCAAGGAGC  
 GGGATGGAGCCTTAGAGAAACCGCATGTCTGGGGAAAGCCTACGCTCAAATGTGGAGTCTCAT  
 GTATTTTTCACAGAAGAGACCTCAGACTAGCATCCAACGCCATATGTTTCAGCAGTACCAGTCCA  
 CTGGGTCCCCACAAGTAGAACGACATGGTCTATTCACGCTCACCATCAGTGGATGACCACAGA  
 AGACATGCTTACTGTCTGGAACAGAGTGTGGATCGAGGACAATCCATGGATGGAAGACAAAA  
 CTCCAGTCACAACCTGGGAAAATGTTCCATATCTAGGGAAGAGAGAAGACCAATGGTGC GGAT  
 CACTTATTGGTCTCACTTCCAGAGCAACCTGGGCCCAGAACATACCCACAGCAATTCAACAGG  
 TTAGAAGCCTTATAGGCAATGAAGAGTTTCTGGACTACATGCCTTCAATGAAGAGATTTAGGA  
 AGGAGGAGGAGTCGGAGGGAGCCATTTGGTAAAACGTAGGAAGTGAAAAAGAGGTTAACTGT  
 CAGGCCATATTAAGCCACAGTACGGAAGAAGCTGTGCTGCCTGTGAGCCCCGTCCAAGGACGT  
 TAAAAGAAGAAGTCAGGCCCCAAAGCCACGTTTGTAGCAAACCGTGCTGCCTGTAGCTCCGTC  
 GTGGGGACGTAAAACCTGGGAGGCTGCAAACCTGTGGAAGCTGTACGCACGGTGTAGCAGACT  
 AGCGGTTAGAGGAGACCCCTCCCATGACACAACGCAGCAGCGGGGGCCCGAGCACTGAGGGAA  
 GCTGTACCTCCTTGCAAAGGACTAGAGGTTAGAGGAGACCCCCGCAAATAAAAAACAGCATAT  
 TGACGCTGGGAGAGACCAGAGATCCTGCTGTCTCCTCAGCATCATTCCAGGCACAGAACGCCA  
 GAAAATGGAATGGTGTGTTGAATCAACAGGTTCT

[0147] SEQ ID NO:7 – DENV4\_Syn\_WT

AGTTGTAGTCTGTGTGGACCGACAAGGACAGTTCCAAATCGGAAGCTTGCTTAACACAGTTCT  
 AACAGTTTGTTTAAATAGAGAGCAGATCTCTGGAAAAATGAACCAACGAAAAAAGGTGGTTA  
 GACCACCTTTCAATATGCTGAAACGCGAGAGAAACCGCGTATCAACCCCTCAAGGGTTGGTGA  
 AGAGATTCTCAACCGGACTTTTTTCTGGGAAAGGACCCCTTACGGATGGTGTAGCATTATCAC  
 GTTTTTGCGAGTCCTTTCCATCCCACCAACAGCAGGGATTCTGAAGAGATGGGGACAGTTGAA  
 GAAAAATAAGGCCATCAAGATACTGATTGGATTTCAGGAAGGAGATAGGCCGCATGCTGAACA  
 TCTTGAACGGGAGAAAAAGGTCAACGATAACATTGTTGTGCTTGATTCCACCGTAATGGCGT  
 TTCCTTGTCAACAAGAGATGGCGAACCCCTCATGATAGTGGCAAAACATGAAAGGGGGAGA  
 CCTCTCTTGTTTAAGACAACAGAGGGGGATCAACAAATGCACTCTCATTGCCATGGACTTGGGTG  
 AAATGTGTGAGGACACTGTCACGTATAAATGCCCCCTACTGGTCAATACCGAACCTGAAGACA

TTGATTGCTGGTGCAACCTCACGTCTACCTGGGTCATGTATGGGACATGCACCCAGAGCGGAG  
AACGGAGACGAGAGAAGCGCTCAGTAGCTTTGACACCACATTCAGGAATGGGATTGGAAACA  
AGAGCTGAGACATGGATGTCATCGGAAGGGGCTTGGAAGCATGCTCAGAGAGTAGAGAGCTG  
GATACTCAGAAACCCAGGATTTGCGCTCTTGGCAGGATTTATGGCTTATATGATTGGGCAAAC  
AGGAATCCAGCGAACTGTCTTCTTTGTCCTAATGATGCTGGTCCCCATCCTACGGAATGCGG  
TGCGTAGGAGTAGGAAACAGAGACTTTGTGGAAGGAGTCTCAGGTGGAGCATGGGTGACCT  
GGTGCTAGAACATGGAGGATGCGTCACAACCATGGCCCAGGGAAAACCAACCTTGGATTTTGA  
ACTGACTAAGACAACAGCTAAGGAAGTGGCTCTGTTAAGAACCTATTGCATTGAAGCCTCAAT  
ATCAAACATAACTACGGCAACAAGATGTCCAACGCAAGGAGAGCCTTATCTGAAAGAGGAAC  
AGGACCAACAGTACATCTGCCGGAGAGATGTGGTAGACAGAGGATGGGGCAATGGCTGTGGC  
TTGTTTGGAAAAGGAGGAGTTGTGACATGTGCGAAGTTTTTCATGTTCGGGGAAGATAACAGGC  
AATCTGGTCCAAATTGAGAACCTTGAATACACAGTGGTTGTAACAGTCCACAATGGAGACACC  
CATGCAGTAGGAAATGACACATCCAATCATGGAGTTACAGCCACGATAACTCCCAGGTCCACA  
TCGGTAGAAGTCAAATTGCCGGACTATGGAGAACTAACACTCGATTGTGAACCCAGGTCTGGA  
ATTGACTTTAATGAGATGATCCTAATGAAAATGAAAAAGAAAACATGGCTCGTGCATAAGCAA  
TGGTTTTTGGATCTGCCTCTTCCATGGACAGCAGGAGCAGACACATCAGAGGTTCACTGGAATT  
ACAAAGAGAGAATGGTGACGTTCAAGGTTCCCTCATGCCAAGAGACAGGATGTGACAGTGCTG  
GGATCTCAGGAAGGAGCCATGCATTCTGCCCTCGCTGGAGCCACAGAAGTGGACTCCGGTGAT  
GGAAATCACATGTTTGCAGGACATCTCAAGTGCAAAGTCCGTATGGAGAAATTGAGAATCAAG  
GGAATGTCATACAGATGTGTTTCAGGAAAGTTTTCAATTGACAAAGAGATGGCAGAAACACAG  
CATGGGACAACAGTGGTGAAAGTCAAGTATGAAGGTGCTGGAGCTCCGTGTAAAGTCCCCATA  
GAGATAAGAGATGTAAACAAGGAAAAAGTGGTTGGGCGCGTTATCTCATCCACCCCTTTGGCT  
GAGAATACCAACAGTGTAACCAACATAGAATTAGAACCCCTTTGGGGACAGCTACATTGTG  
ATAGGTGTTGGAAACAGCGCATTAACTCCATTGGTTCAGGAAAGGGAGTTCCATTGGCAAG  
ATGTTTGAGTCCACATACAGAGGTGCAAAACGAATGGCCATTCTAGGTGAAACAGCTTGGGAT  
TTTGGTTCCGTTGGTGGACTGTTACATCATTGGGAAAGGCTGTACACCAGGTTTTTGGAAAGCG  
TGTATACAACCATGTTTGGAGGAGTCTCATGGATGATTAGAATCCTAATTGGGTTCTTAGTGTT  
GTGGATTGGCACGAATTCAAGGAACACTTCAATGGCCATGACGTGCATAGCTGTTGGAGGAAT  
TACTCTGTTTTTGGGCTTCACAGTTCAAGCGGACATGGGTTGTGTGGTGTGCATGGAGTGGGAGA  
GAATTGAAGTGTGGAAGCGGAATTTTTGTGGTTGACAACGTGCACACTTGGACAGAACAGTAC  
AAATTCCAACCAGAGTCCCCAGCGAGACTAGCGTCTGCAATATTAAATGCCACAAAGATGGG  
GTCTGTGGAATTAGATCAACCACGAGGCTGGAAAATGTTATGTGGAAGCAAATAACCAATGAG  
CTAAACTATGTTCTCTGGGAAGGAGGACATGATCTCACTGTAGTGGCTGGGGATGTGAAAGGG  
GTGTTGACCAAGGGCAAGAGAGCACTCACACCCCCAGCGAGTGATCTGAAATATTCATGGAAG  
ACATGGGGGAAAGCAAAAATCTTACCCCTGAAGCAAGAAACAGCACATTTTTAATAGACGG  
ACCAGACACCTCTGAATGCCCAATGAACGAAGGGCATGGAATTCTTTTGAGGTGGAAGACTA  
TGGATTTGGCATGTTACGACCAACATATGGATGAAATTCGAGAAGGAAGTTCAGAAGTGTG

TGACCACAGGTTAATGTCAGCTGCAATTAAAGACCAGAAAAGCTGTGCATGCTGACATGGGTTA  
TTGGATAGAGAGCTCAAAAAACCAGACCTGGCAGATAGAGAGAGCATCTCTTATTGAAGTGA  
AAACATGTCTGTGGCCCAAGACCCATACACTGTGGAGCAATGGAGTGCTGGAAAGCCAGATGC  
TTATTCCAAAATCATATGCAGGCCCTTTTTACAGCACAATTACCGCCAGGGCTATGCTACGCA  
AACCGTGGGTCCATGGCACTTAGGCAAAGTAGAGATAGACTTTGGAGAATGCCCCGGAACAAC  
AGTCACAATTCAGGAGAATTGTGACCATAGAGGGCCCATCTTTGAGGACCACCACTGCATCTGG  
AAAAGTAGTCACGCAATGGTGTGCGCTCCTGCACGATGCCCCCTTAAGGTTCTTAGGAGA  
AGATGGGTGCTGGTATGGGATGGAGATTAGGCCCTTGAGTGAAAAAGAAGAGAACATGGTCA  
AATCACAGGTGACGGCCGGACAGGGCACATCGGAAACTTTTTCAATGGGTCTGTTGTGCCTGA  
CCTTGTTTGTGGAAGAATGCTTGAGGAGAAGAGTCACCAGGAAACACATGATATTAGCTGTGG  
TAATCACTCTTTGTGCTATCATCTGGGGGGCCTCACATGGATGGACTTGCTACGAGCCCTCAT  
CATGTTGGGGGACACTATGTCTGGTAGAATAGGAGGACAGACCCACCTAGCCATCATGGCAGT  
GTTCAAGATGTCACCGGGATACGTGCTGGGTGTGTTTTTAAGGAACTCACTTCAAGAGAGAC  
AGCACTAATGGTAATAGGAATGGCCATGACAACAACACTTTCAATTCCACATGACCTCATGGA  
ACTCATTGATGGAATATCACTAGGACTAATTTTGCTAAAAATAGTAACACAGTTTGACAACAC  
CCAAGTGGGAACCTTAGCTCTTTCCTTGACTTTCATAAGATCAACAATGTCATTGGTCATGGCT  
TGGAGGACCATTATGGCTGTGTTGTTTGTGGTCACACTCATTCTTTGTGCAGGACAAGCTGTC  
TTCAAAAACAGTCTCATTGGGTAGAAATAACAGCACTCATCCTAGGAGCCCAAGCTCTGCCAG  
TGTACCTAATGACTCTTATGAAAGGAGCCTCAAGAAGATCTTGGCCTCTTAACGAAGGCATAA  
TGGCTGTGGGTTTGGTTAGTCTCTTAGGAAGCGCTCTTTTAAAGAATGATGTCCCTTTAGCTGG  
CCCAATGGTGGCAGGAGGCTTACTTCTGGCGGCTTACGTAATGAGTGGCAGCTCAGCAGATCT  
GTCAGTAGAGAAGGCCGCTAATGTGCAGTGGGATGAAATGGCAGACATAACAGGCTCAAGTC  
CAATCATAGAAGTGAAGCAAGATGAGGATGGCTCTTTCTCCATACGGGACGTCGAGGAAACCA  
ATATGATAACCCTTTTGGTGAAACTGGCACTGATAACGGTGTGAGGTCTCTACCCCTTGGAAT  
TCCAATCACAATGACCTTATGGTACATGTGGCAAGTGAAAACACAAAGATCAGGAGCCCTGTG  
GGACGTCCCTTACCCGCCGCACTCAAAAAGCCGCACTGTCTGAAGGAGTGTACAGGATCAT  
GCAAAGAGGGTTATTCGGGAAAAGTCAAGGTGGAGTAGGGATACACATGGAAGGTGTATTTCA  
CACAATGTGGCATGTTACAAGAGGATCGGTGATCTGCCACGAGACTGGGAGATTGGAGCCATC  
TTGGGCTGATGTCAGGAATGACATGATATCATACGGTGGGGGATGGAGGCTTGGAGATAAATG  
GGACAAAGAAGAAGACGTTCAAGTCTCGCTATAGAACCAGGGAAAAATCCCAAACATGTCC  
AAACGAAACCTGGCCTTTTCAAGACCCTAACTGGAGAAATTGGAGCAGTAACATTAGATTTCA  
AACCCGGAACGTCTGGTTCTCCATTATCAACAGGAAAGGAAAAGTCATCGGACTCTATGGAA  
ATGGAGTGGTCACCAAATCAGGTGATTACGTCAGTGCCATAACACAAGCCGAAAGAATTGGA  
GAGCCAGATTATGAAGTGGATGAGGACATTTTTCGAAAGAAAAGACTAACTATAATGGACTTA  
CACCCCGGAGCCGGAAAGACAAAAAGAATTCTTCCATCAATAGTGAGAGAAGCCTTAAAAAG  
GAGGCTGCGAACTTTGATTTTGGCTCCACGAGAGTGGTGGCGGCCGAGATGGAAGAGGCCCT  
ACGTGGACTGCCAATCCGTTACCAAACCCAGCTGTAAAATCAGAACACACAGGAAGAGAGA

TTGTAGACCTCATGTGCCATGCAACCTTCACAACAAGACTTTTGTTCATCAACCAGAGTTCCAAA  
CTACAACCTTATAGTAATGGATGAAGCACATTTACCGATCCTTCCAGTGTGCGGGCTAGAGG  
ATACATTTTCGACCAGGGTGGAAATGGGAGAGGCAGCAGCCATCTTCATGACCGCAACCCCTCC  
CGGAGCGACAGATCCCTTTCCCCAGAGCAACAGCCCAATAGAAGACATCGAGAGAGAGATTC  
CGGAAAGGTCATGGAACACAGGGTTCGACTGGATAACAGACTACCAAGGGAAAACCTGTGTGG  
TTTGTTCCCAGCATAAAAAGCTGGAAATGACATTGCAAATTGTTTGAGAAAGTCGGGAAAGAAA  
GTTATCCAGTTGAGTAGGAAAACCTTTGATACAGAATATCCAAAAACGAACTCACGGACTGG  
GACTTTGTGGTCACTACAGACATATCTGAAATGGGGGCTAACTTTAGAGCTGGGAGAGTGATA  
GACCCTAGAAGATGCCTCAAGCCAGTTATCCTAACAGATGGGCCAGAGAGAGTTCATCTTAGCA  
GGTCTTATTCCAGTGACTCCAGCAAGCGCTGCTCAGAGAAGAGGGCGAATAGGAAGGAACCC  
AGCACAAGAAGACGACCAATACGTTTTCTCCGGAGACCCACTAAAAAATGATGAAGACCATG  
CCCACTGGACAGAAGCAAAGATGCTGCTTGACAATATCTACACCCAGAAAGGGATCATTCCAA  
CATTGTTTGGTCCGGAAAGGGAAAAAACCCAAGCTATTGATGGAGAGTTTCGCCTCAGAGGGG  
AACAAAGGAAGACTTTTGTGGAATTAATGAGGAGAGGAGACCTTCCGGTGTGGCTGAGTTATA  
AGGTAGCTTCTGCTGGCATTCTTACAAAGATCGGGAATGGTGCTTTACTGGGGAAAGAAATA  
ACCAAATTTTAGAAGAAAACATGGAGGTTGAAATTTGGACTAGAGAGGGAGAAAAGAAAAAA  
CTGAGGCCAAAATGGTTAGATGCACGTGTATACGCTGACCCCATGGCTTTGAAGGATTTCAAG  
GAGTTTGCCAGTGGAAGGAAGAGTATAACTCTCGACATCCTAACAGAGATCGCCAGTTTGCCA  
ACTTACCTTTCCTCTAGGGCCAAGCTCGCCCTTGACAACATAGTTATGCTCCACACAACAGAAA  
GAGGAGGGAGGGCCTATCAACATGCCCTGAACGAACCTCCGGAGTCACTGGAAACACTCATGC  
TTGTAGCCTTACTAGGAGCTATGACAGCAGGTATCTTCCTGTTTTTCATGCAAGGGAAAGGAAT  
AGGGAAATTGTCAATGGGTTTGATAACCATTGCGGTGGCTAGTGGCTTGCTCTGGGTAGCAGA  
AATTCAACCCCAAGTGGATAGCGGCCTCAATCATACTGGAGTTTTTTCTCATGGTACTGTTGATA  
CCAGAACCAGAAAAACAAAGGACCCCAAGACAATCAATTGATCTACGTCATATTGACCATT  
CTCACCATTATTGGTCTAATAGCAGCCAACGAGATGGGGCTGATAGAAAAACAAAAACGGA  
TTTTGGGTTTTACCAGGTAAAAACAGAAACCACCATCCTCGATGTGGACCTGAGACCAGCTTC  
AGCATGGACGCTCTATGCGGTAGCCACCACAATTCTGACTCCCATGCTGAGACACACCATAGA  
AAATACGTGCGCCAACCTATCTTTAGCAGCCATCGCCAACCAGGCAGCCGTCCTAATGGGGCT  
TGGAAGGATGGCCACTCCACAGAATGGACCTCGGTGTGCCGCTGTTAGCAATGGGATGCTA  
TTCTCAAGTGAACCCAACAACCTTGACAGCATCCTTAGTCATGCTTTTAGTCCATTATGCAATA  
ATAGGCCCAAGATTGCAGGCAAAAGCCACAAGAGAGGGCCAGAAAAGGACAGCTGCTGGAAT  
CATGAAAAATCCCACAGTGGACGGGATAACAGTGATAGATCTAGAACCAATATCCTATGACC  
AAAATTTGAAAAGCAATTAGGGCAGGTCATGTTACTCGTCTTGTGTGCTGGACAACCTACTCTTG  
ATGAGAACACATGGGCTTTCTGTGAAGTTTTGACTTTGGCCACAGGACCAATCTTGACCTTGT  
GGGAGGGCAACCCGGGAAGGTTTTGGAACACGACCATAGCCGTATCTACCGCCAACATTTTCA  
GGGGAAGTTATTTGGCAGGAGCTGGACTGGCTTTTCACTCATAAAGAATGCACAAACCCCCA  
GGAGGGGAACCTGGGACCACAGGAGAGACACTGGGAGAGAAGTGGAAGAGACAGCTAAACTC

ATTAGACAGGAAAGAGTTTGAAGAGTATAAAAGAAGTGGAATACTAGAAGTGGACAGGACTG  
AAGCCAAGTCCGCCCTGAAAGATGGGTCTAAAATCAAGCATGCAGTATCTAGAGGGTCCAGTA  
AGATCAGATGGATTGTTGAGAGAGGGATGGTAAAGCCAAAGGGGAAAGTTGTAGATCTTGGC  
TGTGGGAGAGGAGGATGGTCTTATTACATGGCGACACTCAAGAACGTGACTGAAGTGAAAGG  
GTATACAAAAGGAGGTCCAGGACATGAAGAACCGATTCCCATGGCTACTTATGGCTGGAATTT  
GGTCAAACCTCATTACAGGGGTTGACGTGTTCTACAAACCCACAGAGCAAGTGGACACCCTGCT  
CTGTGATATTGGGGAGTCATCTTCTAATCCAACAATAGAGGAAGGAAGAACATTAAGAGTTTT  
GAAGATGGTGGAGCCATGGCTCTCTTCAAACCTGAATTCTGCATCAAAGTCCTCAACCCCTA  
CATGCCAACAGTCATAGAGGAGCTGGAGAACTGCAGAGAAAACACGGTGGGAACCTTGTC  
GATGCCCCGCTGTCCAGGAACCTCACCCATGAGATGTATTGGGTGTCAGGAGCGTCGGGAAATA  
TTGTGAGCTCTGTGAACACAACATCAAAGATGTTGTTGAACAGGTTTACAACAAGGCATAGGA  
AACCCACTTATGAGAAGGACGTAGATCTTGGGGCAGGAACGAGAAGTGTCTCTACTGAAACA  
GAAAAACCAGACATGACAATCATTGGGAGAAGGCTTCAGCGATTGCAAGAGGAGCACAAAGA  
AACATGGCATTATGATCAGGAAAACCCATACAGAACCTGGGCGTATCATGGAAGCTATGAAGC  
TCCTTCGACAGGCTCTGCATCCTCCATGGTGAACGGGGTGGTGAACTGCTAACAAAACCCTG  
GGATGTGATTCCAATGGTGAAGTCTAGTTCAGTACAGATACAACCCCTTTTGGGCAACAAAG  
AGTGTTCAAAGAGAAGGTGGATACCAGAACGCCGCAACCAAAACCAGGCACACGAATGGTTA  
TGACCACGACAGCCAATTGGCTATGGGCCCTCCTTGGAAGAAGAAAAATCCAGACTGTGTA  
CAAGGGAAGAGTTCATCTCAAAAGTTAGATCAAACGCAGCCATAGGCGCAGTCTTTCAGGAAG  
AACAAAGGATGGACATCAGCCAGTGAAGCTGTGAATGACAGCCGTTTTTGGGAACTGGTTGACA  
AAGAAAGGGCCCTTCACCAGGAAGGGAAATGTGAATCGTGTGTCTATAACATGATGGGAAAA  
CGTGAGAAAAAGTTAGGAGAGTTTGGCAGAGCCAAGGGAAGCCGAGCAATCTGGTACATGTG  
GCTGGGAGCGCGTTTTCTGGAATTTGAAGCCCTGGGTTTTTTGAATGAAGATCACTGGTTTTGGC  
AGAGAAAATTCATGGAGTGGAGTGGAAAGGGGAAGGTCTGCACAGATTGGGATACATCCTGGA  
GGAGATAGACAAGAAGGATGGAGACCTAATGTATGCTGATGACACAGCAGGTTGGGACACAA  
GAATCACTGAGGATGACCTTCAAAATGAGGAACTGATCACGGAACAGATGGCTCCCCACCACA  
AGATCCTAGCCAAAGCCATTTTCAAACCTAATCAAAACAAAGTGGTGAAAGTCCTCAGAC  
CCACACCGAGAGGAGCGGTGATGGATATCATATCCAGGAAAGACCAAGAGGTAGTGGACAA  
GTTGGAACATATGGTTTGAACACATTCACCAACATGGAAGTTCAACTCATCCGCCAAATGGAA  
GCTGAAGGAGTCATCACACAAGATGACATGCAGAACCCAAAAGGGTTGAAAGAAAGAGTTGA  
GAAATGGCTGAGAGAGTGTGGTGTGACAGGTTAAAGAGGATGGCAATCAGTGGAGACGATT  
GCGTGGTGAAGCCCCTAGATGAGAGGTTTGGCACTTCCCTCCTCTTCTTGAACGACATGGGAA  
AGGTGAGGAAAGACATTCCGCAGTGGGAACCATCTAAGGGATGGAAAACTGGCAAGAGGTT  
CCTTTTTGCTCCCATCACTTTCACAAGATCTTTATGAAGGATGGCCGCTCACTAGTTGTTCCATG  
TAGAAACCAGGATGAACTGATAGGGAGAGCCAGAATCTCGCAGGGGGCTGGATGGAGCTTAA  
GAGAAACAGCCTGCCTGGGCAAAGCTTACGCCCAGATGTGGTCGCTTATGTACTTCCACAGAA  
GGGATCTGCGTTTAGCCTCCATGGCCATATGCTCAGCAGTTCCAACGGAATGGTTTTCCAACAAG

CAGAACAAACATGGTCAATCCATGCTCATCACCAATGGATGACCACTGAAGACATGCTCAAAGT  
 GTGGAACAGAGTGTGGATAGAAGACAACCCCAATATGATTGACAAGACTCCAGTCCATTTCGTG  
 GGAAGATATACCTTACCTAGGGAAAAGAGAGGATTTGTGGTGTGGATCCCTGATTGGACTTTC  
 TTCTAGAGCCACCTGGGCGAAGAACATTCACACGGCCATAACTCAGGTCAGGAACTTGATCGG  
 AAAAGAGGAATACGTGGATTACATGCCAGTAATGAAAAGATACAGTGCTCCTTCAGAGAGTG  
 AAGGAGTTCTGTAATTACCAACAACAAACACCAAGGCTATTGAAGTCAGGCCACTTGTGCCA  
 CGGTTTGAGCAAACCGTGCTGCCTGTAGCTCCGCCAATAATGGGAGGCGTAATAATCCCTAGG  
 GAGGCCATGCGCCACGGAAGCTGTACGCGTGGCATATTGGACTAGCGGTTAGAGGAGACCCCT  
 CCCATCACTGACAAAACGCAGCAAAAGGGGGCCCGAAGCCAGGAGGAAGCTGTACTCCTGGT  
 GGAAGGACTAGAGGTTAGAGGAGACCCCCCAACACAAAAACAGCATATTGACGCTGGGAAA  
 GACCAGAGATCCTGCTGTCTCTACAACATCAATCCAGGCACAGAGCGCCGCAAGATGGATTGG  
 TGTGTTGATCCAACAGGTTCT

[0148] SEQ ID NO:8 – DENV-4-EMin

AGTTGTTAGTCTGTGTGGACCGACAAGGACAGTTCCAAATCGGAAGCTTGCTTAACACAGTTCT  
 AACAGTTTGTTTAAATAGAGAGCAGATCTCTGGAAAAATGAACCAACGAAAAAAGGTGGTTA  
 GACCACCTTTCAATATGCTGAAACGCGAGAGAAACCGCGTATCAACCCCTCAAGGGTTGGTGA  
 AGAGATTCTCAACCGGACTTTTTTCTGGGAAAGGACCCCTACGGATGGTGCTAGCATTTCATCAC  
 GTTTTTGCGAGTCCTTTCCATCCCACCAACAGCAGGGATTCTGAAGAGATGGGGACAGTTGAA  
 GAAAAATAAGGCCATCAAGATACTGATTGGATTGAGGAAGGAGATAGGCCCGCATGCTGAACA  
 TCTTGAACGGGAGAAAAAGGTCAACGATAACATTGTTGTGCTTGATTCCCACCGTAATGGCGT  
 TTCCTTGTCAACAAGAGATGGCGAACCCCTCATGATAGTGGCAAAACATGAAAGGGGGAGA  
 CCTCTCTTGTTTAAGACAACAGAGGGGGATCAACAAATGCACTCTCATTGCCATGGACTTGGGTG  
 AAATGTGTGAGGACACTGTCACGTATAAATGCCCCCTACTGGTCAATACCGAACCTGAAGACA  
 TTGATTGCTGGTGCAACCTCACGTCTACCTGGGTGATGTATGGGACATGCACCCAGAGCGGAG  
 AACGGAGACGAGAGAAGCGCTCAGTAGCTTTGACACCACATTCAGGAATGGGATTGGAAACA  
 AGAGCTGAGACATGGATGTCATCGGAAGGGGCTTGGAAGCATGCTCAGAGAGTAGAGAGCTG  
 GATACTCAGAAACCCAGGATTTGCGCTCTTGGCAGGATTTATGGCTTATATGATTGGGCAAAC  
 AGGAATCCAGCGAACTGTCTTCTTTGTCCTAATGATGCTGGTTCGCCCCATCCTACGGAATGAGA  
 TCGGTAGGCGTAGGTAATCGCGATTTCTGTTGAGGGAGTGTGAGGCGGAGCATGGGTGATCTG  
 TACTCGAACACGGAGGATGCGTTACGACTATGGCACAGGGAAAACCGACATTGGACTTTGAG  
 TTGACTAAGACAACCGCTAAAGAGGTCGCACTATTGCGAACATACTGTATCGAAGCGTCAATT  
 TCGAATATTACAACCGCTACTAGGTGTCCTACACAGGGCGAACCATACTTAAAGAGGAACAG  
 GACCAACAGTATATTTGTAGAAGAGACGTAGTCGATAGGGGGTGGGGAAACGGATGCGGATT  
 GTTCGGTAAGGGGGGAGTCGTTACATGCGCTAAGTTCTCATGTTCCGGTAAGATTACCGGTAA  
 CTTAGTGCAAATTGAGAATCTCGAATATACCGTAGTCGTTACAGTGCATAACGGAGACACACA  
 CGCAGTCGGAAACGATACATCTAACCATGGCGTAACCGCTACAATTACACCTAGGTCACCATC

CGTTGAGGTAAAGTTGCCCGATTACGGCGAACTGACACTCGATTGCGAACCTAGATCCGGAAT  
AGACTTTAACGAAATGATACTGATGAAAATGAAAAAAAAGACATGGTTAGTGCATAAGCAAT  
GGTTTCTCGACTTACCCCTACCTTGGACCGCCGGAGCCGATACTAGCGAAGTGCACCTGGAATT  
ACAAAGAGAGAATGGTTACATTTAAAGTGCCACACGCTAAGAGACAGGACGTTACAGTGTTA  
GGGTCACAGGAGGGAGCTATGCATAGCGCACTAGCCGGAGCAACCGAAGTCGATAGCGGAGA  
CGGAAATCATATGTTCCCGGACATCTGAAATGCAAAGTGAGAATGGAGAAATTGCGGATTAA  
GGGAATGTCATACACTATGTGTTCCGGTAAGTTTTCGATTGACAAAGAGATGGCCGAAACGCA  
ACACGGAACAACAGTCGTAAAGGTTAAGTACGAAGGAGCCGGAGCTCCGTGTAAAGTGCCAA  
TCGAAATTAGAGACGTTAACAAAGAGAAAGTGGTCGGAAGAGTGATATCTAGTACACCCCTA  
GCCGAAAATACGAATTCCGTTACGAATATCGAACTCGAACCCCCCTTTGGGAGACTCATACATA  
GTGATAGGAGTGGGTAATCCGCACTCACGTTGCACTGGTTCAGAAAGGGATCATCAATCGGG  
AAGATGTTTGAATCAACATATAGGGGAGCGAAAAGAATGGCTATATTGGGCGAAACCGCATG  
GGACTTCGGATCAGTCGGAGGACTGTTTACGAGTCTGGGTAAGGCCGTACATCAGGTATTCGG  
ATCAGTGTATACAACAATGTTTGGCGGAGTGTCATGGATGATACGGATACTGATAGGGTTTCT  
AGTGTGTGGATCGGAACGAACTCACGTAATACGTCTATGGCTATGACATGTATTGCCGTAGG  
GGGGATTACACTGTTTCTGGGATTTACAGTGCAAGCAGACATGGGTTGTGTGGTGTTCATGGAG  
TGGGAGAGAATTGAAGTGTGGAAGCGGAATTTTTGTGGTTGACAACGTGCACACTTGGACAGA  
ACAGTACAAATTCCAACCAGAGTCCCCAGCGAGACTAGCGTCTGCAATATTAAATGCCACAA  
AGATGGGGTCTGTGGAATTAGATCAACCACGAGGCTGGAAAATGTTATGTGGAAGCAAATAA  
CCAATGAGCTAACTATGTTCTCTGGGAAGGAGGACATGATCTCACTGTAGTGGCTGGGGATG  
TGAAAGGGGTGTTGACCAAGGGCAAGAGAGCACTCACACCCCCAGCGAGTGATCTGAAATAT  
TCATGGAAGACATGGGGGAAAGCAAAAATCTTCACCCCTGAAGCAAGAAACAGCACATTTTTTA  
ATAGACGGACCAGACACCTCTGAATGCCCCAATGAACGAAGGGCATGGAATTCTTTTGAGGTG  
GAAGACTATGGATTTGGCATGTTACGACCAACATATGGATGAAATTCCGAGAAGGAAGTTCA  
GAAGTGTGTGACCACAGGTTAATGTCAGCTGCAATTAAAGACCAGAAAGCTGTGCATGCTGAC  
ATGGGTTATTGGATAGAGAGCTCAAAAAACCAGACCTGGCAGATAGAGAGAGCATCTCTTATT  
GAAGTGAAAACATGTCTGTGGCCCAAGACCCATACACTGTGGAGCAATGGAGTGCTGGAAAG  
CCAGATGCTTATTCCAAAATCATATGCAGGCCCTTTTTTACAGCACAATTACCGCCAGGGCTAT  
GCTACGCAAACCGTGGGTCCATGGCACTTAGGCAAACTAGAGATAGACTTTGGAGAATGCCCC  
GGAACAACAGTCACAATTCAGGAGAATTGTGACCATAGAGGCCCATCTTTGAGGACCACCACT  
GCATCTGGAAAAC TAGTCACGCAATGGTGTTGCCGCTCCTGCACGATGCCCCCTTAAGGTTCT  
TAGGAGAAGATGGGTGCTGGTATGGGATGGAGATTAGGCCCTTGAGTGAAAAAGAAGAGAAC  
ATGGTCAAATCACAGGTGACGGCCGGACAGGGCACATCGGAAACTTTTTCAATGGGTCTGTTG  
TGCCTGACCTTGTTTGTGGAAGAATGCTTGAGGAGAAGAGTCACCAGGAAACACATGATATTA  
GCTGTGGTAATCACTCTTTGTGCTATCATCCTGGGGGGCCTCACATGGATGGACTTGCTACGAG  
CCCTCATCATGTTGGGGGACACTATGTCTGGTAGAATAGGAGGACAGACCCACCTAGCCATCA  
TGGCAGTGTTCAAGATGTCACCGGGATACGTGCTGGGTGTGTTTTTAAGGAAACTCACTTCAAG

AGAGACAGCACTAATGGTAATAGGAATGGCCATGACAACAACACTTTCAATTCCACATGACCT  
CATGGAACTCATTGATGGAATATCACTAGGACTAATTTTGCTAAAAATAGTAACACAGTTTGA  
CAACACCCCAAGTGGGAACCTTAGCTCTTTTCCTTGACTTTCATAAGATCAACAATGTCATTGGTC  
ATGGCTTGGAGGACCATTATGGCTGTGTTGTTTGTGGTCACACTCATTCCCTTGTGCAGGACAA  
GCTGTCTTCAAAAACAGTCTCATTGGGTAGAAATAACAGCACTCATCCTAGGAGCCCAAGCTC  
TGCCAGTGTACCTAATGACTCTTATGAAAGGAGCCTCAAGAAGATCTTGGCCTCTTAACGAAG  
GCATAATGGCTGTGGGTTTGGTTAGTCTCTTAGGAAGCGCTCTTTTAAAGAATGATGTCCCTTT  
AGCTGGCCCAATGGTGGCAGGAGGCTTACTTCTGGCGGCTTACGTAATGAGTGGCAGCTCAGC  
AGATCTGTCACTAGAGAAGGCCGCTAATGTGCAGTGGGATGAAATGGCAGACATAACAGGCT  
CAAGTCCAATCATAGAAGTGAAGCAAGATGAGGATGGCTCTTTCTCCATACGGGACGTCGAGG  
AAACCAATATGATAACCTTTTGGTGAAGTGGCACTGATAACGGTGTGAGGTCTCTACCCCTT  
GGCAATTCCAATCACAATGACCTTATGGTACATGTGGCAAGTGAAAACACAAAGATCAGGAGC  
CCTGTGGGACGTCCCTTACCCGCCGCACTCAAAAAGCCGCACTGTCTGAAGGAGTGTACAG  
GATCATGCAAAGAGGGTTATTCGGGAAAACCTCAGGTTGGAGTAGGGATACACATGGAAGGTG  
TATTTACACAATGTGGCATGTTACAAGAGGATCGGTGATCTGCCACGAGACTGGGAGATTGG  
AGCCATCTTGGGCTGATGTCAGGAATGACATGATATCATACGGTGGGGGATGGAGGCTTGGAG  
ATAAATGGGACAAAGAAGAAGACGTTTCAGGTCCTCGCTATAGAACCAGGGAAAAATCCCAA  
CATGTCCAAACGAAACCTGGCCTTTTCAAGACCCTAACTGGAGAAATTGGAGCAGTAACATTA  
GATTTCAAACCCGGAACGTCTGGTTCTCCATTATCAACAGGAAAGGAAAAGTCATCGGACTC  
TATGGAAATGGAGTGGTCACCAAATCAGGTGATTACGTCAGTGCCATAACACAAGCCGAAAG  
AATTGGAGAGCCAGATTATGAAGTGGATGAGGACATTTTTTCGAAAGAAAAGACTAACTATAAT  
GGACTTACACCCCGGAGCCGGAAAGACAAAAAGAATTCTTCCATCAATAGTGAGAGAAGCCTT  
AAAAAGGAGGCTGCGAACTTTGATTTTGGCTCCCACGAGAGTGGTGGCGGCCGAGATGGAAG  
AGGCCCTACGTGGACTGCCAATCCGTTACCAAACCCAGCTGTAAAATCAGAACACACAGGAA  
GAGAGATTGTAGACCTCATGTGCCATGCAACCTTCACAACAAGACTTTTGTGTCATCAACCAGAG  
TTCCAAACTACAACCTTATAGTAATGGATGAAGCACATTTACCGATCCTTCCAGTGTGCGGGC  
TAGAGGATACATTTTCGACCAGGGTGGAAATGGGAGAGGCAGCAGCCATCTTCATGACCGCAA  
CCCCTCCCGGAGCGACAGATCCCTTTCCCAGAGCAACAGCCCAATAGAAGACATCGAGAGAG  
AGATTCCGGAAAGGTCATGGAACACAGGGTTCGACTGGATAACAGACTACCAAGGGAAAACT  
GTGTGGTTTGTTCACGACATAAAAGCTGGAAATGACATTGCAAATTGTTTGAGAAAGTCGGGA  
AAGAAAGTTATCCAGTTGAGTAGGAAAACCTTTGATACAGAATATCCAAAAACGAACTCACG  
GACTGGGACTTTGTGGTCACTACAGACATATCTGAAATGGGGGCTAACTTTAGAGCTGGGAGA  
GTGATAGACCCTAGAAGATGCCTCAAGCCAGTTATCCTAACAGATGGGCCAGAGAGAGTCATC  
TTAGCAGGTCCTATTCCAGTGACTCCAGCAAGCGCTGCTCAGAGAAGAGGGCGAATAGGAAG  
GAACCCAGCACAAGAAGACGACCAATACGTTTTCTCCGGAGACCCACTAAAAAATGATGAAG  
ACCATGCCCCTGGACAGAAGCAAAGATGCTGCTTGACAATATCTACACCCAGAAAGGGATCA  
TTCCAACATTGTTTGGTCCGGAAAGGGAAAAAACCAAGCTATTGATGGAGAGTTTCGCCTCA

GAGGGGAACAAAGGAAGACTTTTGTGGAATTAATGAGGAGAGGAGACCTTCCGGTGTGGCTG  
AGTTATAAGGTAGCTTCTGCTGGCATTCTTACAAAGATCGGGAATGGTGCTTTACTGGGGAAA  
GAAATAACCAAATTTTAGAAGAAAACATGGAGGTTGAAATTTGGACTAGAGAGGGAGAAAAG  
AAAAAACTGAGGCCAAAATGGTTAGATGCACGTGTATACGCTGACCCCATGGCTTTGAAGGAT  
TTCAAGGAGTTTGCCAGTGGAAGGAAGAGTATAACTCTCGACATCCTAACAGAGATCGCCAGT  
TTGCCAACTTACCTTTTCTCTAGGGGCCAAGCTCGCCCTTGACAACATAGTTATGCTCCACACAA  
CAGAAAGAGGAGGGAGGGCCTATCAACATGCCCTGAACGAACCTCCGGAGTCACTGGAAACA  
CTCATGCTTGTAGCCTTACTAGGAGCTATGACAGCAGGTATCTTCCTGTTTTTCATGCAAGGGA  
AAGGAATAGGGAAATTGTCAATGGGTTTGATAACCATTGCGGTGGCTAGTGGCTTGCTCTGGG  
TAGCAGAAATTCAACCCCAGTGATAGCGGCCTCAATCATACTGGAGTTTTTCTCATGGTACT  
GTTGATACCAGAACCAGAAAAACAAAGGACCCACAAGACAATCAATTGATCTACGTCATATT  
GACCATTCTCACCATTATTGGTCTAATAGCAGCCAACGAGATGGGGCTGATAGAAAAAACAAA  
AACGGATTTTGGGTTTACCAGGTAAAAACAGAAACCACCATCCTCGATGTGGACCTGAGACC  
AGCTTCAGCATGGACGCTCTATGCGGTAGCCACCACAATTCTGACTCCCATGCTGAGACACAC  
CATAGAAAATACGTCGGCCAACCTATCTTTAGCAGCCATCGCCAACCAGGCAGCCGTCCTAAT  
GGGGCTTGGAAGAGGATGGCCACTCCACAGAATGGACCTCGGTGTGCCGCTGTTAGCAATGGG  
ATGCTATTCTCAAGTGAACCCAACAACCTTGACAGCATCCTTAGTCATGCTTTTAGTCCATTAT  
GCAATAATAGGCCCAGGATTGCAGGCAAAAGCCACAAGAGAGGGCCAGAAAAGGACAGCTGC  
TGGAATCATGAAAAATCCCACAGTGGACGGGATAACAGTGATAGATCTAGAACCAATATCCTA  
TGACCCAAAATTTGAAAAGCAATTAGGGCAGGTCATGTTACTCGTCTTGTGTGCTGGACAAC  
ACTCTTGATGAGAACAACATGGGCTTTCTGTGAAGTTTTGACTTTGGCCACAGGACCAATCTTG  
ACCTTGTTGGGAGGGCAACCCGGGAAGGTTTTGGAACACGACCATAGCCGTATCTACCGCCAAC  
ATTTTCAGGGGAAGTTATTTGGCAGGAGCTGGACTGGCTTTTCACTCATAAAGAATGCACAA  
ACCCCCAGGAGGGGAACCTGGGACCACAGGAGAGACACTGGGAGAGAAGTGGAAGAGACAGC  
TAAACTCATTAGACAGGAAAGAGTTTGAAGAGTATAAAAGAAGTGGAATACTAGAAGTGAC  
AGGACTGAAGCCAAGTCCGCCCTGAAAGATGGGTCTAAAATCAAGCATGCAGTATCTAGAGG  
GTCCAGTAAGATCAGATGGATTGTTGAGAGAGGGATGGTAAAGCCAAAGGGGAAAGTTGTAG  
ATCTTGGCTGTGGGAGAGGAGGATGGTCTTATTACATGGCGACACTCAAGAACGTGACTGAAG  
TGAAAGGGTATACAAAAGGAGGTCCAGGACATGAAGAACCGATTCCCATGGCTACTTATGGCT  
GGAATTTGGTCAAACCTCATTACAGGGGTTGACGTGTTCTACAAACCCACAGAGCAAGTGGACA  
CCCTGCTCTGTGATATTGGGGAGTCATCTTCTAATCCAACAATAGAGGAAGGAAGAACATTAA  
GAGTTTTGAAGATGGTGGAGCCATGGCTCTTCTCAAACCTGAATTCTGCATCAAAGTCCTCAA  
CCCCTACATGCCAACAGTCATAGAGGAGCTGGAGAACTGCAGAGAAAACACGGTGGGAACC  
TTGTCAGATGCCCGCTGTCCAGGAACCTCCACCCATGAGATGTATTGGGTGTCAGGAGCGTCGG  
GAAATATTGTGAGCTCTGTGAACACAACATCAAAGATGTTGTTGAACAGGTTTACAACAAGGC  
ATAGGAAACCCACTTATGAGAAGGACGTAGATCTTGGGGCAGGAACGAGAAGTGTCTCTACTG  
AAACAGAAAAACCAGACATGACAATCATTGGGAGAAGGCTTCAGCGATTGCAAGAGGAGCAC

AAAGAAACATGGCATTATGATCAGGAAAACCCATACAGAACCTGGGCGTATCATGGAAGCTA  
TGAAGCTCCTTCGACAGGCTCTGCATCCTCCATGGTGAACGGGGTGGTGAAACTGCTAACAAA  
ACCCTGGGATGTGATTCCAATGGTGACTCAGTTAGCCATGACAGATACAACCCCTTTTGGGCA  
ACAAAGAGTGTTCAAAGAGAAGGTGGATACCAGAACGCCGCAACCAAAACCAGGCACACGAA  
TGGTTATGACCACGACAGCCAATTGGCTATGGGCCCTCCTTGGAAGAAGAAAAATCCCAGAC  
TGTGTACAAGGGAAGAGTTCATCTCAAAAGTTAGATCAAACGCAGCCATAGGCGCAGTCTTTC  
AGGAAGAACAAGGATGGACATCAGCCAGTGAAGCTGTGAATGACAGCCGGTTTTGGGAACTG  
GTTGACAAAGAAAGGGCCCTTACCAGGAAGGGAAATGTGAATCGTGTGTCTATAACATGATG  
GGAAAACGTGAGAAAAAGTTAGGAGAGTTTTGGCAGAGCCAAGGGAAGCCGAGCAATCTGGTA  
CATGTGGCTGGGAGCGCGGTTTTCTGGAATTTGAAGCCCTGGGTTTTTTGAATGAAGATCACTGG  
TTTGGCAGAGAAAATTCATGGAGTGGAGTGAAGGGGAAGGTCTGCACAGATTGGGATACAT  
CCTGGAGGAGATAGACAAGAAGGATGGAGACCTAATGTATGCTGATGACACAGCAGGTTGGG  
ACACAAGAATCACTGAGGATGACCTTCAAAATGAGGAACTGATCACGGAACAGATGGCTCCC  
CACCACAAGATCCTAGCCAAAGCCATTTTCAAATAACCTATCAAAACAAAGTGGTGAAAGTC  
CTCAGACCCACACCGAGAGGAGCGGTGATGGATATCATATCCAGGAAAGACCAAGAGGTAG  
TGGACAAGTTGGAACATATGGTTTGAACACATTCACCAACATGGAAGTTCAACTCATCCGCCA  
AATGGAAGCTGAAGGAGTCATCACACAAGATGACATGCAGAACCCAAAAGGGTTGAAAGAAA  
GAGTTGAGAAATGGCTGAGAGAGTGTGGTGTGCACAGGTAAAGAGGATGGCAATCAGTGGA  
GACGATTGCGTGGTGAAGCCCCTAGATGAGAGGTTTGGCACTTCCCTCCTCTTCTTGAACGACA  
TGGGAAAGGTGAGGAAAGACATTCCGCAGTGGGAACCATCTAAGGGATGGAAAAACTGGCAA  
GAGGTTCCTTTTTGCTCCCATCACTTTTACAAGATCTTTATGAAGGATGGCCGCTCACTAGTTGT  
TCCATGTAGAAACCAGGATGAAGTGAAGGAGAGCCAGAATCTCGCAGGGGGGCTGGATGGA  
GCTTAAGAGAAACAGCCTGCCTGGGCAAAGCTTACGCCCAGATGTGGTCGCTTATGTACTTCC  
ACAGAAGGGATCTGCGTTTAGCCTCCATGGCCATATGCTCAGCAGTTCCAACGGAATGGTTTCC  
AACAAGCAGAACAACATGGTCAATCCATGCTCATACCAATGGATGACCACTGAAGACATGCT  
CAAAGTGTGGAACAGAGTGTGGATAGAAGACAACCCCAATATGATTGACAAGACTCCAGTCC  
ATTCGTGGGAAGATATACCTTACCTAGGGAAAAGAGAGGATTTGTGGTGTGGATCCCTGATTG  
GACTTTCTTCTAGAGCCACCTGGGCGAAGAACATTACACGGCCATAACTCAGGTCAGGAACT  
TGATCGGAAAAGAGGAATACGTGGATTACATGCCAGTAATGAAAAGATACAGTGCTCCTTCAG  
AGAGTGAAGGAGTTCTGTAATTACCAACAACAAACACCAAGGCTATTGAAGTCAGGCCACTT  
GTGCCACGGTTTGAGCAAACCGTGCTGCCTGTAGCTCCGCCAATAATGGGAGGCGTAATAATC  
CCTAGGGAGGCCATGCGCCACGGAAGCTGTACGCGTGGCATATTGGACTAGCGGTTAGAGGA  
GACCCCTCCCATCACTGACAAAACGCAGCAAAAGGGGGCCCGAAGCCAGGAGGAAGCTGTAC  
TCCTGGTGGAAAGGACTAGAGGTTAGAGGAGACCCCCCAACACAAAAACAGCATATTGACGC  
TGGGAAAGACCAGAGATCCTGCTGTCTCTACAACATCAATCCAGGCACAGAGCGCCGCAAGAT  
GGATTGGTGTGTTGATCCAACAGGTTCT

[0149] SEQ ID NO:9 – DENV-1-VN-BID-V1774-2007-E-W/Min

AGTTGTTAGTCTACGTGGACCGACAAGAACAGTTTTCGAATCGGAAGCTTGCTTAACGTAGTTCT  
AACAGTTTTTTTATTAGAGAGCAGATCTCTGATGAACAACCAACGGAAAAAGACGGCTCGACCG  
TCTTTCAATATGCTGAAACGCGCGAGAAACCGCGTGTCAACTGTTTCACAGTTGGCGAAGAGA  
TTCTCAAAAGGATTGCTCTCAGGCCAAGGACCCATGAAATTGGTGATGGCTTTCATAGCATTCC  
TAAGATTTCTAGCCATACCCCCAACAGCAGGAATTTTGGCTAGATGGGGTTCATTCAAGAAGA  
GTGGAGCGATCAAAGTGCTACGGGGTTTCAAGAAAGAAATCTCAAACATGTTGAATATAATGA  
ATAGAAGGAAAAGATCTGTGACCATGCTCCTTATGCTGATGCCTACAGCCTTGGCGTTCCATTT  
GACTACACGAGGGGGAGAGCCGCACATGATAGTCAGCAAGCAGGAAAGAGGAAAGTCACTCT  
TGTTTAAGACCTCAGCAGGTGTCAACATGTGCACCCTTATAGCGATGGATTTGGGAGAGTTATG  
TGAGGACACAATGACTTACAAATGCCCTCGAATCACTGAAACTGAACCAGATGACGTTGATTG  
TTGGTGTAATGCCACAGACACATGGGTGACCTATGGAACATGTTCCCAAACCTGGCGAGCACCG  
ACGAGACAAACGTTCCGTCGCACTGGCCCCACACGTGGGACTTGGTTTGGAAACAAGAACCGA  
AACGTGGATGTCCTCTGAAGGCGCTTGGAACAGATACAAAGAGTGGAGACTTGGGCCCTGA  
GACCCCAGGATTCACGGTGATAGCCCTTTTTCTAGCACATGCCATAGGAACATCCATCACCC  
AGAAAGGGATTATTTTCATTTTGTTAATGCTGGTAACACCATCCATGGCCATGCGATGCGTGGG  
AATAGGCAGCAGGGACTTCGTGGAAGGACTGTCAGGAGCAACTTGGGTAGATGTGGTACTGG  
AACATGGAAGTTGCGTCACCACCATGGCAAAAGACAAACCAACATTGGACATTGAACTCTTGA  
AGACGGAAGTCACAAACCCTGCCGTCCTGCGCAAACTGTGCATTGAAGCTAAAATATCAAACA  
CCACCACCGACTCAAGATGTCCAACACAAGGAGAAGCCACACTAGTGGAAGAACAAGACGCG  
AACTTTGTGTGTCGACGAACGTTTGTGGACAGAGGCTGGGGCAATGGCTGTGGCCTCTTCGGA  
AAAGGAAGCCTAATAACGTGTGCAAGTTCAAGTGTGTGACAAAACCTGGAAGGAAAGATAGT  
TCAATATGAGAACTTGAAATATTCAGTAATAGTCACCGTTCACACCGGAGACCAGCATCAAGT  
GGGAAATGAAAGCACAGAACATGGGACAACTGCAACTATAACACCTCAAGCTCCTACGACGG  
AAATACAGCTGACCGACTACGGAGCTCTTACATTGGATTGTTACCTAGAACAGGACTAGACT  
TTAATGAAATGGTGTGTTGACAATGAAAGAAAAATCATGGCTAGTCCACAAACAATGGTTTT  
TAGACCTACCACTGCCTTGGACCTCGGGAGCTTCAACATCACAAGAGACTTGGAACAGACAAG  
ATTTGCTGGTGACATTTAAGACAGCTCATGCAAAGAAGCAGGAAGTAGTAGTGTTAGGGTCAC  
AAGAGGGAGCAATGCATACCGCACTAACCGGAGCAACCGAAATACAGACTAGCGGAACTACA  
ACGATTTTTGCCGGTCACCTGAAATGTAGACTGAAGATGGACAACTGACACTTAAAGGAATG  
TCATACGTTATGTGTACGGGATCCTTTAAGCTCGAAAAAGAGGTTGCCGAAACGCAACACGGA  
ACAGTGCTAGTGCAAATTAATATGAGGGGAACCGACGCACCATGTAAGATACCGTTTAGTACG  
CAAGACGAAAAGGGCGTTACGCAAAACGGAAGACTGATTACCGCTAACCTATCGTTACAGA  
CAAAGAGAAACCCGTTAACATAGAGGCCGAACCACCTTTTGGCGAATCATATATAGTGATAGG  
CGCAGGCGAAAAAGCACTAAAGCTGTTCATGGTTCAAAAAAGGATCTAGCATAGGGAAGATGT  
TCGAAGCAACCGCTAGGGGAGCTAGACGAATGGCAATACTGGGAGATACCGCATGGGACTTC  
GGATCGATAGGGGGAGTGTTTACTAGCGTAGGTAAGTTGGTGCATCAGATATTCGGAACCGCA

TACGGAGTGTGTTTGTAGCGGAGTGTTCATGGACTATGAAGATAGGGATAGGAGTGCTATTGACA  
TGGCTCGGACTGAATTCGAGATCGACTAGCCTATCTATGACATGCATAGCCGTCGGACTGGTTA  
CACTGTATCTAGGCGTAATGGTGCAAGCAGATTCAGGATGTGTAATTAATTGGAAAGGTAGAG  
AACTCAAGTGTGGAAGTGGCATTTTTGTACCAATGAAGTTCACACTTGGACAGAGCAATACA  
AATTTCAAGCTGACTCCCCTAAGAGACTATCAGCAGCCATCGGGAAGGCATGGGAGGAGGGT  
GTGTGTGGAATTCGATCAGCAACTCGTCTCGAGAACATCATGTGGAAGCAAATATCAAATGAA  
CTGAATCACATCTTACTTGAAAATGATATGAAATTCACAGTGGTTGTAGGAGATGTTGCTGGG  
ATCTTGGCTCAAGGAAAGAAAATGATTAGGCCACAACCCATGGAATACAAATACTCGTGGA  
AAGCTGGGGAAAGGCTAAAATCATAGGGGCAGATGTACAGAACACCACCTTCATCATCGATG  
GCCCCAACACCCCAGAATGCCCTGATGACCAAGAGCATGGAACATTTGGGAAGTTGAGGAC  
TATGGATTTGGAATTTTCACGACAAACATATGGCTGAAATTGCGTGATTCTACACCCAAGTGT  
GTGACCACCGGCTAATGTCAGCTGCCATCAAGGACAGCAAGGCAGTTCACGCTGACATGGGGT  
ACTGGATAGAAAGTGAAAAGAACGAGACCTGGAAGCTGGCAAGAGCCTCATTATAGAAGTT  
AAAACATGTATCTGGCCAAAATCCCACACTCTATGGAGCAATGGAGTTCTGGAAAGTGAAATG  
ATAATTCCAAAGATCTATGGAGGACCAATATCTCAGCACAACCTACAGACCAGGATATTTTACA  
CAAGCAGCAGGGCCGTGGCACCTAGGCAAGTTGGAAGTGGATTTTGATTGTGTGAGGGTACC  
ACAGTTGTTGTGGATGAACATTGTGGAATCGAGGACCATCTCTTAGGACCACAACAGTCACA  
GGAAAGATAATTCATGAATGGTGTTCAGATCTTGCACGCTACCACCCTTACGTTTCAGAGGA  
GAAGATGGGTGCTGGTACGGTATGGAAATCAGACCAGTCAAGGAAAAGGAAGAAAATCTAGT  
CAAATCAATGGTCTCTGCAGGGTCAGGGGAAGTGGACAGCTTTTCACTAGGACTGCTATGCAT  
ATCAATAATGATCGAGGAGGTGATGAGATCCAGATGGAGTAGAAGAATGCTGATGACTGGAA  
CACTGGCTGTGTTCTTCTCTCATAATGGGACAATTGACATGGAACGATCTGATCAGATTATG  
CATCATGGTTGGAGCCAACGCTTCCGACAGGATGGGGATGGGAACGACGTACCTAGCCCTGAT  
GGCCACTTTTAAAATGAGACCGATGTTTCGCTGTAGGGCTATTATTTTCGCACTAATCCAGA  
GAAGTTCTTCTTAACAATTGGATTGAGTCTAGTGGCATCTGTGGAGTTACCAAATTCCTTGG  
AGGAGCTGGGGGATGGACTTGCAATGGGCATTATGATTTTAAAATTATTGACTGACTTTCAATC  
ACATCAGCTGTGGGCTACCTTGCTGTCCTTGACATTTATCAAAACAACGTTTTCTTGCCTAC  
GCATGGAAGACAATGGCTATGGTACTGTCAATTGTATCTCTCTTCCCTTTATGCCTGTCCACGA  
CCTCCCCAAAAACAACATGGCTTCCGGTGCTATTGGGATCCCTTGGATGCAAACCACTAACCA  
TGTTTCTTATAGCAGAAAACAAAATCTGGGGAAGGAGAAGTTGGCCCTCAATGAAGGAATCA  
TGGCTGTTGGAATAGTCAGCATCCTACTAAGTTCCTCCTCAAAAATGATGTACCGCTAGCTGG  
GCCACTAATAGCTGGAGGCATGCTAATAGCATGTTATGTTATATCTGGAAGCTCAGCCGACCT  
ATCATTAGAGAAAGCGGCTGAGGTCTCCTGGGAAGAAGAAGCAGAACACTCTGGTGCCTCAC  
ACAACATATTAGTGGAAGTCCAAGATGATGGAACCATGAAGATAAAGGATGAAGAGAGAGAT  
GACACGCTAACCATTCTCCTTAAAGCAACTCTGTTAGCAGTTTCAGGGGTGTACCCATTATCAA  
TACCAGCGACCCTTTTCGTGTGGTACTTTTGGCAGAAAAGAAAACAGAGATCTGGAGTGTTAT  
GGGACACACCCAGCCCTCCAGAAGTGGAAGAGCAGTTCTTGATGATGGTATCTATAGAATTA

TGCAGAGAGGACTGTTGGGCAGGTCCCAAGTAGGGGTAGGAGTTTTCCAAGAAAACGTGTTCC  
ACACAATGTGGCATGTCACCAGGGGAGCTGTACTCATGTATCAAGGGAAGAGATTGGAACCG  
AGCTGGGCCAGTGTCAAAAAAGACCTGATCTCATATGGAGGAGGTTGGAGGCTTCAAGGATCC  
TGGAACACAGGAGAAGAAGTGCAGGTGATTGCTGTTGAACCAGGGAAAAACCCCAAAAATGT  
ACAAACAGCGCCGGGCACCTTTAAGACCCCTGAAGGTGAAGTTGGAGCCATTGCCCTAGACTT  
TAAACCTGGCACATCTGGATCTCCCATCGTGAACAGAGAAGGAAAAATAGTAGGTCTTTATGG  
AAATGGAGTAGTGACAACAAGTGGAACTACGTCAGTGCCATAGCTCAAGCCAAAGCATCAC  
AAGAAGGGCCCCTACCAGAGATTGAAGACGAGGTGTTTAGGAAAAGAACTTAACAATAATG  
GACCTACATCCAGGATCGGGGAAAACAAGAAGATATCTTCCAGCCATAGTCCGTGAGGCCATA  
AAAAGGAAGCTGCGCACACTAATCCTGGCTCCCAACAAGGGTTGTCGCTTCCGAAATGGCAGAG  
GCGCTCAAGGGAATGCCAATAAGGTACCAACAACAGCAGTGAAGAGTGAACATACAGGAAA  
AGAGATAGTTGACCTCATGTGTACGCCACTTTACCATGCGCCTCCTGTCTCCCGTAAGAGTT  
CCCAATTACAACATGATCATCATGGATGAAGCACATTTACCGATCCATCCAGTATAGCGGCC  
AGAGGGTACATCTCAACCCGAGTGGGCATGGGTGAAGCAGCTGCAATCTTCATGACAGCCACT  
CCCCCAGGATCAGTGGAGGCCTTTCCACAGAGCAACGCAGTTATCCAAGATGAGGAAAGAGA  
CATTCTGAGAGATCATGGAACTCAGGCTATGAGTGGATCACTGACTTCCCAGGTAAAACAGT  
TTGGTTTGTTCOAAGCATTAAATCAGGAAATGACATTGCCAACTGCTTAAGAAAGAATGGGAA  
ACGGGTGATTCAATTGAGCAGGAAAACCTTTGATACAGAGTACCAAAAAACAACG  
ACTGGGACTACGTCGTCACAACAGACATCTCCGAAATGGGAGCAAATTTCCGAGCCGACAGGG  
TGATAGACCCAAGACGGTGTCTGAAACCGGTAATACTAAAAGATGGTCCAGAGCGTGTCAATT  
TAGCAGGACCAATGCCAGTGAAGTGTGGCCAGTGCCGCTCAGAGGAGAGGAAGAATTGGAAGG  
AACCACAATAAGGAAGGTGATCAGTACATCTACATGGGACAGCCTTTAAACAACGATGAAGA  
TCACGCTCACTGGACAGAAGCAAAAATGCTCCTTGATAATATAAACACACCAGAAGGGATTAT  
CCCAGCCCTCTTTGAGCCAGAGAGAGAAAAGAGTGCAGCAATAGACGGGGAATACAGACTGC  
GGGGTGAAGCAAGGAAAACGTTTGTGGAGCTCATGAGAAGAGGAGATCTACCTGTCTGGCTAT  
CCTACAAAGTTGCCTCAGAAGGCTTCCAGTACTCTGACAGAAGATGGTGCTTTGACGGGGAAA  
GGAACAACCAGGTGTTGGAGGAGAACATGGACGTGGAGATCTGGACAAAAGAAGGAGAAAAG  
AAAGAACTACGACCCCGCTGGCTGGATGCCAGAACATACTCAGACCCACTAGCCCTGCGCGA  
GTTTAAAGAGTTTGCAGCAGGGAGAAGAAGCGTCTCAGGTGATTTAATATTAGAAATAGGGAA  
GCTTCCACAACACTTGACGCAAAGGGGCCAGAATGCCCTGGACAACCTGGTTATGTTGCACAA  
CTCCGAACAAGGAGGCAGAGCCTATAGACATGCAATGGAAGAACTGCCAGACACCATAGAAA  
CGTTGATGCTCCTAGCTTTGATAGCTGTGTTAACTGGTGGAGTGACACTGTTCTTCCTATCAGG  
AAGGGGCCTAGGGAAAACATCTATCGGCCTACTCTGCGTAATGGCTTCAAGCGTACTGCTATG  
GATGGCCAGTGTGGAGCCCCATTGGATAGCGGCCTCCATCATACTGGAGTTCTTCCTGATGGTG  
CTGCTTATTCCAGAGCCAGACAGACAACGCACTCCGCAGGACAACCAGCTGGCATATGTGGTG  
ATAGGTTTGTATTTCATGATACTGACAGTAGCAGCAATGAGATGGGACTGCTGGAAACCACA  
AAGAAAGACTTAGGGATTGGCCATGTGGCTGTTGAAAATCACCAACCATGCCGCAATGCTGGAC

GTAGACTTACATCCAGCTTCAGCCTGGACCCTCTATGCAGTGGCCACAACAATTATCACTCCCA  
TGATGAGGCACACAATCGAAAACACAACGGCAAACATTTCCCTGACAGCCATTGCAAACCAG  
GCAGCTATATTGATGGGACTTGACAAAGGATGGCCAATATCGAAGATGGACATAGGAGTTCCA  
CTTCTCGCCTTGGGGTGCTATTCCCAGGTGAATCCACTGACGCTGACAGCGCGGTATTGATGC  
TAGTGGCTCATTACGCCATAATTGGACCTGGACTGCAAGCAAAAGCTACTAGAGAAGCTCAAA  
AAAGGACAGCGGCCGGAATAATGAAAAATCCAACCGTTGATGGAATTGTTGCAATAGATTTGG  
ACCCTGTGGTTTATGATGCAAAATTTGAAAAACAACCTAGGCCAAATAATGTTGTTGATACTATG  
CACATCACAGATCCTCTTGATGCGGACTACATGGGCCTTGTGCGAGTCCATCACACTGGCCACT  
GGACCTCTGACCACGCTTTGGGAGGGATCTCCAGGAAAATTTTGGAACACCACGATAGCGGTT  
TCCATGGCAAACATTTTCAGAGGAAGTTATCTAGCAGGAGCAGGTCTGGCCTTCTCATTAAATGA  
AATCTCTAGGAGGAGGTAGGAGAGGCACGGGAGCCCAAGGGGAAACACTGGGAGAGAAATG  
GAAAAGACAGCTGAACCAACTGAGCAAGTCAGAATTTAACACCTATAAAAGGAGTGGGATTA  
TGGAAGTGGACAGATCCGAAGCCAAAGAGGGATTGAAAAGAGGAGAAACAACCAACATGC  
AGTGTGAGAGGAACCGCTAAACTGAGGTGGTTTCGTGGAGAGGAACCTTGTGAAACCAGAAG  
GGAAAGTCATAGACCTCGGTTGTGGAAGAGGTGGCTGGTCATACTATTGCGCTGGGCTGAAGA  
AAGTCACAGAAGTGAAGGGGTATACAAAAGGAGGACCTGGACATGAGGAACCAATCCCAATG  
GCGACCTATGGATGGAACCTAGTAAAGCTGCACTCTGGGAAAGACGTATTTTTTATACCACCT  
GAGAAATGTGACACCCTTTTGTGTGATATTGGTGAGTCCTCTCCAAACCCAACTATAGAGGAA  
GGAAGAACGCTACGCGTCCTAAAGATGGTGGAAACCATGGCTCAGAGGAAACCAATTTTGCATA  
AAAATTCTGAATCCCTACATGCCAAGTGTGGTGGAAACTCTGGAGCAAATGCAAAGAAAACAT  
GGAGGAATGCTAGTGCGAAATCCACTTTCAAGAAATTCTACTCATGAAATGTATTGGGTTTCAT  
GTGGAACAGGAAACATTGTGTCAGCAGTAAACATGACATCTAGAATGTTGCTAAATCGATTCA  
CAATGGCTCACAGGAAACCAACATATGAAAGAGACGTGGACCTAGGCGCCGGAACAAGACAT  
GTGGCAGTGGAAACCAGAGGTAGCCAACCTAGATATCATTGGCCAGAGGATAGAGAACATAAA  
ACATGAACATAAGTCAACATGGCATTATGATGAGGACAATCCATATAAAACATGGGCCTATCA  
TGGATCATATGAGGTCAAGCCATCAGGATCAGCCTCATCCATGGTCAATGGCGTGGTGAAACT  
GCTCACCAAACCATGGGATGTCATCCCTATGGTCACACAAATAGCCATGACTGACACTACACC  
CTTTGGACAACAGAGGGTGTTTAAAGAGAAAAGTTGACACACGCACACCAAAAGCAAAACGGG  
GCACAGCACAATCATGGAGGTGACAGCCAAGTGGTTATGGGGTTTTCTTTCTAGAAACAAGA  
AACCAAGAATTTGCACAAGAGAGGAGTTCACAAGAAAAGTTAGGTCAAACGCAGCCATTGGA  
GCAGTGTTTCGTTGATGAAAATCAATGGAACCTCAGCAAAAGAAGCAGTGGAAAGATGAGCGGTT  
CTGGGACCTTGTGCATAGAGAGAGGGAGCTTCACAAACAGGGAAAATGTGCTACGTGTGTTTA  
CAACATGATGGGGAAGAGAGAGAGAAAAAGCTAGGAGAGTTCGGAAAGGCAAAAGGAAGTCGT  
GCAATATGGTACATGTGGTTGGGAGCACGCTTTCTAGAGTTCGAAGCTCTTGGTTTCATGAACG  
AAGATCACTGGTTCAGCAGAGAGAATTCCTCAGCGGAGTGGAAAGGAGAAGGACTCCACAAA  
CTTGGATATATACTCAGAGACATATCAAAGATTCCAGGGGGAAACATGTATGCAGATGACACA  
GCCGGATGGGATACAAGGATAACAGAGGATGACCTTCAGAATGAGGCCAGAATTACTGACAT

CATGGAACCCGAACATGCCCTCCTGGCTAAGTCAATCTTCAAGTTAACCTACCAAAATAAGGT  
 GGTAAGGGTACAGAGACCAGCAAAAAATGGAACCGTGATGGATGTCATATCCAGACGTGACC  
 AGAGAGGAAGTGGTCAGGTCGGAACCTTATGGCTTAAACACTTTACCAACATGGAAGCCCAGC  
 TGATAAGACAAATGGAGTCTGAGGGAATCTTTTACCCAGCGAATTAGAGACCCCAAATTTAG  
 CCGAGAGAGTTCTCGACTGGCTGGAAAAATATGGCGTCGAAAGGCTGAAAAGAATGGCAATC  
 AGCGGAGATGACTGCGTAGTGAAACCAATTGATGATAGGTTTGCAACAGCCTTGACAGCTCTG  
 AATGATATGGGAAAAGTAAGAAAAGATATACCACAATGGGAACCTTCAAAAGGATGGAATGA  
 TTGGCAACAAGTGCCTTTTTTGTTCACACCACTTCCACCAGCTGATTATGAAGGATGGGAGGGA  
 AATAGTGGTGCCATGCCGCAACCAAGATGAACTTGTGGGTAGGGCTAGAGTATCACAAGGTGC  
 TGGATGGAGCCTGAGAGAACTGCATGCCTAGGCAAGTCATATGCACAAATGTGGCAGCTGAT  
 GTACTTCCACAGGAGAGACCTGAGACTAGCCGCTAATGCTATCTGTTTCAGCCGTTCCAGTTGAT  
 TGGATCCCAACCAGCCGTACCACCTGGTCGATCCATGCCCATCACCAATGGATGACAACAGAA  
 GACATGCTGTCAGTGTGGAATAGGGTTTGGATAGAGGAAAACCCATGGATGGAGGACAAAAC  
 CCACATATCCAGTTGGGGAGATGTTCCATATTTAGGAAAAAGGGAAGACCAATGGTGTGGATC  
 CCTGATAGGCTTAAACAGCAAGGGCCACCTGGGCCACCAACATACAAGTGGCCATAAACCAAGT  
 GAGAAGACTAATTGGGAATGAGAATTATCTAGATTACATGACATCAATGAAGAGATTCAAGA  
 ACGAGAGTGATCCCGAAGGGGCACTCTGGTGAGTCAACACATTTACAAAATAAAGGAAAATA  
 AGAAATCAAACAAGGCAAGAAGTCAGGCCGGATTAAGCCATAGTACGGTAAGAGCTATGCTG  
 CCTGTGAGCCCCGTCTAAGGACGTAAATGAAGTCAGGCCGAAAGCCACGGCTTGAGCAAAC  
 CGTGCTGCCTGTAGCTCCATCGTGGGGATGTAAAAACCTGGGAGGCTGCAACCCATGGAAGCT  
 GTACGCATGGGGTAGCAGACTAGTGGTTAGAGGAGACCCCTCCCGAAACATAACGCAGCAGC  
 GGGGCCCAACACCAGGGGAAGCTGTACCCTGGTGGTAAGGACTAGAGGTTAGAGGAGACCCC  
 CCGCATAACAATAAACAGCATATTGACGCTGGGAGAGACCAGAGATCCTGCTGTCTCTACAGC  
 ATCATTCCAGGCACAGAACGCCAGAAAATGGAATGGTGCTGTTGAATCAACAGGTTCT

[0150] SEQ ID NO:10 – DENV-2-NI-BID-V533-2005-E-W/Min

AGTTGTTAGTCTACGTGGACCGACAAAGACAGATTCTTTGAGGGAGCTAAGCTCAACGTAGTT  
 CTAACAGTTTTTTAATTAGAGAGCAGATCTCTGATGAATAACCAACGAAAAAAGGCGAGAAGT  
 ACGCCTTTCAATATGCTGAAACGCGAGAGAAACCGCGTGCTCAACTGTGCAACAGCTGACAAAG  
 AGATTCTCACTTGGAATGCTGCAAGGACGCGGACCATTAAAACCTGTTTCATGGCCCTTGTGGCGT  
 TCCTTCGTTTCCTAACAATCCCACCAACAGCAGGGATACTAAAAAGATGGGGAACGATCAAAA  
 AATCAAAAGCTATCAATGTTTTGAGAGGGTTTCAGGAAAGAGATTGGAAGGATGCTGAACATCT  
 TGAACAAGAGACGCAGGACAGCAGGCGTGATTGTTATGTTGATTCCAACAGCGATGGCGTTCC  
 ATTTAACCACACGCAATGGAGAACCACACATGATCGTTGGTAGGCAGGAGAAAGGGAAAAAGT  
 CTTCTGTTCAAAACAGAGGATGGTGTAAACATGTGTACTCTCATGGCCATAGACCTTGGTGAAT  
 TGTGTGAAGATACAATCACGTACAAGTGTCTCTCCTCAGACAAAATGAACCAGAAGACATAG  
 ATTGTTGGTGCAACTCTACGTCCACATGGGTAACTTATGGGACATGTACCACCACAGGAGAAC

ACAGAAGAGAAAAAAGATCAGTGGCGCTCGTTCCACATGTAGGTATGGGACTGGAGACACGA  
ACTGAAACATGGATGTCATCAGAAGGGGCCTGGAAACATGTTTCAGAGAATTGAAACCTGGATC  
TTGAGACATCCAGGTTTTTACCATAATGGCAGCAATCCTGGCATAACCCATAGGAACGACACAT  
TTCCAAAGGGCCTTGATTTTCATTTTACTGACAGCTGTCGCTCCTTCAATGACAATGCGCTGCA  
TAGGAATATCAAATAGAGACTTCGTAGAAGGGGTTTCAGGAGGAAGCTGGGTGACATAGTCT  
TAGAACATGGAAGTTGTGTGACGACGATGGCAAAAAACAAACCAACATTGGATTTTGAAGTGA  
TAAAAACAGAAGCCAAACAACCTGCCACTCTAAGGAAGTACTGTATAGAAGCAAAGCTGACC  
AACACAACAACAGAATCGCGTTGCCCAACACAAGGGGAACCCAGTCTAATGAGGAGCAGGAC  
AAAAGGTTTCATCTGCAAACACTCCATGGTAGACAGAGGATGGGGAAATGGATGTGGATTATTT  
GGAAAGGGAGGCATTGTGACCTGTGCTATGTTTACATGCAAAAAGAACATGGAAGGAAAAGT  
CGTGCAGCCAGAAAATTTGGAATACACCATCGTGATAACACCTCACTCAGGAGAGGAGCACGC  
TGTAAGTAATGACACAGGAAAGCATGGCAAGGAAATCAAATAACACCACAGAGCTCCATCA  
CAGAAGCAGAATGACAGGCTATGGCACTGTCACGATGGAGTGCTCTCCGAGAACGGGCCTCG  
ACTTCAATGAGATGGTACTGCTGCAGATGGAAGACAAAGCTTGGCTGGTGCACAGGCAATGGT  
TCCTAGACCTGCCGTTACCATGGCTACCCGGAGCGGACACACAAGGATCAAATTGGATACAGA  
AAGAGACATTGGTCACTTTCAAAAATCCCCACGCGAAGAAACAGGACGTAGTCGTACTCGGAT  
CACAGGAAGGCGCAATGCATACCGCATTGACAGGCGCTACAGAGATACAGATGTCTAGCGGA  
AATCTGTTGTTTACAGGGCATCTGAAATGTAGACTGAGAATGGACAAACTGCAATTGAAGGGA  
ATGTCATACTCTATGTGTACGGGTAAGTTTAAGATAGTCAAAGAGATAGCCGAAACACAACAC  
GGAACAATCGTAATTAGGGTGCAATACGAAGGCGACGGGTACCATGTAAGATACCATTCTGA  
AATTACAGACCTCGAAAAAAGACACGTACTCGGAAGACTGATAACAGTGAATCCGATCGTTAC  
GGAAAAAGACTCACCCGTTAATATCGAAGCCGAACCACCATTCCGAGACTCATAcataataat  
CGGAGTCGAACCCGGACAATTGAACTGAATTGGTTTAAAAAAGGGTCATCAATCGGACAAAT  
GTTTCGAAACAACCTATGAGAGGCGCTAAGCGTATGGCTATACTCGGAGACACAGCATGGGACTT  
CGGATCCTTAGGGGGAGTGTTTACGTCAATCGGTAAAGGCACTACACCAGGTATTCGGAGCGAT  
ATACGGAGCCGCATTTAGCGGAGTGTCGTGGACAATGAAGATACTGATCGGAGTGATAATCAC  
ATGGATCGGAATGAATAGTAGGTCTACAAGTCTATCCGTTAGCTTAGTGTTAGTCGGAGTCGTT  
ACACTGTATCTAGGCGCTATGGTGCAAGCCGATAGTGGTTGCGTTGTGAGCTGGAAAAATAAA  
GAACTGAAATGTGGCAGCGGGATCTTCATCACAGATAACGTACACACATGGACAGAACAAATAT  
AAGTTCCAACCAGAATCCCCCTTCAAACTAGCTTCAGCTATCCAAAAAGCTCATGAAGAGGGC  
ATTTGTGGAATCCGCTCAGTAACAAGATTGGAGAATCTGATGTGGAAACAAATAACACCAGAA  
TTGAATCATATTCTATCAGAAAATGAGGTAAAGTTGACCATTATGACAGGAGACATTAGAGGA  
ATCATGCAGGCAGGAAAACGATCCTTGCGGCCCCAGCCCACTGAGCTGAAGTACTCATGGAAA  
ACATGGGGAAAGGCGAAAATGCTCTCCACAGAGTCTCACAATCAGACCTTTCTTATTGATGGC  
CCTGAAACAGCAGAATGCCCCAACACAAACAGAGCCTGGAACCTCGCTGGAAGTTGAAGACTA  
TGGTTTTGGAGTTTTTACCACCAATATATGGCTGAAATTGAGAGAAAAACAGGATGTATTTGT  
GACTCAAACTCATGTGTCAGCGGCCATTAAAGACAACAGAGCCGTTTCATGCTGATATGGGTTAT

TGGATAGAAAGTGCACCTCAATGACACATGGAAGATGGAGAAAGCCTCCTTCATTGAAGTTAAA  
AGCTGCCACTGGCCAAAGTCACACACCCCTTTGGAGCAATGGAGTATTAGAAAGTGAGATGATA  
ATCCCCAAAAATTTTGGCCGGGCCAGTGTACAAACACAACCTACAGACCAGGCTACCATACACAA  
ACAGCAGGACCTTGGCATCTAGGTAAGCTTGAGATGGACTTTGATCTCTGCGAAGGAACTACA  
GTGGTGGTGACTGAGGACTGTGGAATAGAGGACCCTCTTTAAGAACGACCACTGCCTCTGGA  
AACTCATAACAGAATGGTGCTGCCGATCCTGCACACTACCACCTCTAAGATACAGAGGTGAG  
GATGGATGCTGGTACGGGATGGAAATCAGACCATTGAAAGAGAAAGAAGAGAATTTGGTCAA  
CTCCTTGGTCACAGCCGGACATGGGCAGATTGACAACCTTTTCACTAGGAGTCTTGGGAATGGC  
ACTGTTCTTGGAAGAAATGCTCAGGACCCGAATAGGAACGAAACATGCAATACTGCTAGTTGC  
AGTATCTTTTGTGACATTGATTACTGGGAACATGTCTTTTAGAGACCTGGGAAGAGTGATGGTT  
ATGGTGGGCGCTACCATGACGGATGACATAGGTATGGGAGTGACTTATCTTGCCCTACTAGCA  
GCTTTTAAGGTTAGACCAACTTTTGCAGCTGGACTACTCTTAAGAAAACCTGACCTCCAAGGAAT  
TGATGATGGCCACCATAGGAATCGCACTCCTTTCCCAAAGCACCATAACCAGAGACCATTCTTG  
AACTGACTGATGCATTAGCCCTGGGCATGATGGTCCTCAAAATAGTGAGAAATATGGAAAAAT  
ACCAATTGGCAGTGACTATCATGGCTATTTTCATGTGTCCCAAATGCAGTGATACTGCAAAACGC  
ATGGAAGGTGAGTTGCACAATATTGGCAGCGGTGTCCGTTTCACCACTGCTCTTAACATCCTCA  
CAGCAGAAAGCGGATTGGATACCACTGGCATTGACGATAAAAGGTCTCAATCCAACAGCCATT  
TTTTTAACAACCTCTCTCGAGGACCAGCAAGAAAAGGAGCTGGCCGCTAAATGAAGCTATCATG  
GCAGTTGGGATGGTGAGCATTTTAGCCAGTTCTCTCCTAAAGAATGATATTCCTATGACAGGTC  
CATTAGTGGCTGGAGGACTCCTCACCGTATGTTACGTGCTCACTGGACGATCGGCCGATTTGGA  
ACTGGAGAGAGCTGCCGATGTAAAATGGGAAGATCAGGCAGAAATATCAGGAAGCAGCCCAA  
TCCTGTCAATAACAATATCAGAAGATGGCAGCATGTCGATAAAAAATGAAGAGGAAGAACAA  
ACACTGACCATACTCATCAGAACGGGATTGTTGGTGATCTCAGGAGTCTTTCCAGTATCGATAC  
CAATTACGGCAGCAGCATGGTACCTGTGGGAAGTAAAGAAACAACGGGCTGGAGTACTGTGG  
GACGTCCCTTCACCCCCACCAGTGGAAAAAGCCGAACCTGGAGGATGGAGCCTACAGAATCAA  
GCAAAGAGGGATCCTTGGATATTCTCAGATTGGAGCCGGAGTTTACAAAGAAGGAACATTCCA  
TACAATGTGGCACGTCACACGTGGTGCTGTTCTGATGCATAGAGGGAAGAGGATTGAACCATC  
ATGGGCAGATGTCAAGAAAGACCTAATATCATATGGAGGAGGCTGGAAGCTAGAAGGAGAAT  
GGAAGGAAGGAGAGGAAGTCCAAGTCCTGGCATTGGAACCTGGAAAAAATCCAAGAGCCGTC  
CAAACGAAACCTGGAATATTCAAACCAACACCGGAACCATAGGCGCCGTATCTCTGGACTTT  
TCCCCTGGAACGTCAGGATCTCCAATCGTCGACAGAAAAGGAAAAGTTGTGGGTCTTTACGGT  
AATGGTGTTGTACAAGGAGTGAGCATATGTAAGTGCTATAGCCCAGACCGAAAAAAGCATT  
GAAGACAATCCAGAGATCGAAGATGACATTTTCCGAAAGAAAAGATTGACCATCATGGACCTC  
CATCCAGGAGCAGGAAAGACAAAAAGATACCTTCCAGCCATAGTTAGAGAAGCCATAAAACG  
TGGCTTGAGAACATTGATCCTGGCTCCCACTAGAGTAGTGGCAGCTGAAATGGAGGAAGCTCT  
TAGAGGACTTCCAATAAGATACCAAACCTACAGCCATCAAAACCGAGCATACCGGGCGGGAGA  
TCGTGGACCTAATGTGTCATGCCACATTTACTATGAGGCTGTTATCACCAAGTCAGAGTGCCAAA

TTACAACCTGATCATCATGGACGAAGCCCCTTCACAGACCCAGCAAGTATAGCAGCTAGAGG  
ATACATTTCAACTCGAGTAGAGATGGGTGAAGCAGCCGGGATTTTCATGACAGCCACTCCTCC  
GGGAAGTAGAGACCCATTTCTCAGAGCAATGCACCAATTATGGATGAGGAAAGAGAAATCC  
CTGAGCGTTCATGGAATTCAGGACACGAATGGGTACGGATTTTAAGGGGAAGACTGTTTGGT  
TTGTTCCAAGTATAAAAGCAGGAAATGATATAGCAGCTTGTCTTAGGAAAAATGGAAAGAAA  
GTGATACAACCTCAGTAGGAAGACTTTTGACTCTGAGTATGTTAAGACTAGAGCCAATGATTGG  
GACTTTGTGGTCACAACTGACATTTTCAGAAATGGGTGCCAACTTCAAGGCTGAGAGGGTTATA  
GACCCAGACGTTGCATGAAACCAGTTATACTAACAGATGGCGAGGAGCGGGTGATCTTGGCT  
GGACCTATGCCAGTGACCCACTCTAGTGCAGCGCAAAGAAGAGGGGAGAATAGGAAGAAATCC  
AAAAAATGAAAATGACCAGTACATATACATGGGGGAACCTCTTGAAAATGATGAAGACTGTG  
CACATTGGAAAGAAGCTAAAATGCTCCTAGATAACATCAACACACCTGAAGGAATCATTCTA  
GTATGTTTGAACAGAGCGTGAAAAAGTGGATGCCATTGATGGTGAATACCGTTTGAGAGGAG  
AAGCAAGGAAAACCTTTGTGGACCTAATGAGAAGAGGGGACTTACCAGTCTGGTTGGCCTACA  
AAGTGGCAGCTGAAGGCATCAACTACGCAGACAGAAAGTGGTGTGTTTGATGGAATTAAGAAC  
AACCAAATACTGGAAGAAAATATGGAAGTGGAAATCTGGACAAAAGAAGGGGAAAGGAAAA  
AATTAACCCAGATGGTTGGATGCTAGGATCTATTCTGACCCACTAGCACTAAAAGAATTCA  
AGGAATTTGCAGCTGGAAGAAAATCTTTGACCCTGAACCTAATCACAGAAATGGGTAGGCTTC  
CAACTTTCATGACTCAGAAAGCAAGAAACGCCTGGACAACCTGGCTGTGCTGCATACGGCTG  
AGGCAGGTGGAAGGGCGTACAATCATGCTCTCAGTGAAGTGCCGGAGACCCTGGAGACACTG  
CTCCTACTGACACTTCTGGCAACAGTCACAGGAGGAATCTTCTTATTCTTAATGAGCGGAAAAG  
GTATAGGGAAGATGACCCTGGGAATGTGTTGCATAATCACGGCTAGTATCCTCCTATGGTATG  
CACAGATACAACCACACTGGATAGCAGCTTCAATAATACTGGAGTTTTTCTCATAGTTTTGTCT  
CATTCCAGAACCAGAAAAACAGAGAACACCCCAAGACAACCAATTGACCTACGTTGTCATAGC  
CATCCTCACAGTGGTGGCCGCAACCATGGCAAACGAGATGGGTTCCTGGAAAAAACCAAGA  
AAGACCTCGGATTGGGAAGCATTACAACCCAGGAATCTGAGAGCAATATCCTGGACATAGATC  
TACGCCCTGCATCAGCATGGACGCTGTATGCCGTAGCTACAACATTTGTCACACCAATGTTGAG  
ACATAGCATTGAAAATTCTCAGTGAATGTCTCCCTAACAGCCATTGCTAACCAAGCTACAGTG  
CTAATGGGTCTTGGGAAAGGATGGCCATTGTCAAAGATGGACATTGGAGTTCCCCCTCCTTGCC  
ATTGGATGCTATTACAAGTCAACCCTATACTCTCACAGCAGCTCTCCTTTTATTGGTAGCAC  
ATTATGCCATTATAGGGCCAGGACTTCAAGCAAAAGCAACCAGAGAAGCCCAGAAAAGAGCA  
GCAGCAGGCATCATGAAAAACCAACAGTCGATGGAATAACAGTGATTGACCTAGAACCAAT  
ACCCTATGATCCAAAATTTGAAAAGCAGTTAGGACAAGTAATGCTCCTAATCCTCTGCGTGACT  
CAAGTATTAATGATGAGGACTACATGGGCTTTATGTGAGGCTCTAACCTAGCGACCGGGCCC  
ATCTCCACACTGTGGGAAGGAAATCCAGGGAGGTTTTTGGAACTACTACCATTGCAGTGTCAATG  
GCTAACATCTTTAGGGGGAGCTACTTGGCCGGAGCTGGACTTCTCTTTTCCATCATGAAAAACA  
CAACAAACACAAGAAGAGGAACTGGCAACATAGGAGAGACACTTGGAGAAAAATGGAAAAG  
TCGATTAAACGCACTGGGGAAAAGTGAATTTCAAATCTACAAGAAAAGTGGAAATCCAGGAAG

TGGATAGAACCCTAGCAAAAAGAAGGTATCAAAAGAGGAGAAACGGACCACCATGCTGTGTGCG  
CGAGGTTTCAGCAAAACTGAGATGGTTCGTCGAGAGAAATATGGTCACACCGGAAGGGAAGGT  
GGTGGATCTCGGTTGCGGCAGAGGGGGCTGGTCATACTATTGCGGGGGACTAAAGAATGTAAG  
AGAAGTCAAAGGCCTAACAAAAGGAGGACCAGGACATGAAGAACCCATCCCCATGTCAACAT  
ATGGGTGGAATCTAGTGCGTCTGCAAAGTGGAGTTGACGTTTTCTTCACCCCGCCAGAAAAGT  
GTGATACATTGTTGTGTGACATAGGGGAGTCGTCACCAAATCCCACGATAGAAGCAGGACGAA  
CACTCAGAGTCCTCAACTTAGTGGAATAATTGGTTGAACAATAACACCCAATTTTGCATAAAGG  
TCCTCAACCCATATATGCCTTCAGTCATAGAAAAAATGGAAGCATTACAAAGGAAATATGGAG  
GAGCCTTAGTGAGGAATCCACTCTCACGAACTCCACGCATGAAATGTACTGGGTATCTAATG  
CCACCGGGAACATAGTGTTCATCAGTGAACATGATTTCAAGGATGTTGATTAACAGATTACAA  
TGAAACACAAGAAAGCCACTTACGAGCCAGATGTTGACCTAGGAAGTGGAACCCGCAACATT  
GGAATTGAAAGTGAGATACCAAATCTAGACATAATAGGAAAGAGAATAGAGAAAATAAAACA  
AGAGCATGAAACATCATGGCACTATGATCAAGACCACCCATACAAAACGTGGGCTTACCATGG  
CAGCTATGAAACAAAACAACTGGATCAGCATCATCTATGGTGAACGGAGTGGTCAGATTGCT  
GACAAAACCTTGGGACGTCGTCCTATGGTGACACAGATGGCAATGACAGACACGACTCCTTT  
TGGACAACAGCGCGTTTTCAAAGAGAAAGTAGACACGAGAACCCAAGAACCGAAGGAAGGCA  
CAAAGAACTGATGAAAATTACGGCAGAGTGGCTTTGGAAAGAACTAGGAAAGAAAAAGACA  
CCTAGGATGTGTACCAGAGAAGAATTCACAAGAAAAGTGAGAAGCAATGCAGCCTTGGGGGC  
CATATTCATGATGAGAACAATGGAAATCGGCACGTGAGGCTGTTGAAGATGGTAGGTTCTG  
GGAGCTGGTTGACAGGGAAAGAAATCTCCATCTTGAAGGAAAGTGTGAAACATGTGTGTACA  
ACATGATGGGAAAAAGAGAGAAGAACTAGGGGAGTTTCGGCAAGGCAAAAGGTAGCAGAGC  
CATATGGTACATGTGGCTTGGAGCACGCTTCTTAGAGTTTGAAGCCCTAGGATTCTCTGAATGAA  
GATCACTGGTTCTCCAGAGGGAACTCCCTGAGTGGAGTGGAAAGGAGAAGGGCTGCACAGGCT  
AGGCTACATTTTAAGAGACGTGGGCAAGAAGGAAGGGGGGCAATGTACGCCGATGATACAG  
CAGGATGGGACACAAGAATCACACTAGAAGACTTAAAAAATGAAGAAATGGTAACGAACCAC  
ATGAAAGGAGAACACAAGAACTAGCCGAGGCCATATTCAAATAACGTACCAAAACAAGGT  
GGTGCGTGTGCAAAGACCAACACCAAGAGGTACAGTAATGGATATCATATCGAGAAGAGACC  
AAAGAGGCAGTGGGCAAGTCGGCACCTATGGCCTTAATACCTTCACCAATATGGAAGCCCAAT  
TAATTAGACAGATGGAGGGAGAAGGAATCTTCAAAGCATTTCAGCACCTGACAGCCACAGAA  
GAAATCGCTGTACAGAACTGGCTAGCAAGAGTGGGGCGTGAAAGGCTATCAAGAATGGCAAT  
CAGTGGAGATGATTGTGTTGTAACCTATAGATGACAGATTTGCAAGTGCTTTAACAGCTCTA  
AATGACATGGGAAAAGTTAGAAAAGATATACAACAATGGGAACCTTCAAGAGGATGGAACGA  
TTGGACACAAGTGCCTTTCTGTTACACCACTTTTCATGAGTTAGTCATGAAAGATGGTCGCGTG  
CTCGTAGTCCCATGCAGAAACCAAGATGAACTGATTGGTAGAGCCCGAATTTCCAGGGAGCT  
GGGTGGTCTTTGAAAGAGACGGCCTGTTTGGGAAAGTCTTACGCCCAAATGTGGACTCTGATG  
TACTTCCACAGACGTGACCTCAGACTGGCGGCAAATGCCATCTGCTCGGCAGTCCCGTCACATT  
GGGTTCCAACAAGTCGAACAACCTGGTCCATACACGCTAAGCATGAATGGATGACGACGGAA

GACATGCTGGCAGTCTGGAACAGGGTGTGGATCCAAGAAAACCCGTGGATGGAAGATAAAAC  
TCCAGTGGAATCATGGGAAGAAGTCCCATACTTGGGAAAAAGAGAAGACCAATGGTGCGGCT  
CATTGATTGGGCTAACAAGCAGGGCTACCTGGGCAAAGAACATCCAAACAGCAATAAATCAA  
GTCAGATCCCTTATAGGCAATGAGGAATACACAGACTACATGCCATCCATGAAGAGATTTAGA  
AGGGAAGAGGAAGAGGCAGGTGTCCTGTGGTAGAAGGCAAAACCTAACATGAAACAAGGCTAA  
AAGTCAGGTTCGGATTAAGCCATAGTACGGAAAAAACTATGCTACCTGTGAGCCCCGTCCAAGG  
ACGTTAAAAGAAGTCAGGCCATCACAAAATGCCACAGCTTGAGTAAACTGTGCAGCCTGTAGC  
TCCACCTGAGGAGGTGTAAAAAACCTGGGAGGCCACAAACCATGGAAGCTGTACGCATGGCG  
TAGTGGACTAGCGGTTAGAGGAGACCCCTCCCTTACAAATCGCAGCAAACAACGGGGGGCCCA  
AGGTGAGATGAAGCTGTAATCTCACTGGAAGGACTAGAGGTTAGAGGAGACCCCCCAAAC  
AAAAACAGCATATTGACGCTGGGAAAGACCAGAGATCCTGCTGTCTCCTCAGCATCATTCCA  
GGCACAGAACGCCAGAAAATGGAATGGTGCTGTTGAATCAACAGGTTCT

[0151] SEQ ID NO:11 – DENV-3-VE-BID-V2268-2008-E-W/Min

AGTTGTTAGTCTACGTGGACCGACAAGAACAGTTTTCGACTCGGAAGCTTGCTTAACGTAGTGCT  
AACAGTTTTTTATTAGAGAGCAGATCTCTGATGAACAACCAACGGAAGAAGACGGGAAAACC  
GTCTATCAATATGCTGAAACGCGTGAGAAACCGTGTGTCAACTGGATCACAGTTGGCGAAGAG  
ATTCTCAAAGGACTGCTGAACGGCCAGGGACCAATGAAATTGGTTATGGCGTTCATAGCTTT  
CCTCAGATTTCTAGCCATTCCACCAACAGCAGGAGTCTTGGCTAGATGGGGAACCTTCAAGAA  
GTCGGGGGGCCATTAAGGTCCTGAAAGGCTTTAAGAAGGAGATCTCAAACATGCTGAGCATAAT  
CAACAAACGGAAAAAGACATCGCTCTGTCTCATGATGATATTGCCAGCAGCACTTGCTTTCCA  
CTTGACTTCACGAGATGGAGAGCCGCGCATGATTGTGGGGAAGAATGAAAGAGGAAAATCCC  
TACTTTTTAAGACAGCCTCTGGAATTAACATGTGCACACTCATAGCCATGGACTTGGGAGAGAT  
GTGTGATGACACGGTCACTTACAAATGCCCCCATATTACCGAAGTGGAACCTGAAGACATTGA  
CTGCTGGTGCAACCTCACATCAACATGGGTGACTTATGGAACGTGCAATCAAGCCGGAGAGCA  
TAGACGCGATAAGAGATCAGTGGCGTTAGCTCCCCATGTCGGCATGGGACTGGATACACGCAC  
CCAAACTTGATGTGCGCTGAAGGAGCTTGGAGGCAAGTCGAGAAGGTAGAGACATGGGCCC  
TTAGGCACCCAGGGTTCACCATACTAGCCCTATTTCTTGCCCATACATAGGCACTTCCTTGAC  
CCAGAAGGTGGTTATTTTTATACTGCTAATGCTGGTCACCCCATCCATGACAATGAGATGTGTG  
GGAGTAGGAAACAGAGATTTTGTGGAAGGACTATCAGGAGCTACGTGGGTTGACGTGGTGCTC  
GAGCACGGGGGGTGTGTGACCACCATGGCTAAGAACAAGCCCACGTTGGATATAGAGCTTCA  
GAAGACCGAGGCCACCCAACCTGGCGACCCTAAGGAAGCTATGCATTGAGGGGAAAATCACCA  
ACATAACAACCTGACTCAAGATGTCCTACCCAAGGGGAAGCGGTTTTGCCTGAGGAGCAGGACC  
AAAACCTACGTGTGTAAGCATACATACGTAGACAGAGGCTGGGGGAACGGATGTGGTTTTGTTG  
GTAAGGGAAGCTTGGTAACATGTGCGAAATTTCAATGCCTGGAACCAATAGAGGGAAAAGTG  
GTGCAATATGAGAACCTCAAATACACCGTTATCATCACAGTGACACAGGAGACCAACACCAG  
GTGGGAAATGAAACGCAGGGAGTCACGGCTGAGATAACACCTCAGGCATCAACCACTGAAGC

CATCTTGCCTGAATATGGAACCCCTTGGGCTAGAATGCTCACCACGGACAGGTTTGGACTTCAAT  
GAAATGATCTTGCTAACAATGAAGAACAAAGCATGGATGGTACATAGACAATGGTTTTTTGAC  
CTACCTCTACCATGGACATCAGGAGCTACAACGGAAACACCAACCTGGAACAGGAAGGAGCT  
TCTTGTGACATTTAAAAACGCACATGCGAAGAAACAAGAAGTAGTCGTTTTAGGGTTCACAGGA  
GGGAGCTATGCATACCGCACTAACCGGAGCGACTGAGATACAGAATAGCGGAGGGACATCAA  
TCTTCGCCGGACACCTTAAGTGTAGATTGAAAATGGACAACTTGAGCTTAAGGGGATGTCAT  
ACGCTATGTGTACGAACACATTTCGTGCTGAAAAAAGAGGTAAGCGAAACGCAACACGGAACG  
ATACTGATTAAGGTTGAGTATAAGGGCGAAGACGTCCCATGTAAGATACCTTTTTTCGACAGAG  
GACGGACAGGGTAAGGCCATAACGGAAGACTGATTACCGCTAACCCAGTGGTGACCAAAAA  
AGAGGAACCAGTCAATATCGAAGCCGAACCTCCATTTCGGAGAGTCAAACATAGTGATAGGGA  
TAGGCGATAACGCACTTAAGATTAAGTGGTACAAAAAAGGGTCATCAATCGGTAAAGATGTTTG  
AGGCAACCGCTAGGGGGGGCTAGACGGATGGCCATACTCGGAGACACCGCATGGGACTTCGGA  
TCCGTGGGGGGGGTACTTAAGTCACTCGGTAAAGATGGTGCACCAAATTTTCGGATCCGCATAT  
ACCGCTCTATTTAGCGGAGTGTCATGGGTGATGAAAATCGGAATCGGAGTTCTATTGACATGG  
ATCGGATTGAACTCTAAGAATACATCTATGTCAATTTTCATGTATCGCAATCGGAATTATTACGC  
TATATCTCGGAGCCGTAGTGCAAGCCGACATGGGGTGTGTTATAAACTGGAAAGGCAAAGAAC  
TCAAGTGTGGAAGTGGAATCTTCGTCACCAACGAGGTCCATACCTGGACAGAGCAATACAAAT  
TCCAAGCAGACTCCCCAAAAGATTGGCGACAGCCATTGCAGGCGCTTGGGAGAATGGAGTGT  
GCGGAATTAGGTCAACAACCAGAATGGAGAATCTCCTGTGGAAGCAAATAGCCAATGAACTG  
AACTACATATTGTGGGAAAACAATATCAAATTAACGGTTGTTGTGGGCGATATAATTGGGGTC  
TTAGAGCAAGGGAAAAGAACACTAACACCACAACCCATGGAGCTAAAATACTCATGGAAAAC  
GTGGGGAAAGGCAAAAATAGTGACAGCTGAAACACAAAATTCTTCTTTTCATAATAGATGGACC  
AAACACACCGGAGTGTCCTCAAGAGCATGGAATGTGTGGGAGGTGGAAGATTACG  
GGTTTCGGAGTCTTCACAACCAACATATGGCTGAAACTCCGAGAGGTGTATACCCAACCTATGTG  
ACCATAGGTTAATGTCGGCAGCCGTCAAGGATGAAAGGGCCGTACATGCCGACATGGGCTATT  
GGATAGAAAGTCAAAAGAATGGAAGTTGGAAGCTAGAAAAAGCATCCCTCATAGAGGTGAAA  
ACCTGCACATGGCCAAAATCACATACCCTTTGGAGTAATGGTGTGTTAGAGAGTGACATGATC  
ATTCCAAAAAGTCTAGCTGGTCTCTATCTCGCAACACAACCTACAGGCCCCGGGTACCACACCCAG  
ACGGCGGGACCTTGGCATTTAGGAAAATTAGAGCTGGACTTCAACTATTGTGAAGGAACAACA  
GTTGTCATCACAGAAAACCTGTGGGACAAGAGGCCCATCATTGAGAACAAACAGTGTCAGG  
GAAGTTAATACACGAATGGTGCTGCCGCTCGTGACACTTCCTCCCCTGCGATACATGGGAGA  
AGACGGTTGCTGGTATGGCATGGAAATCAGACCCATCAGTGAGAAAGAAGAAAACATGGTAA  
AGTCTTTAGTCTCAGCGGGAAGTGGAGAGGTGGACAACTTCACAATGGGTGTCTTGTGTTTGG  
CAATCCTCTTTGAAGAGGTGATGAGAGGAAAATTTGGGAAGAAACACATGATTGCGGGGGTTT  
TCTTCACGTTTGTACTCCTTCTCTCAGGGCAAATAACATGGAGAGATATGGCGCACACACTAAT  
AATGATTGGGTCCAATGCATCTGACAGGATGGGAATGGGCGTCACCTACCTAGCTTTAATTGC  
AACATTTAAATCCAGCCATTTTTGGCTTTGGGATTTTTCCTAAGAAAACCTGACATCCAGAGAA

AATTTATTGTTAGGAGTTGGGCTGGCTATGGCAACAACGTTACAACCTGCCAGAGGACATTGAA  
CAAATGGCAAATGGAATCGCTCTGGGGCTCATGGCTCTCAAACCTGATAACACAATTTGAAACA  
TACCAACTATGGACAGCATTAATCTCCTTAACGTGTTCAAATACAATTTTTTACGTTGACTGTTG  
CCTGGAGAACAGCCACCCTGATTTTGGCTGGAGTTTCACTTTTACCAGTGTGCCAGTCTTCGAG  
TATGAGGAAAACAGACTGGCTTCCAATGACAGTGGCAGCTATGGGAGTTCACCTCTACCACT  
TTTTATTTTTAGCTTAAAAGACACACTCAAAAGGAGAAGCTGGCCACTGAATGAAGGGGTGAT  
GGCTGTTGGGCTTGTGAGCATTCTGGCCAGTTCTCTCCTTAGAAATGATGTACCCATGGCTGGA  
CCATTAGTGGCCGGGGGCTTGCTGATAGCGTGCTACGTCATAACTGGCACGTCAGCAGACCTC  
ACCGTAGAAAAAGCAGCAGATGTAACATGGGAGGAAGAGGCTGAGCAAACAGGAGTGTCCCA  
CAACTTAATGATCACAGTTGATGATGATGGAACAATGAGAATAAAAGATGATGAGACTGAGA  
ATATCTTAACAGTGCTTTTGAAAACAGCATTACTAATAGTGTGAGGAATCTTTCCATACTCCAT  
ACCCGCAACATTGTTGGTCTGGCATACTTGGCAAAAGCAAACCCAAAGATCCGGCGTTCTATG  
GGATGTACCCAGCCCTCCAGAGACACAGAAAGCAGAACTGGAAGAAGGGGTCTATAGGATCA  
AACAGCAAGGAATTTTTGGGAAAACCCAAGTAGGGGTGGAGTACAGAAAGAAGGAGTCTTT  
CACACCATGTGGCACGTTACAAGAGGGGGCAGTGTGACATATAATGGGAAAAGACTGGAACC  
AAATTGGGCTAGCGTGAAAAAAGATCTGATTTTCATACGGAGGAGGATGGAGATTGAGCGCAC  
AATGGCAAAAGGGGGAGGAGGTGCAGGTTATTGCCGTAGAGCCTGGGAAGAACCCAAAGAAC  
TTTCAAACCATGCCAGGCACTTTTCAGACTACAACAGGGGAAATAGGAGCAATTGCACTGGAT  
TTCAAGCCCGGAACTTCAGGATCTCCTATCATAAACAGAGAGGGAAAGGTAGTGGGACTGTAT  
GGCAATGGAGTGGTTACAAAGAATGGTGGCTACGTCAGCGGAATAGCGCAAACGAATGCAGA  
ACCAGATGGACCGACACCAGAATTGGAAGAAGAGATGTTCAAAAAGCGAAATCTAACCATAA  
TGGATCTTCATCCTGGGTCAGGAAAGACACGGAAATACCTTCCAGCTATTGTTAGAGAGGCAA  
TCAAGAGACGTTTGAGAACTCTAATTCTGGCACCAACAAGGGTGGTTGCAGCTGAGATGGAAG  
AAGCATTGAAAGGGCTCCCAATAAGGTACCAACAACAGCAACAAAATCTGAACACACAGGA  
AGAGAGATTGTTGATCTGATGTGCCACGCAACGTTTACAATGCGTCTGCTGTCACCAGTTAGG  
GTTCCAAACTATAACTTGATAATAATGGATGAAGCCCATTTACAGACCCAGCCAGTATAGCT  
GCTAGAGGGTACATATCAACTCGTGTTGGAATGGGAGAAGCAGCCGCAATATTCATGACAGCA  
ACGCCCCCTGGAACAGCTGATGCCTTTCCCCAGAGCAACGCTCCAATTCAAGATGAAGAAAGG  
GACATACCAGAACGCTCATGGAATTCAGGCAATGAATGGATAACCGACTTCGCTGGGAAAAC  
GGTGTGGTTTGTCCCCAGCATTAAAGCCGGAAATGACATAGCAAATTGCCTGCGGAAAAACGG  
GAAAAAGGTCATTCAACTTAGTAGGAAGACTTTTGACACAGAATATCAGAAAACCAAACCTGA  
ATGATTGGGACTTTGTGGTGACGACTGACATTTTCAAGAAATGGGGGCCAATTTCAAAGCAGATA  
GAGTGATCGACCCAAGAAGATGTCTCAAACCAGTGATCCTGACAGATGGACCAGAGCGGGTG  
ATCCTGGCTGGACCAATGCCAGTCACCGCAGCGAGTGCTGCGCAAAGGAGAGGGAGAGTTGG  
CAGGAACCCACAAAAAGAAAATGACCAGTACATATTCACGGGCCAGCCTCTCAACAATGATG  
AAGACCATGCTCACTGGACAGAAGCAAAAATGCTGCTGGACAACATTAACACACCAGAAGGG  
ATCATACCAGCTCTCTTTGAGCCAGAAAGGGAGAAGTCAGCCGCCATAGACGGTGAGTATCGC

CTGAAAGGTGAGTCCAGGAAGACTTTTCGTGGAATCATGAGGAGGGGTGACCTTCCAGTCTGG  
TTAGCCCATAAAGTAGCATCAGAAGGGATCAAATATACAGATAGAAAATGGTGCTTTGATGGA  
CAACGTAATAATCAAATTTTAGAAGAGAACATGGATGTGGAAATCTGGACAAAGGAAGGAGA  
AAAGAAAAAATTGAGACCTAGGTGGCTTGATGCTCGCACCTATTCAGATCCCTTAGCACTCAA  
GGAATTCAAGGACTTTGCGGCTGGCAGGAAGTCAATAGCCCTTGATCTTGTGACAGAAATAGG  
AAGAGTGCCTTCACACCTAGCTCATAGAACGAGAAACGCTCTGGACAATCTGGTGATGCTGCA  
TACGTCAGAACATGGCGGTAAGGCCTACAGGCATGCGGTGGAGGAACTACCAGAGACAATGG  
AAACACTCCTACTCTTGGGACTCATGATCTTGTGACAGGTGGAGCAATGCTTTTCTTAATATC  
AGGTAAAGGGATTGGAAAGACTTCAATAGGACTCATTTGTGTAATTGCTTCCAGCGGCATGTT  
GTGGATGGCCGAAATCCCCTCCAATGGATCGCGTCGGCCATAGTCCTGGAGTTTTTTATGATG  
GTGTTGCTTATACCAGAACCAGAGAAGCAGAGAACCCCCCAAGACAACCAACTCGCATATGTC  
GTGATAGGCATACTTACACTGGCAGCAATAATAGCAGCCAATGAAATGGGATTGTTGGAACT  
ACAAAGAGAGATTTAGGAATGTCTAAGGAGCCAGGTGTTGTTTCTCCAACCAGCTATTTAGAT  
GTGGACTTGCACCCAGCATCAGCCTGGACATTGTACGCTGTGGCCACTACAGTAATAACACCA  
ATGTTAAGACATACCATAGAGAATTCCACAGCAAATGTGTCCTTGGCAGCTATAGCCAACCAG  
GCAGTGGTCCTGATGGGTTTGGACAAAGGATGGCCAATATCAAAAATGGACTTAGGAGTACCC  
CTGCTGGCATTGGGTTGCTATTCACAAGTGAACCCACTGACTCTAACAGCGGCAGTACTCTTGC  
TGATCACACATTATGCCATTATAGGTCCAGGATTGCAGGCAAAAGCCACCCGTGAAGCTCAGA  
AAAGGACAGCTGCTGGAATAATGAAGAATCCAACAGTGGATGGGATAATGACAATAGACCTA  
GATCCTGTAATATATGATTCAAAATTTGAAAAGCAACTGGGACAGGTTATGCTCCTGGTTTTGT  
GTGCAGTTCAACTTTTGTTAATGAGAACATCATGGGCCTTGTGTGAAGCTTTAACCTAGCTAC  
AGGACCAATAACAACACTCTGGGAAGGATCACCTGGGAAGTTTTGGAACACCACGATAGCTGT  
TTCCATGGCGAACATTTTTAGAGGGAGCTATTTAGCAGGAGCTGGGCTTGCTTTCTCTATTATG  
AAATCAGTTGGAACAGGGAAAAGAGGAACAGGCTCACAGGGTGAACTTTGGGAGAAAAATG  
GAAAAAGAAGTTAAATCAATTATCCCGGAAAGAGTTTGACCTTTACAAGAAATCTGGAATCAC  
TGAGGTGGATAGAACAGAAGCCAAAGAAGGGTTGAAAAGAGGAGAAATAACACATCATGCCG  
TGTCAGAGGTAGTGCAAAACTTCAATGGTTTTGTGGAGAGAAACATGGTCATTCCCGAAGGAA  
GAGTTATAGACTTGGGCTGTGGAAGAGGAGGCTGGTCATATTACTGTGCAGGACTGAAAAAAG  
TCACAGAAGTGCGAGGATACACAAAAGGCGGTCCAGGACACGAAGAACCAGTACCTATGTCC  
ACATATGGATGGAACATAGTTAAGTTAATGAGTGGAAGGATGTGTTTTATCTTCCACCTGAA  
AAGTGTGACACCCTGTTGTGCGACATTGGAGAATCTTCACCAAGCCCAACAGTGGAAGAAAGC  
AGAACTATAAGAGTTTTGAAGATGGTTGAACCATGGCTAAAGAACAACCAATTTTGTATTAAA  
GTATTGAACCTTACATGCCAACTGTGATTGAGCACCTAGAAAGACTACAAAGGAAACATGGA  
GGAATGCTTGTGAGAAATCCACTTTCACGAACTCCACGCACGAAATGTACTGGATATCCAAT  
GGCACAGGTAACATTGTGCTTCAGTCAACATGGTATCTAGACTGCTACTGAACAGGTTACG  
ATGACACACAGAAGACCCACCATTGAGAAAGATGTGGATTTAGGAGCAGGAACTCGACATGT  
TAATGCGGAACCAGAAACACCCAACATGGATGTCATTGGGGAAAGAATAAAAAGGATCAAGG

AGGAGCATAATTCAACATGGCACTACGATGACGAAAACCCCTACAAAACGTGGGCTTACCATG  
GATCTTATGAAGTCAAAGCCACAGGCTCAGCCTCCTCCATGATAAATGGAGTCGTGAAACTCC  
TCACTAAACCATGGGATGTGGTGCCCATGGTGACACAGATGGCAATGACAGATACAACCTCCAT  
TTGGCCAGCAGAGAGTCTTTAAAGAGAAAGTGGACACCAGGACACCCAGGTCCATGCCAGGA  
ACAAGAAGGGTTATGGGGATCACAGCGGAGTGGCTCTGGAGAACCCTGGGAAGGAATAAAAA  
ACCCAGGTTATGCACAAGGGAAGAGTTTACAAAAAAGGTCAGAACTAACGCAGCCATGGGAG  
CTGTTTTTCACAGAGGAGAACCAATGGGACAGCGCGAAAGCTGCTGTTGAGGATGAGGATTTTT  
GGAACTTGTGGACAGAGAACGTGAACTCCACAACTGGGCAAGTGTGGAAGCTGTGTTTACA  
ACATGATGGGTAAGAGAGAGAAGAACTTGGAGAGTTTGGCAAAGCAAAAGGCAGTAGAGCT  
ATATGGTACATGTGGTTGGGAGCCAGGTACCTTGAGTTCGAAGCCCTTGGATTCTTAAATGAA  
GACCACTGGTTCTCGCGTGAGAACTCTTACAGTGGAGTGGAAAGGAGAAGGACTGCACAAGCTA  
GGCTATATATTAAGGGACATTTCCAAGATACCCGGAGGAGCTATGTATGCTGATGACACAGCT  
GGTTGGGACACAAGAATAACAGAAGATGACCTGCACAATGAGGAAAAGATCACACAGCAAAT  
GGACCCTGAACACAGGCAGTTAGCGAACGCTATATTTAAGCTCACATACCAAAACAAAGTGGT  
CAAAGTTCAACGACCGACTCCAACAGGCACGGTAATGGATATCATATCTAGGAAAGACCAAA  
GAGGCAGTGGACAGGTAGGAACTTATGGTCTGAATACATTCACCAACATGGAAGCCCAGTTAA  
TCAGACAAATGGAAGGAGAAGGTGTGCTGTCAAAGGCAGACCTCGAGAACCCTCATCTGCCA  
GAGAAGAAAATTACACAATGGTTGGAAACCAAGGAGTGGAGAGGTTAAAAAGAATGGCCAT  
AAGTGGGGATGACTGCGTGGTGAAACCAATCGATGACAGGTTGCTAATGCCCTGCTCGCTCT  
GAACGACATGGGAAAGGTTTCGGAAAGACATACCTCAATGGCAGCCATCAAAGGGATGGCATG  
ATTGGCAACAGGTTCCCTTTCTGCTCCCACCACTTTTCATGAATTGATCATGAAAGATGGAAGAAA  
GTTGGTGGTTCCCTGCAGACCCCAGGACGAACTAATAGGAAGGGCAAGAATCTCTCAAGGAGC  
GGGATGGAGCCTTAGAGAAACCGCATGTCTGGGGAAAGCCTACGCTCAAATGTGGAGTCTCAT  
GTATTTTTCACAGAAGAGACCTCAGACTAGCATCCAACGCCATATGTTTCAGCAGTACCAGTCCA  
CTGGGTCCCCACAAGTAGAACGACATGGTCTATTACGCTCACCATCAGTGGATGACCACAGA  
AGACATGCTTACTGTCTGGAACAGAGTGTGGATCGAGGACAATCCATGGATGGAAGACAAAA  
CTCCAGTCACAACCTGGGAAAATGTTCCATATCTAGGGAAGAGAGAAGACCAATGGTGC GGAT  
CACTTATTGGTCTCACTTCCAGAGCAACCTGGGCCCAGAACATACCCACAGCAATTCAACAGG  
TTAGAAGCCTTATAGGCAATGAAGAGTTTCTGGACTACATGCCTTCAATGAAGAGATTTAGGA  
AGGAGGAGGAGTCGGAGGGAGCCATTTGGTAAAACGTAGGAAGTGAAAAAGAGGTTAACTGT  
CAGGCCATATTAAGCCACAGTACGGAAGAAGCTGTGCTGCCTGTGAGCCCCGTCCAAGGACGT  
TAAAGAAGAAGTCAGGCCCCAAAGCCACGGTTTGAGCAAACCGTGCTGCCTGTAGCTCCGTC  
GTGGGGACGTAAAACCTGGGAGGCTGCAAACTGTGGAAGCTGTACGCACGGTGTAGCAGACT  
AGCGGTTAGAGGAGACCCCTCCCATGACACAACGCAGCAGCGGGGGCCCGAGCACTGAGGGAA  
GCTGTACCTCCTTGCAAAGGACTAGAGGTTAGAGGAGACCCCCGCAAATAAAAAACAGCATAT  
TGACGCTGGGAGAGACCAGAGATCCTGCTGTCTCCTCAGCATCATTCCAGGCACAGAACGCCA  
GAAATGGAATGGTGTGTTGAATCAACAGGTTCT

[0152] SEQ ID NO:12 – DENV4\_Syn\_E-W/Min

AGTTGTTAGTCTGTGTGGACCGACAAGGACAGTTCCAAATCGGAAGCTTGCTTAACACAGTTCT  
AACAGTTTGTTTAAATAGAGAGCAGATCTCTGGAAAAATGAACCAACGAAAAAAGGTGGTTA  
GACCACCTTTCAATATGCTGAAACGCGAGAGAAACCGCGTATCAACCCCTCAAGGGTTGGTGA  
AGAGATTCTCAACCGGACTTTTTTCTGGGAAAGGACCCCTACGGATGGTGCTAGCATTTCATCAC  
GTTTTTGCGAGTCCTTTCCATCCCACCAACAGCAGGGATTCTGAAGAGATGGGGACAGTTGAA  
GAAAAATAAGGCCATCAAGATACTGATTGGATTTCAGGAAGGAGATAGGCCCGCATGCTGAACA  
TCTTGAACGGGAGAAAAAGGTCAACGATAACATTGTTGTGCTTGATTCCCACCGTAATGGCGT  
TTCATTGTCAACAAGAGATGGCGAACCCCTCATGATAGTGGCAAAACATGAAAGGGGGAGA  
CCTCTCTTGTTTAAGACAACAGAGGGGGATCAACAAATGCACTCTCATTGCCATGGACTTGGGTG  
AAATGTGTGAGGACACTGTCACGTATAAATGCCCCCTACTGGTCAATACCGAACCTGAAGACA  
TTGATTGCTGGTGCAACCTCACGTCTACCTGGGTCATGTATGGGACATGCACCCAGAGCGGAG  
AACGGAGACGAGAGAAGCGCTCAGTAGCTTTGACACCACATTCAGGAATGGGATTGGAAACA  
AGAGCTGAGACATGGATGTCATCGGAAGGGGCTTGGAAGCATGCTCAGAGAGTAGAGAGCTG  
GATACTCAGAAACCCAGGATTTGCGCTCTTGGCAGGATTTATGGCTTATATGATTGGGCAAAC  
AGGAATCCAGCGAACTGTCTTCTTTGTCCTAATGATGCTGGTTCGCCCCATCCTACGGAATGCGG  
TGCGTAGGAGTAGGAAACAGAGACTTTGTGGAAGGAGTCTCAGGTGGAGCATGGGTTCGACCT  
GGTGCTAGAACATGGAGGATGCGTCACAACCATGGCCCAGGGAAAACCAACCTTGGATTTTGA  
ACTGACTAAGACAACAGCTAAGGAAGTGGCTCTGTAAAGAACCTATTGCATTGAAGCCTCAAT  
ATCAAACATAACTACGGCAACAAGATGTCCAACGCAAGGAGAGCCTTATCTGAAAGAGGAAC  
AGGACCAACAGTACATCTGCCGGAGAGATGTGGTAGACAGAGGATGGGGCAATGGCTGTGGC  
TTGTTTGGAAAAGGAGGAGTTGTGACATGTGCGAAGTTTTTCATGTTCTGGGGAAGATAACAGGC  
AATCTGGTCCAAATTGAGAACCTTGAATACACAGTGGTTGTAACAGTCCACAATGGAGACACC  
CATGCAGTAGGAAATGACACATCCAATCATGGAGTTACAGCCACGATAACTCCCAGGTCACCA  
TCGGTAGAAGTCAAATTGCCGGACTATGGAGAACTAACACTCGATTGTGAACCCAGGTCTGGA  
ATTGACTTTAATGAGATGATCCTAATGAAAATGAAAAAGAAAACATGGCTCGTGCATAAGCAA  
TGGTTTTTGGATCTGCCTCTTCCATGGACAGCAGGAGCAGACACATCAGAGGTTCACTGGAATT  
ACAAAGAGAGAATGGTGACGTTCAAGGTTCCCTCATGCCAAGAGACAGGACGTTACAGTGTTAG  
GGTCACAGGAGGGAGCTATGCATAGCGCACTAGCCGGAGCAACCGAAGTCGATAGCGGAGAC  
GGAAATCATATGTTTCGCCGGACATCTGAAATGCAAAGTGAGAATGGAGAAATTGCGGATTAA  
GGGAATGTCATACACTATGTGTTCCGGTAAGTTTTTCGATTGACAAAGAGATGGCCGAAACGCA  
ACACGGAACAACAGTCGTTAAGGTTAAGTACGAAGGAGCCGGAGCTCCGTGTAAAGTGCCAA  
TCGAAATTAGAGACGTTAACAAGAGAAAGTGGTCGGAAGAGTGATATCTAGTACACCCCTA  
GCCGAAAATACGAATTCCGTTACGAATATCGAACTCGAACCCCCCTTTGGAGACTCATAcata  
GTGATAGGAGTGGGTAATTCGCACTCACGTTGCACTGGTTCAGAAAGGGATCATCAATCGGG  
AAGATGTTCGAATCAACATATAGGGGAGCGAAAAGAATGGCTATATTGGGCGAAACCGCATG

GGACTTCGGATCAGTCGGAGGACTGTTTACGAGTCTGGGTAAGGCCGTACATCAGGTATTCGG  
ATCAGTGTATACAACAATGTTTGGCGGAGTGTTCATGGATGATACGGATACTGATAGGGTTTCT  
AGTGTGTGGATCGGAACGAACTCACGTAATACGTCTATGGCTATGACATGTATTGCCGTAGG  
GGGGATTACACTGTTTCTGGGATTTACAGTGC AAGCAGACATGGGTTGTGTGGTGTTCATGGAG  
TGGGAGAGAATTGAAGTGTGGAAGCGGAATTTTTGTGGTTGACAACGTGCACACTTGGACAGA  
ACAGTACAAATTCCAACCAGAGTCCCCAGCGAGACTAGCGTCTGCAATATTAAATGCCACAA  
AGATGGGGTCTGTGGAATTAGATCAACCACGAGGCTGGAAAATGTTATGTGGAAGCAAATAA  
CCAATGAGCTAACTATGTTCTCTGGGAAGGAGGACATGATCTCACTGTAGTGGCTGGGGATG  
TGAAAGGGGTGTTGACCAAGGGCAAGAGAGCACTCACACCCCCAGCGAGTGATCTGAAATAT  
TCATGGAAGACATGGGGGAAAGCAAAAATCTTCACCCCTGAAGCAAGAAACAGCACATTTTTTA  
ATAGACGGACCAGACACCTCTGAATGCCCAATGAACGAAGGGCATGGAATTCTTTTGAGGTG  
GAAGACTATGGATTTGGCATGTTACGACCAACATATGGATGAAATCCGAGAAGGAAGTTCA  
GAAGTGTGTGACCACAGGTTAATGTCAGCTGCAATTAAAGACCAGAAAGCTGTGCATGCTGAC  
ATGGGTTATTGGATAGAGAGCTCAAAAAACCAGACCTGGCAGATAGAGAGAGCATCTCTTATT  
GAAGTGAAAACATGTCTGTGGCCCAAGACCCATACACTGTGGAGCAATGGAGTGCTGGAAAG  
CCAGATGCTTATTCAAAATCATATGCAGGCCCTTTTTACAGCACAATTACCGCCAGGGCTAT  
GCTACGCAAACCGTGGGTCCATGGCACTTAGGCAAAC TAGAGATAGACTTTGGAGAATGCCCC  
GGAACAACAGTCACAATTCAGGAGAATTGTGACCATAGAGGCCCATCTTTGAGGACCACCACT  
GCATCTGGAAAAC TAGTCACGCAATGGTGTGCGCTCCTGCACGATGCCCCCTTAAGGTTCT  
TAGGAGAAGATGGGTGCTGGTATGGGATGGAGATTAGGCCCTTGAGTGAAAAAGAAGAGAAC  
ATGGTCAAATCACAGGTGACGGCCGGACAGGGCACATCGGAAACTTTTTCAATGGGTCTGTTG  
TGCCTGACCTTGTTTGTGGAAGAATGCTTGAGGAGAAGAGTCACCAGGAAACACATGATATTA  
GCTGTGGTAATCACTCTTTGTGCTATCATCCTGGGGGGCCTCACATGGATGGACTTGCTACGAG  
CCCTCATCATGTTGGGGGACACTATGTCTGGTAGAATAGGAGGACAGACCCACCTAGCCATCA  
TGGCAGTGTTC AAGATGTCACCGGGATACGTGCTGGGTGTGTTTTTAAGGAAACTCACTTCAAG  
AGAGACAGCACTAATGGTAATAGGAATGGCCATGACAACAACACTTTCAATTCCACATGACCT  
CATGGAAC TCATTGATGGAATATCACTAGGACTAATTTTGCTAAAAATAGTAACACAGTTTGA  
CAACACCCAAGTGGGAACCTTAGCTCTTTCCTTGACTTTCATAAGATCAACAATGTCATTGGTC  
ATGGCTTGAGGACCATTATGGCTGTGTTGTTTGTGGTCACACTCATTCTTTGTGCAGGACAA  
GCTGTCTTCAAAAACAGTCTCATTGGGTAGAAATAACAGCACTCATCCTAGGAGCCCAAGCTC  
TGCCAGTGTACCTAATGACTCTTATGAAAGGAGCCTCAAGAAGATCTTGGCCTCTTAACGAAG  
GCATAATGGCTGTGGGTTTGGTTAGTCTCTTAGGAAGCGCTCTTTTAAAGAATGATGTCCCTTT  
AGCTGGCCCAATGGTGGCAGGAGGCTTACTTCTGGCGGCTTACGTAATGAGTGGCAGCTCAGC  
AGATCTGTCACTAGAGAAGGCCGCTAATGTGCAGTGGGATGAAATGGCAGACATAACAGGCT  
CAAGTCCAATCATAGAAGTGAAGCAAGATGAGGATGGCTCTTTCTCCATACGGGACGTCGAGG  
AAACCAATATGATAACCCTTTTGGTGAAACTGGCACTGATAACGGTGTGAGGTCTCTACCCCTT  
GGCAATTCCAATCACAATGACCTTATGGTACATGTGGCAAGTGAAAACACAAAGATCAGGAGC

CCTGTGGGACGTCCCTTCACCCGCCGCCACTCAAAAAGCCGCACTGTCTGAAGGAGTGTACAG  
GATCATGCAAAGAGGGTTATTCGGGAAAACCTCAGGTTGGAGTAGGGATACACATGGAAGGTG  
TATTTACACAATGTGGCATGTTACAAGAGGATCGGTGATCTGCCACGAGACTGGGAGATTGG  
AGCCATCTTGGGCTGATGTCAGGAATGACATGATATCATACGGTGGGGGATGGAGGCTTGGAG  
ATAAATGGGACAAAGAAGAAGACGTTTCAGGTCCTCGCTATAGAACCAGGGAAAAATCCCAA  
CATGTCCAAACGAAACCTGGCCTTTTCAAGACCCTAACTGGAGAAATTGGAGCAGTAACATTA  
GATTTCAAACCCGGAACGTCTGGTTCTCCATTATCAACAGGAAAGGAAAAGTCATCGGACTC  
TATGGAAATGGAGTGGTCACCAAATCAGGTGATTACGTCAGTGCCATAACACAAGCCGAAAG  
AATTGGAGAGCCAGATTATGAAGTGGATGAGGACATTTTTTCGAAAGAAAAGACTAACTATAAT  
GGACTTACACCCCGGAGCCGGAAAGACAAAAAGAATTCTTCCATCAATAGTGAGAGAAGCCTT  
AAAAAGGAGGCTGCGAACTTTGATTTTGGCTCCCACGAGAGTGGTGGCGGCCGAGATGGAAG  
AGGCCCTACGTGGACTGCCAATCCGTTACCAAACCCAGCTGTAAAATCAGAACACACAGGAA  
GAGAGATTGTAGACCTCATGTGCCATGCAACCTTCACAACAAGACTTTTGTTCATCAACCAGAG  
TTCCAAACTACAACCTTATAGTAATGGATGAAGCACATTTACCGATCCTTCCAGTGTGCGGGC  
TAGAGGATACATTTTCGACCAGGGTGGAAATGGGAGAGGCAGCAGCCATCTTCATGACCGCAA  
CCCCTCCCGGAGCGACAGATCCCTTTCCCAGAGCAACAGCCCAATAGAAGACATCGAGAGAG  
AGATTCCGGAAAGGTCATGGAACACAGGGTTCGACTGGATAACAGACTACCAAGGGAAAACCT  
GTGTGGTTTGTTCAGCATAAAAGCTGGAAATGACATTGCAAATTGTTTGAGAAAGTCGGGA  
AAGAAAGTTATCCAGTTGAGTAGGAAAACCTTTGATACAGAATATCCAAAAACGAACTCACG  
GACTGGGACTTTGTGGTCACTACAGACATATCTGAAATGGGGGCTAACTTTAGAGCTGGGAGA  
GTGATAGACCCTAGAAGATGCCTCAAGCCAGTTATCCTAACAGATGGGCCAGAGAGAGTCATC  
TTAGCAGGTCTTATTCCAGTGACTCCAGCAAGCGCTGCTCAGAGAAGAGGGCGAATAGGAAG  
GAACCCAGCACAGAAGACGACCAATACGTTTTCTCCGGAGACCCACTAAAAAATGATGAAG  
ACCATGCCCCTGGACAGAAGCAAAGATGCTGCTTGACAATATCTACACCCAGAAAGGGATCA  
TTCCAACATTGTTTGGTCCGGAAAGGGAAAAAACCAAGCTATTGATGGAGAGTTTCGCCTCA  
GAGGGGAACAAAGGAAGACTTTTGTGGAATTAATGAGGAGAGGAGACCTTCCGGTGTGGCTG  
AGTTATAAGGTAGCTTCTGCTGGCATTCTTACAAAGATCGGGAATGGTGCTTTACTGGGGAAA  
GAAATAACCAAATTTTAGAAGAAAACATGGAGGTTGAAATTTGGACTAGAGAGGGAGAAAAG  
AAAAAACTGAGGCCAAAATGGTTAGATGCACGTGTATACGCTGACCCCATGGCTTTGAAGGAT  
TTCAAGGAGTTTGCCAGTGGAAGGAAGAGTATAACTCTCGACATCCTAACAGAGATCGCCAGT  
TTGCCAACTTACCTTTCTCTAGGGCCAAGCTCGCCCTTGACAACATAGTTATGCTCCACACAA  
CAGAAAGAGGAGGGAGGGCCTATCAACATGCCCTGAACGAACCTCCGGAGTCACTGGAAACA  
CTCATGCTTGTAGCCTTACTAGGAGCTATGACAGCAGGTATCTTCCTGTTTTTCATGCAAGGGA  
AAGGAATAGGGAAATTGTCAATGGGTTTGATAACCATTGCGGTGGCTAGTGGCTTGCTCTGGG  
TAGCAGAAATTCAACCCAGTGGATAGCGGCCTCAATCATACTGGAGTTTTTTCTCATGGTACT  
GTTGATACCAGAACCAGAAAAACAAAGGACCCCAAGACAATCAATTGATCTACGTCATATT  
GACCATTTCTACCATTATTGGTCTAATAGCAGCCAACGAGATGGGGCTGATAGAAAAAACAA

AACGGATTTTGGGTTTTACCAGGTAAAAACAGAAACCACCATCCTCGATGTGGACCTGAGACC  
AGCTTCAGCATGGACGCTCTATGCGGTAGCCACCACAATTCTGACTCCCATGCTGAGACACAC  
CATAGAAAATACGTTCGGCCAACCTATCTTTAGCAGCCATCGCCAACCAGGCAGCCGTCCTAAT  
GGGGCTTGAAAAGGATGGCCACTCCACAGAATGGACCTCGGTGTGCCGCTGTTAGCAATGGG  
ATGCTATTCTCAAGTGAACCCAACAACCTTGACAGCATCCTTAGTCATGCTTTTAGTCCATTAT  
GCAATAATAGGCCCAGGATTGCAGGCAAAAGCCACAAGAGAGGGCCAGAAAAGGACAGCTGC  
TGGAATCATGAAAAATCCCACAGTGGACGGGATAACAGTGATAGATCTAGAACCAATATCCTA  
TGACCCAAAATTTGAAAAGCAATTAGGGCAGGTCATGTTACTCGTCTTGTGTGCTGGACAAC  
ACTCTTGATGAGAACAAACATGGGCTTTCTGTGAAGTTTTGACTTTGGCCACAGGACCAATCTTG  
ACCTTGTTGGGAGGGCAACCCGGGAAGGTTTTGGAACACGACCATAGCCGTATCTACCGCCAAC  
ATTTTCAGGGGAAGTTATTTGGCAGGAGCTGGACTGGCTTTTTCTACTCATAAAGAATGCACAA  
ACCCCCAGGAGGGGAACCTGGGACCACAGGAGAGACACTGGGAGAGAAGTGGAAGAGACAGC  
TAAACTCATTAGACAGGAAAGAGTTTGAAGAGTATAAAAGAAGTGGAATACTAGAAGTGAC  
AGGACTGAAGCCAAGTCCGCCCTGAAAGATGGGTCTAAAATCAAGCATGCAGTATCTAGAGG  
GTCCAGTAAGATCAGATGGATTGTTGAGAGAGGGATGGTAAAGCCAAAGGGGAAAGTTGTAG  
ATCTTGGCTGTGGGAGAGGAGGATGGTCTTATTACATGGCGACACTCAAGAACGTGACTGAAG  
TGAAAGGGTATACAAAAGGAGGTCCAGGACATGAAGAACCGATTCCCATGGCTACTTATGGCT  
GGAATTTGGTCAAACCTCATTACAGGGGTTGACGTGTTCTACAAACCCACAGAGCAAGTGAC  
CCCTGCTCTGTGATATTGGGGAGTCATCTTCTAATCCAACAATAGAGGAAGGAAGAACATTAA  
GAGTTTTGAAGATGGTGGAGCCATGGCTCTCTTCAAACCTGAATTCTGCATCAAAGTCCTCAA  
CCCCTACATGCCAACAGTCATAGAGGAGCTGGAGAACTGCAGAGAAAACACGGTGGGAACC  
TTGTCAGATGCCCGCTGTCCAGGAACCTCACCCATGAGATGTATTGGGTGTCAGGAGCGTCGG  
GAAATATTGTGAGCTCTGTGAACACAACATCAAAGATGTTGTTGAACAGGTTTACAACAAGGC  
ATAGGAAACCCACTTATGAGAAGGACGTAGATCTTGGGGCAGGAACGAGAAGTGTCTCTACTG  
AAACAGAAAAACCAGACATGACAATCATTGGGAGAAGGCTTCAGCGATTGCAAGAGGAGCAC  
AAAGAAACATGGCATTATGATCAGGAAAACCCATACAGAACCTGGGCGTATCATGGAAGCTA  
TGAAGCTCCTTCGACAGGCTCTGCATCCTCCATGGTGAACGGGGTGGTGAAACTGCTAACAAA  
ACCCTGGGATGTGATTCCAATGGTGAAGTCTAGCCATGACAGATACAACCCCTTTTGGGCA  
ACAAAGAGTGTTCAAAGAGAAGGTGGATACCAGAACGCCGCAACCAAAACCAGGCACACGAA  
TGGTTATGACCACGACAGCCAATTGGCTATGGGCCCTCCTTGGAAGAAGAAAAATCCCAGAC  
TGTGTACAAGGGAAGAGTTCATCTCAAAGTTAGATCAAACGCAGCCATAGGCGCAGTCTTTC  
AGGAAGAACAAGGATGGACATCAGCCAGTGAAGCTGTGAATGACAGCCGTTTTTGGGAACCTG  
GTTGACAAAGAAAGGGCCCTTCACCAGGAAGGGAAATGTGAATCGTGTGTCTATAACATGATG  
GGAACCGTGAGAAAAAGTTAGGAGAGTTTGGCAGAGCCAAGGGAAGCCGAGCAATCTGGTA  
CATGTGGCTGGGAGCGCGGTTTTCTGGAATTTGAAGCCCTGGGTTTTTTGAATGAAGATCACTGG  
TTTGGCAGAGAAAATTCATGGAGTGGAGTGAAGGGGAAGGTCTGCACAGATTGGGATACAT  
CCTGGAGGAGATAGACAAGAAGGATGGAGACCTAATGTATGCTGATGACACAGCAGGTTGGG

ACACAAGAATCACTGAGGATGACCTTCAAAATGAGGAACTGATCACGGAACAGATGGCTCCC  
 CACCACAAGATCCTAGCCAAAGCCATTTTCAAACCTAACCTATCAAAACAAAGTGGTGAAAGTC  
 CTCAGACCCACACCGAGAGGAGCGGTGATGGATATCATATCCAGGAAAGACCAAAGAGGTAG  
 TGGACAAGTTGGAACATATGGTTTGAACACATTCACCAACATGGAAGTTCAACTCATCCGCCA  
 AATGGAAGCTGAAGGAGTCATCACACAAGATGACATGCAGAACCCAAAAGGGTTGAAAGAAA  
 GAGTTGAGAAATGGCTGAGAGAGTGTGGTGTGACAGGTTAAAGAGGATGGCAATCAGTGGA  
 GACGATTGCGTGGTGAAGCCCCTAGATGAGAGGTTTGGCACTTCCCTCCTCTTCTTGAACGACA  
 TGGGAAAGGTGAGGAAAGACATTCCGCAGTGGAACCATCTAAGGGATGGAAAACTGGCAA  
 GAGGTTCCCTTTTGTCTCCCATCACTTTTACAAGATCTTTATGAAGGATGGCCGCTCACTAGTTGT  
 TCCATGTAGAAACCAGGATGAACTGATAGGGAGAGCCAGAATCTCGCAGGGGGCTGGATGGA  
 GCTTAAGAGAAACAGCCTGCCTGGGCAAAGCTTACGCCCAGATGTGGTCGCTTATGTACTTCC  
 ACAGAAGGGATCTGCGTTTAGCCTCCATGGCCATATGCTCAGCAGTTCCAACGGAATGGTTTCC  
 AACAGCAGAACAACATGGTCAATCCATGCTCATCACAATGGATGACCACTGAAGACATGCT  
 CAAAGTGTGGAACAGAGTGTGGATAGAAGACAACCCCAATATGATTGACAAGACTCCAGTCC  
 ATTCGTGGGAAGATATACCTTACCTAGGGAAAAGAGAGGATTTGTGGTGTGGATCCCTGATTG  
 GACTTTCTTCTAGAGCCACCTGGGCGAAGAACATTACACGGCCATAACTCAGGTCAGGAACT  
 TGATCGGAAAAGAGGAATACGTGGATTACATGCCAGTAATGAAAAGATACAGTGCTCCTTCAG  
 AGAGTGAAGGAGTTCTGTAATTACCAACAACAAACACCAAAGGCTATTGAAGTCAGGCCACTT  
 GTGCCACGGTTTGAGCAAACCGTGCTGCCTGTAGCTCCGCCAATAATGGGAGGCGTAATAATC  
 CCTAGGGAGGCCATGCGCCACGGAAGCTGTACGCGTGGCATATTGGACTAGCGGTTAGAGGA  
 GACCCCTCCCATCACTGACAAAACGCAGCAAAAGGGGGCCCGAAGCCAGGAGGAAGCTGTAC  
 TCCTGGTGGAAAGGACTAGAGGTTAGAGGAGACCCCCCAACACAAAAACAGCATATTGACGC  
 TGGGAAAGACCAGAGATCCTGCTGTCTCTACAACATCAATCCAGGCACAGAGCGCCGCAAGAT  
 GGATTGGTGTGTTGATCCAACAGGTTCT

[0153] The present invention provides a composition for inducing an immune response in a subject comprising any of the attenuated viruses described herein and a pharmaceutically acceptable carrier. In various embodiments, the composition is a vaccine composition and the immune response is a protective immune response.

[0154] It should be understood that an attenuated virus of the invention, where used to elicit an immune response in a subject (or protective immune response) or to prevent a subject from or reduce the likelihood of becoming afflicted with a virus-associated disease, is administered to the subject in the form of a composition additionally comprising a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known to those skilled in the art and include, but are not limited to, one or more of 0.01-0.1M and preferably 0.05M phosphate buffer, phosphate-buffered saline (PBS), or 0.9% saline. Such carriers also include aqueous or non-aqueous solutions, suspensions, and emulsions. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, saline and buffered media. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl

oleate. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Solid compositions may comprise nontoxic solid carriers such as, for example, glucose, sucrose, mannitol, sorbitol, lactose, starch, magnesium stearate, cellulose or cellulose derivatives, sodium carbonate and magnesium carbonate. For administration in an aerosol, such as for pulmonary and/or intranasal delivery, an agent or composition is preferably formulated with a nontoxic surfactant, for example, esters or partial esters of C6 to C22 fatty acids or natural glycerides, and a propellant. Additional carriers such as lecithin may be included to facilitate intranasal delivery. Pharmaceutically acceptable carriers can further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives and other additives, such as, for example, antimicrobials, antioxidants and chelating agents, which enhance the shelf life and/or effectiveness of the active ingredients. The instant compositions can, as is well known in the art, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to a subject.

[0155] In various embodiments of the instant composition or vaccine composition, the attenuated virus (i) does not substantially alter the synthesis and processing of viral proteins in an infected cell; (ii) produces similar amounts of virions per infected cell as wt virus; and/or (iii) exhibits substantially lower virion-specific infectivity than wt virus. In further embodiments, the attenuated virus induces a substantially similar immune response in a host animal as the corresponding wt virus.

[0156] This invention also provides a modified host cell line specially isolated or engineered to be permissive for an attenuated virus that is inviable in a wild type host cell. In embodiments wherein the attenuated virus cannot grow in normal (wild type) host cells, it is absolutely dependent on the specific helper cell line for growth. This provides a very high level of safety for the generation of virus for vaccine production. Various embodiments of the instant modified cell line permit the growth of an attenuated virus, wherein the genome of said cell line has been altered to increase the number of genes encoding rare tRNAs.

#### *Methods of eliciting an immune response*

[0157] Various embodiments provide for a method of eliciting an immune response in a subject comprising administering to the subject an effective dose of a composition comprising a modified Flavivirus of the present invention. Particular embodiments provide for a method of eliciting a protective immune response in a subject comprising administering to the subject a prophylactically or therapeutically effective dose of a vaccine composition comprising a modified Flavivirus of the present invention. In various embodiments, the immune response is cross-protective against a heterologous Flavivirus virus.

[0158] In various embodiments, the method further comprises administering to the subject at least one adjuvant. Non-limiting examples of adjuvants are discussed herein. Particular embodiments provide for a method of eliciting an immune response in a subject, comprising: administering to the subject a prophylactically or therapeutically effective dose of a vaccine composition comprising a modified dengue virus the present invention.

[0159] Various embodiments provide for a method of eliciting an immune response in a subject, comprising: administering to the subject an effective dose of a composition comprising a modified dengue virus the present invention.

[0160] Various embodiments provide for a method of eliciting a protective immune response in a subject, comprising: administering to the subject a prophylactically or therapeutically effective dose of a vaccine composition comprising a modified dengue virus the present invention.

[0161] In various embodiments, the method further comprises administering to the subject at least one adjuvant. Non-limiting examples of adjuvants are described herein.

[0162] In various embodiments, the immune response is cross-protective against a heterologous dengue virus.

[0163] Various embodiments of the present invention provide for a method of eliciting an immune response in a subject in need thereof, comprising: administering a prime dose of an attenuated Flavivirus produced by a method other than codon-pair deoptimization or codon deoptimization, or increasing of CpG or UpA di-nucleotides, or a modified Flavivirus in which expression of viral proteins is reduced compared to a parent virus, wherein the reduction in expression is the result of recoding the prM, or envelope (E) region; and administering one or more boost dose of the attenuated Flavivirus produced by methods other than codon-pair deoptimization or codon deoptimization, or increasing of CpG or UpA di-nucleotides, or the modified Flavivirus to the subject in need thereof, wherein at least the prime dose or the one or more boost dose is the modified virus. In various embodiments, a first of the one or more boost dose is administered about 2 weeks after the prime dose.

[0164] In various embodiments, the Flavivirus is a dengue virus.

[0165] In various embodiments, one or both of the E protein-encoding sequence protein-encoding sequence is recoded by reducing the codon pair bias or codon usage bias of the protein-encoding sequence. In various embodiments, reducing the codon-pair bias comprises identifying a codon pair in the parent protein-encoding sequence having a codon-pair score that can be reduced, and reducing the codon-pair bias by substituting the codon pair with a codon pair that has a lower codon-pair score.

[0166] In various embodiments, reducing the codon-pair bias comprises rearranging the codons of a parent protein-encoding sequence. In various embodiments, the E protein-encoding sequence is recoded by increasing the number of CpG or UpA di nucleotides compared to a parent virus. In various embodiments, each of the recoded prM/E protein-encoding sequence have a codon pair bias less than  $-0.05$ , or less than  $-0.06$ , or less than  $-0.07$ , or less than  $-0.08$ , or less than  $-0.09$ , or less than  $-0.1$ , or less than  $-0.11$ , or less than  $-0.12$ , or less than  $-0.13$ , or less than  $-0.14$ , or less than  $-0.15$ , or less than  $-0.16$ , or less than  $-0.17$ , or less than  $-0.18$ , or less than  $-0.19$ , or less than  $-0.2$ , or less than  $-0.25$ , or less than  $-0.3$ , or less than  $-0.35$ , or less than  $-0.4$ , or less than  $-0.45$ , or less than  $-0.5$ . In various embodiments, one or both of the E protein-encoding sequence is recoded by replacing one or more codons with synonymous codons that are less frequent in the viral host (e.g., human). In some embodiments, the number of codons substituted with synonymous codons is at least 5, or at

least 10, or at least 30, or at least 30, or at least 40, or at least 50, or at least 75, or at least 100, or at least 200 or at least 300, or at least 400, or at least 500.

[0167] In addition, the present invention provides a method for eliciting a protective immune response in a subject comprising administering to the subject a prophylactically or therapeutically effective dose of any of the vaccine compositions described herein. This invention also provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of any of the instant vaccine compositions. In embodiments of the above methods, the subject has been exposed to a pathogenic virus. “Exposed” to a pathogenic virus means contact with the virus such that infection could result.

[0168] The invention further provides a method for delaying the onset, or slowing the rate of progression, of a virus-associated disease in a virus-infected subject comprising administering to the subject a therapeutically effective dose of any of the instant vaccine compositions.

[0169] As used herein, “administering” means delivering using any of the various methods and delivery systems known to those skilled in the art. Administering can be performed, for example, intranasally, intraperitoneally, intracerebrally, intravenously, orally, transmucosally, subcutaneously, transdermally, intradermally, intramuscularly, topically, parenterally, via implant, intrathecally, intralymphatically, intralesionally, pericardially, or epidurally. An agent or composition may also be administered in an aerosol, such as for pulmonary and/or intranasal delivery. Administering may be performed, for example, once, a plurality of times, and/or over one or more extended periods.

[0170] Eliciting a protective immune response in a subject can be accomplished, for example, by administering a primary dose of a vaccine to a subject, followed after a suitable period of time by one or more subsequent administrations of the vaccine. A suitable period of time between administrations of the vaccine may readily be determined by one skilled in the art, and is usually on the order of several weeks to months. The present invention is not limited, however, to any particular method, route or frequency of administration.

[0171] In various embodiments, the present invention provides for a method of eliciting an immune response in a subject in need thereof, comprising: administering a prime dose of an attenuated Flavivirus produced by a method other than codon-pair deoptimization or codon deoptimization, or increasing of CpG or UpA di-nucleotides, or a modified Flavivirus in which expression of viral proteins is reduced compared to a parent virus, wherein the reduction in expression is the result of recoding the prM, or envelope (E) region, or both; and administering one or more boost dose of the attenuated Flavivirus by methods other than codon-pair deoptimization or codon deoptimization, or increasing of CpG or UpA di-nucleotides, or the modified Flavivirus to the subject in need thereof, wherein at least the prime dose or the one or more boost dose is the modified virus.

[0172] In various embodiments, the one or more boost dose is administered about 2 weeks after a prime dose. In various embodiments, 2, 3, 4, or 5 boost doses are administered. In various embodiments, the intervals between the boost doses can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 weeks. In additional embodiments, the intervals between the boost doses can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months. As a non-limiting example, the

prime dose can be administered, about two weeks thereafter a first boost dose can be administered, about one month after the first boost dose, a second boost dose can be administered, about 6 months after the second boost dose, a third boost dose can be administered. As another non-limiting example, the prime dose can be administered, about two weeks thereafter a first boost dose can be administered, about six months after the first boost dose, a second boost dose can be administered, about 12 months after the second boost dose, a third boost dose can be administered. In further embodiments, additional boost dosages can be periodically administered; for example, every 5 years, every 10 years, etc.

[0173] In various embodiments, the Flavivirus is a dengue virus. In various embodiments, the Flavivirus is selected from the group consisting of dengue fever virus, Zika virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, Spondweni virus, Saint Louis encephalitis virus, and Powassan virus.

[0174] In various embodiments, one or both of the E protein-encoding sequence is recoded by lowering the codon pair bias or codon usage bias of the protein-encoding sequence. In various embodiments, the E protein-encoding sequence is recoded by increasing the number of CpG or UpA di nucleotides compared to a parent virus.

[0175] In various embodiments, reducing the codon-pair bias comprises identifying a codon pair in the parent protein-encoding sequence having a codon-pair score that can be reduced, and reducing the codon-pair bias by substituting the codon pair with a codon pair that has a lower codon-pair score.

[0176] In various embodiments, reducing the codon-pair bias comprises rearranging the codons of a parent protein-encoding sequence.

[0177] In various embodiments it includes the increase of the CpG dinucleotide in the modified virus

[0178] In various embodiments it includes the increase of the UpA dinucleotide in the modified virus

[0179] In various embodiments, the recoded prM/E protein-encoding sequence each have a codon pair bias less than  $-0.05$ , or less than  $-0.06$ , or less than  $-0.07$ , or less than  $-0.08$ , or less than  $-0.09$ , or less than  $-0.1$ , or less than  $-0.11$ , or less than  $-0.12$ , or less than  $-0.13$ , or less than  $-0.14$ , or less than  $-0.15$ , or less than  $-0.16$ , or less than  $-0.17$ , or less than  $-0.18$ , or less than  $-0.19$ , or less than  $-0.2$ , or less than  $-0.25$ , or less than  $-0.3$ , or less than  $-0.35$ , or less than  $-0.4$ , or less than  $-0.45$ , or less than  $-0.5$ .

[0180] In certain embodiments, the codon pair bias of the recoded prM-protein encoding sequence, E protein-encoding sequence, or both is reduced by at least  $0.05$ , or at least  $0.06$ , or at least  $0.07$ , or at least  $0.08$ , or at least  $0.09$ , or at least  $0.1$ , or at least  $0.11$ , or at least  $0.12$ , or at least  $0.13$ , or at least  $0.14$ , or at least  $0.15$ , or at least  $0.16$ , or at least  $0.17$ , or at least  $0.18$ , or at least  $0.19$ , or at least  $0.2$ , or at least  $0.25$ , or at least  $0.3$ , or at least  $0.35$ , or at least  $0.4$ , or at least  $0.45$ , or at least  $0.5$ , compared to the parent prM/E protein encoding sequence from which it is derived.

[0181] In various embodiments, the prM-protein encoding sequence, E protein-encoding sequence, or both are recoded by replacing one or more codons with synonymous codons that are less frequent in the viral host. In some embodiments, the number of codons substituted with synonymous codons is at least  $5$ , or at least  $10$ , or at least  $30$ , or at least  $30$ , or at least  $40$ , or at least  $50$ , or at least  $75$ , or at least  $100$ , or at least  $200$  or at least  $300$ , or at least  $400$ , or at least  $500$ .

[0182] In various embodiments, the prime dose is administered subcutaneously, intramuscularly, intradermally, or intranasally.

[0183] In various embodiments, the one or more boost dose is administered intratumorally, intravenously, or intrathecally.

[0184] The timing between the prime and boost dosages can vary, for example, depending on the stage of infection or disease (e.g., non-infected, infected, number of days post infection), and the patient's health. In various embodiments, the one or more boost dose is administered about 2 weeks after the prime dose. That is, the prime dose is administered and about two weeks thereafter, a boost dose is administered.

[0185] In various embodiments, the dosage amount can vary between the prime and boost dosages. As a non-limiting example, the prime dose can contain fewer copies of the virus compared to the boost dose.

[0186] In other embodiments, the type of attenuated virus produced by a method other than codon-pair deoptimization or codon deoptimization, or increasing of CpG or UpA di-nucleotides or modified virus of the present invention can vary between the prime and boost dosages. In one non-limiting example, a modified virus of the present invention can be used in the prime dose and an attenuated virus (produced by a method other than codon-pair deoptimization or codon deoptimization, or increasing of CpG or UpA di-nucleotides) of the same or different family, genus, species, group or order can be used in the boost dose.

[0187] In other embodiments, the route of administration can vary between the prime and the boost dose. In a non-limiting example, the prime dose can be administered subcutaneously, and the boost dose can be administered via injection into the tumor; for tumors that are in accessible, or are difficult to access, the boost dose can be administered intravenously.

[0188] Certain embodiments of any of the instant immunization and therapeutic methods further comprise administering to the subject at least one adjuvant. An "adjuvant" shall mean any agent suitable for enhancing the immunogenicity of an antigen and boosting an immune response in a subject. Numerous adjuvants, including particulate adjuvants, suitable for use with both protein- and nucleic acid-based vaccines, and methods of combining adjuvants with antigens, are well known to those skilled in the art. Suitable adjuvants for nucleic acid based vaccines include, but are not limited to, Quil A, imiquimod, resiquimod, and interleukin-12 delivered in purified protein or nucleic acid form. Adjuvants suitable for use with protein immunization include, but are not limited to, alum, Freund's incomplete adjuvant (FIA), saponin, Quil A, and QS-21.

[0189] The invention also provides a kit for immunization of a subject with an attenuated virus of the invention. The kit comprises the attenuated virus, a pharmaceutically acceptable carrier, an applicator, and an instructional material for the use thereof. In further embodiments, the attenuated virus may be one or more dengue virus, one or more Japanese encephalitis virus, one or more West Nile virus, one or more yellow fever virus, one or more Zika virus, etc. More than one virus may be preferred where it is desirable to immunize a host against a number of different isolates of a particular virus. The invention includes other embodiments of kits that are known to those skilled in the art. The instructions can provide any information that is useful for directing the administration of the attenuated viruses.

[0190] Throughout this application, various publications, reference texts, textbooks, technical manuals, patents, and patent applications have been referred to. The teachings and disclosures of these publications, patents, patent applications and other documents in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which the present invention pertains. However, the citation of a reference herein should not be construed as an acknowledgement that such reference is prior art to the present invention.

[0191] It is to be understood and expected that variations in the principles of invention herein disclosed can be made by one skilled in the art and it is intended that such modifications are to be included within the scope of the present invention. The following Examples further illustrate the invention but should not be construed to limit the scope of the invention in any way. Detailed descriptions of conventional methods, such as those employed in the construction of recombinant plasmids, transfection of host cells with viral constructs, polymerase chain reaction (PCR), and immunological techniques can be obtained from numerous publications, including Sambrook et al. (1989) and Coligan et al. (1994). All references mentioned herein are incorporated in their entirety by reference into this application. The contents of WO 2008/121992 and WO 2011/044561 are incorporated by reference.

## EXAMPLES

### *Example 1*

[0192] *Rapid design and construction of SAVE-deoptimized, live-attenuated dengue vaccine candidates.* To select our target sequences, we started with all prM-E sequences of all DENV virus isolates of the last decade and performed an amino acid consensus sequence analysis, available at the NCBI Virus Variation Database. As the consensus sequence usually never exists as an actual virus, it is unwise to use it as the basis of our designs. We prefer natural virus evolution to tell us what works and what does not. Thus, the consensus sequence for each serotype is then searched against the entire Genbank using the tblastn algorithm to identify an actual genome of a replicating virus which is most identical to the consensus sequence; we then used this sequence as our target sequence. In addition, the target sequence must not be unique in the database (possible sequencing artifacts), in which case we select the next highest identity sequence to the consensus, which is represented by two or more independent virus isolates. This search algorithm to determine the most relevant and replicating human isolate result in a sequence that is 1) a genuine human isolate and 2) as homologous to the rest of DENV sequence space as a single sequence can be. Using this approach, we identified the following viruses from which to select out target prM-E antigen sequences: DENV-1/VN/BID-V1774/2007, DENV-2/NL/BID-V533/2005, DENV-3/VE/BID-V2268/2008, DENV-4/US/BID-V2448/1999. We initiated our DENV vaccine program using the E-Min of DENV-2/NL/BID-V533/2005 and generated live-attenuated strains containing the other three E genes selected via this process (Figure 1). The CPB of wild-type prM/E genes fall within the normal range of human host cell's genes. Following codon pair-'deoptimization' via SAVE, the resulting deoptimized prM/E gene segments were now encoded predominately by under-represented human codon-pairs as evident by their extremely negative CPB, and are drastically different from any human gene. The SAVE-deoptimized

synthetic prM/E from Figure 1 were synthesized *de novo* and using overlapping PCR subcloned individually into the WT DENV genomes - yielding six independent cDNA genomes each containing a synthetically ‘de-optimized’ fragment(s). We constructed infectious cDNA genomes for wt DENV1-4 and then recovered fully infectious, replicating virus for the deoptimized DENV vaccine candidates via transfection of RNA into Vero or BHK cells.

### Example 2

#### *Leveraging SAVE platform flexibility to create second-generation*

##### *Dengue virus vaccine candidates*

[0193] To fine-tune attenuation and immunogenicity, a second generation of Dengue virus vaccine candidates were constructed using the SAVE platform (Figure 2). The second generation of dengue vaccine candidates leverages the flexibility of the SAVE platform to reduce the deoptimized region from 2014 bp (E-min) to 997 bp (W-E-Min) or further to 664 bp (W-W-E-Min) while keeping the amino acid sequence 100% identical in a homologous backbone.

### Example 3

#### *Growth of heterologous backbone dengue vaccine candidates in Vero cells under animal-component-free conditions*

[0194] To optimize production conditions for future cGMP manufacture and test for attenuation *in vitro*, DENV1-4 E-Min were used to infect Vero cells under animal-component free conditions at a MOI of 0.01 and supernatant titrated daily in a multiple-step growth curve over the course of 10 days post-infection. DENV2, DENV3, and DENV4 candidates reached titers of  $1-2 \times 10^5$  FFU/ml while DENV1 E-Min titer was reduced by  $\sim 1 \log_{10}$  compared to the others. (Figure 3).

### Example 4

#### *Growth of homologous backbone dengue virus type 1 vaccine candidates in Vero cells and tests for temperature-sensitivity as a mechanism of attenuation*

[0195] Growth kinetics conducted at low (33°C), medium (37°C), and high (39°C) temperatures were used to optimize production conditions for the deoptimized candidates, test for attenuation *in vitro* and examine CPD variants for increase temperature sensitivity as a means of explaining the mechanism of attenuation. Multiple step growth curves were conducted in Vero cells for synthetic DENV1 WT virus (in a full-length DENV1 backbone) and attenuated live vaccine candidates DENV1 E-W/MIN and E-MIN derived from DENV1 WT. Synthetic DENV1 WT grows well in Vero cells at 33°C and 37°C. Typical of DENV, a transient reduction in virus yield was observed at 39 °C, however, titers recovered to 37°C levels by 7 dpi. DENV1 E-W/MIN, however, reached serviceable titers  $\sim 10$ -fold lower than DENV1 WT at both 33°C and 37°C. DENV1 E-MIN was highly attenuated in Vero cells and only reached detectable titers at 33°C starting on days 10-14 post-infection.

*Example 5**Growth of homologous backbone dengue virus type 2 vaccine candidates in Vero cells and tests for temperature-sensitivity as a mechanism of attenuation*

[0196] Growth kinetics conducted at low (33°C), medium (37°C), and high (39°C) temperatures were used to optimize production conditions for the deoptimized candidates, test for attenuation *in vitro* and examine CPD variants for increase temperature sensitivity as a means of explaining the mechanism of attenuation. Multiple step growth curves were conducted in Vero cells for synthetic DENV2 WT virus (in a full-length, homologous DENV2 backbone) and attenuated live vaccine candidates DENV2 E-W/MIN and E-MIN derived from DENV2 WT. DENV2 E-W/MIN and E-MIN were both attenuated *in vitro* with a 1-2 log<sub>10</sub> FFU/ml reduction for E-W/MIN and a more pronounced 2-3 log<sub>10</sub> FFU/ml reduction for DENV2 E-MIN (Figure 3). While growth kinetics were delayed, with regular medium replacement every 1-2 days virus titers reached >10<sup>6</sup> FFU/ml for DENV2 E-W/MIN. Importantly, attenuation was correlated with the extent of deoptimization in the E region. While temperature sensitivity (difference between titers at 37°C and 39°C) was similar for DENV2-WT and DENV2 E-W/MIN through day 4 post-infection, there were significant differences on days 5, 6, and 7. Temperature sensitivity was not observed for DENV2 E-MIN because there was no replication at any temperature through 6 DPI. However, starting at day 7-14 DENV2 E-MIN started producing detectable virus (but only at 33°C and 37°C).

*Example 6**Growth of homologous backbone dengue virus type 3 vaccine candidates in Vero cells and tests for temperature-sensitivity as a mechanism of attenuation*

[0197] Growth kinetics conducted at low (33°C), medium (37°C), and high (39°C) temperatures were used to optimize production conditions for the deoptimized candidates, test for attenuation *in vitro* and examine CPD variants for increase temperature sensitivity as a means of explaining the mechanism of attenuation. Multiple step growth curves were conducted in Vero cells for synthetic DENV3 WT virus (in a full-length DENV3 backbone) and attenuated live vaccine candidates DENV3 E-W/MIN and E-MIN derived from DENV3 WT. It was apparent that DENV3 E-W/MIN was more temperature sensitive at 39 °C than the WT with a significantly greater difference observable on days 3, 4, 5, and 7 post-infection. Because DENV3 E-MIN had minimal levels of replication in Vero cells at 39°C, the difference in virus yield from 37°C to 39°C were as high as 10<sup>7</sup> FFU/ml. When grown at permissible temperatures, however, DENV3 E-MIN reached high titers which is promising for cGMP manufacture.

*Example 7**Growth of homologous backbone dengue virus type 4 vaccine candidates in Vero cells and tests for temperature-sensitivity as a mechanism of attenuation*

[0198] Growth kinetics conducted at low (33°C), medium (37°C), and high (39°C) temperatures were used to optimize production conditions for the deoptimized candidates, test for attenuation *in vitro* and examine CPD variants for increase temperature sensitivity as a means of explaining the mechanism of attenuation. Multiple step growth curves were conducted in Vero cells for synthetic DENV4 WT virus (in a full-length DENV4 backbone) and attenuated live vaccine candidates DENV4 E-W/MIN and E-MIN derived from DENV4 WT. Both DENV4 WT and E-W/MIN grew to high titers in Vero cells, with the peak DENV4 E-W/MIN titers approximately 10-fold lower but still high ( $\sim 10^7$  FFU/ml) at 33 °C and 37 °C. Both viruses were partially restricted at 39°C, but not to the extent seen with DENV1-3. On day 5 a small but significant ( $\sim 5$ -fold) change in titer from 37 °C to 39 °C compared to WT was observed. DENV4 E-MIN was attenuated in Vero cells with peak titers 100-fold lower than WT. DENV4 E-MIN replication at 33°C and 37°C was similar, however, DENV4 E-MIN was not viable at 39°C with no detectable virus on days 1-14 post-infection.

### Example 8

#### *Evaluation of the attenuation, immunogenicity and efficacy of DENV2 vaccine candidates in AG129 mice*

[0199] As described above, the AG129 adult mouse model is gaining acceptance for studies of flavivirus vaccines and therapeutics. We used AG129 mice to test: 1) each synthetically derived wild-type virus DENV at a dose of  $10^6$  (positive control); 2) two doses ( $10^4$  and  $10^6$  PFU) of the vaccine candidates. Survival, weight, and clinical sign data were collected daily throughout the course of the experiment. SAVE deoptimized DENV strains were attenuated compared to synthetic wild-type viruses. DENV-2 E-min based on a DENV2 16681 backbone has been shown to be attenuated and immunogenic in neonatal ICR mice. In this immunogenicity/dose escalation study, the vaccine was evaluated for the first time in AG129 mice. Animals were immunized with DENV-2 E-min or DENV-2 16681 at two different concentrations. Resultant neutralizing antibody titers were determined, and the protective efficacy afforded evaluated against a mouse-adapted lethal strain of DENV2, D2S10[3]. None of the animals immunized with either virus at either dose showed clinical signs. Serum was collected from the immunized mice two days after the first immunization and viremia determined by RT-PCR. Viral RNA was detected in 55% (5/9) animals immunized with the higher inoculum of DENV-2 16681 and 11% (1/9) that received the lower inoculum, but was not detected in any of the mice immunized with DENV-2 E-min. The RT-PCR primers used do not target the viral E gene which has been codon deoptimized in this virus and, they successfully amplified DENV-2 E-min viral RNA included in the assay. Consequently, we do not believe that lack of detection of viremia in this study is a result of suboptimal RT-PCR amplification but indicates that the vaccine virus produced very low-level viremia *in vivo*. Upon completion of the immunization regimen serum was collected from all mice prior to virus challenge. All of the immunized animals had detectable DENV-2 neutralizing antibody titers prior to virus challenge with D2S10. A scatterplot of the data for each vaccine group demonstrating that there was an increase in neutralizing antibody titers with increasing vaccine dose for both DENV-2 E-min and DENV-2 16681, and that titers seen in E-min immunized mice were lower than those in mice immunized with the corresponding dose of DENV-2 16681. Animals in the media control group developed a rapid progressive infection with all animals dying. Mice

immunized with the low dose of DENV-2 E-min vaccine were not protected, experiencing high lethality (67%) and a mean day of death (MDD) that was not significantly different to that seen in the media controls. In contrast, animals immunized with the high dose of DENV-2 E-min vaccine and with both doses of DENV-2 16681 experienced significant protection against DENV-2 D2S10 challenge. There was no lethality, or morbidity as indicated by a >10% loss in body weight, in any of these groups during the 30 day observation period. As anticipated high levels of viral RNA were detected in the sera of all media control animals on both of the days sampled. Viral RNA was also detected in all of the animals immunized with the lower dose of E-min on both days. Levels in these animals were comparable to those in controls on day 2 but were significantly lower on day 3. For animals immunized with the high dose of Emin, viral RNA was detected in the serum of 2/4 animals on day 2 with the RNA levels in the viremic animals being significantly lower than controls. On day 3, viral RNA was not detected in the sera of any of the high dose E-min animals. Overall, immunization with the high dose of Emin significantly reduced the number of animals in which viremia was detected (2/8 vs 8/8;  $p < 0.01$ ). For mice immunized with DENV-2 16681, no viral RNA was detected in the serum from any of the animals at either immunization dose on either of the two days sampled.

#### Example 9

##### *Titration of Codon-Pair Deoptimization leads to an improved*

##### *DENV2 vaccine candidate in AG129 mice*

[0200] To improve the clinical relevance of our DENV2 candidate, we next constructed D2-E-min and D2-1/2-E-min with E sequence derived from DENV-2/NI/BID-V533/2005 in the heterologous DENV2 16681 backbone. We tested D2-1/2-E-min, with the E region consisting of half wt DENV-2/NI/BID-V533/2005 sequence and half CPD, to improve the immunogenicity of our virus as previous studies have shown that the extent of attenuation can be titrated in DENV2 by reduction of CPD sequence. AG129 and BALB/c mice (n=5) were vaccinated with  $10^6$  or  $10^4$  FFU of D2-E-min, D2-1/2-E-min, or D2-WTE (DENV2 16681 backbone with WT DENV-2/NI/BID-V533/2005 E region). Interestingly, the introduction of the modern DENV-2/NI/BID-V533/2005 E region resulted in increased virulence, with all AG129 mice infected with  $10^6$  or  $10^4$  FFU requiring euthanasia. No mortality or morbidity was observed in infected BALB/c mice or in any CPD DENV2 group.

[0201] Reduction of CPD sequence in the E region was associated with a significant, approximately 4-fold, increase ( $p = .0002$ , Student's t-test) in the PRNT50 values of serum from D2-1/2-E-min compared to D2-E-Min vaccinated AG129 mice. Additionally, high neutralizing antibody titers were maintained with D2-1/2-E-min vaccination as no significant difference was observed between the  $10^6$  (GM=3447) and  $10^4$  (GM= 2867) FFU vaccinated groups. In immune-competent BALB/c mice, both D2-E-min and D2-1/2-E-min engendered levels of neutralizing antibody comparable to wild-type.

#### Example 10

##### *Evaluation of the Immunogenicity and Protective Efficacy of*

##### *DENV3 vaccine candidates in AG129 mice*

[0202] AG129 mice were used to test the immunogenicity and protective efficacy of DENV-3 vaccine candidate DENV D2/D3-E-min, which comprises the DENV-2 strain 16681 backbone with a codon-deoptimized prME cassette from DENV-3/VE/BID-V2268/2008. This study was designed to evaluate the immunogenicity and efficacy of this candidate vaccine against challenge with virulent DENV-3 CO360/94. The first immunization was well tolerated by all of the animals with no major associated weight loss and none of the animals developed clinical signs. Similar results were seen after the second immunization although unexpectedly, one animal in Group 3 ( $10^6$  FFU DENV D2/D3-WT) developed rapid progressive weight loss and became moribund requiring euthanasia on day 2 after the immunization. A second animal from the same group subsequently died unexpectedly two weeks after the immunization and prior to challenge with virulent DENV-3. After lethal challenge with  $1.2 \times 10^7$  PFU DENV-3 CO360/94, animals in the media control group developed a rapid progressive infection that was lethal in 8/9 animals with the mean day of death (MDD) among the animals that died of  $4.0 \pm 0.8$  days. Immunization with the higher inoculum of DENV D2/D3-E-min provided significant protection with no lethality or morbidity (as measured by  $>10\%$  weight loss) among the animals in the group. Immunization with the lower inoculum of DENV D2/D3-E-min was also protective with only a single animal developing a lethal infection. Animals that received the DENV D2/D3-WT virus prior to DENV-3 challenge were also protected with no lethality in either group, although, 2 animals in the higher inoculum group lost  $>10\%$  of their original body weight.

#### *Example 11*

##### *Evaluation of the Immunogenicity and Protective Efficacy of*

##### *DENV4 vaccine candidates in AG129 mice*

[0203] AG129 mice (n=12) were used to test the immunogenicity and protective efficacy of heterologous D2/D4-E-min and D2/D4-1/2-E-Min viruses compared to D2/D4-WTE (n=12) and media-immunized mock control mice (n=9) at a dose of  $10^6$  FFU delivered subcutaneously. All mice were immunized on days 0 and 21 of the study and sera collected on day 2 to determine viremia and on day 35 for titration of neutralizing antibodies. On day 35, the mice were challenged with intraperitoneal injection of  $10^7$  PFU DENV4 703/4. Challenged mice were weighed and monitored for morbidity to assess the impact of viral challenge. In addition, 5 animals from each group were anesthetized and blood collected by retro-orbital bleed on day 2 post challenge and the remaining animals on day 3 to determine viremia levels by qRT-PCR. On day 30 post challenge the study was concluded, and serum collected from all surviving animals for determination of post-challenge PRNT50 values. The first immunization with all strains was well tolerated by all groups of animals with no sustained weight loss over the 5 day observation period, however, in the D2/D4-WTE group one mouse had to be euthanized prior to the second immunization and additional animals died after the second immunization. No animals in any of the other vaccine groups experienced progressive weight loss. At 2 days post-challenge (DPC), viremia was detected in 4/12 mice inoculated with D2/D4-WTE. For all of the mice immunized with the other two viruses, viremia levels were below the limit of detection of the assay (500 genome equivalents/ml). DENV-4 703/4 challenge produced rapid progressive infection with universal lethality in the media control group. In

addition, three animals immunized with D2/D4-E-min experienced lethal infection with the other animals in this group remaining healthy for the duration of the study. Importantly, no lethality or evidence of morbidity as determined by weight loss was seen in any of the D2/D4-1/2-E-min immunized animals after DENV-4 703/4 challenge.

#### *Example 12*

##### *Immunogenicity of homologous DENV1-4 vaccine candidates in A129 mice*

[0204] We have tested DENV1-4 WT as well as vaccine candidates for DENV2-4 for immunogenicity in IFN $\alpha$  receptor knockout mice. All WT viruses were highly immunogenic in these mice, with neutralizing antibody titers >1024. DENV2-E-W/MIN was equally immunogenic to DENV2 WT virus at both a 10<sup>6</sup> and 10<sup>4</sup> FFU dose. Immunogenicity of DENV3 viruses waned with decreasing dose and increased deoptimization, however, DENV3 E-W/MIN was still highly immunogenic at a 10<sup>4</sup> FFU dose (~1024 FRNT50). We noticed a pronounced improvement in the immunogenicity of DENV4 E-W/MIN and WT as compared to the heterologous DENV4 WT in the DENV2 16681 backbone, which was poorly immunogenic in A129 mice.

#### *Example 13*

##### *Tetavalent Vaccination in AG129 Mice and Efficacy vs DENV3 Challenge*

[0205] AG129 mice, homozygous for a double-knockout of IFN $\alpha$ / $\beta$  and IFN $\gamma$  receptors are commonly used to test *Flavivirus* vaccine candidates due to increased susceptibility to infection. We used AG129 mice to test a tetavalent formulation of our DENV vaccine by vaccinating them on days 0 and 21 with 10<sup>6</sup> IFU monovalent D2/D3-E-min vaccine (N=16; 10 male and 6 female), tetavalent vaccine containing 10<sup>6</sup> IFU of each of the four monovalent DENV E-min viruses (N=16; 10 male and 6 female), or with media (N=13; 8 male and 5 female). Both of the immunizations were well tolerated by all of the animals with none of the animals developing clinical signs and no major weight loss ( $\geq 10\%$ ). Serum was collected prior to challenge for measurement of neutralizing antibodies by FRNT50. All of the mice immunized with the monovalent vaccine developed detectable neutralizing antibody titers (range 20 - 160). In mice immunized with the tetavalent vaccine formulation, titers were generally lower (range <20 - 80). On day 35, all remaining mice were challenged with 10<sup>7</sup> IFU DENV3 CO360/94 delivered by the intraperitoneal route. As anticipated, animals in the media control group developed a rapid progressive infection that was lethal in 8/9 (89%) animals with the mean day of death (MDD) among the animals that died of  $4.1 \pm 0.4$  days. Immunization with monovalent DENV D2/D3-E-min or the tetavalent vaccine provided significant protection with no lethality or morbidity (as measured by >10% weight loss) among the animals in either group. Viral RNA was detected in 8/9 control animals with the titer being comparable on days 2 and 3 post challenge.

#### *Example 14*

[0206] *In vivo* LD50 data for tetavalent and each strain of the homologous vaccine shows neuroattenuation. Week-old mice were injected with 10 $\mu$ l of inoculum containing synthetic wt DENV1-4

viruses as indicated doses. Each mouse was weighed daily for up to 2 weeks and mortality determined by humane early-endpoints (absence of weight gain, paresis, hind-limb paralysis) whenever possible.

| <b>Virus</b>        | <b>LD50<br/>(FFU)</b> | <b>MTD (10<br/>FFU)</b> |
|---------------------|-----------------------|-------------------------|
| DENV1 WT            | 0.4                   | 7                       |
| DENV1 E-W/MIN       | 2.2                   | 10                      |
| DENV2 WT            | ≤3.4                  | 9                       |
| DENV2 E-W/MIN       | 17.8                  | >14                     |
| DENV3 WT            | 3.7                   | 10                      |
| DENV3 E-W/MIN       | 1,931                 | N.D.                    |
| DENV4 WT            | 0.13                  | 8                       |
| DENV4 E-W/MIN       | 2.5                   | 11.5                    |
| Tetravalent E-W/Min | 7.9                   | 10                      |

[0207] Various embodiments of the invention are described above in the Detailed Description. While these descriptions directly describe the above embodiments, it is understood that those skilled in the art may conceive modifications and/or variations to the specific embodiments shown and described herein. Any such modifications or variations that fall within the purview of this description are intended to be included therein as well. Unless specifically noted, it is the intention of the inventors that the words and phrases in the specification and claims be given the ordinary and accustomed meanings to those of ordinary skill in the applicable art(s).

[0208] The foregoing description of various embodiments of the invention known to the applicant at this time of filing the application has been presented and is intended for the purposes of illustration and description. The present description is not intended to be exhaustive nor limit the invention to the precise form disclosed and many modifications and variations are possible in the light of the above teachings. The embodiments described serve to explain the principles of the invention and its practical application and to enable others skilled in the art to utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed for carrying out the invention.

[0209] While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that, based upon the teachings herein, changes and modifications may be made without departing from this invention and its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as are within the true spirit and scope of this invention. It will be understood by those within the art that, in general, terms used herein are generally intended as “open” terms (*e.g.*, the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.).

[0210] As used herein the term “comprising” or “comprises” is used in reference to compositions, methods, and respective component(s) thereof, that are useful to an embodiment, yet open to the inclusion of unspecified elements, whether useful or not. It will be understood by those within the art that, in general, terms used herein are generally intended as “open” terms (*e.g.*, the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be

interpreted as “includes but is not limited to,” etc.). Although the open-ended term “comprising,” as a synonym of terms such as including, containing, or having, is used herein to describe and claim the invention, the present invention, or embodiments thereof, may alternatively be described using alternative terms such as “consisting of” or “consisting essentially of.”

## WHAT CLAIMED IS:

1. A modified dengue virus, comprising
  - a recoded prM protein, a recoded envelope (E) protein, or both,
  - wherein the recoded prM protein has a reduced codon pair bias compared to its parent prM protein encoding sequence, or has at least 5 codons substituted with synonymous codons less frequently used, or has an increased number of CpG or UpA di-nucleotides compared its parent prM protein encoding sequence, and
  - wherein the recoded E protein has a reduced codon pair bias compared to its parent E protein encoding sequence, or has at least 5 codons substituted with synonymous codons less frequently, or has an increased number of CpG or UpA di-nucleotides compared its parent E protein encoding sequence.
2. The modified dengue virus of claim 1, wherein expression of the prM protein or E protein or both are reduced compared to its parent dengue virus.
3. The modified dengue virus of claim 1, wherein the recoded prM protein has a reduced codon pair bias compared to its parent prM protein encoding sequence.
4. The modified dengue virus of claim 1, wherein the recoded prM protein has at least 5 codons substituted with synonymous codons less frequently used.
5. The modified dengue virus of claim 1, wherein the recoded prM protein has an increased number of CpG or UpA di-nucleotides compared its parent prM protein encoding sequence.
6. The modified dengue virus of claim 1, wherein the recoded E protein has a reduced codon pair bias compared to its parent E protein encoding sequence.
7. The modified dengue virus of claim 1, wherein the recoded E protein has at least 5 codons substituted with synonymous codons less frequently used.
8. The modified dengue virus of claim 1, wherein the recoded E protein has an increased number of CpG or UpA di-nucleotides compared its parent E protein encoding sequence.
9. The modified dengue virus of claim 1, wherein each of the recoded prM or E protein-encoding sequence has a codon pair bias of less than -0.05.
10. The modified dengue virus of claim 1, wherein the codon pair bias of each of the recoded prM or E protein-encoding sequence is reduced by at least 0.05.
11. The modified dengue virus of claim 1, wherein the modified dengue virus is selected from type 1, type 2, type 3, type 4 or a combination thereof.
12. The modified dengue virus of claim 1, where the modified dengue virus is a modified tetravalent dengue virus.
13. A dengue vaccine composition for inducing a protective immune response in a subject, comprising a modified dengue virus of any one of claims 1-12, and a pharmaceutically acceptable excipient or carrier.
14. A method of eliciting an immune response in a subject, comprising: administering to the subject an effective dose of a composition comprising a modified dengue virus of any of claims 1-12.

15. The method of claim 14, wherein the immune response is a protective immune response, and a prophylactically effective or therapeutically effective dose of a vaccine composition of claims is administered.
16. The method of claim 14, further comprising administering to the subject at least one adjuvant.
17. The method of claim 14, wherein the immune response is cross-protective against a heterologous dengue virus.
18. A method of eliciting an immune response in a subject in need thereof, comprising:
  - administering a prime dose of (i) an attenuated dengue virus produced by a method other than codon-pair deoptimization or codon deoptimization, or increasing of CpG or UpA di-nucleotides, or (ii) a modified dengue virus comprising a recoded prM protein, a recoded envelope (E) protein, or both, wherein the recoded prM protein has a reduced codon pair bias compared to its parent prM protein encoding sequence, or has at least 5 codons substituted with synonymous codons less frequently used, or has an increased number of CpG or UpA di-nucleotides compared its parent prM protein encoding sequence, and wherein the recoded E protein has a reduced codon pair bias compared to its parent E protein encoding sequence, or has at least 5 codons substituted with synonymous codons less frequently, or has an increased number of CpG or UpA di-nucleotides compared its parent E protein encoding sequence; and
  - administering one or more boost dose of (i) the attenuated dengue virus produced by methods other than codon-pair deoptimization or codon deoptimization, or increasing of CpG or UpA di-nucleotides, or (ii) the modified dengue virus to the subject in need thereof, wherein at least the prime dose or the one or more boost dose is the modified dengue virus.
19. The method of claim 18, wherein a first of the one or more boost dose is administered about 2 weeks after the prime dose.
20. The method of claim 18, wherein expression of the prM protein or E protein or both are reduced compared to its parent dengue virus.
21. The method of claim 18, wherein the recoded prM protein has a reduced codon pair bias compared to its parent prM protein encoding sequence.
22. The method of claim 18, wherein the recoded prM protein has at least 5 codons substituted with synonymous codons less frequently used.
23. The method of claim 18, wherein the recoded prM protein has an increased number of CpG or UpA di-nucleotides compared its parent prM protein encoding sequence.
24. The method of claim 18, wherein the recoded E protein has a reduced codon pair bias compared to its parent E protein encoding sequence.
25. The method of claim 18, wherein the recoded E protein has at least 5 codons substituted with synonymous codons less frequently used.
26. The method of claim 18, wherein the recoded E protein has an increased number of CpG or UpA di-nucleotides compared its parent E protein encoding sequence.

27. The method of claim 18, wherein each of the recoded prM or E protein-encoding sequence has a codon pair bias of less than -0.05.
28. The method of claim 18, wherein the codon pair bias of each of the recoded prM or E protein-encoding sequence is reduced by at least 0.05.
29. The method of claim 18, wherein the modified dengue virus is selected from type 1, type 2, type 3, type 4 or a combination thereof.
30. The method of claim 18, where the modified dengue virus is a modified tetravalent dengue virus.
31. A method of making a modified dengue virus genome comprising:
  - obtaining a nucleotide sequence encoding the envelope protein of a dengue virus;
  - recoding the envelope encoding nucleotide sequence to reduce protein expression, and
  - substituting a nucleic acid having the recoded envelope-encoding nucleotide sequence into a parent dengue virus genome to make a modified dengue virus genome; whereby expression of the recoded envelope-encoding nucleotide sequence is reduced compared to the parent virus.

FIG. 1A




FIG. 1B




FIG. 2




FIG. 3




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 5




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B




FIG. 9




FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 8B

